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ABSTRACT
Numerous pathological amyloid proteins spread from cell-to-cell during
neurodegenerative disease, facilitating the propagation of cellular pathology and
disease progression. Understanding the mechanism by which disease-associated
amyloid protein assemblies enter target cells and induce cellular dysfunction is
therefore key to understanding the progressive nature of such neurodegenerative
proteinopathies. In this study, we utilized an imaging-based assay to monitor the ability
of disease-associated amyloid assemblies to induce the rupture of intracellular vesicles
following endocytosis, as well as to elucidate the cellular consequences of this damaging
mechanism of invasion. We observed that the ability to induce vesicle rupture is a
conserved feature of fibrillar amyloid assemblies of a-synuclein, tau, and polyglutamineexpanded huntingtin. In the case of a-synuclein amyloid assemblies, we determined
that Serine 129 phosphorylation and strain conformation dictate the potency of
endocytic vesicle rupture. We also demonstrated that vesicles ruptured by a-synuclein
are lysosomes, and that these damaged vesicles are targeted to the autophagic
degradation pathway. We observed that vesicles ruptured by a-synuclein can
accumulate and fuse into large, intracellular structures resembling Lewy bodies in vitro,
and showed that the same markers of vesicle rupture surround Lewy bodies in brain
sections from PD patients. These data underscore the importance of this conserved
xxv

endocytic vesicle rupture event as a damaging mechanism of cellular invasion by
amyloid assemblies of multiple neurodegenerative disease-associated proteins, and
suggest that proteinaceous inclusions such as Lewy bodies form as a consequence of
continued fusion of autophagic vesicles in cells unable to degrade ruptured vesicles and
their amyloid contents.
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CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Neurodegenerative diseases represent one of the most formidable challenges
facing biomedical science and medicine. Despite intensive study and significant
advances in understanding of disease pathology and pathogenesis, patients afflicted by
diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease (HD), amyotrophic lateral sclerosis (ALS), or Creutzfeldt-Jakob disease (CJD) are
only treated symptomatically, as no disease-modifying therapy exists to target the
etiology of these diseases.
Despite tremendous heterogeneity in the spectrum of clinical symptoms
resulting from dysfunction and degeneration of the central nervous system (CNS) in
these diseases, each similarly exhibit pathological accumulation of misfolded proteins
into amyloid, a term referring to insoluble protein aggregates of a fibrillar, b-sheet-rich
structure. Because each disease is characterized and defined by the aggregation of a
specific disease-related protein, these disorders are collectively known as
proteinopathies, and the research community has focused on understanding the
mechanisms by which specific proteins become misfolded and ultimately cause
neuronal dysfunction and death. Intriguingly, an explosion of insight into the
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pathogenesis of neurodegenerative proteinopathies has grown from an idea that was
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once considered heretical.
In 1982, Stanley B. Prusiner first described the concept of a prion, a
proteinaceous infectious particle [1], and determined that a protein alone was the
etiological agent of transmissible spongiform encephalopathies (TSEs) such as CJD in
humans, scrapie in sheep and goats, and bovine spongiform encephalopathy (BSE) in
cows. The idea that a misfolded protein aggregate could occupy the same infectious
domain previously thought to be only that of bacteria, viruses, fungi, protozoa, and
helminths was just as much controversial as it was groundbreaking [2]. In the years since
this discovery, the list of proteins that behave in a similar fashion to CJD prions in
converting from a normal, soluble form to a disease-associated, insoluble amyloid form
and amplifying through templated recruitment of additional soluble counterparts has
grown to encompass b-amyloid (Ab) and tau in AD, a-synuclein (a-syn) in PD,
polyglutamine-rich huntingtin (HTTExon1-Q³37) in HD, and TAR DNA-binding protein-43
(TDP-43) and superoxide dismutase 1 (SOD-1) in ALS, among others [3]. Considering
neurodegenerative amyloid proteins as “prion-like” in their aggregation behavior has
not only yielded new knowledge of disease mechanisms, but also led to novel avenues
of exploration for therapeutic development.
In addition to their misfolded amyloid structure, another key feature of all prions
is their self-propagation between affected and naïve neuronal cells and brain regions,
and ultimately their transmission from one infected host organism to another. While the

“prion-like” analogy for Ab, tau, a-syn, HTTExon1-Q³37, TDP-43, and SOD-1 does not

3

extend so far as to say that the neurodegenerative proteinopathies caused by these
misfolded amyloid proteins are transmissible between hosts, the similarity with prions
spreading from cell-to-cell and between different brain regions has been demonstrated
for each disease, suggesting a unifying role for prions in neurodegenerative diseases [3].
While insights into the prion-like behavior of amyloid proteins will have important
therapeutic potential for preventing disease progression, much remains to be elucidated
about the mechanisms by which misfolded amyloid aggregates corrupt their soluble
counterparts, disrupt cellular homeostasis, and propagate their infectious pattern of
protein misfolding.
In seeking to understand amyloid protein propagation more completely, and
elucidate the specific steps in the life cycle of cellular infection that allow this process to
occur, insights can be gained by examining other paradigms of infection in different
contexts. In the situation of a-syn in PD, it is known that the process of aggregate
cellular entry resembles the infectious mechanism of cellular invasion by some bacteria
and viruses, which escape from the endocytic vesicle by inducing membrane rupture [4].
However, specific factors that determine the potency of this a-syn cellular invasion
mechanism are unknown. Furthermore, whether amyloid assemblies of other
neurodegenerative disease-associated proteins are capable of invading target cells in
this manner remains to be elucidated, as does the effect of this damaging mechanism of

entry on cellular homeostatic processes, aggregate cell-to-cell propagation, and
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inflammatory responses.
The studies discussed in this dissertation focus on endocytic vesicle rupture as a
mechanism of cellular invasion for several neurodegenerative disease-related proteins,
focusing for a-syn aggregates on both specific protein modifications that influence
vesicle rupture potency as well as the effects of a-syn-induced vesicle rupture on
cellular homeostasis and aggregate propagation. A more complete appreciation of how
amyloid protein aggregates invade target cells and propagate their misfolding in a prionlike manner will aid in the development of novel disease-modifying therapies to benefit
millions of patients worldwide.
The Prion Principle of Infectious Proteinopathy
Protein as Infectious Agent.
At the center of Stanley Prusiner’s definition of a prion is the fact that a protein
alone is the sole infectious agent causing TSEs [1]. There are several unique features of
prions that confer this infectious potential. When the scrapie-associated prion protein
PrPSc was isolated from infected animals [5], it became known that this protein is highly
resilient against proteolytic digestion [6], indicating that it is composed of stable protein
aggregates with few enzymatic digestion sites accessible in its assembled form.
Furthermore, this aggregated, protease-resistant characteristic of PrPSc is necessary to
maintain its infectious capability, as prolonged proteolytic digestion or disaggregation
procedures sterilize prions and abolish infectivity [6, 7]. As researchers sought to learn
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more about the nature and source of prions, a startling discovery was that prion protein
(PrP) is encoded by a normal cellular gene (PRNP) in the host, and because this gene and
protein product are not uniquely associated with infection, the prion infectious agent
was no longer considered to be a foreign entity [8-10]. Hence two different forms of PrP
exist, a normal “cellular” form (PrPC) that is completely degraded upon protease
digestion and a disease (“scrapie”)-associated aggregated form (PrPSc) that is resistant to
protease digestion. Because the primary structure of PrP encoded by PRNP is the same
in healthy and infected animals, the differences between PrPC and PrPSc are due to posttranslational events [10]. PrPC is composed mainly of a-helix (42%) and has little b-sheet
secondary structure (3%), wheras PrPSc has a much higher b-sheet content (43%) and a
lower a-helical structure (30%) [11]. Limited digestion of PrPSc by proteinase K produces
an N-terminally truncated form known as PrP27-30, named for the molecular weight of
this protease-resistant core present in infectious preparations, which also consists
mainly of b-sheet secondary structure (54%) with low a-helical content (21%) and is
known to polymerize into rod-shaped amyloid fibrils as seen in PrP amyloid plaques [11,
12]. These structural studies brought about the idea that conversion of the precursor
PrPC to PrPSc involves posttranslational modification during which the protein becomes
both enriched in beta-sheet structure and resistant to limited proteolysis, and is then
capable of producing infection because of these characteristics.
Further confirmation of the protein-only hypothesis is demonstrated by
examining different forms of disease. Although transmissible forms of prion diseases

may be most well-known, sporadic CJD with no known cause other than the
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hypothesized spontaneous misfolding of PrPC into PrPSc represents 85% of cases, and
over 40 different mutations of PRNP are known to cause genetic prion disease [2]. All
families affected by heritable forms of prion diseases exhibit an earlier age of onset and
longer duration of illness than sporadic cases [13]. One such form of heritable prion
disease is known as Gerstmann-Straussler-Scheinker (GSS) syndrome, wherein affected
family members inherit a leucine to proline substitution at PrP codon 102 in an
autosomal-dominant fashion, leading to the development of PrP27-30 accumulation and
PrP-immunoreactive amyloid plaques in the brain [14]. Transgenic animal models have
also illuminated the proteinaceous source of prion diseases. One study utilized mice
expressing two point mutations in mouse PrP affecting the structure of its globular
domain to demonstrate that these genetic alterations in PrP result in a fully-penetrant
lethal spongiform encephalopathy with cerebral PrP plaques [15]. These findings
indicate that infectious prion diseases can also be genetic in nature, and suggest that
mutations in the PRNP gene may cause prion disease by facilitating conversion of the
protein into the prion state.
Template for Misfolding.
Another unique feature of prions that defines their infectious nature is the ability
of misfolded, aggregated PrPSc to serve as a template and trigger for the further
misfolding of PrPC, facilitating amplification of the prion state and propagation of its
misfolded structure through naïve counterparts. This templated conversion of PrPC by
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PrP is illustrated profoundly in transgenic mice expressing both hamster and mouse
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prion protein, where inoculation with hamster prions greatly expands the number of
hamster prions but not mouse prions, and vice versa with inoculation of mouse prions
[16]. This observation reveals a species specificity of prion infectivity dictated by the PrP
sequence, and indicates that interactions between PrPSc and homologous PrPC initiate
prion synthesis. Direct evidence that this interaction promotes PrPSc production is seen
when radiolabeled PrPC is incubated with PrPSc, resulting in the formation of proteaseresistant radiolabeled PrP, indicating that the protease-resistant properties of PrPSc
were imparted to incorporating PrPC counterparts [17]. Dramatically, this PrPSctemplated conversion of PrPC into additional PrPSc is necessary for the development of
clinical disease and neuronal death, as PrPC-deficient mice are resistant to prion
diseases [18-20] and only grafted neurons overexpressing PrPC incur cellular damage
when implanted into the brains of infected PrPC-deficient mice [21]. This latter finding
demonstrates that PrPSc alone is not neurotoxic, but must interact with expressed PrPC
and template its conversion into PrPSc for neuronal death to occur. In addition to
protease resistance, subtle conformational details of PrPSc seeds are templated onto the
incorporating naïve PrPC proteins, as evidenced by the recapitulation of the same fully
penetrant lethal spongiform changes induced by mutant PrP when subsequently
inoculated into mice overexpressing WT PrP, and then from these mice into normal WT
mice [15]. Structural studies of infectivity and PrPC to PrPSc conversion suggest that the
PrP aggregates that most potently perform these activities are 17-27 nm in size (300-

600 kilodalton (kD), 14-28 PrP molecules), not larger fibrils or smaller oligomers (less

8

than or equal to 5 PrP molecules)[22].
Perhaps the strongest support of the protein-only hypothesis comes from the
induction of prion disease in vivo from PrPSc generated in vitro. Soto and colleagues
developed a system whereby PrPSc originally isolated from an infected hamster is
amplified in vitro through successive cycles of sonication and PrPC to PrPSc conversion
steps [23, 24]. This process, termed protein misfolding cyclic amplification (PMCA),
exploits the templated misfolding and seeding property of prion proteins by
fragmenting PrPSc aggregates into smaller seeds that can continue to amplify individually
upon co-incubation with PrPC, resulting in a PCR-like enrichment of PrPSc in vitro that can
be used as an inoculum in vivo. The in vitro generated PrPSc has been shown to be
similar biochemically and structurally to the PrPSc isolated from infected hamsters, and
upon inoculation of wild-type (WT) hamsters with in vitro PrPSc, prion disease is induced
identical to the disease induced by PrPSc isolated from infected brain [24]. This process
of PrPSc fragmentation into multiple smaller seeds that independently amplify may also
be important for authentic prion disease, and may represent a mechanism whereby
even slowly growing PrPSc aggregates can have a widespread physiological impact [25].
Propagation.
While the propagation of protein misfolding occurs due to templated conversion
of PrPC into PrPSc, prions are also capable of physically propagating between cells and
even between host organisms to spread infection. While spreading between cells has

been demonstrated for misfolded aggregates of amyloid proteins in many
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neurodegenerative diseases, bringing about the “prion-like” analogy, only prions have
been demonstrated to be transmissible between hosts. One form of infectious human
prion disease is known as kuru, and was transmitted by ritualistic cannibalism in New
Guinea where people ate the brains of their dead relatives in an attempt to immortalize
them [26]. Iatrogenic transmission of CJD has been documented through the use of
contaminated neurosurgical instruments [27, 28] or human growth hormone derived
from cadaveric pituitary extracts [29], or as a result of corneal transplantation [30] or
dura mater grafting [31]. Finally, another form of CJD known as variant CJD (vCJD) arose
through dietary exposure to prion-contaminated beef products from cattle infected with
BSE, commonly known as “mad cow” disease [32-35]. Variant CJD has even been
transmitted through a blood transfusion from a donor who subsequently developed
vCJD [36]. These examples of disease transmission due to propagation of prions
illustrate the paradigm-shifting nature of Stanley Prusiner’s definition, as they represent
the only proteinaceous particles capable of transmitting neurodegenerative disease
between hosts.
The spreading of prions between cell populations, organ systems, and brain
regions has been intensely investigated. Neuronal prion spreading between
interconnected brain regions was shown following retinal inoculation, with subsequent
progressive colonization of the entire visual system from superior colliculus to lateral
geniculate and terminating in the optical cortex [37]. When prions are taken up
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peripherally, as in the case of non-iatrogenic infectious transmission, prions have been
shown to expand and neuroinvade by way of the lymphohematopoietic system,
particularly by interacting with differentiated B cells [38]. The spleen seems to represent
an extraneuronal reservoir for prions, whose arrival there depends on components of
the lymphohematopoietic system such as B cells; PrP transit into the spleen and further
neuroinvasion requires host expression of PrP presumably because of its role as a
substrate for templating of further prions [39]. Once the splenic compartment has been
colonized, prions exploit an interaction between follicular dendritic cells and splenic
sympathetic nerves to invade these peripheral nerve cells and eventually gain access to
the CNS [40, 41]. These steps along the pathway of prion spreading in the periphery or
in the nervous system represent attractive therapeutic targets for preventing the spread
of infection and the onset of neurologic symptoms.
While some knowledge has been gained regarding the specific cellular
mechanisms of prion cell-to-cell propagation, much remains to be elucidated about the
complete life cycle of cellular infection [42]. While endogenous PrPC is known to localize
to the plasma membrane, its localization there is not required for exogenous PrPSc
binding or internalization [43-45]. Instead, incoming PrPSc interacts with
glycosaminoglycans (GAGs) at the cell surface that facilitate its binding, and is
internalized via nonspecific endocytic routes such as pinocytosis or transcytosis into
vesicles positive for markers of late endosomes or lysosomes, but not synaptic, early
endocytic, or raft-derived vesicles [43, 44]. This internalized PrPSc is then transported

within the infected cell along neurites to positions of intercellular contact, perhaps
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facilitating cell-to-cell movement. Cellular uptake can be a rapid process, within 2 hours
of exposure, but may not occur for all cells equivalently, as uptake depends on both the
membrane microenvironment and host cell-specific factors encountered upon binding,
as well as the size of the aggregates themselves, with smaller aggregates more
efficiently taken up than larger ones [45]. When membrane-associated PrPC encounters
exogenous PrPSc, pathological conversion of membrane-associated PrPC by the infecting
PrPSc occurs within minutes at the cell surface in lipid rafts, followed by endocytosis of
the newly formed PrPSc into early endosomes and either recycling to the plasma
membrane or retrograde transport to the Golgi and eventual lysosomal degradation, the
main degradative process at this early stage of infection [46].
Once successful infection of a target cell has been established, and replicating
prions evade degradative processes as they multiply, their trafficking to additional cells
has been shown to occur through multiple mechanisms. Cell-to-cell spreading is
facilitated by cell-to-cell contact, and tunneling nanotubes (TNTs) allow transfer of both
exogenous and endogenous PrPSc between infected and naïve neuronal cells or from
infected dendritic cells to neurons as relevant for neuroinvasion from peripheral
lymphoid organs [47, 48]. Significantly, because of their nature as a transient direct
conduit between the cytoplasm of interconnected cells, TNTs may allow more efficient
transmission of endogenous PrPSc, which may have fewer options for cellular release
and intercellular transfer compared to internalized exogenous PrPSc [48]. In addition to
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transferring through direct cell-to-cell contacts, both PrP and PrP are known to be
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released into the extracellular environment from naïve and infected neuronal cells,
respectively, in association with exosomes, which can then efficiently initiate infection in
uninfected cells [49, 50]. Learning more about the mechanisms of prion transmission
between hosts will alleviate public health concerns, and elucidating specific steps in the
pathway of intracellular and intercellular infection may allow therapeutic development
for prions and other neurodegenerative disease-related amyloid proteins that share the
prion-like ability to propagate between cells and brain regions.
Strains.
Upon pathological examination of infected brain tissue, all forms of human prion
disease exhibit PrP deposition, astrocytic gliosis, and prominent vacuolation of neural
tissue, the characteristic appearance of which led to the spongiform descriptor of this
group of encephalopathies [2]. Despite sharing a similar pathological appearance and
the same misfolded protein as the etiological agent, TSEs differ in phenotypic
characteristics such as incubation time, clinical signs of disease, brain regions and cell
types affected, and vacuolation and protein deposition patterns [51, 52]. When different
phenotypes of disease arise from inoculation with different prion preparations, despite
precisely controlling for parameters such as prion titer, tissue, infection route, PrP
genotype, age, gender, and immune system status, these different disease phenotypes
define unique prion strains [51]. This strain phenomenon was first observed when
animals infected with the same inoculum developed prion disease with differing clinical

features [53, 54], and subsequently these observed differences in the localization and
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appearance of CNS spongiform degeneration are the most well-accepted criteria to
distinguish strains [55, 56]. True to the templating nature of prion propagation, these
distinguishing phenotypic characteristics of different prion strains are faithfully
propagated to other infected animals upon serial passage [57]. Indeed, the
recapitulation of strain-specific pathology allowed the identification of vCJD as the
human counterpart of BSE, as characterization of the new vCJD pathology demonstrated
features distinct from sporadic CJD but similar to BSE [32-35]. Strain-specific
accumulation in distinct brain regions has been demonstrated using histoblot
quantification of prion deposition [58, 59], and immunohistochemistry studies have
revealed strain-specific cell type tropism [60]. While identifying induction of spongiform
degeneration in specific brain regions has been a reliable indicator of prion strain
differences, this approach is limited because prions can also accumulate in brain regions
where overt degeneration is not observed, and specific cellular or structural parameters
that further distinguish prion strains and that may dictate cell type and brain region
tropism cannot be elucidated in this fashion.
At the structural level, prion strains have been distinguished from one another
through biochemical properties such as epitope accessibility for antibody binding,
differential sensitivity to proteinase K digestion, and variable sedimentation and gel
electrophoretic properties [61, 62]. These results, in addition to the observation that
strain-specific differences in gel migration properties were preserved through animal
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transmission [63] have led to the view that strain diversity is encoded by differences in
PrPSc conformation that serve as unique templates for the corruption of expressed PrPC.
This structural heterogeneity of PrPSc has been seen in electron microscopic (EM)
studies where fibrillar protofilaments of different strains exhibited different widths and
periodicities [64], or when differential immunoreactivity is observed between strains
upon incubation under denaturing conditions [65]. Another distinguishing factor
between various prion strains is their conformational stability, their relative propensity
for spontaneous disassociation or fragmentation, although there is some debate about
whether decreasing conformational stability results in a shortening or lengthening of
disease incubation time [25, 66, 67]. Similar distinguishing features have been observed
between prion strains produced entirely in vitro from bacterially-derived recombinant
PrP, further highlighting the idea that strain phenotypic diversity results from
differences in protein aggregate conformation [66, 68-70]. Elucidating the structural
differences that distinguish different prion strains and dictate their toxicity, seeding, and
propagation properties may elucidate the underpinnings of differing disease phenotypes
and highlight opportunities for inhibiting or preventing disease onset and progression.
Alpha-Synucleinopathies
Clinical Features.
PD, Dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are all
neurodegenerative proteinopathies that exhibit aggregation of a-syn, and hence are
named a-synucleinopathies. PD is the most common and well-known a-
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synucleinopathy, first described by James Parkinson in 1817 in his Essay on the Shaking
Palsy [71]. Parkinson described the essential motor symptoms of the “paralysis agitans”
disease that would later bear his name, noting an “involuntary tremulous motion, with
lessened muscular power, in parts not in action and even when supported”. He also
described “a propensity to bend the trunk forward, and to pass from a walking to a
running pace: the sense and intellects being uninjured.” The essential characteristics of
the disease were later refined by Jean-Martin Charcot, the father of modern neurology,
who named the disorder Parkinson’s disease and clearly described its characteristic
bradykinesia, or slowness of movement, as distinct from muscle weakness, noting “a
slowness in execution of movement rather than real weakness” [72]. Charcot used the
name Parkinson’s disease rather than paralysis agitans or shaking palsy because he
recognized that PD patients are not very weak and do not necessarily have a tremor
[73]. The Parkinson’s Disease Foundation estimates that as many as 1 million Americans
and more than 10 million people worldwide are currently living with PD, although
prevalence rates are projected to greatly increase as the population continues to age
[74]. PD prevalence in industrialized countries is estimated at 0.3% of the entire
population and about 1% of people over 60 years of age [75]. Age is known to be the
greatest risk factor for the development of PD, as onset is rarely before age 50 and
prevalence and incidence increase nearly exponentially with age, peaking after age 80
[75-78]. The incidence of PD is 8-18 per 100,000 person-years [75]. Gender and ethnicity
also affect rates of PD, with a 3:2 higher prevalence of men affected than women and

incidence highest among Hispanics, then non-Hispanic Whites, Asians, and Blacks [77,
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79]. As the second-most common neurodegenerative disease and the most common
movement disorder, PD represents a significant burden of morbidity and mortality for
an aging population.
Because there is no definitive test for the diagnosis of PD, the disease must be
diagnosed based on clinical criteria which differ between PD, DLB, and MSA. The
International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic
Criteria for Parkinson’s disease (MDS-PD Criteria) place the motor syndrome at the
center of disease diagnosis, characterized by bradykinesia and either rigidity, resting
tremor, or both [80]. These characteristic motor features result from the death of
dopaminergic neurons in the substantia nigra pars compacta (SNpc), a hallmark feature
of PD observable at autopsy even at the gross anatomical level due to the loss of the
dark neuromelanin “black substance” pigment that gives the substantia nigra its name
(Figure 1). Without the input of dopamine (DA) from nigral projections to the striatum,
the ability of the basal ganglia circuitry to control normal movement is compromised,
resulting in the aforementioned motor manifestations of PD [81]. By the time these
parkinsonian motor symptoms manifest, there has already been at least a 70% decrease
in striatal DA, an amount that will continue to decrease over time as the disease
progresses [82]. In addition to these cardinal signs of PD, loss of postural reflexes, or the
inability to maintain balance, is also considered a hallmark of PD [83]. Although
substantial heterogeneity can exist in the clinical phenotype of PD, other secondary
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Figure 1. Degeneration of the SNpc in PD. Gross unstained cross section of human
midbrain in normal case (left) and in PDD (right). Normal case (left) from 74-year old
female with cause of death as multiple myeloma. PDD case (right) from 68-year old male
with pathologically confirmed LBs in substantia nigra and in the cingulate cortex, in the
absence of diffuse LB disease. Neuromelanized dopaminergic neurons in SNpc visible
dorsal to cerebral peduncles, seen best in normal case. Neuromelanin, a byproduct of
DA synthesis, is responsible for the black pigment which gives the substantia nigra its
name, which in Latin means “black substance”. In the case of PDD, loss of neuromelanin
results in nigral pallor (arrows), indicating dopaminergic degeneration. (Image courtesy
of John Lee, MD, PhD, used with permission).
motor features may include hypomimia (masked facies), dysarthria (slow or slurred
speech), dysphagia (difficulty swallowing), micrographia (small handwriting), shuffling
gait, festination (quickening and shortening of strides), freezing, or dystonia (involuntary
muscle contractions causing repetitive or twisting movements) [83].
In addition to these symptoms affecting movement, it is now widely accepted
that PD patients exhibit a variety of non-motor symptoms, often preceding the onset of
the motor syndrome by months to decades and persisting for the duration of the
disease [84-87]. Dysfunction of the autonomic nervous system is commonly experienced

as evidenced by symptoms such as constipation, postural hypotension, excessive
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sweating or salivation, bladder irritability, or urinary urgency [88]. Anosmia (loss of the
sense of smell) is so often associated with PD that its symptomatic presence constitutes
a supportive criterion in the MDS-PD Criteria alongside resting tremor and
responsiveness to dopaminergic medication [80]. PD can also cause rapid eye
movement (REM) sleep behavioral disorder (RBD) where patients act out their dreams
[85, 88]. PD patients also experience neuropsychiatric symptoms, with anxiety present
to varying degrees in 45% of PD patients and depression occurring in around 35% of
patients [89-91]. Finally, cognitive decline leading to dementia commonly occurs in PD,
seen in 46% of PD patients 10 years after diagnosis and 83% of patients 20 years after
diagnosis [92, 93]. Although in the past the presence of dementia or the temporal
relationship of its onset to the onset of parkinsonian symptoms was used to exclude a
diagnosis of PD and suggest separate disorders of PD dementia (PDD) or DLB [94, 95],
these conditions are considered by many to be part of the same pathological spectrum,
and the MDS-PD Criteria considers DLB to be a subtype of PD [80].
Although treatment of the underlying neurodegenerative process does not exist,
patient quality of life can be significantly improved for many years with symptomatic
therapies. The most effective medication available for treating the motor symptoms of
PD is levodopa (L-DOPA), a DA precursor, intended to more easily facilitate DA synthesis
in degenerating dopaminergic neurons [96]. Additionally, DA agonists can be used to
stimulate DA receptors, and monoamine oxidase type B inhibitors (MAOBIs) can be used

to maintain as high a level of endogenous DA as possible by preventing its catabolism
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[96]. Eventually, however, these treatments begin to fail when patients report that the
effects are “wearing off”, not lasting until the next dose, and eventually patients
experience marked “on-off” motor fluctuations with some doses being completely
ineffective [88]. In addition, when patients have been taking L-DOPA for many years,
they can begin to experience involuntary movements called L-DOPA-induced dyskinesias
that can be debilitating. As dopaminergic degeneration proceeds inexorably, patients
then face the challenging decision to either remain on L-DOPA to experience its limited
benefits despite the debilitating dyskinesias or reduce their dose of L-DOPA resulting in
a concomitant reduction of dyskinesia severity but an increase in time spent in an “off”
state, often one of the most frightening PD symptoms [88]. This may be the point when
patients opt for symptomatic surgical intervention through deep brain stimulation
(DBS), where adjustable implanted electrodes utilize high frequency electrical
stimulation of brain regions such as the subthalamic nucleus (STN) and globus pallidus
internus (GPi) to improve motor features and allow for a reduction in L-DOPA dosage
[97]. Although almost a quarter of patients have a good outcome at 10 years after
diagnosis, living free of dementia or postural instability [92], these symptoms become
more prevalent and severe in the end stages of the disease, and postural instability and
hypotension can cause especially severe complications for patients, with 81%
experiencing falls and 23% sustaining fractures by 15 years after diagnosis [98]. Despite

these end-stage challenges, PD is a substantial contributor to death in only 20% of
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patients, with the most common cause instead being pneumonia [92].
Multiple system atrophy is known as a distinct a-synucleinopathy from PD
because of the differences exhibited in the spectrum of patient symptoms. The average
age of onset is younger for MSA compared to PD, 54 compared to 68, and is generally
considered to evolve much more quickly than PD [88, 92, 99]. Autonomic dysfunction
features prominently in MSA along with parkinsonism, but significant cerebellar
dysfunction may also be present as distinct from PD [100], and MSA patients may not
respond as well as PD patients to L-DOPA. MSA is also less common than PD, with a
prevalence of 4.4 per 100,000 person-years [101]. While both PD and MSA exhibit
dopaminergic degeneration of the SNpc, histopathologic examination on autopsy is the
most reliable way to distinguish these disorders, as the characteristic signature of a-syn
aggregates differs between the two disorders.
Lewy Bodies.
The histopathologic hallmark of a-synucleinopathies was first described in 1912
by Fritz Heinrich Lewy when he observed neuronal inclusions in the dorsal motor
nucleus of the vagus nerve, the basal nucleus of Meynert, the globus pallidus, and the
thalamus of a PD patient [102, 103]. These neuronal inclusions were later given the
name “Lewy bodies” (LBs) by Konstantin Tretiakoff who reported in his doctoral
dissertation the presence of “corps de Lewy” in the substantia nigra, noting a
degeneration of the substantia nigra in PD and postulating a connection between this

nigral cell loss and the characteristic symptoms of rigidity and tremor seen in PD [104,
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105]. LBs have subsequently been identified as widely distributed throughout multiple
tissues [106]. In the central nervous system (CNS), in addition to the areas discovered by
Lewy and Tretiakoff mentioned above, LBs have been found in the olfactory bulb,
hypothalamus, posterior pituitary, locus ceruleus, dorsal raphe nucleus, cerebellum,
amygdala, and the cerebral cortex [106]. Beyond the CNS, LBS have been identified in
multiple areas of the peripheral nervous system (PNS) such as sympathetic ganglia and
enteric neurons, and in tissues as diverse as heart, pelvic organs, adrenal medulla,
salivary gland, and skin [106]. This widespread LB distribution underscores the
multisystem nature of PD and a-synucleinopathies in general, which is also evident by
the diversity of symptoms experienced by patients.
Classical, brainstem-type LBs are seen by light microscopic examination of
hematoxylin and eosin (H&E)-stained sections as intracytoplasmic, single or multiple,
spherical or elongated, eosinophilic masses possessing a dense core and a lighter
peripheral halo [106] (Figure 2A). Antibodies for ubiquitin were initially used as the most
useful marker of LBs since the fibrillar components comprising their ultrastructure were
known to be heavily ubiquitinated [107, 108], but the discovery of insoluble a-syn fibrils
as the main proteinaceous component of LBs led to staining for a-syn replacing staining
for ubiquitin as the most sensitive and preferred method of detection for LBs [109-111].
Additionally, insoluble a-syn fibrillar aggregates were also identified as the main
component of glial cytoplasmic inclusions (GCIs), or Papp-Lantos bodies, present
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Figure 2. Demonstration of Lewy bodies in SNc dopaminergic neurons in sporadic PD.
Conventional haematoxylin (blue) and eosin (pink) histological staining (A) reveals a
spherical Lewy body (arrow) in SNc dopamine neurons with a distinct central core and a
peripheral halo. Electron micrograph of a Lewy body (B) reveals that the core (c)
contains granular material and the outer halo (h) is composed of radiating filaments. A
standard immunohistochemical protocol shows two Lewy bodies (arrow) with ubiquitin
concentrated in the core (C) and two Lewy bodies (arrow) with a-synuclein
concentrated in the halo (D). Reprinted from The Lancet Neurology, Volume 3, Issue 8, C
Warren Olanow, Daniel P Perl, George N DeMartino, Kevin St P McNaught, Lewy-body
formation is an aggresome-related process: a hypothesis, Page 496-503 (Reference 118),
Copyright 2004, with permission from Elsevier (License Number 4057260798096).
http://www.sciencedirect.com/science/journal/14744422.
exclusively in oligodendrocytes that specifically characterize MSA pathology [112-114].
This difference in localization of neuronal LBs in PD and oligodendroglial LBs in MSA
allows these two disorders to be definitively distinguished by pathological examination,

in combination with the differences in clinical phenotype. Not only was the a-syn
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protein identified in all LBs from the diverse tissues they inhabit and diseases they
characterize, a-syn was not identified as a component of other neuronal or glial
inclusions characteristic of other diseases such as AD, motor neuron disease, or tripletrepeat diseases [115]. It was subsequently found that the insoluble a-syn fibrils
comprising the LB were the substrate for ubiquitination [116], although not all LBs
exhibit the same a-syn/ubiquitin labeling pattern; some LBs show a-syn and ubiquitin
evenly distributed and overlapping homogenously across the inclusion body, while
others appear in a concentric pattern where a-syn is concentrated peripherally and
ubiquitin inhabits the central core region [117] (Figure 2C-D). This appearance, where
insoluble a-syn fibrils segregate to the periphery of LBs, agrees with electron
microscopic examination of LBs demonstrating an outward-radiating filamentous halo
surrounding a dense granular core [118] (Figure 2B), and is consistent with the
hypothesis that insoluble a-syn is continually deposited into LB inclusions [117].
An important advance came when phosphorylation was identified as a key posttranslational modification (PTM) of a-syn fibrils enriched in LB inclusions. Almost 90% of
a-syn present in LBs was shown to be extensively and selectively phosphorylated at
Serine 129 (pS129), whereas only 5% of a-syn in unaffected brain tissue is similarly
modified [119-122]. Many other LB components have been identified including PDlinked gene products in addition to a-syn such as DJ-1, leucine-rich repeat kinase 2
(LRRK2), parkin, and phosphatase and tensin homolog (PTEN)-induced putative kinase 1
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(PINK1), as well as lipids, kinases, mitochondria-related proteins, and molecules involved
in protein folding, membrane trafficking, oxidative stress, the ubiquitin-proteasome
system, autophagy, and aggresome formation [106, 117, 123]. This list of components
can give clues to the pathological mechanisms leading to LB formation.
It was originally believed that LBs, as the histopathologic hallmark of PD and
other a-synucleinopathies, are directly toxic to the cells that contain them, and their
formation led to neurodegeneration. More recently, however, LB formation has been
considered a protective mechanism which may occur when the cell is overwhelmed by
accumulating protein aggregates that are unable to be effectively refolded by
chaperones or cleared by proteasomal or autophagic mechanisms [118, 124]. As part of
the cellular response to protein misfolding and to better facilitate degradation and
cellular protection from aggregate toxicity, aggregates can be specifically delivered to
proteinaceous perinuclear inclusion bodies called aggresomes formed at the
centrosome by dynein-dependent retrograde transport on microtubules [118, 124]. The
prevailing hypothesis by Kopito, Olanow and others regarding LB formation as an
aggresome-related process proposes that trafficking to the perinuclear aggresome
occurs when cellular quality control mechanisms such as chaperones or proteasomes
are overwhelmed and become unable to cope with the increasing burden of misfolded
protein “waste” [118, 124]. Hence the aggregate accumulation that is represented by
inclusion formation serves to concentrate these misfolded proteins and increase the
efficiency of their capture by autophagic degradative mechanisms which properly

“recycle” components of this waste for other cellular purposes [118, 124]. It is only
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when their recycling capacity also becomes overwhelmed and fails that aggresomes
become cellular “junkyards” where continual deposition of misfolded protein waste
serves to protect the cell from further aggregate toxicity but consequentially promotes
abnormal growth and persistence of proteinaceous inclusions [118, 124].
This aggresome hypothesis is supported by studies of the stages of LB
development. a-syn in LB-related pathology first becomes evident as diffuse or granular
neuronal cytoplasmic staining in otherwise morphologically normal-looking cells, but
can then begin to form thread-like or dot-like structures that first appear in neurites
(Lewy neurites, LNs) and eventually inhabit the perikarya [106, 125, 126]. This pattern
gives way via coalescence and incorporation of p62, ubiquitin, and other components
first to irregularly shaped, uneven staining in neurons that are often poorly pigmented,
indicating early cellular dysfunction, and then to discrete staining corresponding to welldefined pale bodies (PBs) which are less eosinophilic than classical LBs and do not
exhibit a halo [106, 126, 127]. PBs are known to be composed of sparse granular and
vesicular structures among a-syn filaments, corresponding to observations that early
stages of inclusion formation involve clustering of a-syn-associated vesicles [128] as well
as enrichment and aggregation of lysosomes and mitochondria in the juxtanuclear
inclusion body that suggest an ongoing cellular degradation effort [129]. PBs
occasionally display condensations or one or more small LBs at their periphery,
eventually developing into ring-like classic LBs through a compaction mechanism [106,
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126]. Despite expressing the autophagic marker microtubule-associated protein 1A/1Blight chain 3 (LC3) [130-133], exhibiting lysosome-associated membrane protein 2
(LAMP2) expression at the periphery [133], and containing lysosomal enzymes such as
cathepsins [131, 134] and glucocerebrosidase [135], LB inclusions are associated with
the accumulation of abnormal autophagosomes and lysosomes consistent with
aggresomes failing to fulfill their degradative intention [131, 134]. Much debate exists
regarding the role of ubiquitination and S129 phosphorylation in LB inclusion formation,
as studies have demonstrated conflicting reports on whether these PTMs occur at early
stages of protein aggregation to promote inclusion formation, or happen after inclusion
formation has already occurred and thus represent a cellular attempt to mark these
inclusions for degradation [119, 136-138]. Evidence that LB inclusion formation may
represent a protective cellular response was also seen when a potential therapeutic
compound that promotes inclusion formation in cellular models of PD and HD
prevented dysfunction and toxicity associated with misfolded protein aggregates,
supporting the idea that promoting inclusion formation to potentially boost cellular
mechanisms of degradation may represent a viable treatment approach for patients
[139].
a-Synuclein Physiological Function.

a-syn is a 140 amino-acid protein that was first identified with an antibody
against synaptic vesicles from the electromotor nucleus of Torpedo californica; its
localization to the synapse and the nuclear envelope result in the name
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Figure 3. Human ASYN. Scheme representing the structure of human ASYN with the
three distinct domains (N-terminal, NAC and C-terminal). Amino acid residues are
indicated in the bottom. Brown bars inside protein domains represent the imperfect
hexameric KTKEGV repeats. Arrows indicate the sites of phosphorylation and the broken
lines show the mutated sites. Adapted and reprinted from PLoS Genetics, Volume 10,
Issue 11, Diana F. Lazaro, Eva F. Rodrigues, Ramona Langohr, Hedieh Shahpasandzadeh,
Thales Ribeiro, Patrıcia Guerreiro, Ellen Gerhardt, Katharina Krohnert, Jochen Klucken,
Marcos D. Pereira, Blagovesta Popova, Niels Kruse, Brit Mollenhauer, Silvio O. Rizzoli,
Gerhard H. Braus, Karin M. Danzer, Tiago F. Outeiro, Systematic Comparison of the
Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation, e1004741,
doi:10.1371/journal.pgen.1004741 (Reference 256), Copyright 2014, reproduced under
the terms of the Creative Commons Attribution License.
“synuclein” [140]. Homologs to the Torpedo synuclein protein were then identified in rat
and human brain, as were two other members of a synuclein family of proteins, thus
giving rise to the names a-, b-, and g-synuclein for these individual isoforms [140-142].
At the time a-syn was identified in human brain, its full-length sequence was
determined to be identical to the previously-identified precursor of the non-Ab
component (NACP) [142], the name of which is derived from its cleaved fragment, later
determined to correspond with amino acid residues 61-95 of a-syn (Figure 3), the nonAb component (NAC) of AD amyloid plaques [143]. Studies of NACP, equivalent to fulllength a-syn, confirmed its association with synaptic vesicles at the presynaptic terminal
[142, 144]. The human a-syn gene, SNCA, maps to chromosome 4q21.3-q22 [145, 146],
and while a-syn protein expression has been detected in non-neural tissues such as red
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blood cells (RBCs) [147], it is abundantly expressed mainly in the nervous system where
it comprises an estimated one percent of total protein in soluble cytosolic brain
fractions [144]. While the endogenous state of a-syn has been the subject of much
debate, as some have suggested a native helically-folded tetramer as the normal form of
a-syn [148], most findings agree that the native form of a-syn is an unfolded,
unstructured monomer [149, 150].
Despite this debate about its native state, numerous findings clearly reveal that
the first ~100 amino acids in the N-terminus of a-syn, which contain seven imperfect 11residue repeats with a highly conserved hexameric KTKEGV motif (Figure 3), mediate a
structural transition from natively unfolded to an amphipathic a-helix upon association
with lipid membranes [140, 143, 151-153]. a-syn can adopt two distinct a-helical
conformations in association with lipids depending on the lipid composition or charge or
on the diameter of the vesicle. In one conformation, two curved a-helical regions, from
Valine 3-Valine 37 and from Lysine 45-Threonine 92, are separated by a short linker
region and have an antiparallel arrangement resembling a broken or bent a-helix or an
a-helix horseshoe [154-157]. This conformation has been proposed for interactions
between a-syn and smaller-diameter, highly-curved vesicles for which a-syn has a
preferential affinity [151, 155, 156, 158]. In another conformation, an extended,
uninterrupted curved a-helix spans a similar stretch of N-terminal amino acids as for the
two a-helices in the previous conformation [156, 157]. This conformation is preferable
for interaction between a-syn and larger-diameter vesicles, although the two a-syn

conformations may also co-exist within the same vesicle [155-157]. In both

29

conformations, the C-terminal part of a-syn, from Aspartic acid 98 to Alanine 140
(Figure 3), is highly charged and mobile and does not associate with lipids, remaining
free and unfolded [152, 155]. The N-terminal a-helical region of a-syn is key for
anchoring the protein to lipid bilayers [159], possibly through interactions with lipid
rafts or ganglioside GM1 [160, 161]. The various conformational transitions between
natively unfolded and multiple a-helical structures are encoded within the a-syn amino
acid sequence and can be triggered and tuned by lipid composition and charge as well
as membrane curvature [158, 162].
The membrane binding capacity of the a-syn protein is crucial for its cellular
function. a-syn knockout (KO) mice are viable and are largely normal in their brain
architecture, cell bodies, fibers, and synapses, but exhibit increased DA release with
some stimuli and a deficiency of undocked presynaptic vesicles in the reserve pool,
pointing to a role for a-syn as a pre-synaptic regulator of vesicle mobilization and DA
neurotransmission [163-165]. Through its binding affinity for membranes of high
curvature, a-syn is targeted to negatively-charged endocytic or post-Golgi vesicles [166],
possibly through interacting with membrane-associated GTP-bound Rab3a rather than
cytosolic GDP-Rab3a [167]. In line with a role in vesicle trafficking, the synuclein family is
required for the fast kinetics of synaptic vesicle endocytosis [168], and has been shown
to induce the clustering of synaptic vesicles [169]. Furthermore, a-syn has been shown
to act as a chaperone for the folding and refolding of soluble N-ethylmaleimide–

sensitive factor attachment protein receptor (SNARE) proteins, binding to
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synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) and promoting
assembly of the SNARE complex [170, 171]. This function is clearly important for proper
neuronal homeostasis, as KO mice lacking the synuclein family develop neurological
impairments with age and died prematurely [171]. Recently, additional functions have
been proposed for a-syn that do not necessarily involve its lipid-binding functionality. asyn can bind to tubulin to facilitate microtubule nucleation and increase growth rate and
catastrophe [172], and a-syn can also interact with ATP synthase in mitochondria to
increase efficiency of ATP synthesis [173]. While the function of a-syn is still
incompletely understood, and its role is continuing to be elucidated [174], it clearly
influences very important cellular processes, leading some to hypothesize that a-syninduced pathology may be a toxic combination of the gain-of-function induced by a-syn
aggregation and the loss-of-function caused by displacement from its native role
following sequestration into insoluble protein aggregates [175, 176].
a-syn Pathological Aggregation.

Characterization and process. To learn more about how the a-syn protein
aberrantly abandons its native conformation and role to become an aggregated,
insoluble fibrillar component of LB inclusions, researchers have focused on
characterizing a-syn aggregates from human brain and in vitro systems and on modeling
the aggregation process. Characterizing a-syn aggregates found in patients has yielded
many clues as to the mechanisms of fibril and inclusion formation. In addition to the
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fibrillar composition and detergent insolubility identified from studies of LB inclusions in
situ, a-syn fibrils isolated from brains of patients are partially resistant to proteinase K
digestion [177] and exhibit a consistent orientation of monomeric constituents as
evidenced by antibodies against the C-terminal region labeling filaments along their
entire length whereas antibodies for the N-terminal region label only one filament end
[178]. In addition to the filamentous a-syn pathology observed in LBs, smaller prefibrillar a-syn oligomers have been identified in brains of transgenic mice expressing
human a-syn prior to neurological symptom onset; as opposed to a-syn fibrils, these
oligomers are detergent-soluble, proteinase K-sensitive, and are found both in regions
containing LB inclusions as well as histologically unaffected regions [179]. However,
oligomers from inclusion-bearing regions accelerate in vitro a-syn aggregation and
cause neurodegeneration, while oligomers from unaffected regions are not toxic and
delay in vitro a-syn aggregation [179]. These various properties unique to a-syn
oligomers and distinct from native and fibrillar a-syn suggest that oligomers represent a
separate a-syn species that may evolve from monomer and develop into more mature
fibrils and inclusions, and further imply that different functional conformations of
oligomers may exist, each with their own specific cellular consequences. Employing the
proximity ligation assay (PLA) for the specific detection of oligomeric forms of a-syn in
human brain revealed previously unrecognized extensive diffuse deposition of a-syn
oligomers, often in brain areas mildly affected by PD, and preferentially labeling earlystage, diffuse or loosely compacted lesions such as PBs rather than more heavily

compacted mature LBs [180]. These findings indicate that oligomeric forms of a-syn
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may precede the development of classical PD pathology, and in demonstrating that
oligomeric a-syn exhibits an intermediate proteinase K resistance different from the
proteinase K sensitivity of native a-syn and resistance of a-syn in LBs, this work
supports the view that oligomers represent an a-syn species distinct from native and
fibrillar forms [180]. These studies of brain-derived a-syn aggregates illuminate
potential mechanisms of a-syn aggregation in authentic disease processes, and are
essential to establish the physiological relevance of in vitro characterization methods.
Studies of a-syn aggregation from in vitro experiments or molecular simulations
have highlighted the essential role of the central hydrophobic domain of a-syn, known
as NAC for its accumulation as the non-Ab component of amyloid plaques in AD, in
promoting the aggregation process. Although native, monomeric a-syn is essentially
disordered, studies of its conformation under physiological cell conditions have
demonstrated that the central hydrophobic NAC domain is shielded from exposure to
the cytoplasm, perhaps counteracting spontaneous aggregation [181]. However,
molecular simulations have revealed that a-syn can sample conformations that place
the NAC domain in a solvent exposed and extended conformation that can form cross-b
structure, and that frequent long-range contacts formed between the a-syn N-and Ctermini promote this solvent-exposed orientation of the NAC domain [182] (Figure 4). In
addition to spontaneous conformational changes into aggregation-prone states,
decreasing pH or increasing temperature have been shown to transform a-syn into a
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Figure 4. Protein misfolding and aggregation into infectious fibrillar assemblies.
Natively unfolded polypeptide chain (sphere) undergoes conformational changes that
lead to distinct abnormal (cube or cylinder) forms. The rates depend on the propensity
of the polypeptide to populate a given conformation. According to the “template
assistance” model, the abnormal folding intermediates interact with the native form of
the infectious protein and convert it into abnormal forms. The distinct abnormal forms
of the polypeptide interact transiently with like conformers and establish longitudinal or
lateral interactions following the “seeded polymerization” model. The oligomeric
species are unstable and dissociate because the inter-molecular interactions do not
outweigh the entropic cost of binding. Once longitudinal and lateral interactions have
been established between abnormal forms of the polypeptide, distinct stable seeds are
formed (in brackets). These seeds grow indefinitely by incorporation of like molecules,
yielding fibrils of distinct physical properties. The different fibrils can break into smaller
fragments because, amongst other things, of Brownian movement. The rate of breakage
depends on the number of bonds established between the molecules. Each resulting
fragment acts as seed. Reprinted from Journal of Parkinson’s Disease, Volume 5, Ronald
Melki, Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities
with other Neurodegenerative Diseases, Pages 217-227, doi: 10.3233/JPD-150543
(Reference 304), Copyright 2015, reproduced under the terms of the Creative Commons
Attribution Non-Commercial License.
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partially folded conformation [183], and native interactions between a-syn and lipids at
the plasma membrane or on/in vesicles or exosomes may also promote its initial
misfolding and aggregation [184-187]. Finally, abnormal cytosolic interactions between
a-syn and histones released from nuclei due to disruption of nuclear membrane
integrity during apoptosis may also contribute to de novo aggregation of a-syn [188,
189].
While the specific events leading to initial a-syn misfolding remain to be
elucidated, the NAC domain clearly plays an integral role in aggregation, as a 12-amino
acid stretch (Valine 71- Valine 82) in the middle of this hydrophobic region is necessary
and sufficient for fibrillization [190]. Introduction of a single charged amino acid into this
12-amino acid stretch significantly slows aggregation, deletion of this stretch completely
abolishes aggregation, and synthetic peptides of these 12 amino acids are sufficient to
form filaments in vitro which promote the aggregation of full-length a-syn [190]. Even a
deletion of two amino acids, Alanine 76 and Valine 77, dramatically impairs fibril
polymerization due to the combination of the location and hydrophobicity of these
residues within the a-syn protein sequence as key factors contributing to its aggregation
propensity [191]. Crystals formed of amino acid residues Glycine 68 to Alanine 78 in the
NAC region were used for structure determination by micro-electron diffraction,
revealing protofibrils built of pairs of face-to-face b-sheets, a pattern very similar to
fibrils of full-length a-syn [192], known to contain parallel-in-register b-sheets and
hydrophobic core residues [193]. The hydrophobic NAC region comprises the highly-
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ordered core of a-syn fibrils, and while the N and C termini are unfolded and proteinase
K sensitive in the fibrillar state, the NAC domain imparts its proteinase K resistance to
the larger fibrils [177, 194]. In vitro studies of a-syn aggregation are made possible
through the propensity of the a-syn protein to form filaments resembling those isolated
from diseased brain [195], as well as by amyloidogenic dyes such as Thioflavin T (ThT) or
K114 that allow quantitative monitoring of a-syn fibril formation through their amyloidsensing fluorescence [196]. These studies have resulted in molecular insights that have
informed research efforts to better model the stages of the aggregation process from
monomer to LB inclusion.
Following the first step in the aggregation process, the conversion of the native
unfolded a-syn monomer to an aggregation-competent form [183], the next step
involves the misfolded monomer serving as a nucleus and template for the further
misfolding of additional soluble a-syn counterparts that become recruited to the seed
nucleus [197, 198] (Figure 4). This nucleation-dependent growth is known to follow firstorder kinetics with respect to a-syn concentration and to occur via a stop-and-go
mechanism, either extending at a homogenous rate or stopping for variable intervals
[197, 199]. When pre-formed seeds of fibrillar a-syn are exogenously introduced into
cultured neuronal cells, these seeds are taken up into target cells by adsorptivemediated endocytosis and trigger intracellular a-syn aggregation by recruiting
expressed a-syn into insoluble, hyperphosphorylated, and ubiquitinated inclusions that
resemble LBs and LNs in PD [200-204]. These findings demonstrate that once the
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internalized misfolded a-syn pre-formed fibril encounters the cytosolic expressed a-syn,
it serves as a template for the conversion of native a-syn into its same misfolded
conformation, an event which triggers fibril growth and eventual inclusion formation.
Furthermore, this seeding process eliminates the lag phase of aggregate growth
dependent on the slow, energetically-unfavorable conversion of native to aggregationcompetent a-syn monomer, and dramatically accelerates fibril formation [197, 205].
Amyloid self-replication through this seeding process has been shown to be tightly
dependent on the molecular sequence compatibility between the fibrillar seed and the
native protein, such that cross-seeded aggregation between human and mouse a-syn is
bi-directionally restricted [206]. In a direct analogy to prion infectivity, seeding of the
misfolded a-syn conformation by exogenous a-syn aggregates is the basis for
amplification and transmission of a-syn misfolding.
As the initial misfolded a-syn monomeric seed nucleus grows by recruiting
additional soluble a-syn monomers, the growing aggregate is now considered an
oligomer, a term encompassing a wide variety of a-syn aggregates but defined simply by
a composition of multiple a-syn monomers, as few as two or as many as a hundred or
more [205, 207]. Oligomers exhibit an intermediate b-sheet content between that of
monomers and fibrils, and may initially be somewhat disordered structures that
undergo slow conversion to more compact proteinase-K resistant oligomers [207-209].
Oligomers can then undergo another conversion to more mature fibrils that can
elongate by further monomeric addition, indicating that oligomers represent a

continuum of species ranging from unstable low molecular weight particles to stable
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elongated oligomers to mature fibrils [209, 210] (Figure 4). The prion-like capacity of asyn aggregates to seed further a-syn misfolding can occur at any stage along this
continuum, with aggregation-competent monomers, various forms of oligomers, and
fibrils all demonstrating seeding activity, albeit to varying degrees. The a-syn fibrillar
conformation is regarded as most effective for seeding, and if larger amyloid-like fibrils
are fragmented into smaller components of 50 nm or less that maintain the b-sheet-rich
composition characteristic of fibrillar architecture, these short, fragmented fibrils most
efficiently promote cellular accumulation of pS129 a-syn and represent the key
pathogenic seeds that trigger a-syn misfolding [209-211]. Certain forms of larger stable
a-syn oligomers also possess seeding capacity, although to a lesser degree than a-syn
fibrils, whereas smaller more disordered unstable oligomers are unable to induce
seeding and may instead inhibit fibril formation because their “off-pathway”
conformation does not lead to fibril formation [208, 210]. In some circumstances, larger
a-syn fibrils may fragment into multiple smaller fibrillar or stable-oligomeric
components that can each serve as independent seeds, representing a mechanism for
the amplification of misfolding [207] (Figure 4). While it seems feasible that even a
single misfolded a-syn seed is capable of nucleation-dependent growth and
amplification through fragmentation and propagation resulting in an overall
acceleration of aggregation and genesis of a-syn-induced neurodegenerative pathology,
other unknown factors may influence this process such that a sufficiently high amount
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of a-syn misfolding must occur for pathology to ensue. Indeed, one study found that a
very high number of oligomeric or fibrillar seeds, on the order of 104, was required for
efficient seeding that bypasses the slow rate of aggregation through spontaneous
primary nucleation [209]. Because much lower numbers of a-syn seeds also generate
cellular dyshomeostasis by increasing reactive oxygen species (ROS), other factors such
as cellular stress may be required to synergize with seed concentration to achieve
sufficiently potent a-syn seeding [209]. The templated seeding ability of misfolded asyn aggregates plays an essential role in disease pathology, as numerous animal models
in mice, rats, and monkeys have demonstrated that the introduction of exogenous
aggregated a-syn triggers the conversion and misfolding of endogenous a-syn to an
aggregated form identical to the exogenous seed, propagating and accelerating a-syn
protein misfolding pathology [212-219].
Regulating factors. Genetic variants. A major breakthrough in the understanding
of PD pathogenesis came with the identification of missense mutations in the a-syn
protein that cause autosomal-dominant, early-onset familial PD. These mutations
include A53T [220], A30P [221], E46K [222], and the more recently identified G51D
[223], H50Q [224], A18T [225], A29S [225], and A53E [226]. These mutations clearly
demonstrate, through their recapitulation of the a-syn LB pathology and PD motor
syndrome characteristic of idiopathic PD, that a-syn misfolding induced by missense
mutations cause PD. Furthermore, when A53T was identified as the first of what would
eventually become the aforementioned several known a-syn missense mutations, a-syn

was soon after identified as the main component of LBs, firmly establishing the a-syn
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protein as central to PD pathogenesis. Additionally, increasing the baseline level of asyn expression through SNCA gene locus triplication or duplication also causes PD,
exhibiting a clear a-syn dose-dependence for age of onset and disease progression, with
triplication patients developing a rapidly-progressive PD much earlier than the slowlyprogressing, late onset of PD in duplication patients [227, 228]. Importantly, the
presence of a-syn-rich LB inclusions in these patients indicates that increasing the
expression level of a-syn promotes its pathological aggregation. Despite the causal
relationship between a-syn mutation or multiplication and inherited PD, only 10-15% of
PD cases have a familial cause, whereas 85-90% of cases are idiopathic, exhibiting
inclusions of WT a-syn expressed at a normal level [229, 230]. The link between a-syn
and idiopathic PD came with genome-wide association studies (GWAS) that recognized
single nucleotide polymorphisms (SNPs) in the SNCA gene or its promoter or enhancer
elements that increase risk for PD [231-234], firmly establishing the role of a-syn
pathology in all cases of PD, not just rare familial forms.
Because all familial missense mutations in the a-syn protein occur within the Nterminal amphipathic a-helical domain responsible for lipid binding (Figure 3), much
effort has been made to understand the effects of these mutations on the membrane
binding of monomeric and fibrillar a-syn as well as to establish a link between these
missense substitution mutations and alterations in native protein function and/or
pathological aggregation. Despite early reports that the A30P and A53T point mutations

had little or no effect on lipid binding or a-helicity [235, 236], later findings agree that
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the A30P mutant exhibits defective binding to phospholipid membranes perhaps
because of a perturbation in the helical structural around the site of the mutation [237240]. A30P was shown to interrupt a helix turn, destabilizing the preceding one as well
as shifting the helix register after the mutation disturbing the proper amphipathic
sequence of polar and hydrophobic residues for at least two turns [239]. The A53T and
E46K mutations, by contrast, exhibit stronger interactions with lipids because of
stabilizing hydrogen bonds that form between these protein variants and the lipid
bilayer [238, 240, 241]. Finally, the recently described G51D and A53E mutations have
been shown to exhibit decreased lipid binding affinity compared to WT, behaving
similarly to the A30P mutation [242, 243]. Interestingly, the weakly-membrane binding
A30P and G51D mutants were shown to populate an exposed membrane-bound form
where the NAC domain is dissociated from the bilayer more than in the WT form,
resulting in a greater membrane-induced aggregation propensity [244]. a-syn missense
mutations clearly alter membrane affinity, and may be relevant for promoting
pathological instead of native conformations and increasing susceptibility to
aggregation.
Studies of the effects of a-syn mutations on aggregation behavior paralleled
investigation of WT a-syn aggregation, as the discovery of the first known mutation,
A53T, was the first to implicate a-syn as the aggregation-prone pathogenic protein in
PD. Early studies of the in vitro aggregation behavior of WT and mutant a-syn

demonstrated their shared ability to abandon a natively disordered state to self-
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aggregate and assemble into insoluble filaments that resembled those in LB inclusions,
and suggested that both A53T and A30P mutations accelerated this aggregation process
[245-247]. Later findings then clarified the nuanced influence of these mutations on the
various stages of the aggregation process; both A30P and A53T share the ability to
accelerate oligomerization by consuming their component monomers faster than WT
monomers, but this translates into an acceleration of fibrillization only for A53T,
whereas A30P was shown to ultimately fibrillize more slowly than WT a-syn [248]. The
observation that A53T a-syn accelerates oligomerization and fibrillization correlates
with the increased severity of disease experienced by transgenic mice expressing A53T
compared to WT a-syn, where A53T mice developed age-dependent filamentous
intracytoplasmic neuronal a-syn inclusions, motor impairment, paralysis, and death
[249]. The E46K mutation increases the rate of a-syn assembly to a similar extent as the
A53T mutation [241], and because the artificial E46A, E83K, and E83A mutations exhibit
a similar acceleration, glutamic acid residues residing within N-terminal KTKEGV repeats
critical for amphipathic a-helical structure significantly modulate a-syn fibrillar
assembly [250]. Additionally, E46K fibrils seeded aggregation more efficiently than WT
fibrils, whereas A30P fibrils were less efficient seeds for aggregation [251]. The G51D
and A53E mutations are known to attenuate a-syn aggregation relative to WT [223, 242,
243, 252, 253], whereas the H50Q mutation accelerates aggregation [252, 254, 255].
While these studies provide key insights into the pathogenic effects of these PD-causing

mutations, they are also limited in their comparative value because of variability in
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approach. Several recent studies have sought to systematically compare the effects of
each disease-causing mutation within the same experimental system, either in vitro,
with cell-free protein expression, or within living cells. These studies have concluded
that a-syn missense mutation does indeed significantly impact on seeding capacity,
oligomerization, fibrillization, and inclusion formation, and they reveal molecular
insights into the initiation and spreading of a-syn aggregation [256-258].
Serine 129 phosphorylation. a-syn undergoes multiple PTMs such as
phosphorylation, ubiquitination, sumoylation, acetylation, nitration, and truncation, but
S129 phosphorylation represents the modification most preferentially and consistently
up-regulated in PD and other a-synucleinopathies [259, 260] (Figure 3). a-syn S129
phosphorylation was first identified as a constitutive modification in immortalized cell
lines [261], but the discovery that S129 phosphorylation affected 90% of insoluble a-syn
in LBs compared to only 5% of normal soluble a-syn raised the possibility that this
modification influences a-syn aggregation or toxicity [119-122]. Phosphorylation of asyn S129 not only occurs in brains of PD and MSA patients [119-122, 125, 262, 263], but
also in a-syn overexpressing mouse models of PD and MSA [262, 264] and in
dopaminergic neurons of the monkey SNpc with normal aging [265]. While insoluble
pS129 a-syn increases, the initially elevated levels of soluble a-syn decrease over the
course of PD [266], suggesting that a-syn phosphorylation level depends directly on the
amount of substrate available, where high initial levels of soluble a-syn enhance S129

phosphorylation and consume soluble a-syn into insoluble inclusions [265, 267]. It
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remains unclear, however, if S129 phosphorylation is a cause or a consequence of this
transition from soluble to insoluble a-syn. The existence of a low level of normal soluble
a-syn phosphorylated at S129 suggests that this LB-associated form is produced during
normal metabolism of a-syn and may promote aggregation and inclusion formation
[121, 122]. However, a-syn could also be phosphorylated after fibrillization or inclusion
formation [122, 268-270] as a mechanism to identify and promote the clearance of
misfolded proteins [271], a possibility supported by the buildup of pS129 a-syn
following proteasome inhibition and elevated autophagic or proteasomal degradation of
a-syn induced by overexpressing specific kinases such as polo-like kinase 2 (PLK2) or Gprotein-coupled receptor kinase 5 (GRK5) [272-274]. Investigation into the identities of
the responsible kinases as well as studies of the influence of S129 phosphorylation on asyn membrane binding, aggregation, and toxicity have worked toward a higher level of
clarity regarding these two opposing possibilities.
When pS129 was first identified as an a-syn PTM, it was noted that this site is
located within a consensus recognition sequence of casein kinase 1 (CK1) [261], and it
was later found that casein kinase 2 (CK2) could also be responsible for S129
phosphorylation that increased under oxidative or proteasomal stress [275].
Additionally, G-protein-coupled receptor kinase 2 and 5 (GRK2, GRK5) preferentially
phosphorylate a-syn at S129 [137, 276, 277]. Finally, members of the polo-like kinase
(PLK) family such as PLK1, PLK2, and PLK3 are also capable of a-syn S129

phosphorylation, and unlike other kinases that only partially phosphorylate a-syn at
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S129, these PLK family members induce complete phosphorylation [268, 278]. Studies of
PLK2 have found an increased expression within neurons of older monkeys and in asynucleinopathy patient brains, perhaps contributing to the increase in pS129 a-syn
[265, 273]. While several responsible kinases have been identified, the overall effects of
their action remain to be determined.
One tool to examine the specific consequences of S129 phosphorylation on asyn behavior has been in vitro biochemical assays. In vitro studies of membrane binding
suggest that the pS129 modification of WT a-syn does not perturb a-syn membrane
affinity [270, 272, 279, 280], but S129 phosphorylation can increase membrane affinity
of the normally weakly-binding A30P a-syn and decrease the normal binding affinity of
A53T a-syn [272, 280]. These results implicate long-range interactions between pS129 in
the unstructured a-syn C-terminal tail with the membrane binding ability of the Nterminal amphipathic a-helix and the familial mutations that are be present there in
affected patients [236, 280]. In vitro study of the influence of pS129 on a-syn
aggregation has yielded inconsistent results, with some studies demonstrating increased
aggregation [119, 280], others showing decreased aggregation [279], and still others
showing no effect with S129 phosphorylation [281]. These inconclusive results are
mirrored by similarly varied findings when pS129 levels are modulated in cells or
animals by expression of kinases capable of performing S129 phosphorylation. Some
findings using this strategy to upregulate pS129 a-syn demonstrate an increase in

aggregation and inclusion formation [277, 282-284] while others demonstrate a
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decrease or no effect [136, 137, 279, 285]. Finally, utilization of artificial mutants to
mimic (S129D, S129E) or prevent (S129A) phosphorylation at the S129 position generally
revealed that mimicking pS129 decreases membrane affinity while preventing S129
phosphorylation has the opposite effect, indicating that pS129 may decrease membrane
binding [286-288]. These findings are inconsistent with those obtained by in vitro
methods perhaps because of the limited ability of amino acid substitutions to truly
mimic the effects of phosphorylation or its inhibition on a-syn behavior [279].
Furthermore, phosphorylation mimic or null mutants had a differential effect on a-syn
aggregation propensity. Some studies demonstrated that preventing S129
phosphorylation with S129A expression rescues neuronal loss caused by WT a-syn that
is capable of being phosphorylated, whereas S129D a-syn increases pathology [137,
282]. Other studies had the opposite finding, where S129A a-syn caused severe
pathology that was absent or prevented with S129D a-syn expression, and still other
studies found no difference in pathology between S129A or S129D a-syn expressing
systems [281, 289]. These various approaches to study the consequences of S129
phosphorylation are each limited in their own way; biochemical approaches omit
important cellular factors that impinge on phosphorylation and aggregation processes,
and model systems that rely on kinase or a-syn overexpression may be confounded by
potential off-target effects. Nevertheless, dissecting the influence of this highly
prevalent S129 phosphorylation PTM remains a high priority for its potential therapeutic

implications to intervene on a process that directly modulates a-syn aggregation and
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toxicity.
Solution conditions. Several factors in the cytosolic milieu of dopaminergic
neurons in the SNpc also influence the tendency of a-syn to form insoluble fibrils and
inclusions. One factor present in cells of this region is DA itself, the synthesis of which is
required for nigrostriatal signal transduction. DA synthesis is known to be highly
oxidative in nature, and upon its oxidative ligation to a-syn, DA inhibits conversion of asyn protofibrils to fibrils resulting in accumulation of protofibrillar species [290]. DA, LDOPA, other catecholamines, and their respective oxidative breakdown products have
been shown to inhibit in vitro a-syn fibrillization or dissolve a-syn fibrils already formed
by creating an environment where formation of non-amyloidogenic protofibrils or
oligomers is favored over fibril formation [291-294]. In cellular models of a-syn
aggregation, increasing DA levels has a similar effect as observed in vitro, inhibiting
aggregate formation and instead promoting formation of non-toxic oligomeric
intermediates [294, 295]. These results implicate decreased DA levels in SNpc neurons
as a factor promoting a-syn aggregation in PD, which could then result in a positive
feedback loop of a-syn-induced dopaminergic degeneration and additional a-syn
aggregation [292]. Moreover, the lysosomal protease cathepsin B (CatB) triggers
intracellular a-syn aggregate formation [296], as do cellular stressors such as oxidation
or cytochrome-c released from mitochondria [297, 298]; these factors would all be
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increased with a-syn-mediated cellular toxicity, and would feed into the same positive
feedback loop promoting a-syn aggregation.
Finally, the morphology of a-syn and the aggregates formed are highly sensitive
to solution conditions such as ionic strength and pH [299, 300]. At mildly acidic pH such
as would be encountered in the environment of endosomes or lysosomes, the rate of
secondary nucleation processes such as fragmentation and surface-assisted nucleation
is dramatically faster than at physiological pH, leading to an increase in both aggregate
size as well as total number [301]. a-syn remains unfolded at neutral pH, but acidic pH is
associated with rigidification and compaction of the highly hydrophobic and negativelycharged C-terminal region leading to its increased interaction with the NAC domain
rather than long-range contacts with the N-terminus [302]. These conformational
changes may underlie an increased propensity to become misfolded or a stabilization of
a-syn oligomeric intermediates and a concomitant decreased energetic barrier to
fibrillization [303]. While the process of a-syn aggregation is a multifactorial equation,
factors such as genetic variants in protein sequence or expression, PTMs such as S129
phosphorylation, and solutions conditions represent some of the most important
influences.
Strains. Just as prions exhibit the structural heterogeneity to fold into multiple
self-replicating strains that produce distinct disease phenotypes [52], a-syn has also
been shown to adopt distinct strain conformations, perhaps underlying the phenotypic
diversity of a-synucleinopathies caused by aggregates of a single protein [304]. The
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strain phenomenon for a-syn was first elucidated by Ronald Melki and colleagues, who
demonstrated that two distinct conformations of a-syn fulfilled the molecular criteria to
be designated as different strains by exhibiting differences in structure, level of toxicity,
and in vitro and in vivo seeding and propagation properties [305] (Figure 4).
Subsequently, these two strains, named a-syn fibrils and ribbons for their different
conformational architectures, were shown to induce distinct histopathological and
behavioral phenotypes when injected into rat brain [218]. Both a-syn strains faithfully
seeded aggregation and templated their unique conformations onto expressed a-syn to
amplify in vivo, but a-syn fibrils exhibited a higher level of toxicity with accompanying
progressive motor impairment and cell death compared to a-syn ribbons, which caused
a different phenotype with characteristics resembling both PD and MSA [218]. Multiple
different a-syn strains, or polymorphs, have been produced in vitro by varying solution
conditions during aggregation, and they have been rigorously characterized by solidstate nuclear magnetic resonance (NMR) spectroscopy and atomic-force microscopy
(AFM) to differ by morphology and physical properties [306-310]. The existence of
different a-syn strains was confirmed in other studies by demonstrating differences in
cross-seeding efficiency between different a-syn strains and tau protein [311], by
detecting differences in biochemical properties between in vitro-prepared a-syn strains
and a-syn extracted from PD brain [311], and by transmitting a distinct a-syn pathology
from MSA brain samples to a-syn overexpressing mice different from that induced by
injection of PD brain samples or brain homogenate from diseased mice [312-314]. The
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conditions under which a-syn aggregates are formed can therefore significantly impact
the conformation of the resulting fibrils and the pathological phenotype they induce.
Additionally, the presence of the bacterial endotoxin lipopolysaccharide (LPS) during the
a-syn aggregation process produces a structurally distinct fibril strain that causes a
unique pattern of a-synucleinopathy, raising the possibility that exposure to exogenous
pathogens may also influence the aggregation process and contribute to the diversity of
disease phenotype [315]. Finally, a-syn S129 phosphorylation also induces formation of
a distinct a-syn strain with a different structure, propagation pattern, and higher
cytotoxicity compared to WT a-syn, indicating that this highly prevalent PTM enriched in
LB inclusions strongly influences strain conformation and increases aggregate toxicity
[316]. Overall, the concept that a-syn aggregates can adopt unique strain conformations
has only recently become apparent, but it has an incredible potential to explain the
wide variety of disease phenotypes experienced with a-synucleinopathies and may
underlie unique aspects of a-syn pathological behavior.
Degradation and Disease-Induced Dysfunction.
Maintaining homeostasis in cells burdened by misfolded protein aggregates is
the role of degradative processes tasked with both the clearance of aberrant proteins
and the recycling of their individual amino acid constituents. Both the ubiquitinproteosome system (UPS) and the autophagy-lysosome pathway (ALP) are involved in
the degradation of misfolded a-syn, although the work of degrading higher-molecular
weight aggregates of a-syn is mainly performed by the ALP, the only known mechanism
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in eukaryotic cells to degrade protein aggregates or damaged organelles that cannot be
processed by the proteasome [317]. Autophagy, which means “self-eating” in Greek,
was originally viewed as only active in response to nutrient deprivation, but more
recently has been appreciated as playing a key constitutive role in promoting neuronal
survival through its basal level of activity [318]. Consequently, dysfunction in this
process can also contribute to neurodegeneration [319, 320]. Since the discovery that asyn is contained within autophagosomes [321], the double-membrane structures that
engulf cytoplasmic contents and eventually fuse with lysosomes to degrade the cargo,
investigation of this process has elucidated the circular mechanisms of autophagymediated a-syn degradation and a-syn-induced autophagic dysfunction, and focused on
promoting degradation through the ALP as a possible therapeutic approach for PD.
Within the ALP, there are three autophagic pathways through which substrates
destined for degradation can be processed. The first type of autophagy is known as
microautophagy, where substrates are directly taken up into lysosomes via invagination
of the lysosomal membrane and promptly degraded by proteolytic enzymes, although
this form of autophagic degradation has not been demonstrated for a-syn [317, 318].
The second form of autophagic degradation, chaperone-mediated autophagy (CMA), is
known to be important for a-syn degradation [322, 323]. CMA substrates such as a-syn
are first bound at the consensus KFERQ motif by the chaperone heat shock cognate 71
kD protein (HSC70) which induces the unfolding of the target [317]. Substrates then
bind the CMA receptor lysosomal-associated membrane protein type 2A (LAMP2A) at

the lysosomal membrane which induces membrane translocation and subsequent
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proteolytic digestion of the target [324]. Despite the importance of CMA for degradation
of misfolded a-syn monomers and dimers, it is not capable of degrading a-syn
oligomers or higher molecular weight aggregates because of the requirement to
translocate across the lysosomal membrane [324, 325]. Thus, it is the role of the third
form of autophagic degradation, macroautophagy, to degrade larger a-syn aggregates
that accumulate in diseased neuronal cells, and because this process is the most wellcharacterized of the three forms of autophagy and most important for bulk degradation
of dysfunctional organelles or misfolded protein aggregates, the use of the general term
“autophagy” most often refers to this process of macroautophagy, a convention that
will also be used here in the discussion that follows.
Autophagy involves the engulfment of cytoplasmic cargo by a double-membrane
phagophore, further expansion into an autophagosome, and fusion with a lysosome to
become an autophagolysosome where the cargo is degraded by proteolytic enzymes
active in this low pH compartment [317]. This process plays an essential role in
degrading protein complexes like oligomers and aggregates that fail to pass through the
proteasome barrel or translocate through the lysosomal membrane in CMA [326]. When
the UPS is inhibited, low pH compartments containing cathepsin D (CatD) are increased,
representing a compensatory increase in autolysosomes and lysosomes that degrade
misfolded a-syn [327]. Inhibiting autophagic or lysosomal degradation results in an
increase in large cytoplasmic a-syn inclusions, whereas activation of autophagy causes

dissolution of these inclusions and increases the number of smaller a-syn aggregates
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[327]. Autophagic components are known to be significantly increased in the brains of
DLB patients and transgenic mice overexpressing mutant a-syn, indicating that
autophagy is induced to facilitate clearance of a-syn aggregates [328]. Moreover,
overexpression of transcription factor EB (TFEB), a master regulator of the autophagylysosomal pathway, or Ras-related protein Rab7 (Rab7), a regulator of endosomal and
autophagosomal trafficking, reduced accumulation of aggregated a-syn by inducing its
autophagic clearance, further supporting a role for this pathway in degradation of a-syn
[329, 330]. PLK2 and PLK3, kinases involved in phosphorylation of a-syn S129, enhance
a-syn autophagic degradation by forming a complex with pS129 a-syn and acting as a
target for polyubiquitination, allowing the selective recognition of the complex by the
autophagic machinery [273, 331]. Additionally, phosphorylation of S129 is implicated in
targeting a-syn for autophagic degradation because cellular expression of the S129A
mutant failed to cause the induction of autophagy seen with expression of WT a-syn
[271]. Once the a-syn cargo encounters the environment of the lysosome, the actions of
proteolytic enzymes such as CatD have been shown to be effective in degrading a-syn
[332, 333], although mature fibrillar a-syn inclusion bodies have been shown to be
refractory to lysosomal or autophagic clearance [134, 334]. Lysosomal clearance of asyn has been demonstrated in vivo by the detection of a-syn within the lumen of
lysosomes isolated from mouse midbrain, colocalization in nigral tissue of a-syn with
LAMP2A staining, and elevation of LAMP2A expression in a-syn overexpressing mice

[335]. These findings implicate the ALP as a key mediator of a-syn degradation and a
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first-line strategy for maintaining cellular homeostasis in the face of increased protein
aggregation.
Given the importance of the ALP for degradation of a-syn aggregates, one of the
most challenging aspects of PD pathology is the circular positive-feedback effect of asyn aggregates inducing dysfunction in ALP degradation processes. This a-syn-induced
dysfunction occurs in both CMA and macroautophagy. In the CMA pathway, a-syn
familial mutants A53T and A30P as well as DA-modified a-syn are known to bind the
LAMP2A receptor on lysosomal membranes with increased affinity compared to WT asyn and act as uptake blockers, impairing their own degradation as well as that of other
autophagic substrates [322, 325, 336]. CMA inhibition by a-syn is known to produce a
compensatory increase in macroautophagy, but this autophagic mechanism is also
dysfunctional because of a-syn aggregation. Nigral dopaminergic neurons of PD patients
have been shown to undergo both apoptosis and autophagic degeneration,
characterized by an increased number of autophagic vacuoles found in diseased
neurons [337], and the level of LC3 is known to be elevated in insoluble fractions from
brains of patients with DLB [132]. This abnormal accumulation of autophagosomes and
increase in LC3 is also seen in cell culture models of PD [338, 339], indicating a
combination of both upregulation due to increased burden of misfolded proteins and
persistence due to dysfunctional clearance. While an increased abundance of
autophagosomes may represent ongoing cellular attempts to combat accumulation of

misfolded proteins, a more detailed examination reveals that these accumulating
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autophagosomes are abnormal and dysfunctional [131, 339]. In cell culture models and
in brains of a-syn transgenic mice and DLB patients, the accumulating autophagosomes
are significantly enlarged compared to normal autophagosomes and irregular in
appearance, some of which only having a single membrane rather than the
characteristic double-membrane structure [131, 134, 339].
There are several mechanisms whereby accumulation of a-syn induces
dysfunction in autophagy. One cause of compromised autophagy is the inhibition by asyn of Rab1a, which then causes mislocalization of autophagy-related protein (Atg) 9, a
key regulator of membrane transport to the degradation site, preventing proper
autophagosome formation [340]. Another reason for the accumulation of
autophagosomes unable to degrade their cargo is the permeabilization of lysosomal
membranes by mitochondrial-derived ROS, induced by parkinsonian neurotoxin 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or a-syn, and the subsequent
release of lysosomal proteases into the cytosol [130]. This lysosomal depletion results in
defective clearance of autophagosomes since fusion with lysosomes for final
degradation is impaired. Additionally, excessive a-syn in nigral dopaminergic neurons is
associated with cytoplasmic retention of TFEB by sequestration into LBs, resulting in an
inability of this key transcriptional regulator of the ALP to translocate into the nuclear
compartment [341]. Finally, a-syn aggregates are known to activate Toll-like receptor 2
(TLR2) [342], and TLR2 activation in neurons results in inhibition of autophagy through
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activation of AKT and mammalian target of rapamycin (mTOR) [343]. Thus, an additional
positive-feedback loop exists whereby activation of TLR2 by a-syn aggregates impairs
autophagy and results in accumulation of additional a-syn aggregates. In addition to
impairing autophagy, a-syn aggregation induces dysfunction in lysosomal degradation
as well. In a similar situation to that of autophagosomes, lysosomes are abundant in
cells exhibiting a-syn aggregation as a compensatory effort to degrade the burden of
misfolded proteins [344, 345], but these lysosomes are dysfunctional as evidenced by
decreases in lysosome-associated membrane protein 1 (LAMP1) and CatD in human and
rat nigral neurons containing a-syn inclusions [346]. These several mechanisms by which
a-syn impairs the ALP illustrate the difficulty in maintaining proteostasis when the
buildup of protein aggregates directly contributes to dysfunction in the autophagic and
lysosomal degradative machinery.
While a-syn aggregation clearly induces ALP dysfunction, and one result of this
dysfunction is a further accumulation of a-syn aggregates [323, 328, 334, 347-349],
additional insight into functional and dysfunctional a-syn degradation can be gained by
examining genetic diseases that exhibit impairments in degradative processes.
Homozygous loss-of-function mutations in the GBA1 gene encoding the lysosomal
hydrolase b-glucocerebrosidase (GCase) cause Gaucher’s disease, the most common
lysosomal storage disorder, characterized by a toxic buildup of the GCase substrate
glucosylceramide (GlcCer) [350, 351]. Interestingly, mutations in GBA1 are also
considered the most common genetic risk factor for PD, such that PD patients are more

than 5 times more likely to carry a GBA1 mutation than normal healthy controls [350,
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352]. The association between a-synucleinopathy and GBA1 mutation status is even
more pronounced for DLB, where DLB patients are more than 8 times more likely than
controls to carry a GBA1 mutation [353]. GBA mutation-associated PD and DLB patients
have an earlier age of disease onset than non-carriers, are more likely to have affected
relatives, and exhibit a more rapid progression of motor impairment and cognitive
decline [352-354]. GCase enzymatic activity was lower in Gaucher’s patients with a
homozygous GBA1 mutation than in carriers with only a heterozygous mutation,
although the heterozygous mutant GBA1 patients exhibited a lower GCase activity than
non-carriers [355]. When all PD patients were compared with controls, GCase activity
was diminished in diseased patients even in idiopathic PD, when GBA mutants were
excluded, and after adjusting for age and gender, suggesting that both GBA mutation
carriers and PD patients without GBA mutations exhibit loss of GCase function, and that
this diminished lysosomal degradative activity may contribute to PD pathogenesis [355].
The molecular explanation for this unexpected link between PD and Gaucher’s
disease was established when it was discovered that loss of GCase function results in
compromised lysosomal degradation and a consequential accumulation of a-syn [356,
357]. Moreover, the GCase substrate GlcCer also accumulates, and can stabilize a-syn
oligomers to promote amyloid formation [356]. Finally, the accumulating a-syn inhibits
the activity of normal GCase, forming a positive feedback loop of compromised
lysosomal degradation, accumulation of a-syn and GlcCer, and further degradative

impairment which leads to a progressive neurotoxicity in both GBA1 mutation carriers
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and idiopathic PD patients [356]. Recently, the disruptive influence of a-syn
accumulation in sporadic PD was more completely understood with the observation that
a-syn disrupts the proper trafficking of multiple lysosomal hydrolases by interfering with
the normal association between GM130 and Rab1a and inhibiting their cis-Golgi
tethering activity, critically impairing Golgi structure and vesicular trafficking [358].
Consistent with the view that a-syn aggregation impairs GCase and overall lysosomal
degradative capacity, reductions in GCase expression and activity are seen in brain
tissue of idiopathic PD patients just as in that of GBA1-mutation carrying PD patients
[359-361], and GCase depletion often occurs in brain regions burdened by increased asyn levels [360]. Other regulatory factors may certainly impinge on the bidirectional
interplay between a-syn and GCase, as decreases in GCase mRNA have been
documented in SN of PD and DLB patients [361] and GCase activity gradually diminishes
with age in the SN and putamen of healthy controls to a level comparable with that of
GBA1-mutation carrier PD patients [362]. Impaired GCase results in increased GlcCer
and asyn, perturbations in autophagic degradation, and dysfunctional and enlarged
lysosomes in affected neurons [360, 363-366]. While additional factors, perhaps
dependent on age, may influence GCase activity and alter the threshold for disease
initiation, a-syn aggregation has been firmly established as a primary cause of
decreased GCase activity, initiating a positive-feedback cycle of degeneration central to
PD pathogenesis.
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Other genetic diseases that exhibit a relationship with a-syn through impairment
of degradative processes include Kufor-Rakeb syndrome (KRS) and neuronal ceroidlipofuscinosis (NCL). KRS is an autosomal recessive form of early-onset familial
parkinsonism with pyramidal degeneration and dementia caused by homozygous lossof-function mutations in a late-endosomal and lysosomal transmembrane P-type ATPase
known as ATP13A2 [367-369]. Even single heterozygous mutations in ATP13A2 have
etiological relevance for young onset PD [368]. Decreased ATP13A2 function results in
impaired lysosomal acidification, reduced proteolytic processing of lysosomal enzymes
and degradation of substrates, diminished clearance of autophagosomes, and
accumulation of abnormal lysosomes [369, 370]. ATP13A2 has also been shown to be
decreased in dopaminergic nigral neurons from patients with PD, where it instead
accumulates within LBs, implicating ATP13A2-mediated lysosomal dysfunction in
settings other than just its genetic mutation [370]. In vitro studies have demonstrated
that loss of ATP13A2 function leads to accumulation of a-syn and a-syn-mediated
neurotoxicity through impairment of its degradation [371], but animal models with
deficient ATP13A2 observed defects in protein trafficking, accumulation of ubiquitinated
protein aggregates, and endolysosomal abnormalities occurring in the absence of a-syn
pathology, suggesting an additional contribution by a-syn-independent mechanisms to
endolysosomal dysfunction and neurotoxicity [372]. NCL is a lysosomal storage disorder
characterized by early onset, progressive neurodegeneration with gliosis and
autofluorescent deposits of lipofuscin known to be caused by homozygous deficiency of
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CTSD, the gene encoding the lysosomal protease CatD [372, 373]. CatD is instrumental
for the degradation of a-syn in the lysosome, and thus expectedly its pharmacological
inhibition, introduction of a catalytically inactive mutant form, or loss-of-function
genetic mutation result in a-syn misprocessing and accumulation [333, 373, 374].
Although complete loss of CatD elicits the most profound inhibition of lysosomal
function, heterozygous mutations that result in a partial loss of CatD still reduce
lysosomal activity and cause accumulation of intracellular a-syn aggregates [373]. In
addition to highlighting the key role of the ALP in degradation of a-syn, these studies
demonstrate that slight perturbations in lysosomal acidification or a partial loss of CatD
activity, occurring even in the absence of ATP13A2 or CTSD mutations, may be sufficient
to cause a reduction in lysosomal function and result in a-syn aggregation in PD. This,
coupled with the dysfunction in degradative processes induced by a-syn aggregates,
results in a vicious cycle of protein aggregate accumulation and degradative dysfunction.
Given the dysfunction induced by a-syn in degradative processes, and the critical
role of these processes in clearance of a-syn aggregates, some therapeutic approaches
have sought to augment autophagic or lysosomal degradation as a strategy to
ameliorate a-syn induced dysfunction, reduce the burden of misfolded a-syn, and
prevent neurotoxicity. Expression of the autophagy related protein beclin 1 was shown
to activate autophagy and lysosomes, reduce accumulation of a-syn, and ameliorate
neuritic pathology caused by a-syn overexpression [339]. Likewise, overexpression of
the transcription factor TFEB, known to be aberrantly retained in the cytosol of PD

neurons, reverses the PD-linked decline in lysosome function and facilitates
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neuroprotection via clearance of a-syn aggregates [341]. Overexpression of LAMP2A
attenuates a-syn-induced dysfunction in CMA by upregulating this degradative process,
reducing both total and misfolded a-syn levels, and preventing a-syn-mediated
neurotoxicity [375]. Finally, boosting expression or activity of GCase in the lysosomal
compartment has been shown to ameliorate histopathological abnormalities such as
accumulation of GlcCer, ubiquitin, tau, and a-syn, and to reverse perturbations in
hydrolase trafficking and lysosomal dysfunction caused by the previously accumulating
a-syn [357, 376, 377]. Correcting the defects in a-syn degradation have the therapeutic
potential to break the cycle of protein aggregation and impaired degradation, and allow
both reversal and prevention of dysfunctional a-syn proteostasis.
Cytotoxicity.
Given all the pathologic events associated with a-syn aggregation, there are
many possibilities for how protein aggregation contributes to neuronal cell death in PD.
Aside from the accumulation of misfolded a-syn into LB inclusions, the histologic
hallmark of PD is dopaminergic neurodegeneration in the SNpc. Aggregates of a-syn, or
even just the NAC domain, induce apoptotic cell death in cultured neuronal cells [378],
and gene transfer of human a-syn to rat SN results in 50% loss of dopaminergic neurons
13 weeks after infection with the gene-carrying viral vector [379], although several
mechanisms have been proposed to explain this neuronal loss. One mechanism for
induction of cytotoxicity may relate to the physiologic role of a-syn in associating with
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pre-synaptic membranes, such that a-syn aggregation both sequesters functional forms
of a-syn into insoluble aggregates and further impairs the actions of other synaptic
proteins involved in membrane fusion events at synaptic terminals [176, 380]. While the
knockdown of a-syn and the resulting loss of its physiologic function has been shown to
be toxic for nigrostriatal dopaminergic neurons [175], a-syn overexpression and
aggregation results in decreased synaptic proteins involved in exocytosis and
endocytosis, enlarged synaptic vesicles, deficits in neurotransmitter release,
impairments in excitability and connectivity, and eventual neurotoxicity [202, 381]. One
reason for a-syn aggregates causing dysfunctional excitability and neurotransmitter
release may be due to sequestration of a subunit of the Na+/K+-ATPase within
membrane bound a-syn clusters, reducing local densities of this subunit and decreasing
efficiency of Na+ extrusion following stimulus [382]. Another mechanism whereby a-syn
aggregation results in neurotoxicity is its impairment of its own degradation. Not only
has a-syn been causally linked to impairments in the ALP which result in toxicity [336,
356, 383], Golgi fragmentation and subsequent toxic impairments in trafficking are
known to be a specific consequence of a-syn aggregation as well [129, 358]. Finally, asyn aggregation may cause neuronal dysfunction and toxicity by disrupting normal
axonal transport [384, 385], a key process for movement of signaling components and
degradative vesicles throughout the long, elaborate axonal network of dopaminergic
neurons. Axonal transport motor proteins such as kinesin and dynein are decreased in
brains of sporadic PD patients prior to the onset of dopaminergic neurodegeneration,

with significantly greater reductions observed in nigral neurons containing a-syn
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inclusions [386]. Kinesin motor proteins facilitate anterograde transport from the soma
to the presynaptic terminal while dynein motor proteins facilitate retrograde transport
in the opposite direction, from the terminals back to the soma. Animal models of PD
that overexpress A53T or A30P a-syn observe decreased kinesin levels and increased
dynein levels in the striatum, the site where nigrostriatal dopaminergic neurons
synapse, and increased kinesin levels in the SNpc where the cell bodies of nigrostriatal
neurons reside [386, 387]. These findings suggest that a-syn causes motor proteins to
be trapped at their respective origins, unable to bind to microtubule tracks to facilitate
axonal transport [384]. These effects may be due to direct actions of a-syn on
microtubules themselves, as a-syn pathology is known to begin in axons as LNs before
progressing to more mature LB pathology in the soma. a-syn is known to act in its
monomeric state as a microtubule-dynamase, binding tubulin and promoting
microtubule nucleation and enhancing growth rate and catastrophe frequency [172],
although this role may be perturbed when a-syn becomes misfolded into aggregates.
Indeed, tubulin levels are decreased in nigral neurons overexpressing a-syn [387], and
both a-syn fibrils and protofibrils inhibit microtubule assembly by binding to tau and
promoting its aggregation, depleting the tau available for microtubule polymerization
and inhibiting its microtubule stabilizing function [388]. The great variety of neurotoxic
insults brought on by a-syn aggregation underscores the importance of understanding
this complex process more fully.
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One of the most highly debated questions regarding a-syn-induced cytotoxicity
is whether smaller forms of a-syn aggregates represent the more toxic a-syn species, or
if instead the larger histopathologic hallmark a-syn inclusions induce the most cellular
toxicity. Although structured intermediates in the fibrillization spectrum from single
monomer to elongated fibril may be known by various names such as protofibrils or
oligomers, there are two key differences between the multitude of oligomeric forms
and larger a-syn inclusions; the first difference seems to be the overall size of the
assembly, with inclusions being many times larger than individual a-syn oligomers, and
the second difference is the likelihood of a-syn self-association or clustering, which is
necessary to generate a compact LB inclusion from multiple elongated a-syn fibrils.
While the subject of the most toxic a-syn species is still actively contested, smaller asyn oligomeric forms have emerged as likely candidates for pathological induction of cell
death [129, 389, 390]. Smaller a-syn oligomeric or fibrillar species have been shown to
directly induce cytotoxicity in a multitude of experimental settings [391-393]. In
contrast, a-syn forms that fibrillize to larger sizes more quickly are less toxic [393, 394],
consumption of excess soluble a-syn into fibrillar forms is neuroprotective [204], and
promoting elongation and clustering of fibrils may reduce fragmentation, seeding, and
the resulting toxicity [395]. These findings agree with the protective role of larger LB
inclusions containing fibrillar a-syn and suggest that smaller oligomeric or fibrillar a-syn
forms represent the most toxic aggregate species. While there are many possibilities for
mechanisms of neurotoxicity induced by the various forms of a-syn aggregates, and
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multiple mechanisms may independently or cooperatively contribute to PD, elucidating
new therapeutic targets within these impaired pathways will result in disease-modifying
treatments.
Cell-to-Cell Propagation
a-Synuclein.

Braak hypothesis. The foundation for investigating the prion-like cell-to-cell
transmission of a-syn was formed with the pioneering work of Heiko Braak, who
elucidated a neuroanatomical staging system of a-syn pathology in PD demonstrating
the topographical progression of pathologic a-syn from early to advanced cases of
idiopathic PD [396]. Braak noted specific disease induction sites, such as the dorsal
motor nucleus (DMN) of the glossopharyngeal and vagal nerves and the olfactory bulb
(OB), where LBs and LNs containing pathologic a-syn initially occur [397]. From lower
brainstem or olfactory regions initially affected, a-syn lesions then progress in a
topographically-predictable ascending fashion through six stages, progressively involving
olfactory, autonomic, limbic, and somatosensory brain regions with little variation
between affected individuals [397-399]. The early presence of a-syn inclusions in the
submucosal Meissner plexus of the gastrointestinal (GI) tract, whose axons reach within
the intestinal mucosa near mucosal glands, or in olfactory neurons, whose olfactory
receptors reside in the nasal epithelium, highlights the exposure of both neuronal cell
types to potentially hostile environmental factors, and formed the basis for what is now
known as the “Braak hypothesis”, that a-syn pathology in PD originates outside the CNS

prior to its stereotypic CNS expansion pattern [400-402]. While Braak’s original theory
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postulated the existence of a yet unidentified pathogen capable of crossing the GI
mucosal barrier, invading post- and pre-ganglionic enteric neurons, and eventually
entering the CNS by way of transneuronal and retrograde axonal transport through
visceromotor projections of the vagus nerve, such a pathogen has not been shown to
exist [400]. The Braak hypothesis has thus expanded to include the idea that exposure
to environmental factors may induce initial a-syn misfolding in the peripheral enteric or
olfactory neurons, and then set into motion the prion-like cell-to-cell propagation of asyn aggregates through seeded templating of further aggregation in the aforementioned
uninterrupted series of susceptible neurons extending from the periphery to the CNS
[401, 402]. While controversial, the Braak hypothesis has the potential to explain many
relevant aspects of PD pathology.
In agreement with Braak’s hypothesis and pathological staging system, LBs are
frequently observed in the GI tract, in paraspinal sympathetic ganglia, in the vagus
nerve, and in the spinal cord of PD and DLB patients [403-405]. GI tract immunostaining
for a-syn occurs prior to the onset of first motor PD symptom, and was not observed in
healthy control samples or in subjects with inflammatory bowel disease, suggesting that
a-syn histopathology is not a non-specific consequence of inflammation or oxidative
stress [406, 407]. Constipation and anosmia are both frequent complaints of PD patients
prior to the onset of classic motor symptoms [80, 85, 88], possibly reflecting an earlystage alteration in normal gut motility and olfaction induced by a-syn accumulation in
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enteric and olfactory neurons. If, as the Braak hypothesis postulates, exposure of enteric
neurons to environmental factors present in the GI tract can create conditions
promoting the initial misfolding of a-syn, the intestinal microbiome, with its diverse
ecosystem of trillions of microbes, represents one of the most prominent exposures and
has the potential to influence a multitude of immunologic and metabolic processes
relevant for the microenvironment of neurons in the GI tract. Analysis of intestinal
microbiomes by bacterial genome sequencing revealed that bacterial populations are
altered in PD patients compared to controls, with a significant reduction in
Prevotellaceae and an association between the abundance of Enterobacteriaceae and
the severity of postural instability and gait difficulty [408]. In addition to alterations in
microbiome bacterial populations, the presence of gut microbiota is required for motor
deficits, microglial activation, and a-syn pathology in mice overexpressing a-syn [409].
In this mouse model of PD, removal of gut microbes with antibiotic treatment or germfree conditions reduced microglial activation, a-syn inclusions, and motor deficits,
whereas gut re-colonization worsens neurological disease [409]. Recolonization with
microbiota derived from PD patients results in exacerbated motor symptoms compared
to recolonization with healthy control microbiota, indicating that microbiome dysbiosis
in the PD gut influences the development of a-syn pathology in the brain [409]. While
neuroinflammation has been implicated as playing a key role in gut-brain signaling and
the prion-like behavior of a-syn [410], identifying the specific microbiome alterations
that pose an increased risk for PD as well as elucidating the events, mediators, and

routes involved in signaling are tasks for future study. Despite the lack of clarity
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regarding the factors that initiate a-syn pathology in the gut and/or OB, the Braak
hypothesis of peripheral-to-central transmission of disease is nevertheless supported by
the finding that full truncal vagotomy is associated with a decreased risk for subsequent
PD [411]. This study and many others highlight the need for a deeper understanding of
the mechanisms underlying disease transmission.
Because of the theory that environmental insults contribute to pathological asyn misfolding in peripheral nervous tissue and trigger the prion-like invasion of
pathology into and throughout the CNS [412], various animal models have been
employed to demonstrate the feasibility of a-syn peripheral-to-central transmission.
Injection of a-syn-containing PD brain lysate or recombinant a-syn aggregates into the
intestinal wall leads to a-syn transport via the vagal nerve to the DMN in the brainstem
in a time-dependent manner [413]. Retrograde transport on axonal microtubules has
been implicated in this gut to brain translocation, both through the vagal nerve when asyn is injected into the gut and through the sciatic nerve when a-syn is injected
intramuscularly (IM) into the hind limb [413, 414]. a-syn aggregates are also capable of
invading the CNS via intraperitoneal (IP) injection or crossing the blood-brain barrier
following intravenous (IV) injection, although IM injection has been shown to be more
efficient in inducing CNS pathology compared to IP or IV injections [218, 415, 416].
Despite this experimental evidence for the feasibility of ascending disease from PNS to
CNS, another proposed theory, contrary to Braak’s hypothesis, instead postulates a

lower functional threshold for emergence of non-motor symptoms prior to classical
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motor symptoms, but that both CNS and PNS exhibit parallel degeneration [417]. Finally,
there is also evidence that a-syn pathology can propagate in the reverse direction to
that proposed by Braak, that upon its midbrain overexpression pathological a-syn can
reach the medulla, then the DMN of the vagus nerve, and finally utilize vagal projections
as a conduit for transmission to the GI tract [418]. Despite conflicting theories regarding
the origins of a-syn pathology, these studies illustrate the centrality of a-syn cell-to-cell
propagation in PD progression and underscore the importance of continued work to
understand this process more completely.
Clinical evidence of propagation. The first studies to uncover cell-to-cell
propagation of a-syn in the PD brain involved pathological examination of brain tissue
from PD patients who had received grafts of fetal dopaminergic neurons into the
striatum many years prior to death. Although grafted dopaminergic neurons remained
viable and exhibited extensive innervation of the host striatum more than a decade
following transplantation, long-term clinical benefit was not observed from this therapy
and grafted nigral neurons developed pathological LB inclusions containing a-syn and
ubiquitin (Figure 5C-E) identical to those observed in host brain (Figure 5A-B) [419, 420].
These matching findings from both the Kordower and Brundin groups were the first to
demonstrate that ongoing a-syn pathology can propagate from affected to naïve
neurons in PD brain [419, 420], although another report observing long-term
dopaminergic graft survival in the absence of infiltrative a-syn pathology suggests that
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Figure 5. Parkinson’s disease–like pathology in long-term nigral grafts.In the
nongrafted host’s nigra, typical a-synuclein (a) and ubiquitin (b) neuropathology was
observed (arrows). (c) Extensive a-synuclein pathology was seen in grafted neurons,
including cytoplasmic and aggregated a-synuclein (arrows) as well as a-synuclein
neurites. (d,e) Pathological aggregates of ubiquitin were also seen in grafted neurons
(arrows) and fibers (arrowheads). Scale bar, 40 mm. Reprinted by permission from
Macmillan Publishers Ltd: Nature Publishing Group, Nature Medicine, Volume 14, Issue
5, Jeffrey H Kordower, Yaping Chu, Robert A Hauser, Thomas B Freeman, C Warren
Olanow, Lewy body–like pathology in long-term embryonic nigral transplants in
Parkinson's disease (Reference 419), Copyright 2008. (License Number 4057251374706).
http://www.nature.com/nm/index.html.
a-syn transmission may not occur equally in all patients [421]. While most grafted
dopaminergic neurons remain unaffected by a-syn pathology, various studies have
reported the presence of a-syn-containing LBs in 2%-27% of grafted neurons, illustrating
varying degrees of propagation from host to graft [422-426]. LBs that form within

grafted neurons are indistinguishable from LBs in host brain, as both are composed of
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fibrillar pS129-a-syn and ubiquitin and exhibit positive staining for thioflavin-S [422,
423]. Furthermore, the distinct stages of LB development observed in host brain are also
present in grafted tissue, which contains both loose meshwork aggregates and classical
compact LBs [423]. When dopaminergic neurons are implanted into the striatum in a rat
model of PD, about 6% of grafted cells contain a-syn 5 weeks following a-syn
overexpression in a neighboring host brain region, indicating that a-syn host-to-graft
propagation is a possible mechanism to explain graft a-syn pathology and the observed
results in human grafts are not due solely to non-specific responses to possible
inflammation in the graft area [424]. Despite the positive observations that graft cells
exhibit long-term viability, provide DA re-innervation to a widespread area of the
striatum, and in some cases result in albeit temporary major motor improvement, the
lack of sustained clinical improvement following transplantation could reflect
progression of degenerative changes into grafted cells induced by infiltrating a-syn
pathology [425, 426].
Another set of clinical observations that support a-syn cell-to-cell propagation
are those that have identified a-syn within the cerebrospinal fluid (CSF) of PD patients.
The presence of a-syn in the CSF reflects a process of neuronal release that would be
relevant for cell-to-cell propagation if taken up by neighboring naïve cells. Following the
identification of a-syn in human CSF and blood plasma [427], further investigation
revealed that a-synucleinopathy patient CSF exhibited lower total a-syn but elevated

levels of oligomeric or aggregated a-syn compared to healthy control CSF [428-432].
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Even pS129 a-syn has been identified in CSF of PD patients [432, 433], and despite high
levels of a-syn expression in blood, the principal source of a-syn in CSF is known to be
neurons of the brain and spinal cord [434]. Additionally, a-syn was detected in the CSF
of patients with traumatic brain injury and with CJD, implicating cell death processes as
an additional mechanism for neuronal release of a-syn [429, 435]. Methods such as
enzyme-linked immunosorbent assay (ELISA) and mass spectrometry (MS) have been
employed for detection of a-syn in CSF samples [427-430, 433, 435], although one
recent study utilized PMCA to successfully identify PD patients with a sensitivity of
88.5% and specificity of 96.9% by detecting as little as 0.1 pg/mL of a-syn oligomers in
CSF [436]. Critically, despite a-syn detection in the extracellular environment of the CNS
and in blood, a large-scale retrospective cohort study of nearly 1.5 million blood
transfusion patients over more than 50 years did not observe any evidence of PD
transmission, nor transmission of any neurodegenerative disease investigated, despite
2.9% of included patients receiving a transfusion from a donor diagnosed with one of
the studied neurodegenerative diseases [437]. While the presence of a-syn in biological
fluids does not result in disease transmission between hosts in the manner of prion
infection, and thus is the reason its propagation is referred to as “prion-like”, a-syn
aggregates released from diseased cells into CSF certainly impact neighboring
susceptible cell populations. Although the presence of a-syn in grafted dopaminergic
neurons and in the extracellular environment of the CSF implies a process for its release,

intercellular trafficking, and uptake, the specific mechanisms involved in this life cycle
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remain unclear (Figure 6).
Axonal transport. Just as in Braak’s hypothesis for transfer of pathological a-syn
from peripheral neurons to the CNS, axonal transport has been a central focus for the
movement of a-syn within cells and between interconnected brain regions [385, 438].
The propagation of a-syn to distant brain regions through axonal connections was first
demonstrated in young asymptomatic a-syn transgenic mice following intracerebral
injections of brain homogenates from older a-syn transgenic mice which had developed
a-syn pathology [212]. Coincident with the propagation of pathological a-syn through
axonal transport to interconnected brain regions is an acceleration of LB inclusion
formation, consistent with seeded templating of endogenous a-syn by exogenous
aggregates, as well as a quicker onset of neurological symptoms and reduced survival in
animals receiving a-syn injections [212]. Crucially, an identical phenotype of PD-like LB
formation, a-syn propagation to interconnected brain regions, neuronal loss, and
eventual neurological symptoms is observed following intracerebral or intrastriatal
inoculation of both a-syn transgenic and WT nontransgenic mice with synthetic a-syn
fibrils assembled from recombinant a-syn [212, 213]. Because synthetic a-syn fibrils are
sufficient to initiate and propagate disease, these findings implicate the prion-like cellto-cell transmission of a-syn aggregates as underlying neuronal degeneration and
clinical progression of PD.
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Figure 6. Potential mechanisms mediating cell-to-cell transmission of cytosolic protein
aggregates. (a,b) Misfolded protein seeds (for example, oligomers and protofibrils) first
form in the cytoplasm of the releasing neuron (left), where soluble native monomers are
recruited into large intracellular aggregates and a positive feedback loop can be initiated
by generation of more seeds through fragmentation or secondary nucleation. A small
amount of protein aggregates can be released into the extracellular space in the ‘naked’
form (a) or via membrane-bound vesicles such as exosomes (b). Free-floating seeds may
directly penetrate the plasma membrane of the recipient neuron (1) or enter by fluidphase endocytosis (2) or receptor-mediated endocytosis (3), whereas exosomes
containing seeds may fuse with the membrane of the recipient neuron (4). Intercellular
transfer of seeds may also occur by nanotubes that directly connect the cytoplasm of
two cells (5). Internalized seeds then nucleate the fibrillization of native monomers in
the cytoplasm of the recipient neuron. Reprinted by permission from Macmillan
Publishers Ltd: Nature Publishing Group, Nature Medicine, Volume 20, Issue 2, Jing L
Guo, Virginia M Y Lee, Cell-to-cell transmission of pathogenic proteins in
neurodegenerative diseases (Reference 465), Copyright 2014. (License Number
4057270285760). http://www.nature.com/nm/index.html.

These initial observations of a-syn transmission through axonal contact have
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been substantiated using several other model systems. When pathological a-syn
contained within LB-enriched isolates from the SN of postmortem PD brain were
injected into the SN or striatum of mice or monkeys, the exogenous human a-syn was
quickly taken up by host neurons where seeding of expressed a-syn then occurred
[216]. This was followed by both anterograde and retrograde axonal transport to
interconnected brain regions and eventual nigrostriatal degeneration that required the
presence of a-syn in both PD brain extracts and host cells, implying that both exogenous
and expressed a-syn play a role in transmission and toxicity [216]. Although fibrillar
forms of injected a-syn induce a greater accumulation of pS129 a-syn LB pathology in
rat striatum, injection of non-aggregated a-syn can also produce this effect, and both
injection forms produce LBs in brain regions that supply innervation to the striatum
injection site [217]. Another study revealed pS129 LB inclusions are found at first-order
afferent sites in the piriform and entorhinal cortices, amygdala, and hippocampus three
months following infusion of a-syn fibrils into the OB of mice, whereas areas nearby but
without axonal connections to the injection site lacked LB inclusions, supporting
movement of a-syn through axonal routes rather than simple diffusion [439]. Finally,
targeted overexpression of a-syn using unilateral intracerebral injection of an a-syn
lentiviral vector caused axonal propagation of expressed a-syn to the contralateral side
along with axonal degeneration and behavioral deficits in mice [440]. These findings
implicate trafficking of a-syn aggregates through axonal networks as a key mediator of
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pathological propagation, and indicate the importance of elucidating both the species of
a-syn involved as well as mechanisms facilitating intercellular spreading.
It is of utmost importance to elucidate the molecular form of a-syn most capable
of cell-to-cell transmission so that therapeutic efforts targeting these propagating forms,
such as immunotherapy, will have maximum success in halting disease progression
[440]. Just as smaller forms of a-syn aggregates have emerged as the molecular species
most capable of seeding further aggregation and inducing the most cytotoxicity, smaller
a-syn aggregates also appear to propagate from one cell to another with much greater
efficiency. Most PD models utilizing exposure to exogenous a-syn aggregates generated
in vitro from purified recombinant a-syn will perform sonication to fragment larger asyn fibrils into multiple smaller components that retain their original structure although
with a much-decreased population size distribution [200, 202, 203, 212, 213, 219, 439].
These smaller fragments of previously elongated a-syn fibrils are known as “pre-formed
fibrils” (PFFs) and are widely utilized to examine the impact of exogenous a-syn on
seeding aggregation, intracellular toxicity, and intercellular transmission precisely
because their smaller size distribution allows them to be readily taken up by recipient
cells [202, 203]. The increased propagation efficiency of smaller a-syn aggregates is
illustrated in recent work examining transmission of a-syn from OB to other brain
structures. When monomeric, oligomeric, and elongated fibrillar preparations of a-syn
aggregates were injected into the mouse OB, monomeric and oligomeric a-syn, but not
the larger fibrillar forms, were readily taken up by OB neurons and transferred to

axonally interconnected brain regions within minutes to hours, although these non-
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fibrillar preparations are cleared from the brain within a few days following injection
[441]. In contrast, when elongated a-syn fibrils were fragmented to smaller sizes by
vigorous sonication to create PFFs prior to injection into mouse OB, they efficiently seed
the aggregation of endogenous a-syn into pS129 LB inclusions and spread over several
months via axonal connections first within the olfactory network and later in distant
connected brain regions [219]. Another study found that waterbath sonication of fibrils
for 1 hour significantly reduced fibril size by EM compared to 1 minute probe sonication,
and this results in improved a-syn cell-to-cell transmission [439]. Finally, viral vectorbased overexpression of a-syn in the medulla results in monomeric, oligomeric, and
fibrillar immunoreactivity in donor neurons at this site, but only the non-fibrillar forms
of a-syn were similarly detected in pontine recipient neurons, indicating that larger asyn fibrils have significant barriers to propagation because of their larger size [442].
These studies demonstrate that smaller a-syn fibrils, because of their decreased size,
are readily taken up by recipient neurons, efficiently seed aggregation of expressed asyn, and are quickly spread along axonal connections to naïve brain regions, facilitating
further aggregation and disease propagation.
Investigation into the mechanisms of a-syn axonal propagation have been
ongoing, but studies utilizing microfluidic devices where axons project through small
channels to terminate in a microenvironment isolated from that of their respective cell
bodies have brought new insights regarding the steps in the process. a-syn fibrils have

been shown to be transferred from axons to second-order neurons following axonal
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transport through a process that did not require direct cell-to-cell contacts, implying the
existence of an extracellular phase between donor and recipient cell [443] (Figure 6). In
addition, this release of a-syn following axonal transport was not due to axonal lysis, but
occurred in healthy, intact neurons [444]. Contrary to these findings, however, a-syn
has also been shown to transit from donor to acceptor cells through TNTs inside
lysosomal vesicles, and even to increase cellular formation of TNTs, eventually resulting
in seeding of further a-syn aggregation in the cytoplasm of acceptor cells [445]. Since
TNTs are F-actin containing membranous bridges that connect the cytoplasm of remote
cells, this direct transfer of lysosomal vesicles and their a-syn cargo would avoid an
extracellular phase in the intercellular journey [445] (Figure 6). While multiple
mechanisms of transmission may play a role in a-syn cell-to-cell spreading, the specific
form of propagating a-syn as well as its accessibility to therapeutic targeting during this
transit are crucial factors for the success of immunotherapy treatment approaches
[440].
Despite the highly reproducible nature of the findings detailing a-syn cell-to-cell
propagation via axonal transport by multiple independent groups, this phenomenon has
not been without contradiction. One study found that injected a-syn PFFs induced
widespread LB inclusion formation only in transgenic mice expressing A53T a-syn but
not in non-transgenic mice or transgenic mice expressing E46K a-syn, which instead
exhibited inclusion pathology restricted to the site of injection and had no evidence of

spreading [446]. This observation suggests that alternative processes may also
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contribute to a-syn inclusion formation and neurotoxicity in addition to or instead of asyn prion-like spreading. Also, seeding and propagation processes may operate
independently of one another, as evidenced by the observation that a lack of
endogenous a-syn expression does not counteract axonal transport and intercellular
transmission of exogenous asyn, but instead results in its more pronounced intercellular
movement [442]. Although the seeding process induces neurotoxicity and explains the
amplifying nature of a-syn aggregation throughout the brain, this finding indicates that
seeding endogenous aggregation may also consume exogenous propagating seeds into
larger aggregates that propagate less efficiently. Thus, intercellular transmission of asyn may also occur in the absence of seeding, suggesting two separate but intertwined
processes. Axonal transport has been extensively implicated in the cell-to-cell
propagation of pathological a-syn, and forms the rationale for further investigation into
the mechanistic steps of its intercellular life cycle.
Endocytosis. The process of endocytosis, where cells sample their extracellular
environment through plasma membrane invaginations and inward budding of vesicles
containing extracellular components [447], has been repeatedly implicated as a central
mechanism for the cellular uptake of a-syn aggregates (Figure 6). The endocytic route of
uptake features prominently in the cellular life cycle of a-syn aggregate propagation as
a mechanism of entry into recipient cells [448]. The first evidence for the importance of
the endocytic process in the cellular uptake of a-syn aggregates was the correlation

between neuronal cell death induced by the addition of exogenous a-syn and Rab5A-
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specific endocytosis [449]. Expression of a GTPase-deficient Rab5A resulted in a
decrease of a-syn-induced cytotoxicity due to its incomplete endocytosis [449].
Additionally, internalization of oligomeric and fibrillar forms of a-syn aggregates could
be inhibited by low temperature or expression of a dominant-negative mutant of
dynamin, a component of the endocytic machinery essential for scission of endocytic
intermediates to form vesicles [450]. These observations implicate endocytosis as the
mechanism of internalization for a-syn aggregates, although since the cellular entry of
monomeric a-syn was unaffected by these manipulations, single a-syn monomers are
likely capable of entering cells via direct membrane translocation [450] (Figure 6).
Several other studies have used similar methodologies in various model systems to
verify the involvement of endocytosis in a-syn aggregate uptake by many different
recipient cell types. Neurons, astrocytes, oligodendrocytes, and microglia all internalize
a-syn aggregates through endocytosis, and inhibition of endocytic uptake results in
impaired intercellular a-syn propagation, underscoring the importance of this method
of cellular entry for the a-syn transmission life cycle [450-457].
Once a-syn fibrillar aggregates bind to the cellular membrane, a process that
occurs through lateral binding of the fibrillar aggregate [458], endocytic vesiclemediated internalization matches the efficacy of membrane binding [280]. a-syn
aggregates gain entry to recipient cells through either fluid-phase endocytosis, where
membrane binding stimulates membrane ruffling and endocytic uptake [459], or
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receptor-mediated endocytosis, where specific interactions between a-syn aggregates
and membrane components or receptors such as heparan sulfate proteoglycans (HSPGs)
or lymphocyte-activation gene 3 (LAG3) initiate endocytosis [460, 461] (Figure 6). Once
inside the cell, a-syn aggregates are first contained within endosomes that transition
into lysosomes for degradation of the a-syn cargo [450, 462, 463]. However, a-syn
aggregates taken up by endocytosis are well known to serve as seeds for the templated
misfolding of monomeric a-syn expressed in the cytosol of the recipient cell, triggering
the formation of LB inclusions [202, 347, 454, 464]. The mechanism by which a-syn
aggregates escape the endocytic vesicle compartment to access the cytosol and proceed
with seeded templating of further a-syn misfolding was until recently an open question
[448, 465] (Figure 6), but the demonstration that a-syn aggregates induce lysosomal
rupture following endocytosis provided an explanation [4]. The identification of a-syninduced lysosomal rupture following endocytosis illuminates the connection between
exogenous and expressed a-syn necessary for seeding to occur and, moreover,
implicates a-syn propagation as contributing to degradative dysfunction through
inducing lysosomal damage. Cellular entry of a-syn aggregates through endocytosis is an
essential step in the propagation pathway, and contributes to many other aspects of
prion-like neurodegeneration.
Exocytosis. Given the presence of a-syn in the CSF and multiple synapses
separating neurons along the a-syn cell-to-cell propagation pathway, the cellular
release of a-syn from cells burdened by its misfolding and accumulation is necessary for

cell-to-cell propagation to occur [448, 466, 467] (Figure 6). Several mechanisms have
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been proposed to account for the jettison of a-syn from affected cells into the
extracellular environment, each a variation on the theme of exocytosis. a-syn, because
its lacks a secretory signal peptide sequence, has been shown to be secreted from cells
via non-classical endoplasmic reticulum (ER)/Golgi-independent exocytosis [468].
Intracellular a-syn can be contained within the lumen of vesicles, often in an oxidized
and aggregation-prone state, and the fusion of these vesicles with the plasma
membrane results in the release of the intralumenal abnormal a-syn contents into the
extracellular environment [468, 469]. Unconventional ER/Golgi-independent exocytosis
of a-syn can also be caused by exophagy, the exocytosis of autophagosomes or their
contents upon fusion with the plasma membrane [470, 471]. Late endosomes or
recycling endosomes may also play a role in the release of a-syn cargo through
exocytosis to the extracellular environment, as evidenced by inhibition of a-syn release
upon disruption of Rab27a or Rab11a which are involved in endosomal regulation [470,
472, 473]. Regardless of the identity of the intracellular vesicle compartment fusing with
the plasma membrane to release a-syn, these various forms of exocytosis discharge asyn in a free state, no longer associated with lipid membranes, given that the vesicular
membrane remains associated to the plasma membrane upon fusion (Figure 6). Free asyn outside the cell would be susceptible to cleavage by matrix metalloproteinases
(MMPs) operating in the extracellular environment [474], but would also be available
for uptake into neighboring cells by endocytosis to further the propagation life cycle.

Additionally, a-syn has also been shown to be released from affected cells
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contained within exosomes, a type of extracellular vesicle originating from the plasma
membrane fusion of multivesicular bodies (MVBs) which are endosomal compartments
containing multiple internal vesicles generated from inward budding [475-477] (Figure
6). Exosomes have been found to contain both monomeric and oligomeric a-syn, and
exosome-associated a-syn is more likely to be taken up by recipient neurons where it
causes more toxicity than free a-syn released by exocytosis in a non-membrane bound
form [478, 479]. a-syn within exosomes, as well as a-syn within extracellular vesicles
derived from plasma membrane blebbing and shedding [473], are immune to the hostile
extracellular environment because of their protected membrane-bound state. Sorting of
a-syn into exosomes may be regulated by post-translational addition of small ubiquitinlike modifier (SUMO) which facilitates a-syn interaction with the endosomal sorting
complex required for transport (ESCRT) machinery and eventual extracellular release
[480]. Interestingly, the ESCRT pathway is also important for a-syn transport through
MVBs for degradation, but a-syn is known to promote degradation of the ESCRT protein
charged multivesicular body protein (CHMP2B), resulting in impaired ESCRT activity,
accumulation of a-syn unable to be degraded, and increased exocytosis of a-syn [481].
Exosomes represent another mechanism for the cellular release of a-syn via exocytosis,
and given their utility for intercellular delivery of biochemical information to directly
modify signaling pathways or proteostasis in receiving cells [475], elucidating the
underlying mechanisms prompting their release is of utmost importance.

Stress-induced propagation. Despite the detrimental consequences of a-syn
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release for the propagation of protein misfolding and its associated neurotoxicity
throughout the brain, paradoxically, the release of a-syn aggregates is also a protective,
last-resort response of stressed cells overwhelmed by a-syn accumulation and their
ineffective or dysfunctional degradative clearance mechanisms [318, 482, 483]. When
cellular degradative mechanisms are insufficient to cope with the continued
accumulation of misfolded a-syn aggregates, or increasing mitochondrial stress perturbs
cellular homeostasis, this prompts a-syn clearance through cellular release instead.
Pharmacological inhibition of the proteasome or of mitochondrial complex I increases
the release of both monomeric and aggregated a-syn, although more aggregated forms
are present in the released proteins [468, 469]. Furthermore, elevated ROS occurring as
a byproduct of DA synthesis results in mitochondrial dysfunction and increased
secretion of a-syn oligomers, but not monomers, into the extracellular space [294].
Perhaps the most significant stressor contributing to a-syn release and
propagation in PD is dysfunction in the ALP, as this pathway is the main mechanism for
degradation of a-syn aggregates. Failure of autophagic processes, modeled by
pharmacological or genetic inhibition, increases the exocytosis of a-syn [484], as does
the lowering of autophagosomal mobility and the prevention of fusion with lysosomes
[470, 471]. Lysosomal failure has even more far-reaching consequences, as lysosomal
degradation is responsible for ultimate clearance of both autophagic and endocytic
compartments. Dysfunctional lysosomal degradation, which has been extensively

modeled by treatment with bafilomycin A1 (Baf) to inhibit the acidifying action of the
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lysosomal H+-ATPase, also results in increased a-syn release from affected cells [469471, 473, 479, 485]. Deficiency of lysosomal enzymes CatD or GCase, occurring
profoundly when mutated in genetic forms of PD but still contributing to lysosomal
dysfunction even in sporadic PD, also results in increased a-syn secretion to the
extracellular environment [364, 366, 373, 486]. Lysosomal degradation is also known to
be impaired during normal aging, and as a result, the rate of cell-to-cell transmission of
a-syn aggregates was also increased in an aging model [487]. These findings highlight
the essential nature of the ALP in the degradation of a-syn aggregates, and illustrate
how its dysfunction can result in the pathological release of a-syn from affected cells as
a last-resort mechanism of clearance.
Tau.
The microtubule-associated protein tau (MAPT), pathologically aggregated in
diverse tauopathies including AD, chronic traumatic encephalopathy (CTE), tangle-only
dementia (TD), Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), agyrophilic grain disease (AGD), and frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17T), exhibits many similarities to a-syn
as a prion-like amyloid protein [488]. Just as for a-syn, tau aggregation from a soluble,
unfolded, phosphorylated monomer to an insoluble, hyperphosphorylated neuropil
thread (NT) or neurofibrillary tangle (NFT) results in unique strain conformations, arising
due to seeded templating of aggregation, which impart tropism for different cell types

and brain regions and result in distinct patterns of pathology for human tauopathies
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[314, 488-492]. Although alternative mRNA splicing results in tau expression as six
different isoforms, composed of 0, 1, or 2 N-terminal inserts (0N, 1N, 2N) and either 3 or
4 C-terminal repeats (3R, 4R), the various compositions of tau isoforms (1N3R vs. 1N4R,
for example) allow higher-order aggregates to adopt different shapes or conformations
that behave as distinct strains [488].
Tau strains propagate their conformation through seeding aggregation of
additional monomeric tau, and a specific strain conformation and its associated
pathological phenotype of affected cell types and brain regions can be faithfully
reproduced when tau strains are re-introduced into naïve cells or successively
inoculated into mice [490, 492, 493]. Distinct tau strains may also exhibit varying levels
of potency in their seeding of further aggregation because of their unique
conformations, as strains purified from AD brain exhibited increased seeding potency
compared with synthetic tau fibrils [491]. Seeding occurs between like isoforms, as
aggregation of expressed 4R tau will occur following cellular uptake of 4R fibrils but not
3R fibrils, and vice versa when 3R tau is expressed in target cells [201]. This nucleationdependent, composition-specific aggregation of tau recapitulates Prusiner’s proteinonly hypothesis by the induction of NFT insoluble aggregates following cellular uptake of
tau fibrils [494]. If seeding of further aggregation is inhibited by suppressing the
expression of soluble tau, cellular degradative mechanisms are no longer overwhelmed
by amyloid accumulation and tau aggregates can be cleared by the ALP, just as a-syn

aggregates are cleared, although both the UPS and ALP have difficulty clearing large
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aggregates [495]. Tau inclusions formed within affected cells are highly dynamic
structures, undergoing fission and fusion events that facilitate pathological propagation
by additional seeding events [495]. The observation that different tauopathies are
associated with different sets of strains [490] raises the possibility, just as for asynucleinopathies or prion diseases, that conformational diversity of tau aggregation
dictates the phenotype of clinical disease [492].
Another feature of tau pathology that is analogous to a-syn is in the prion-like
cell-to-cell propagation of tau aggregates. Heiko Braak and colleagues also described a
staging system for tau pathology in AD just as for a-syn in PD, detailing six distinct
stages of an evolving characteristic distribution pattern for NT and NFT pathology [496].
An ordered and predictable progression of hyperphosphorylated tau pathology was also
seen in CTE co-occurring with axonal disruption and death, leading to the progressive
staging of pathology through 4 stages [497]. These findings suggest, through the
predictable, conserved expansion pattern of tau pathology in different tauopathies, that
cell-to-cell propagation of tau aggregates may also contribute to unique clinical
phenotypes and may be an etiological factor for disease progression and increasing
severity. Cell-to-cell spreading of aggregated tau has been observed in numerous
experimental models, where expressed tau adopts characteristics of the pathological
tau seeds and spreads to neighboring cultured cells or interconnected brain regions.
Extracellular tau aggregates, but not monomer, become internalized into recipient cells
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where they induce formation of expressed tau aggregates which then transfer between
co-cultured cells [498]. When brain extracts are prepared from mice expressing human
P301S mutant tau, the tau mutation that causes FTDP-17T in humans and results in
widespread hyperphosphorylated tau and neurodegeneration in transgenic mice,
extract injection into the brains of transgenic WT human tau-expressing mice which do
not normally develop tau filaments or neurodegeneration induces aggregation of WT
tau and the spreading of these aggregates to neighboring brain regions [499]. Similar
results were observed when brain extracts from humans with AD, AGD, PSP, and CBD
were injected into the brain of WT mice and caused the seeding and cell-to-cell
propagation of endogenous tau with a phenotype that recapitulated the hallmark
disease lesions of the extract source [500, 501]. Even intracerebral injection of synthetic
tau PFFs into mice overexpressing P301S mutant tau induces NFT inclusions and
propagation of tau pathology to connected brain regions over time [502]. In the process
of spreading between interconnected brain regions [491, 502], synaptic connections
appear to enhance tau propagation [503], although transmission can also occur via nonsynaptic mechanisms such as along glymphatic or CSF pathways [504, 505]. The prionlike cell-to-cell propagation of tau aggregates represents a mechanism for the
amplification and dissemination of tau pathology throughout the brain of affected
patients, and thus understanding the mechanisms underlying cellular uptake and
release of tau aggregates are of utmost importance.

Examination of potential mechanisms of tau cellular entry and egress again
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reveals numerous similarities with a-syn and prions. Endocytosis is again the
predominant mechanism for cellular uptake of tau aggregates as for a-syn aggregates
[498, 506-508], perhaps occurring after interaction at the plasma membrane between
tau aggregates and HSPGs [460]. Tau uptake depends on both the conformation and the
size of the aggregates, as low-molecular weight aggregates or short fibrils, but not
monomers, long fibrils, or long filaments, were capable of cellular entry via endocytosis
[509]. This endocytic uptake process is regulated in part by the neuronal isoform of the
BIN1 protein which serves as a negative regulator of endocytic flux, preventing tau
propagation through endocytosis when functional but promoting tau propagation when
downregulated in AD brain [507]. The conserved role of endocytosis in the uptake of tau
and a-syn aggregates underscores the importance of this pathway in the cellular life
cycle of these amyloid proteins, allowing for the propagation of misfolded structure
from affected to naïve cells. Endocytosis allows for the induction of expressed tau
aggregation by exogenous tau seeds, as extracellular seeds come into direct contact
with intracellular tau as seen by Förster resonance energy transfer (FRET) following
endocytosis [498, 510]. Just as for a-syn aggregates taken up via endocytosis, the
process by which endocytosed tau aggregates escape the endocytic vesicle and thus
become competent to seed the aggregation of expressed tau in the cytosol remains
unanswered [465].

As for the process of tau cellular release, monomeric tau is constitutively
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released, even from normal healthy cells, into the interstitial fluid (ISF) and CSF for
unknown reasons [511-513], although this release process can be stimulated by
neuronal activity and calcium-influx and blocked by inhibiting pre-synaptic vesicle
release [512]. Although the CSF level of tau correlates with the burden of
hyperphosphorylated tau and NFT pathology [514], levels of tau in ISF are significantly
higher than in CSF, and following spontaneous or seed-induced tau aggregation, levels
of monomeric ISF tau decrease significantly as monomers are consumed into insoluble
aggregates [513]. This finding is additional evidence for the seeding-dependent
equilibrium between monomeric and aggregated tau occurring in both the extracellular
and intracellular environments. Tau secretion can occur through a non-classical pathway
that is prevented by low temperature but not blocked by inhibitors of the conventional
secretory pathway [511]. This form of tau secretion results in extracellular tau that is not
associated with membranes, and thus illustrates the mechanism of therapeutic efficacy
underlying antibody-mediated reduction in insoluble tau aggregates and inhibition of
tau seeding and propagation [510, 515]. Tau can also be released from affected cells in a
membrane-bound form, either in ectosomes formed from outward budding of the
plasma membrane or in exosomes released upon plasma membrane fusion of MVBs
containing internal vesicles [516-519]. Similar to a-syn release, tau secretion is
increased under conditions of cellular stress [518]. Finally, just as for a-syn and prions,
TNTs have been implicated in the intercellular transmission of tau aggregates, and tau,

like a-syn, promotes the formation of TNT connections that facilitate its transmission
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[520, 521]. There are many similarities in the aggregation and propagation processes of
tau and a-syn as prion-like amyloid proteins, and there may also be similar therapeutic
approaches to arrest progression of the diverse diseases caused by these different
proteins with similar pathological activities.
Huntingtin.
HD is among a group of neurodegenerative disorders exclusively caused by
dominantly-inherited genetic mutations that expand a CAG repeat sequence in the
coding region of the affected gene and result in expression of proteins with expanded
tracts of uninterrupted polyglutamine (polyQ) residues that are longer than in the WT
protein [522]. In the case of HD, this trinucleotide repeat expansion occurs in the gene
encoding the huntingtin protein, HTTExon1, and a polyQ tract greater than 37Q causes
HD [523]. When the polyglutamine expansion is in the pathogenic range, for HTTExon1Q³37, this alteration induces the formation of insoluble, high-molecular weight
aggregates that adopt a fibrillar morphology like that of prions, a-syn, and tau [524].
Since this discovery of the effect of polyQ expansion on the structure of the huntingtin
protein, several commonalities have been revealed between HTTExon1 aggregates and
other prion-like amyloid aggregates such as those of a-syn and tau [522].
Just as for a-syn and tau, the aggregation process of HTTExon1-Q³37 exhibits
prion-like properties. PolyQ repeat lengths of greater than 37 increase the kinetics and
thermodynamic favorability of the spontaneous misfolding reaction into amyloid

aggregates, and although shorter repeats do not undergo spontaneous aggregation,
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they are capable of adding to an already formed aggregate and will be recruited into
insoluble aggregates when exposed to extended polyQ tracts [525, 526]. Indeed, in
addition to the length- and concentration-dependence of aggregation, exposure to preformed seeds significantly abbreviates the normal lag phase associated with
spontaneous misfolding just as for other prion-like amyloid proteins [527]. This seeded
recruitment and templating of further misfolding continues the prion-like aggregation
theme of a-syn, tau, and others, and just as for these other amyloid proteins that adopt
b-sheet ThT-positive filamentous structures, the smaller, more finely-divided aggregates
of HTTExon1 are much more efficient at recruiting additional polyQ peptides than larger
aggregates [525, 527].
Again like a-syn and tau, prion-like mechanisms of cell-to-cell propagation have
been implicated in the progression of HD pathology [522]. In the cell-to-cell propagation
pathway, the membrane association mechanisms of monomeric and assembled
HTTExon1 are of significant interest. The N-terminus of monomeric HTTExon1 binds to
membranes through a charge-based mechanism where it forms an amphipathic a-helix
that inserts into the lipid bilayer [528]. PolyQ expansion allows for a greater depth of ahelix membrane insertion that may perturb the function of cellular membranes and
alter the normal membrane-bound cellular localization of HTTExon1 [528, 529]. Once in
an aggregated form, HTTExon1 aggregates will become internalized into recipient cells
following binding of cell surface membrane proteins that uniquely recognize its fibrillar

amyloid structure [530]. This membrane binding occurs, as for a-syn aggregates,
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through lateral association between the fibrillar aggregate and the cell membrane [458],
although HSPGs do not seem to be involved for binding and internalization of HTTExon1
aggregates as they were for aggregates of a-syn and tau [460]. Once bound to the
membrane, HTTExon1 aggregates are internalized via endocytosis and directed to the
lysosome [531], although the process of escaping the vesicle to gain access to the
cytosol following endocytic uptake remains unclear [522, 531]. Despite the question of
the specific vesicle escape mechanism remaining open just as for a-syn and tau,
exogenous HTTExon1 aggregates do gain entry to the cytoplasm following
internalization where they become sequestered into aggresomes and recruit additional
soluble homologous counterparts through seeded templating [531-533]. The technique
of bimolecular fluorescence complementation (BiFC) illustrates that exogenous
HTTExon1 aggregate seeds contact cytosolic HTTExon1 and induce its misfolding in the
cell-to-cell transmission pathway [534]. Cell-to-cell propagation of HTTExon1 aggregates
can occur through direct cell-to-cell contact, where TNT-mediated transmission is
implicated and expression of mutant HTT can, like a-syn and tau, increase formation of
TNTs to facilitate transmission [535]. HTTExon1 aggregates can be transported within
the cell in both anterograde and retrograde directions, and can also be secreted from
axons of affected cells following anterograde transport to spread trans-neuronally in the
absence of axonal lysis [444]. These various prion-like characteristics of HTTExon1
aggregates illustrate similarities with aggregates of a-syn and tau, and highlight the

importance of more clearly understanding steps in the intercellular propagation
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pathway so that new effective therapeutic strategies can be developed.
Vesicle Rupture
Membrane Pores.
In considering the means through which prion-like amyloid aggregates of a-syn
escape the vesicular compartment following their endocytosis to proceed with
propagating protein misfolding, investigation of their effects on vesicle membranes
begins with the proposed physiological role of monomeric a-syn, involving interaction
through its amphipathic N-terminal domain with phospholipid membranes in synaptic
vesicles [143]. a-Syn has been shown to induce membrane thinning and curvature by
inserting its N-terminal amphipathic domain as a wedge into the membrane, resulting in
the conversion of large low-curvature vesicles into highly curved membrane tubules and
vesicles [536-540]. This curvature and membrane tubulation is caused only by
monomeric a-syn [538], and can result in the disruption of membrane integrity [536,
540]. While it is tempting to speculate that these same membrane curvature
mechanisms underlie cellular invasion by a-syn amyloid fibrils at the plasma or
endocytic membrane, the actions of an unfolded or a-helical a-syn monomer on
biological membranes are not likely to translate to higher-order b-sheet amyloid
assemblies of a-syn, as assembly of a-syn monomers into an insoluble fibrillar
conformation involves both multimerization and a conformational change.
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Once aggregation of a-syn begins, however, aggregates do not lose their affinity
for membranes. Specific pre-fibrillar intermediates called protofibrils are b-sheet-rich
annular ring-like or wreath-like assemblies resembling a pore-forming bacterial toxin,
and these a-syn protofibrillar assemblies have been shown to permeabilize vesicle
membranes via a pore-forming mechanism that allows passage of ions or low-molecular
mass structures [541-545]. The pore-like structure of a-syn protofibrils containing a
central channel illustrates how membrane penetration of the annular protofibrils results
in perforation of the lipid bilayer [546, 547]. Protofibril membrane insertion and
subsequent membrane pore formation results in an increase in the conductance of the
lipid bilayer, eliciting ion-channel currents as a result of the non-selective passage of
ions [548, 549]. Especially critical for the survival of neurons, a dysregulated influx of
Ca2+ ions through a-syn membrane pores results in cell death [550-552]. Alternatively,
other studies have found an a-syn oligomer-mediated increase in plasma membrane ion
conductance in the absence of pore formation [553], possibly occurring through a
thinning of the plasma membrane hydrophobic core resulting from oligomer insertion
between tightly packed lipids [554]. In any case, these studies examine the actions of asyn monomers or oligomers on lipid membranes, and while related, they do not
necessarily apply to the actions of a-syn amyloid fibrils on biological membranes. While
some characteristics of a-syn monomers or oligomers may remain upon fibril formation,
it is doubtful that the same membrane association properties of a-syn monomers or
oligomers will be maintained following fibril assembly. Thus, membrane perturbations

induced by a-syn monomers, oligomers, protofibrils, and fibrils are likely distinct
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processes. Whereas monomers can induce membrane curvature possibly due to their
physiological role and oligomers can form membrane pores, the vesicular escape of asyn fibrillar assemblies likely occurs via a different mechanism due to their larger size.
Amyloid-Induced Vesicle Rupture.
Investigation into the effects on biological membranes of amyloid proteins in the
fibrillar assembly conformation is most relevant for aggregate cell-to-cell propagation
and has yielded some new insight, but the understanding of how these membrane
interactions relate to disease pathogenesis remains largely incomplete. To determine
the specific effect of fibrillar amyloid forms on membrane structure and integrity,
amyloid fibrils generated in vitro are often incubated with artificial liposome
suspensions. Fibrillar forms of amyloid proteins, just like monomeric and oligomeric
forms, are known to associate with lipid membranes, and in vitro association of a-syn or
HTTExon1 fibrils with artificial liposomes is known to induce permeabilization or
destruction of the liposomal membrane [555, 556]. Membrane disruption or
permeabilization of artificial liposomes and natively derived membranes was enhanced
when fragmentation of fibrils was performed, suggesting an increased toxic action on
membrane integrity by smaller fibrillar amyloid forms rather than larger entangled
amyloid inclusions [557]. In addition, the binding of amyloid fibrils to the plasma
membrane is known to induce cellular Ca2+ influx through a mechanism that has yet to
be defined, but may be similar to its lipid permeabilization of artificial liposomes that
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allows the release of intravesicular indicator dyes [210, 556]. While these models of asyn fibril association with lipids are certainly relevant for membrane interactions that
may occur within the endocytic compartment during pathological cell-to-cell
propagation, the mechanisms of membrane perturbation by a-syn fibrils on the external
face of artificial liposomes or at the plasma membrane may not directly relate to the
process of intravesicular escape and cellular invasion.
The most authentic representation of endocytic vesicle integrity relies on the
identification of specific factors enriched within intact endocytic vesicles or that become
enriched in the endocytic compartment upon loss of membrane integrity. Our group
was the first to apply one such approach to the study of cellular invasion by a-syn
aggregates. By exploiting the ability of cytosolic galectin 3 (Gal3) to become enriched at
the site of intracellular vesicle damage due to its binding of target b-galactoside residues
exposed as a result of damage, we determined that aggregates of a-syn are capable of
inducing membrane rupture of lysosomes following their endocytic uptake [4, 280].
Utilizing both the cellular uptake of exogenous a-syn aggregates prepared in vitro from
recombinant purified protein as well as the cell-to-cell transmission of a-syn aggregates
from over-expressing donor cells to naïve recipient cells, this study demonstrated
induction of vesicle rupture through the colocalization between a-syn aggregates and
distinct Gal3 puncta formed at the site of vesicle rupture (Figure 7). These findings
illuminated a potential mechanism for exogenous a-syn fibrillar amyloid assemblies to
escape the endocytic compartment to access the cytosol, and did so in a model that
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Figure 7. Vesicle rupture following the cell to cell transfer of a-synuclein. N27 cells
stably expressing a-synuclein and treated with MPP+ for 24 hours. N27chGal3 cells were
then added to the culture and co-cultured for 48 hours. Cells were then fixed and
stained for a-synuclein (green). The boxed areas in the left panel are enlarged to allow
visualization of a-synuclein and chGal3 colocalization. Reprinted from PLoS One,
Volume 8, Issue 4, David Freeman, Rudy Cedillos, Samantha Choyke, Zana Lukic,
Kathleen McGuire, Shauna Marvin, Andrew M. Burrage, Stacey Sudholt, Ajay Rana,
Christopher O’Connor, Christopher M. Wiethoff, Edward M. Campbell, Alpha-Synuclein
Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species
Following Endocytosis, e62143, doi:10.1371/journal.pone.0062143 (Reference 4),
Copyright 2013, reproduced under the terms of the Creative Commons Attribution
License.

recapitulates both the neuronal endocytic membrane components and the proper
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orientation of escape, from intravesicular to cytosolic, that are involved in pathologic asyn amyloid cell-to-cell propagation.
a-Syn-induced lysosomal rupture not only allowed cellular invasion of misfolded
amyloid fibrils, but also resulted in a CatB-dependent increase in ROS in target cells
following proteolytic enzyme leakage from damaged lysosomes. A later study found that
the induction of cytosolic a-syn misfolding by exogenous a-syn seeds was enhanced by
the actions of CatB, proposed to increase the amount of smaller a-syn seeds in the
lysosome through partial digestion that could then trigger intravesicular aggregation by
recruiting additional membrane-bound monomers and, through further growth within
the vesicular compartment, result in vesicle rupture and escape [296]. While CatB may
perform this facilitative role for a-syn aggregation in the lumen of the lysosome prior to
rupture, its leakage from the lysosome following rupture may also result in its action on
expressed monomeric a-syn in the cytosol, perhaps accounting for its enhancement of
cytosolic aggregate formation. This process of intravesicular aggregation and eventual
vesicle rupture due to the large size of the resulting aggregate is one mechanism
proposed for the induction of a-syn amyloid-mediated vesicle rupture. Additionally,
recruitment of a-syn monomers away from the vesicular membrane and into a growing
intravesicular aggregate may result in membrane destabilization through lipid
extraction, another possible mechanistic explanation for a-syn fibril-mediated rupture
[558]. Finally, uptake of rigid a-syn amyloid fibrils into endocytic vesicles could result in

physical-mechanical perturbations of the vesicle membrane as another mechanistic
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possibility, due to trafficking of intracellular vesicles through the dense cytoplasmic
environment carrying their rigid fibrillar cargo [559].
Endocytic vesicle rupture has also been suggested as a mechanism of cellular
invasion for fibrillar assemblies of other amyloid proteins. Tau aggregates have been
proposed to rupture the endocytic membrane during cellular uptake, although the
evidence supporting this conclusion is limited by a lack of specificity in defining tau
aggregates that cause this damage [507, 560]. Exposure of artificial liposomes to fibrillar
assemblies of Ab has been shown to result in vesicle permeabilization [561], and
endocytic uptake of degradation-resistant Ab1-42 into target cells results in lysosomal
permeabilization indicated by cytosolic release of the endocytic tracer Lucifer Yellow as
well as the lysosomal enzymes CatD and b-hexosaminidase [562]. Finally, amyloid fibrils
composed of b2-microglobulin, associated with dialysis-related amyloidosis, have also
been shown to disrupt lipid bilayers in vitro resulting in membrane leakage, and this
effect was enhanced by low pH conditions such as those in the endocytic pathway [563,
564]. While less is known about the actions of amyloid fibrils on biological membranes
compared to monomers or oligomers of these proteins, insights into membrane
association in vitro or upon cellular uptake have postulated a vesicle rupture mechanism
for the cellular invasion of amyloid fibrils through the endocytic compartment.

Utility and Role of Galectin Proteins.
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Galectin family proteins derive their name from their function as galactosidebinding lectins, and b-galactoside recognition by the galectin carbohydrate recognition
domain (CRD) mediates their diverse functions in cell communication, inflammation,
development, and differentiation [565-569]. One such function, critical for innate
immunity, is the action of cytosolic galectins as membrane sensing pattern recognition
receptors (PRRs) or danger receptors that continually ensure intracellular endosomal
and lysosomal membrane integrity through their lack of binding to carbohydrate targets
that are sequestered within intact intracellular vesicles and thus absent from the cytosol
[570, 571]. The ability of cytosolic galectins to recognize exposed b-galactoside targets
upon vesicular membrane permeabilization highlights their utility for studying the
vesicle membrane rupture ability of fibrillar amyloid aggregates following endocytosis.
Galectins detect vesicle rupture induced by the cellular invasion of numerous
pathogens, such as Salmonella enterica serovar Typhimurium, Shigella flexneri, Listeria
monocytogenes, Mycobacterium tuberculosis, Burkholderia cenocepacia, Ureaplasma
parvum, and non-enveloped viruses such as adenovirus [572-575], that each damage
the endocytic compartment to gain entry to the cytoplasm as part of their infectious life
cycle. Following the rupture of the endocytic compartment that formed around the
pathogen during host cell uptake, galectins become selectively, specifically, and
instantly recruited to the site of vesicle damage, serving as a novel tool to spot vesicle

rupture and to identify the molecular and cellular mechanisms of rupture during
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pathogenic invasion [570, 576-580].
In addition to this utility for the study of vesicle rupture mechanisms, the
recruitment of cytosolic galectins to the site of intracellular vesicle damage also plays a
physiologic role in innate immune signaling and inflammation [581-586], initiated as a
response to vesicle rupture by any cause; bacteria, virus, or amyloid fibril alike. Within
affected cells stimulated by ischemia or a-syn aggregate exposure, a resulting increase
in Gal3 expression and/or activity prompts a signaling cascade that is required for
proper microglial activation and proliferation [587-589]. Additionally, Gal3 expression is
markedly increased in prion-infected brain tissue after central or peripheral inoculation,
where it plays a detrimental role for survival as evidenced by Gal3 KO mice exhibiting
prolonged survival times [590]. Gal3 KO mice also had decreased LAMP2 protein levels,
suggesting that a regulation of lysosomal function may underlie the detrimental role of
Gal3 in prion infections [590]. In additions to its actions within affected cells, Gal3 can
also be secreted from cells through a non-classical leaderless secretory pathway where
now in the extracellular environment it acts as an endogenous danger signaling
molecule producing proinflammatory responses from nearby cells [591-593].
Extracellular Gal3, released in a paracrine fashion in response to diverse stimuli such as
ischemia, LPS exposure, or traumatic brain injury (TBI), has been proposed to act as an
alarmin, promoting inflammation and neuronal loss through its binding to Toll-Like
Receptor 4 (TLR4) [594-596]. Gal3-mediated TLR4 activation could result in excessive
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and prolonged microglial activation with resulting inflammation becoming detrimental
[594], a view supported by the neuroprotective phenotype in Gal3 KO or Gal3
neutralizing antibody-treated animals despite TBI insult [596]. These actions not only
highlight the potential application of galectin proteins to the study of endocytic vesicle
rupture by invading fibrillar amyloid protein assemblies, but also portend the
consequences of such vesicle damage in the resulting intracellular and extracellular
galectin-mediated inflammatory responses that could contribute as one of many causes
for neurotoxicity.
Infectious Pathogens and Sterile Damage.
Insight into the mechanisms and consequences of amyloid protein-mediated
vesicle rupture can be gained from examining other paradigms of cellular infection by
pathogens that are also confronted with this vesicular escape hurdle en route to cellular
invasion and continuation of their infectious life cycle. While physical damage to the
endocytic vesicle membrane allows invading pathogens to subvert lysosomal
degradation and escape into the cytosol where replication proceeds, this mechanism of
cellular invasion is particularly damaging to intracellular vesicles and induces their
autophagic degradation. Once a pathogen breaks the vacuolar membrane to gain access
to the cytosol, a diverse set of cellular responses ensues. PRRs, with cytosolic galectins
being some of many, respond to danger by identifying both pathogen-associated
molecular patterns (PAMPs) associated with the invading bacterium or virus as well as
damage-associated molecular patterns (DAMPs) associated with the damaged vesicles

[592]. The vesicular membrane remnants act as a signaling node for PRR activity,
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triggering both galectin- and polyubiquitination-mediated autophagic degradation [570,
576, 579, 597-600]. This upregulation of autophagic degradation mechanisms not only
helps to remove and recycle vesicular debris, but can also serve an antibacterial function
to restrict intracellular proliferation of invading pathogens through their degradation
[570, 579, 601, 602]. Even in the absence of pathogen invasion, sterile vesicle
membrane damage caused by transfection reagents such as calcium phosphate
precipitates (CPPs) or latex beads coated with Effectene also result in ubiquitination and
subsequent autophagic degradation of the damaged vesicles [597, 603]. In addition to
binding exposed b-galactosides, galectins 3 and 8 are an essential component of the
pathway facilitating recruitment of the autophagic machinery to the site of vesicle
damage [570, 579, 602, 603]. Autophagy-mediated degradation of invading pathogens
and ruptured vesicular debris is one adaptive mechanism for cells to survive these forms
of stress.
One specific example of a pathogen infection that closely resembles the
mechanism of a-syn cellular invasion is that of adenovirus, where both the process of
vesicular escape and the consequences of lysosomal rupture are shared. As a nonenveloped virus, adenovirus enters cells via endocytosis where it must then escape from
the endocytic compartment [575]. Upon exposure to the low pH of the late endosome
or early lysosome, the viral capsid undergoes a conformational change that allows a
membrane-perturbing protein known as protein VI to associate with the lipid membrane

and generate a positive membrane curvature, resulting in the physical rupture of the
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endosome [604, 605]. This vesicular membrane fragmentation ability of adenoviral
protein VI closely resembles that of a-syn monomers, perhaps mediated by their shared
amphipathic nature. Endocytic vesicle rupture induced by adenovirus also results in Gal3
recruitment to the site of rupture, occurring for adenovirus most often in the early
stages of the endosomal pathway for the evolutionary reason that adenovirus thus
avoids enzymatic digestion in the lysosome [606, 607]. Adenovirus, like a-syn, has also
been shown to induce small plasma membrane lesions through the actions of protein VI,
resulting in Ca2+ influx and lysosomal exocytosis to repair plasma membrane piercing
[608]. Endocytic vesicle rupture by adenovirus, like a-syn, results in release of activated
cathepsins and a consequent upregulation in mitochondrial ROS [609]. Examining the
process of cellular infection by various pathogens or sterile damage in endocytic vesicle
membranes has illuminated similarities with the cellular invasion of a-syn aggregates, as
well as highlighted several detrimental cellular consequences resulting from endocytic
vesicle rupture.
Lysosomal Membrane Permeabilization.
Lysosomal rupture induced by a-syn aggregates after their endocytic uptake is
one of many diverse causes of lysosomal membrane permeabilization (LMP), a common
programmed cell death pathway induced by various cytotoxic stimuli and stressful
cellular conditions [610, 611]. Just as observed in response to a-syn endocytic uptake
and lysosomal rupture, the LMP pathway causes the release of lysosomal cathepsins

105
and other hydrolases from the lumen to the cytosol, causing aberrant digestion of vital
proteins, oxidative stress, and inflammatory sequelae [610]. In addition to endocytic
vesicle rupture by fibrillar assemblies of amyloid proteins or invading pathogens, other
stimuli such as ROS, endogenous cell death effectors like Bax, lysosomotropic
compounds with detergent activity like L-leucyl-L-leucine methyl ester (LLOMe), high
doses of the quinolone antibiotic ciprofloxacin, uptake of mineral crystals such as silica
and monosodium urate (MSU), and even adherent noningested bacteria like Type 1fimbriated Escherichia coli also induce LMP [610, 612-615]. There is additional evidence
that the nucleotide-binding oligomerization domain-like receptor family, pyrin domaincontaining 3 (NLRP3) inflammasome, activated in response to many of the same stimuli
as LMP, may also contribute to its induction [616].
The ectopic presence of lysosomal proteases in the cytosol resulting from LMP
causes caspase activation indirectly through cathepsin-mediated cleavage and activation
of Bid, inducing mitochondrial outer membrane permeabilization (MOMP), cytochrome
c release and caspase activation during apoptotic cell death [610]. This induction of the
mitochondrial apoptotic pathway through Bid activation synergizes with a concomitant
degradation of antiapoptotic Bcl-2, Bcl-xL, or Mcl-1 by lysosomal proteases [614].
However, if LMP is massively increased, cell death can occur through necrosis in the
absence of caspase activation [610, 617]. This LMP cell death pathway can be regulated
under physiologic conditions or can contribute to cell death in in pathological situations,
including PD [611, 618]. In PD pathogenesis, lysosomal depletion is known to be caused

by ROS-mediated LMP, which results in defective clearance and subsequent
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accumulation of autophagosomes and dopaminergic cell death mediated by the
released lysosomal proteases [130]. Additionally, dysfunctional lysosomal degradation
and the resulting accumulation of autophagosomes leads to LB inclusion formation, as
LBs contain markers of autophagosomes in PD brain [130]. These findings highlight the
important role of LMP in neurodegenerative pathology as a consequence of amyloidmediated lysosomal rupture, oxidative stress, or a combination of the two.
LMP has been noted, similar to pathogen-induced endocytic vesicle rupture,
through a variety of techniques that rely on detecting either the release of normal
lysosomal factors, such as cathepsins or fluorescent dextran, or the localized
accumulation of membrane damage sensors upon permeabilization, like the enrichment
of galectin puncta [617, 619-623]. These methods have been employed to determine
that cells can survive limited LMP that occurs at a basal, resting state, but can also be
overwhelmed by LMP and succumb to this insult following more significant incidence
[620]. Following membrane permeabilization, damaged lysosomes are selectively
engulfed by autophagosomes following the recruitment of autophagic machinery to the
site of damage, resulting in their recovery of low pH and degradation capacity [615].
This autophagosomal clearance of damaged lysosomes begins with lysine 63 (K63)linked ubiquitination of damaged membranes and the recruitment of p62, followed by
translocation of the ubiquitin-directed AAA-ATPase p97, which cooperates with
cofactors UBDX1, PLAA, and the deubiquinating enzyme YOD1 as components of the

endolysosomal damage response (ELDR) to remove lysine 48 (K48)-linked ubiquitin
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conjugates and promote autophagosome formation [560]. If autophagic degradation is
compromised in the setting of LMP, this causes inhibition of lysosomal biogenesis since
functional, degradation-competent lysosomes cannot be regenerated through
autophagy [615]. Particularly relevant for the cell-to-cell propagation of amyloid fibrils
following entry via endocytic vesicle rupture, elevated intracellular Ca2+ induced by
exogenous amyloid proteins [210, 382, 550, 551, 556, 624] triggers lysosomal exocytosis
to repair membrane ruptures, releasing lysosomal contents to the extracellular
environment [478, 512, 625]. Autophagy, too, may be involved in the unconventional
secretion of leaderless cytosolic proteins such as a-syn and Gal3, as lysosomal damage
leads to the recognition of unconventional secretory cargo by specialized cytosolic cargo
receptors and a dedicated SNARE system to facilitate secretion [626]. Overall, LMP has
important consequences for invading fibrillar amyloid assemblies that are relevant to
both their impaired degradation and their pathological release from the cells into which
they have invaded.
Concluding Remarks
The prion-like characteristics of amyloid proteins in various neurodegenerative
diseases not only provide a platform for in-depth examination of disease pathogenesis,
but also raise the possibility that similar therapeutic strategies may be effective to
combat shared mechanisms of neurotoxicity in this group of progressive, currently
intractable diseases. Misfolded aggregates of a-syn in PD, tau in AD, and HTTExon1 in
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HD are considered “prion-like” for their many shared characteristics with prions but also
for the important lack of transmissibility between host organisms only seen with true
prions. Even so, considering the pathogenesis of these diverse proteinopathies from the
cell biological perspective of host-pathogen interactions yields novel insight into disease
mechanisms that were previously poorly understood. Although the “pathogen” is
derived from pathological aggregation of a host protein, many aspects of its cellular life
cycle such as cellular invasion, amplification, and propagation are similar to an infection
by a foreign agent.
Three aspects of prion-like amyloid proteins make combating cellular “infection”
by these protein aggregates particularly challenging. First, the ability of misfolded
amyloid proteins to serve as both seeds and templates for further misfolding of naïve
counterparts represents the mechanism by which a pathologic protein aggregate can
replicate and amplify its protein misfolding pathology [197, 200-202, 212, 213, 347, 490,
492, 525, 526, 533]. Second, the ability of misfolded amyloid proteins to interfere with
the very mechanisms that cells employ to degrade them represents a positive feedback
mechanism for degradative dysfunction and amyloid protein accumulation [130, 340,
341, 356, 358]. Finally, the ability of misfolded amyloid proteins to propagate from
affected to naïve cells represents the mechanism of disease progression and
dissemination [212, 213, 419, 420, 498, 502, 535].
Endocytic vesicle rupture, an event occurring during cellular invasion by fibrillar
amyloid protein assemblies, exerts influence on all three challenging aspects of prion-

like pathology. Rupture of endocytic vesicles represents the mechanism of amyloid
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protein vesicular escape following uptake, an essential step in the cell-to-cell
propagation pathway, which induces degradative dysfunction through damage to
lysosomal membranes and allows seeding of further aggregation by the escaped seed
nucleus. As an event that impacts these critical pathological activities of misfolded
protein aggregates, a clear understanding of its mechanisms and consequences is
essential for a complete understanding of disease pathogenesis.
The goal of this dissertation is to better understand endocytic vesicle rupture as
a mechanism of cellular invasion for several amyloid proteins, focusing for a-syn on
specific modifications that influence vesicle rupture potency as well as the effects of asyn-mediated rupture on cellular homeostasis and aggregate propagation. Taken
together, these studies demonstrate the ability of fibrillar amyloid protein assemblies to
induce endocytic vesicle rupture, and provide a clear understanding of the impact of this
damaging mechanism of cellular invasion on the pathogenesis and progression of
proteinopathies.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines and Media
The human neuroblastoma cell line SH-SY5Y was obtained from the American
Type Culture Collection (ATCC, Manassas, VA). The rat dopaminergic neuronal cell line
N27 was a kind gift from Dr. Anumantha Kanthasamy [627]. SH-SY5Y cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15%
fetal bovine serum (FBS) (Hyclone) and 100 IU/mL penicillin, 100 µg/mL streptomycin,
and 10 µg/mL ciprofloxacin. N27 cells were maintained in Roswell Park Memorial
Institute (RPMI) 1640 media with 10% FBS and the same additives used for SH-SY5Y
cells. Human embryonic kidney 293T cells were cultured in DMEM supplemented with
10% FBS and the same additives used for SH-SY5Y cells. SH-SY5Y and N27 cells were
plated on fibronectin (Sigma)-treated glass coverslips or Delta T dishes (Bioptechs) at
least 12 hr prior to experiments. Human dopaminergic neurons differentiated from
human induced pluripotent stem cells (hiPSC-derived dopaminergic neurons) were
obtained from Cellular Dynamics International (iCell DopaNeurons, CDI, Madison, WI).
hiPSC-derived dopaminergic neurons were grown on dishes pre-coated with poly-Lornithine and laminin according to the supplier’s instructions. One half of the hiPSCderived dopaminergic neuron complete maintenance media was changed at
110
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24 hr post thaw and every other day thereafter until the start of experiments, between
4-14 days post thawing. Cells were maintained in a 37°C incubator with 5% CO2.
Generation of Stable Cell Lines
The mCherry-galectin 3 (chGal3) lentiviral plasmid was generated by inserting
the galectin 3 open reading frame (ORF) into a mCherry-pLVX backbone (Takara Bio
USA, Mountain View, CA). Lentiviruses for transduction were produced by
polyethylenimine (PEI) (molecular weight, 25,000; Polysciences) transfection of 293T
cells seeded at 60% confluency in a 15 cm dish with 8.33 µg PLVX mCherry-Gal3, 8.33 µg
vesicular stomatitis virus glycoprotein (VSV-G), and 8.33 µg PsPax2 (lentiviral packaging
plasmid, AIDS Reagent Repository). Fresh media was added 24 hr after transfection and
viruses were harvested 48 hr after transfection. Following filtration through a 0.45-µm
filter (Millipore), viruses were used to transduce SH-SY5Y, N27, and hiPSC-derived
dopaminergic neurons. Twenty-four hours after infection, vector was removed and
replaced with fresh media. Forty-eight hours after transduction, SH-SY5YchGal3 or
N27chGal3 cells were selected in media containing 5 µg/mL puromycin (Sigma-Aldrich).
The yellow fluorescent protein (YFP)-LC3 lentiviral plasmid was generated by
inserting the YFP-LC3 open reading frame into pLVX (Takara Bio USA, Mountain View,
CA). Lentiviruses for transduction were prepared in an identical fashion to above, and
used to transduce SH-SY5YchGal3 cells previously transduced to express chGal3 with a
retroviral vector [4]. SH-SY5YchGal3 YFP-LC3 cells were selected in media containing 400
µg/mL Geneticin (G418, Gibco) and 5 µg/mL puromycin.

Amyloid Proteins
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Alpha-Synuclein.
Wild type and familial mutant alpha-synuclein assemblies. A pET-28a plasmid
containing human WT a-syn cDNA was generously provided by Dr. Anurag Tandon
[280]. Human a-syn cDNAs for familial mutants (A53T, A30P, E46K, and G51D) were
subcloned into this pET-28a plasmid using NcoI and HindIII restriction sites. a-syn was
purified as previously described [628]. Briefly, a-syn was overexpressed in Escherichia
coli BL21 via an isopropyl-1-thio-b-D-galactopyranoside (IPTG)-inducible T7 promoter.
The bacterial pellet was resuspended in phosphate-buffered saline (PBS) containing 1
mM phenylmethylsulfonyl fluoride (PMSF). The bacterial pellet was then sonicated for
15 sec several times, boiled for 15 min, and centrifuged at 10,000 x g for 20 min. The
supernatant was then ultracentrifuged at 150,000 x g for 30 min. The supernatant
containing the heat-stable a-syn was dialyzed against 50 mM Tris, pH 8.3, loaded onto a
Q-Sepharose column (GE Healthcare), and eluted with a 0-500 mM NaCl linear gradient.
Ion exchange fractions were analyzed by sodium docedyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Coomassie Brilliant Blue (CBB) staining and
western blotting for a-syn to confirm purity. Appropriate ion exchange fractions were
pooled, dialyzed against 20 mM Tris, pH 7.4, sterile filtered, flash frozen in liquid
nitrogen, and stored at -80 °C. Protein concentration was determined by spectrometer
absorbance at 280 nm using an extinction coefficient of 5960 M-1cm-1.

a-syn samples were prepared for aggregation by standardizing protein and
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solute concentrations, as well as total sample volume, across all samples according to
our previously published aggregation conditions [4, 280]. Specifically, 200 µL of purified
a-syn (1 mg/mL) was prepared in a pH 7.4 buffer containing the following solute
concentrations: 323.3 mM NaCl, 20 mM Tris-HCl, 9 mM Na2HPO4, 2.43 mM KCl, and 1.62
mM KH2PO4. Sample preparations were then incubated for 3 days at 37 °C under
constant agitation (300 revolutions per minute (rpm), Benchmark Incu-Shaker Mini),
followed by flash freezing in liquid nitrogen and storage at -80 °C. Assemblies were
fluorescently labeled with DyLight488 N-hydroxysuccinimide (NHS) ester fluorophores
(Thermo Scientific) according to the manufacturer’s protocol prior to use. Briefly, 100 µL
of aggregated protein at 1 mg/mL was dialyzed into 0.1 M sodium phosphate buffer, pH
8.0, for 2 hr at 4°C using 10,000 molecular weight cutoff (MWCO) minidialysis units
(Thermo Scientific). The protein solution was then transferred to the vial containing the
dye and was labeled as per the supplier’s instructions for 30 min at room temperature
(RT). After incubation, the labeling reaction was quenched with 40 mM Tris (final
concentration), and extensive dialysis was performed at 4 °C using 10,000 MWCO
dialysis units into a buffer containing 40 mM Tris and 150 mM NaCl for about 24 hr to
remove excess unlabeled dye. Following labeling, samples were flash frozen in liquid
nitrogen and stored at -80°C.
Phosphorylated serine-129 alpha-synuclein aggregates. Recombinant WT, A30P,
and A53T a-syn were expressed in E. coli with or without PLK2, purified as described

previously [628], and stored in 20 mM Tris-Cl, pH 7.4 at -80 °C. Samples containing
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monomeric WT, WT pS129, A30P, A30P pS129, A53T, and A53T pS129 a-syn were
aggregated under identical protein and solute concentrations and in the same volume
as for WT and mutant a-syn assemblies above, followed by storage at 4 °C. Fluorescent
labeling was also performed in a manner identical to that of WT and mutant a-syn
assemblies as above, followed by storage at 4 °C.
Alpha-synuclein polymorphic assemblies. To generate distinct fibrillar
polymorphs of a-syn, the WT protein was expressed in Escherichia coli strain BL21(DE3)
(Stratagene, La Jolla, CA) transformed with the expression vector pET3a (NovagenTM)
encoding wild-type, full-length a-syn. The expression of a-syn was induced by 0.5mM
IPTG for 2 hr when the bacteria grown in lysogeny broth (LB) medium at 37 °C reached
an optical density of 1.0 at 660 nm. Soluble, monomeric a-syn was purified from the
bacteria lysate as previously described [629]. a-syn concentration was determined
spectrophotometrically using an extinction coefficient of 5960 M-1cm-1 at 280 nm. Pure
a-syn (0.2-0.5mM) in 50mM Tris-HCl, pH 7.5, 150mM KCl was filtered through sterile
0.22-µm filters and stored at -80 °C. To obtain on-fibrillar assembly pathway a-syn
oligomers, a-syn was incubated at 800 µM in 50mM Tris-HCl, pH 7.5, 150mM KCl at 4°C,
without shaking, for 7 days, followed by separation from monomeric a-syn by size
exclusion chromatography using a Superose6 HR10/30 column (GE Healthcare)
equilibrated in PBS buffer [210, 382, 556, 630]. To obtain the polymorph “fibrils”, a-syn
(400 µM) was assembled in 50 mM Tris-HCl, pH 7.5, 150 mM KCl as described [305]; to
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obtain the polymorph “ribbons”, a-syn (400 µM) was dialyzed overnight against 5 mM
Tris-HCl pH 7.5 prior to assembly [305]; to obtain the polymorph “fibrils-91”, a-syn (400
µM) was dialyzed overnight against 20 mM KPO4 pH 9.1 prior to assembly as described
[309]; to obtain the polymorph “fibrils-65”, a-syn (400 µM) was dialyzed for 3 hours
against 20 mM MES pH 6.5, 150 mM NaCl prior to assembly. Assembly was achieved by
incubating the samples for one week at 37 °C under continuous shaking in an Eppendorf
Thermomixer set at 600 rpm. Fibrillar assemblies were spun at 15,000 x g for 10 min and
resuspended in PBS. Labeling of all polymorphs was achieved by addition of 2 molar
equivalent of lysine reactive ATTO-488 (ATTO-TEC, GMBH) for 1 hr at RT. The unreacted
fluorophore was removed from fibrillar preparations by a cycle of two centrifugations at
15,000 x g for 10 min and resuspensions of the fibrillar pellets in PBS. Unreacted
fluorophore was removed from oligomeric preparations by size exclusion
chromatography. Fibrillar preparations homogenous in size were obtained through
sonication by fragmenting fibrillar polymorphs for 20 min at a constant temperature
(20°C) in 2 mL Eppendorf tubes in a VialTweeter powered by an ultrasonic processor
UIS250v (250 watts, 24 kHz, Hielscher Ultrasonic, Teltow, Germany) set at 75%
amplitude, 0.5 sec pulses every 1 sec. On-fibrillar assembly pathway oligomeric a-syn
was not fragmented.
Alpha-synuclein pre-formed fibrils. a-syn monomer to generate PFFs (Proteos,
Inc, Kalamazoo, MI) was prepared according to the manufacturer’s protocol [203].
Briefly, a-syn was assembled in PBS at 5 mg/mL by incubation for 7 days at 37 °C under
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constant agitation (300 rpm, Benchmark Incu-Shaker Mini), followed by flash freezing in
liquid nitrogen and storage at -80°C. Samples were fluorescently labeled with Dylight488
or Dylight650 NHS ester fluorophores as above, with the exception that pre-labeling
dialysis was omitted as samples could be sufficiently labeled in PBS buffer, and postlabeling dialysis was performed using PBS at RT. Following labeling, samples were flash
frozen in liquid nitrogen and stored at -80°C. Immediately prior to use, PFFs were
generated from aliquots of Dylight488 or Dylight 650-labeled a-syn assemblies by
diluting each sample to 0.1 mg/mL in PBS and sonicating with 60 pulses at 20% power
for 0.5 sec each using a Sonics Vibra Cell sonicator (VCX 130PB, Sonics and Materials Inc,
Newtown, CT).
Tau.
Full-length human tau 1N3R and tau 1N4R cloned in pET14b vector were
expressed in E. coli BL21 DE3 codon + cells (Stratagene). Cells were grown in LB medium
to an optical density of 0.8 absorbancy units at 600nm. Tau isoform expression was
induced by 0.5 mM IPTG for 3 hr. The cells were then centrifuged (4,000 x g, 10 min),
resuspended in lysis buffer (20 mM MES pH 6.8, 500 mM NaCl, 1 mM EGTA, 0.2 mM
MgCl2, 5 mM dithiothreitol (DTT), 1 mM PMSF + 1 tablet of Complete (Roche)) per liter
and lysed by sonication. Bacterial homogenates were clarified by centrifugation at
14,000 x g for 30 min. The supernatant was heated to 80 °C for 20 min and centrifuged
at 14,000 x g for 30 min. The supernatant was dialyzed against 100 volumes of buffer A
(20 mM MES pH 6.8, 50 mM NaCl, 1 mM EDTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF)
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at 4 °C. The dialyzed protein mixture was loaded on SP Sepharose column (60 mL bed
volume). Proteins were separated with a linear gradient of 0 to 100% buffer B (20 mM
MES pH 6.8, 1 M NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0.1 mM PMSF). Fractions
were analyzed on SDS-PAGE stained with CBB. Fractions containing human tau isoforms
were pooled and dialyzed against 100 volumes of PBS buffer containing 1 mM DTT. The
protein concentration was determined spectrophotometrically using an extinction
coefficient of 7450 M-1cm-1 at 280nm. Tau 1N3R and tau 1N4R at a concentration of 50
to 100 µM were aliquoted and stored at -80 °C. Tau 1N3R and tau 1N4R (40 µM) were
assembled in the presence of 10 µM heparin at 37 °C in an Eppendorf Thermomixer set
at 600 rpm for 4 days. Fibrils were spun for 20 min at 20 °C, 16,000 rpm. Tau assemblies
were spun at 15,000 x g for 10 min and resuspended in PBS, followed by fluorescent
labeling in an identical fashion to labeling of a-syn polymorphic assemblies. Fibrillar tau
preparations homogenous in size were obtained through sonication as for a-syn
polymorphic assemblies.
Huntingtin.
Recombinant HTTExon1 with a polyQ stretch of 45 glutamine residues
(HTTExon1-Q45) was expressed and purified as described [631]. For fibril formation,
HTTExon1-Q45 was incubated in assembly buffer B (20 mM Tris-HCl, pH 7.5, 150 mM
KCl, 10% glycerol) at 37 °C without agitation. HTTExon1-Q45 assemblies were spun at
15,000 x g for 10 min and resuspended in PBS, followed by fluorescent labeling in an
identical fashion to labeling of a-syn polymorphic assemblies. Fibrillar HTTExon1-Q45

preparations homogenous in size were obtained through sonication as for a-syn
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polymorphic assemblies.
Electron Microscopy
WT and familial mutant a-syn assemblies were diluted to 0.1 mg/mL and added
to carbon-coated, 200 mesh copper grids (Electron Microscopy Sciences) for 60 sec.
Grids were stained with 2% uranyl acetate for 5 seconds. Grids were dried overnight and
transmission electron microscopy (TEM) performed on a Hitachi H-600 transmission
electron microscope.
The morphology of a-syn, tau and HTTExon1-Q45 polymorphs was assessed by
TEM in a Jeol 1400 transmission electron microscope following adsorption onto carboncoated 200 mesh grids and negative staining with 1% uranyl acetate. The images were
recorded with a Gatan Orius CCD camera (Gatan).
mCherry-Galectin 3 Relocalization Assay
At least 12 hr following the plating of SY5YchGal3 or N27chGal3 cells onto
fibronectin-coated glass coverslips or dishes, or at least 48 hr following chGal3 lentiviral
transduction of hiPSC-derived dopaminergic neurons, amyloid assemblies were added to
the cell culture media. For comparisons of the effect of a-syn missense mutation and
S129 phosphorylation, WT and familial mutant a-syn assemblies and pS129 a-syn
aggregates were added at a concentration of 200 nM. For comparisons of the effect of
amyloid strain conformation, a-syn monomer, oligomers, fibrils, ribbons, fibrils-65,
fibrils-91, and assemblies of HTTExon1-Q45, tau 1N3R and tau 1N4R were added at a
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concentration of 660 nM. Following 24-48 hrs of treatment time as specified for each
experiment, cells were either fixed to be mounted on coverslips or imaged directly via
live cell imaging.
Immunofluorescence Microscopy
Cells were fixed with 3.7% formaldehyde (Polysciences) in 0.1 M piperazine-N,
N’bis(2-ethanesulfonic acid) (PIPES) buffer, pH 6.8, for 5 min. When immunofluorescent
staining was performed, cells were stained with rabbit anti-human LAMP1 antibodies
(1:1000, ab24170, Abcam, Cambridge, MA) in PBS with 10% normal donkey serum (NDS)
and 0.1% saponin (Sigma-Aldrich) for 1 hr. Primary antibodies were then secondarily
labeled for 20 mins with fluorophore-conjugated donkey anti-rabbit 647 antibodies
(1:400, Jackson ImmunoResearch) at the same time as 4ʹ,6-diamidine-2ʹ-phenylindole
(DAPI) staining. When vesicle rupture was examined in the absence of
immunofluorescent staining, cells were stained with DAPI alone for 20 min in PBS.
Coverslips were then mounted on glass slides using Fluoro-Gel with Tris Buffer (Electron
Microscopy Sciences) and allowed to dry before image acquisition. Images were
collected with a DeltaVision wide-field deconvolution microscope (Applied Precision)
equipped with a digital camera (CoolSNAP HQ or Cascade 2 Electron Multiplying Charge
Coupled Device (EMCCD); Photometrics), using either a 1.4-numerical aperture (NA)
100X oil-immersion objective lens or a 1.42-NA 60X oil-immersion objective lens with
immersion oil (N=1.514, Applied Precision) at RT. Images were then acquired and
constrained iterative deconvolution performed using SoftWoRx software (Applied
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Precision). Tif images and quantification data were collected from each image data file
using Imaris software (Bitplane). To exclude the possibility that the image deconvolution
process affects the quality of images or localization pattern of any fluorescent signal, an
image from Figure 15 is displayed again in Figure 33 where a single field, in addition to
enlarged inset images, is displayed as overlay or individual fluorescent channels in both
an undeconvolved and deconvolved setting.
Live Cell Imaging
Images and videos were acquired on a DeltaVision wide-field deconvolution
microscope (Applied Precision) equipped with a Weather StationTM chamber utilized to
maintain cells at 37 °C in 5% CO2. Images were acquired using either a 1.4-NA 100X oilimmersion objective lens or a 1.42-NA 60X oil-immersion objective lens and a Cascade 2
EMCCD (Photometrics) digital camera. Acquisition was performed at 37 °C using
immersion oil (N=1.520, Applied Precision), and images were deconvolved as described
above. In some experiments LysoTracker Deep Red (Thermo Scientific) was utilized to
identify acidic organelles in live cells. 60 min prior to imaging, cells were incubated in
the presence of 20 nM LysoTracker Deep Red for 30 min, washed with fresh media, and
imaged 30 min later.
Image Analysis
Deconvolved images of experiments utilizing WT and familial mutant a-syn
assemblies as well as polymorphic assemblies of a-syn, tau, and HTTExon1-Q45 were
analyzed for chGal3+ puncta formation by blinded manual quantification using the
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Imaris software program (Bitplane). Each experiment collected at least 20 images per
treatment type. Values for number of chGal3 puncta per cell were pooled across all
experiments for statistical analysis. Values for mean number of chGal3 puncta per cell
induced by each treatment type from at least three independent experiments were
compared with one another and to unexposed cells by use of student’s t-test or oneway analysis of variance with Tukey’s post-hoc multiple comparison test as appropriate
for each data set, and expressed as fold increases relative to unexposed cells which
were normalized to 1.
Deconvolved images of experiments utilizing pS129 a-syn aggregates were
analyzed for puncta formation by use of the Surpass Mode of the Imaris software
package (Bitplane). Specifically, a three-dimensional surface was created around chGal3
puncta by designing an algorithm for each experiment that specifically detected
punctate events that increased in intensity sufficiently above background fluorescence
(Figure 34). This same algorithm was uniformly applied to each image in the data set,
and the number of surfaces created by the algorithm was divided by the number of cells
in the field to measure puncta per cell. Each experiment collected at least 20 images per
treatment type. Algorithm-detected values for number of chGal3 puncta per cell were
pooled across all experiments for statistical analysis. Values for mean number of chGal3
puncta per cell induced by each a-syn treatment type from at least three independent
experiments were compared with one another and to untreated cells by use of one-way
analysis of variance and Tukey’s post hoc multiple comparison test. When mean number
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of chGal3 puncta per cell values from each experiment are normalized for pS129 a-syn
isoforms relative to their non-pS129 counterparts in the same experiment (set to 1),
unpaired t tests were performed to compare each a-syn pS129 isoform to its non-pS129
counterpart.
Parkinson’s Disease Brain Tissue Imaging
Brains were obtained at autopsy from 5 subjects (4 male, 1 female) with a clinical
and neuropathological diagnosis of PD. All patients with PD were diagnosed by
neurologists in the Section of Movement Disorders in the Department of Neurological
Sciences at Rush University Medical Center. Post mortem, the clinical diagnosis was
confirmed by neuropathologists at Rush University Medical Center. For PD, inclusion
criteria included a history compatible with idiopathic PD and at least two of the four
cardinal signs (rest tremor, rigidity, akinesia/bradykinesia, and gait disturbance/postural
reflex impairment). The Unified Parkinson's Disease Rating Scale (UPDRS “on”) and
Hoehn and Yahr staging (H&Y “on”) were recorded, and for this study, tissue sections
from patients at H&Y Stage 5 were used. The pathological diagnosis was based on
finding Lewy bodies in catecholamine nuclei such as the SN. Exclusion criteria included
familial PD, dementia with Lewy bodies, the Lewy body variant of AD, or the
combination of PD and AD.
At autopsy, the brains were removed from the calvarium and processed as
described previously [346, 632]. Briefly, each brain was cut into 1 cm coronal slabs using
a plexiglass brain slice apparatus and then hemisected. The slabs were fixed in 4%
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paraformaldehyde for 48 hr at 4 °C. The left side brain slabs were used for pathological
diagnoses. The right side brain slabs were cryoprotected in 0.1 M PBS (pH 7.4)
containing 2% dimethyl sulfoxide (DMSO), 10% glycerol for 48 hr followed by 2% DMSO,
20% glycerol in PBS for at least 2 days prior to sectioning. The fixed slabs containing the
SN were cut into 18 adjacent series of 40 µm thick sections on a freezing sliding
microtome for this study. All sections were collected and stored in a cryoprotectant
solution prior to processing.
A double-label immunofluorescence procedure was employed to determine
whether Gal3 colocalized with a-syn in LBs. The sections through the SN from each brain
were blocked for 1 hr in a solution containing 5% goat serum, 2% bovine serum albumin
(BSA), and 0.3% TritonX-100 in Tris buffered saline (TBS) and then incubated with asynuclein (pS129) (EP1536Y, ab51253; 1:1000; Abcam, Cambridge, MA) rabbit
monoclonal antibody overnight at RT. Following 6 washes in TBS, the sections were
sequentially incubated with goat anti-rabbit antibody coupled to Cy2 (1:200; Jackson
ImmunoResearch, West Grove, PA) for 1 hr. After 6 washes in TBS, the sections were
blocked again for 1 hr in a solution containing 5% goat serum, 2% BSA, and 0.3% Triton
X-100 in TBS. Sections were then incubated with Gal3 (1:300; 556904, BD Biosciences,
San Jose, CA) mouse monoclonal antibody overnight at RT. After 6 washes, the sections
were sequentially incubated in goat anti-mouse antibody coupled to Cy5 (1:200; Jackson
ImmunoResearch) for 1 hr. The sections were mounted on gelatin-coated slides and
allowed to air dry overnight. To block autofluorescence, the sections were rinsed in
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distilled water, dehydrated in 70% alcohol for 5 min, incubated in the autofluorescent
eliminator reagent (Millipore) for 5 min, and immersed in three changes of 70% alcohol.
After rinsing in distilled water, the sections were coverslipped using polyvinyl alcohol
with 1,4-Diazabicyclo[2.2.2]octane (DABCO) (Sigma-Aldrich).
Autofluorescence represents a potentially confounding factor using
immunofluorescence techniques in this tissue. However, we employed two means to
effectively minimize autofluorescence. First, Cy5 is a fluorophore in the infrared range,
and the autofluorescence from lipofuscin is minimized within this range of the visual
spectrum. Second, use of the autofluorescent eliminator reagent further blocked autofluorescence in the tissue [346]. Immunohistochemical control experiments included
omission of the primary antibodies (which control for the specificity of the staining
procedure and the secondary antibody) and inclusion of images taken in the A594
channel which is between Cy2 and Cy5 emission spectra (to control for signal bleedthrough to adjacent channels). The control sections were processed in a manner
identical to that described above. All control experiments resulted in the absence of
specific staining.
Brain sections were imaged using a DeltaVision wide-field deconvolution
microscope equipped with a digital camera (CoolSNAP HQ; Photometrics), using a 1.42NA 60X oil-immersion objective lens and N=1.515 immersion oil (Applied Precision) at
RT. Images were acquired and deconvolved and tif images generated as before. At least
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25 images of LBs were collected from each PD patient, and images were analyzed using
the Imaris software (Bitplane).

CHAPTER THREE
SERINE-129 PHOSPHORYLATION AND STRAIN CONFORMATION DETERMINE ENDOCYTIC
VESICLE RUPTURE POTENCY OF ALPHA-SYNUCLEIN AMYLOID ASSEMBLIES
Rationale
As previously discussed, the prion-like cell-to-cell propagation of a-syn
aggregates underlies the spreading of PD pathology throughout the brain and results in
the inexorable progression of clinical symptoms for affected patients. Understanding
the mechanism by which disease-associated a-syn aggregates enter target cells and
induce cellular dysfunction is therefore key to understanding the progressive nature of
PD as a neurodegenerative disease, and for developing effective disease-modifying
therapeutic strategies. Although much has been learned regarding the life cycle of a-syn
aggregates as they accumulate in diseased cells, traverse the extracellular environment,
and come to invade recipient cells to propagate protein misfolding and neurotoxicity,
much remains to be elucidated about this pathological disease transmission [380, 448,
465, 466, 633-637].
One central aspect of a-syn aggregate-induced pathology that defines the prionlike designation of a-syn aggregates is their ability to serve as seeds and templates for
further a-syn misfolding and assembly, and that internalization of a-syn seeds results in
the propagation and amplification of protein misfolding from diseased cells to their
126

normal neighbors when the seed encounters the naïve, expressed a-syn in the
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cytoplasmic environment [200, 202, 212, 213, 347, 454]. While endocytosis is the
predominant process for cellular uptake of a-syn aggregates [280, 450, 454], the
mechanisms by which misfolded extracellular a-syn aggregates then escape this
endocytic compartment to access the cytosol and directly interact with normal
intracellular a-syn remained poorly understood [448, 465].
By noting the striking similarity between a-syn infection and the infectious
mechanism of pathogens like adenovirus, Salmonella, or Shigella, our group contributed
an important mechanistic advancement in demonstrating that a-syn aggregates induce
lysosomal vesicle rupture following endocytosis, triggering cathepsin-mediated
oxidative stress and inflammasome activation [4]. Although this finding provided the
mechanism of contact between extracellular a-syn aggregates internalized in the
endocytic vesicle and soluble a-syn monomers in the cytosol, and linked a-syn spread
with known lysosomal, autophagic, oxidative, and mitochondrial stress in PD [326, 346,
638, 639], numerous questions remain about this damaging mechanism of cellular
invasion and its contribution to PD pathology. These previous studies did not elucidate
the molecular determinants of a-syn-induced vesicle rupture potency or pinpoint the
specific aggregate species of a-syn responsible for this vesicle damage, both of which
are mechanistic questions essential for a more complete understanding of endocytic
vesicle rupture in the cell-to-cell propagation pathway.

With the aim of determining specific modifications to a-syn assemblies that
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increase vesicle rupture potency, we sought to examine the impact of familial missense
mutation, S129 phosphorylation, and strain conformation on a-syn-induced vesicle
rupture, hypothesizing that these disease-associated modifications will increase potency
of vesicle rupture induced by a-syn assemblies. To measure the influence of these
modifications on the ability of a-syn to access the cytoplasm of cells following
endocytosis, we employed the chGal3 relocalization assay, as previously described [4,
280], to demonstrate enrichment of chGal3 at the site of intracellular vesicle rupture
induced by a-syn aggregates carrying each individual modification. This assay, as
described earlier, which we and others have also used to study both cellular entry by
pathogenic organisms [576-578, 606] and the LMP cell death pathway [560, 615, 620],
exploits the ability of chGal3 to bind target b-galactosides present exclusively on the
outer leaflet of the plasma membrane or the topologically-equivalent inner leaflet of an
internalized vesicle. In the context of an intact vesicular membrane, these b-galactoside
targets remain unavailable for binding and the cytoplasmic localization of chGal3
remains diffuse. In a situation of vesicle rupture following endocytosis of an invading
pathogen or a-syn fibril, these sugars are now exposed to the cytoplasmic chGal3
protein, resulting in the accumulation of chGal3 puncta that are visible by fluorescent
microscopy as distinct from the diffuse chGal3 cytoplasmic expression (Figure 8). In the
sections described below, we note vesicle rupture induced by fluorescently-labeled asyn assemblies carrying each modification as indicated by colocalization between chGal3
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Figure 8. Schematic of chGal3 relocalization assay. Galectin 3, fused to an mCherryfluorophore, recognizes through the CRD its target b-galactoside sugars present on the
extracellular leaflet of the plasma membrane or the inner leaflet of an internalized
vesicle. In the situation of an intact vesicle (left), the cytoplasmic localization of chGal3 is
diffuse. In the situation of a ruptured vesicle (right), luminal b-galactosides are now
exposed to the cytosolic milieu, allowing chGal3 binding and the resulting localization of
chGal3 is punctate, with discrete puncta localizing to the site of vesicle rupture.
puncta and a-syn fluorescence. Upon quantification of vesicle rupture induced by each
a-syn assembly type, we find that S129 phosphorylation and strain conformation dictate
the potency of a-syn-induced vesicle rupture. These results indicate the importance of
these a-syn modifications for influencing a-syn-induced vesicle rupture damage during
cell-to-cell propagation, and illuminate more details of how endocytic vesicle rupture is
involved in PD pathology.

WT and Mutant Alpha-Synuclein Assemblies Exhibit Similar Potency of
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Intracellular Vesicle Rupture
We first sought to determine if a-syn mutations associated with familial forms of
disease conferred to high-molecular weight assemblies of this protein an increased
ability to induce vesicle rupture. We hypothesized that assemblies of mutant forms of asyn associated with familial, autosomal dominant, early-onset PD would demonstrate an
increased potency of endocytic vesicle rupture compared to WT assemblies, thereby
accounting for their increased pathogenicity. To test this hypothesis, we utilized
purified, recombinant a-syn, including WT a-syn and familial mutants A53T [220], A30P
[221], E46K [222] and G51D [223]. To assess the ability of disease-associated a-syn
assemblies to induce vesicle rupture, we generated a-syn aggregates by shaking
recombinant a-syn for 3 days at 37 °C under identical protein and solute aggregation
conditions, followed by labeling of these assemblies with amine-reactive fluorophore, a
commonly utilized technique to follow a-syn microscopically [218, 454, 640]. Electron
microscopic examination of the reaction products revealed that following aggregate
formation and fluorophore labeling, fibrillar species were present in preparations of WT
and mutant a-syn associated with familial forms of disease, and a-syn aggregate
populations exhibited a similar size distribution (Figure 9).
Following the standardized in vitro aggregation and fluorophore labeling just
described, we investigated the relative abilities of these a-syn assemblies to induce
vesicle rupture following endocytosis. To test this hypothesis, we employed the chGal3
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Figure 9. Structural characterization of WT and familial mutant a-syn assemblies.
Morphologies of WT, E46K, A53T, A30P, and G51D a-syn assemblies. Representative
negatively-stained TEM of a-syn assemblies before and after Dylight488 labeling.
Assemblies were aggregated for 3 days at 37 °C under constant agitation followed by
fluorescent labeling with DyLight488 NHS ester fluorophores as described in the
Materials and Methods. Images are magnified 30,000X, scale bar = 1 µm.

relocalization assay in SH-SY5YchGal3 human neuroblastoma cells following 24 hr
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exposure to WT, A53T, A30P, E46K, and G51D a-syn assemblies in the culture media.
While untreated SH-SY5YchGal3 cells maintained a diffuse cytosolic localization of the
chGal3 marker of vesicle rupture (Figure 10), cells that were exposed to assemblies
made of WT or mutant a-syn associated with familial forms of PD demonstrated
pronounced relocalization of chGal3 to discrete punctate or annular structures that
colocalized with a-syn fluorescence (Figure 10, arrowheads). This punctate chGal3
phenotype and colocalization with a-syn is indicative of endocytic vesicle rupture
induced by a-syn assemblies. Moreover, consistent with the ability of a-syn to associate
with vesicular membranes, Dylight488-labeled a-syn aggregates can frequently be seen
adopting a curved or arc-shaped localization at the periphery of chGal3+ ruptured
vesicles. Quantification of this vesicle rupture by a-syn assemblies revealed that WT and
mutant a-syn associated with familial forms of PD induced vesicle rupture to the same
extent (2.5-3 fold increase relative to unexposed cells, p<0.0001) (Figure 11). These
results demonstrate that endocytic vesicle rupture induced by a-syn assemblies is not
tightly dependent on mutations associated with early disease onset.
Serine-129 Phosphorylation Increases Potency of Alpha-Synuclein-Induced
Vesicle Rupture
The experiments above suggest that individual familial disease-associated
mutations do not substantially influence the ability of aggregated a-syn to induce
vesicle rupture following endocytosis. However, a-syn can also be modified by multiple
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Figure 10. Vesicle rupture induced by WT and familial mutant a-syn assemblies.
SY5YchGal3 cells were subjected to 24 hr exposure in the culture media to 200nM
exogenous Dylight488-labeled assemblies of WT, E46K, A53T, A30P, or G51D a-syn,
followed by fixation and DAPI staining in PBS. a-Syn-induced vesicle rupture
(arrowheads) identified by chGal3 puncta colocalizing with a-syn. Left panel inset box is
enlarged and separated in right panels. Images representative of at least 20 images per
treatment in 4 independent experiments. Scale bar=10 µm (left), 1 µm (right 3 panels).
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Figure 11. WT and familial mutant a-syn assemblies exhibit similar potency of vesicle
rupture. Manual quantification of fold change in mean number of chGal3 puncta per cell
+/- standard error of the mean (SEM) induced by each treatment type relative to
unexposed cells, with N>190 cells per type in total from 4 independent experiments.
ANOVA p <0.0001, * denotes significance (p<0.0001) compared to unexposed cells as
determined by Tukey’s post-hoc multiple comparison test.
covalent PTMs and truncations that may affect both aggregation and cell-to-cell
propagation by influencing a-syn conformation and modifying membrane association,
complex formation, and degradation [259]. Perhaps the most ubiquitous PTM is S129
phosphorylation [260, 641], and given the fact that almost 90% of a-syn in LBs is
phosphorylated at S129 while only 5% of a-syn in normal brains carries this PTM [119122], S129 phosphorylation is tightly associated with pathological a-syn forms. We
therefore utilized the chGal3 relocalization assay to investigate the ability of

endocytosed non-phosphorylated and phosphorylated a-syn to rupture vesicular
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membranes and to test the hypothesis that this PTM alone or in combination with
disease-associated familial missense mutations can differentially affect the potency of
a-syn entry via this disruptive mechanism. We again generated a-syn aggregates by
shaking recombinant WT, A30P, or A53T a-syn in either their non-phosphorylated or
pS129 forms for 3 days at 37 °C under identical protein and solute aggregation
conditions, followed by labeling of these assemblies with amine-reactive fluorophore.
SY5YchGal3 cells were then exposed in the cell culture medium for 24 hr to these
labeled non-pS129 or pS129 a-syn aggregates, followed by an assessment of the
formation of chGal3 puncta as a measurement of vesicle rupture induction. Again, each
type of a-syn was able to induce chGal3 relocalization to intracellular punctate
structures when compared with the diffuse cytoplasmic localization in unexposed cells
(Figure 12), and the profound co-localization of a-syn and chGal3 puncta implicates asyn as the causative agent of membrane permeabilization. a-Syn aggregates again
adopted curved or arc-shaped appearances at the periphery of chGal3+ ruptured
vesicles in many instances.
To quantify vesicle rupture in a semi-automated, unbiased fashion and to
compare the relative abilities of each a-syn species to cause this membrane
permeabilization, algorithm-assisted identification of chGal3 puncta was employed in
unexposed and exposed cells. This algorithm reliably identified cytoplasmic chGal3
puncta (Figure 34). When the mean number of chGal3 puncta per cell values were
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Figure 12. Vesicle rupture induced by WT and familial mutant a-syn assemblies with or
without S129 phosphorylation. SY5YchGal3 cells were subjected to 24 hr exposure in
the culture media to 200nM exogenous Dylight488-labeled aggregates of WT, A30P, and
A53T a-syn with and without pS129, followed by fixation and DAPI staining in PBS. aSyn-induced vesicle rupture (arrows) identified by chGal3 puncta colocalizing with asyn. Left panel inset box is enlarged and separated in right panels. Images
representative of at least 20 images per treatment in 3 independent experiments. Scale
bar=10 µm (left), 3 µm (right 3 panels). Reproduced with permission from [280].

normalized so that pS129 a-syn isoforms were expressed as a fold change relative to
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their non-pS129 counterparts within the same experiments, all pS129 a-syn types show
an approximately 50% increase in the mean number of chGal3 puncta per cell relative to
their non-pS129 counterparts (Figure 13). Although pS129 A30P asyn was the only
pS129 a-syn aggregate to induce a statistically significant increase in chGal3 puncta per
cell relative to its non-pS129 counterpart, both pS129 WT a-syn and pS129 A53T a-syn
showed trends above their non-pS129 counterparts, although not reaching statistical
significance. This finding suggests that S129 phosphorylation impacts the potency of
vesicle rupture following endocytosis regardless of the influence of familial missense
mutation, and thus significantly contributes to neurotoxicity in the a-syn cell-to-cell
propagation pathway.
Alpha-Synuclein Strain Conformation Dictates Vesicle Rupture Potency
While previous results suggest that S129 phosphorylation significantly increases
the potency of a-syn-induced vesicle rupture, and that a-syn familial mutation has little
effect on membrane damage following endocytosis even when combined with S129
phosphorylation, the size and structural heterogeneity of the aggregates generated in
the manner described above prevents the identification of specific high-molecular
weight oligomeric or fibrillar species capable of inducing vesicle rupture. To more
precisely define a-syn high-molecular weight species responsible for endocytic vesicle
rupture, we utilized structurally well-defined WT a-syn assemblies and the chGal3
relocalization assay in SY5YchGal3 cells following 24 hr exposure to a-syn assemblies in
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Figure 13. S129 Phosphorylation increases potency of a-syn-induced vesicle rupture.
Algorithm-based quantification of fold change in mean number of chGal3 puncta per cell
+/- SEM induced by each treatment type relative to non-pS129 counterpart, with N> 200
cells per type in total from 3 independent experiments.* denotes significance (p<0.05)
compared to non-pS129 counterpart as determined by unpaired t test. Reproduced with
permission from [280].
the culture media. Generated in vitro by varying the aggregation conditions for
recombinant monomeric a-syn, the 7-day aggregation protocol results in fully elongated
a-syn assemblies of varying strain conformations which are then fragmented by
sonication, resulting in structurally well-characterized, homogenous assembly
populations of a smaller size distribution capable of cellular uptake by endocytosis
(Figure 14). This preparation protocol resembles that of a-syn PFFs, whose fibrillar
conformation and smaller size distribution make it the a-syn species most efficient for
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Figure 14. Structural characterization of WT α-syn polymorphs. Morphologies of a-syn
oligomers and fibrillar assemblies/strains. Representative negatively stained TEM of asyn on-fibrillar assembly pathway oligomers, fibrils, ribbons, fibrils-65, and fibrils-91,
shown before and after fragmentation for all except oligomers which were not
fragmented. Fibrillar assemblies were fragmented for 20 min at a constant temperature
(20 °C) in 2 mL Eppendorf tubes in a VialTweeter powered by an ultrasonic processor
UIS250v (250 watts, 24 kHz, Hielscher Ultrasonic, Teltow, Germany) set at 75%
amplitude, 0.5 s pulses every 1 s. Scale bar, 200 nm.

inducing seeding, propagating from cell-to-cell, and causing neurotoxicity [129, 200,
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202-204, 209-213, 219, 389-395, 439, 441, 442]. When a-syn monomers and on-fibrillar
assembly pathway oligomers were assessed in the chGal3 relocalization assay, these asyn forms were unable to induce significant vesicle rupture. Cells exposed to these
forms of a-syn exhibited a predominantly diffuse phenotype of chGal3 fluorescence
resembling that of untreated cells (Figure 15).
a-syn has been previously shown to assemble into fibrils that exhibit different
intrinsic structures, surfaces, seeding and persistence propensities [305]. These distinct
fibrillar polymorphs yield different synucleinopathies when injected into recipient
animals [218]. We hypothesized that differences in the surface and physical properties
of the distinct fibrils will influence their vesicle rupture potency. We therefore examined
the relative ability of four different a-syn fibrillar polymorphs, fluorescently labeled and
fragmented to produce fibrillar assemblies with uniform size distribution (Figure 14), to
induce vesicle rupture following endocytosis. We observed that a-syn fibrils, ribbons,
fibrils-65, and fibrils-91 potently induced endocytic vesicle rupture in target SY5YchGal3
cells as demonstrated by chGal3 relocalization to punctate or annular structures that
colocalize with a-syn fluorescence (Figure 15, arrowheads). Interestingly, quantification
of chGal3+ ruptured vesicles per cell revealed that a-syn fibrils, fibrils-65, and fibrils-91
significantly induced vesicle rupture compared to unexposed cells (2.5-4 fold increase,
p<0.0001 for fibrils and fibrils-65; p=0.0047 for fibrils-91), whereas a-syn ribbons were
unable to demonstrate a similar significant induction of vesicle rupture (p=0.2646).
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Figure 15. Vesicle rupture induced by WT a-syn polymorphs. SY5YchGal3 cells were
subjected to 24 hr exposure to 660nM exogenous Atto488-labeled fragmented
assemblies of WT a-syn fibrils, ribbons, fibrils-65, and fibrils-91, as well as a-syn
monomers and oligomers in the culture media, followed by fixation and DAPI staining in
PBS. a-Syn-induced vesicle rupture (arrowheads) identified by chGal3 puncta
colocalizing with a-syn. Left panel inset box is enlarged and separated in right panels.
Images representative of at least 20 images per treatment in 3 independent
experiments. Scale bar=15 µm (left), 3 µm (right 3 panels).
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Furthermore, a-syn fibrils were shown to be significantly more potent in their induction
of vesicle rupture compared to a-syn monomers, on-fibrillar assembly pathway
oligomers, and ribbons (p=0.0009 compared to monomers, p<0.0001 compared to
oligomers, p=0.0004 compared to ribbons), and a-syn fibrils-65 were shown to be
significantly more potent compared to a-syn oligomers (p<0.0001) (Figure 16). While asyn ribbons failed to demonstrate a statistically significant increase in vesicle rupture
induction compared to unexposed cells, we did observe instances where chGal3+
ruptured vesicles colocalized with a-syn ribbons (Figure 15). These data demonstrate
that the fibrillar nature of a-syn assemblies is an essential but not sufficient factor for
the induction of endocytic vesicle rupture by a-syn assemblies, and that the intrinsic
structural conformation of a-syn fibrillar polymorphs dictates the potency with which
this endocytic vesicle rupture occurs. Furthermore, given that distinct a-syn strains are
associated with different synucleinopathies, strain-specific differences in disease
phenotype may arise from varying levels of vesicle rupture potency induced by each asyn strain. Overall, the potency of a-syn aggregate-induced vesicle rupture is
determined by a unique combination of aggregate size and conformation that initiates
membrane damage following endocytosis.
Significance
The above findings reveal new information regarding the ability of a-syn
aggregates to induce vesicle rupture during the cell-to-cell propagation pathway.
Transmission of a-syn aggregates from diseased cells and brain regions to unaffected
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Figure 16. a-Syn strain conformation dictates vesicle rupture potency. Manual
quantification of fold change in mean number of chGal3+ puncta per cell +/- SEM
induced by each treatment type, with N>412 cells per type in total from 3 independent
experiments. ANOVA p <0.0001, * denotes significance compared to unexposed cells
(p<0.0001 for fibrils and fibrils-65, p=0.0047 for fibrils-91), # denotes significance
compared to monomer (p=0.0009 for fibrils), + denotes significance compared to
oligomer (p<0.0001), and ^ denotes significance (p=0.0004) compared to ribbons as
determined by Tukey’s post-hoc multiple comparison test.
ones underlies the widespread pathological progression of PD and the onset of
increasingly severe symptoms affecting an ever-growing number of brain functions [542,
642, 643]. Additionally, the infiltration of a-syn pathology into previously healthy brain
regions may also contribute to the failure of striatal dopaminergic neuronal grafts as a
potential therapeutic replacement for degenerating dopaminergic innervation in PD

[426, 644]. Insights into the mechanisms of cell-to-cell propagation have enormous
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potential to uncover new therapeutic targets that could be used to stem the tide of asyn deadly spread [448, 635, 645].
Prior to the work of our group, there was an unaddressed disconnect between
the uptake of a-syn amyloid aggregates via endocytosis and the seeding of further a-syn
aggregation in the cytosol [448, 465]. Since the endocytic pathways results in uptake of
a-syn aggregates sequestered within the vesicular compartment, the process by which
exogenous a-syn aggregates escape this compartment to contact cytosolic a-syn and
serve as misfolded templates was unclear. Our group was the first to directly address
this question of a-syn aggregate vesicular escape by employing the chGal3 relocalization
assay, a novel approach to investigating a-syn vesicular membrane damage having
previously been used only in the investigation of cellular invasion by infectious
pathogens [576-578, 606]. The application of this assay from the world of infectious
diseases is particularly appropriate given the parallels between a-syn aggregate cell-tocell propagation and the infectious mechanism of prions in TSEs. Just as bacteria or
viruses need to escape the vesicular compartment of entry to propagate their infection
by hijacking host replication machinery in the cytosol, so too must an a-syn aggregate
leave the endocytic vesicle to contact its own “replication machinery”, the pool of naïve
monomeric a-syn expressed in the cytosol. The demonstration that a-syn aggregates
are capable of inducing lysosomal rupture following endocytosis explained the
disconnect between the method of entry and the seeding of aggregation [4], although

many questions remained about which a-syn species is most capable of this entry
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mechanism and if various modifications to a-syn aggregates may modulate the potency
of rupture.
The above results illuminate the a-syn species most capable of inducing
endocytic vesicle rupture, short fragments of a-syn fibrils, and determined that S129
phosphorylation and strain conformation influence vesicle rupture potency. Using
several variations of in vitro a-syn aggregates prepared from recombinant forms of WT
or familial mutant a-syn, also with S129 phosphorylation in some cases, we have
demonstrated that all forms of fibrillar a-syn aggregates were capable of inducing
chGal3 relocalization to the site where they caused vesicle rupture. Consistent with our
previous findings [4], this vesicle rupture phenomenon is not induced in response to
treatment with a-syn monomers. We extend the nuances of vesicle rupture
determinants by showing specific a-syn structures such as on-fibrillar assembly pathway
oligomers that also do not induce vesicle rupture in target cells. Despite the early-onset
of PD associated with familial missense mutations in a-syn, aggregates created from asyn monomers carrying these mutations did not exhibit changes in vesicle rupture
potency compared with WT a-syn aggregates, but instead were each capable of
endocytic vesicle rupture to an equal extent. In contrast, aggregates created from a-syn
monomers phosphorylated at S129 were shown to be more potent compared with nonpS129 forms, implicating this PTM in increasing a-syn aggregate pathogenicity in the
cell-to-cell propagation pathway. That pS129 a-syn aggregates are more potent
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inducers of endocytic vesicle rupture and the resulting neurotoxicity may underlie the
enrichment of this PTM in pathological a-syn LB inclusions. Finally, the conformation
with which a-syn monomers pack into a larger fibrillar assembly is a critical modifier of
endocytic vesicle rupture potency, and highlights one mechanism for the variations in
disease phenotype caused by distinct a-syn strains. These findings are significant for the
new insights they bring into the damaging mechanism of cellular invasion by aggregates
of a-syn in their cell-to-cell transmission life cycle.

CHAPTER FOUR
AMYLOID ASSEMBLIES OF TAU AND POLYGLUTAMINE-EXPANDED HUNTINGTIN INDUCE
ENDOCYTIC VESICLE RUPTURE
Rationale
In addition to its relevance for a-syn in synucleinopathies, the prion-like cell-tocell propagation of amyloid proteins has also been implicated in the pathogenesis and
progression of numerous other neurodegenerative proteinopathies such as AD, CTE, HD,
and ALS, where it has been blamed, as in PD, for contributing to worsening pathology
and increasingly debilitating symptomatology [3, 42, 505, 522, 642, 646-650]. Although
the monomeric protein building blocks differ, there are many similarities among the
higher-order amyloid assemblies of each causative protein, and mechanistic insight
regarding the cell-to-cell propagation of one amyloid protein form may be relevant for
understanding the pathological behavior of others. Many aspects of the intracellular and
intercellular life cycle of amyloid proteins are yet to be fully understood, but the
prospect of translating insight from one proteinopathy to others holds enormous
promise toward developing a potential therapeutic strategy to stem the progressive tide
of numerous incurable neurodegenerative diseases.
In the case of tau in tauopathies and polyglutamine-expanded huntingtin in HD,
these proteins also perform prion-like seeding and templating of additional monomeric
constituents in the cytosol of naïve cells
147
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[201, 489-491, 493, 494, 498, 502, 505, 508, 510, 531, 533, 534]. Faithful templating of
misfolded structure and subsequent intracellular inclusion formation necessitates direct
contact between exogenous tau or HTTExon1 seeds and soluble cytosolic monomers,
and this direct contact has been demonstrated for exogenous and expressed versions of
tau, using FRET, and HTTExon1, using BiFC [510, 534]. Endocytosis is again the
predominant mechanism for cellular uptake of amyloid assemblies of tau and HTTExon1
[498, 506, 531], although like a-syn, its mechanism of vesicular escape remains an
enigma [465, 522, 531]. Because all the aforementioned fibrillar a-syn polymorphs
exhibited the ability to induce vesicle rupture in target cells, we explored whether this
damaging mechanism of cellular invasion was a specific consequence of a-syn aggregate
cellular entry, or if other neurodegenerative-related proteins could also induce vesicle
rupture. Endocytic vesicle rupture induced by these amyloid aggregates would provide
an explanation for contact between extracellular seeds and intracellular expressed
monomers, and in a manner similar to a-syn, also contribute to degradative,
mitochondrial, and oxidative stress in diseased cells.
With the aim of determining the conserved nature of amyloid cellular invasion
through endocytic vesicle rupture, we sought to examine the cellular uptake of fibrillar
assemblies composed of full-length WT tau isoforms 1N4R and 1N3R and HTTExon1Q45, hypothesizing that short fibrillar forms of these prion-like amyloid proteins would
also induce vesicle rupture following endocytosis. Investigation of this form of cellular
entry by assemblies of HTTExon1 is entirely novel, and while a limited number of reports

have examined the vesicle rupture capability of tau aggregates [507, 560], no other
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study has thus far utilized multiple isoforms of WT full-length tau in a neuronal model,
let alone employed rigorous assembly characterization to ensure specificity of effect. To
measure vesicle rupture induced by tau and HTTExon1-Q45 amyloid assemblies, we
again employed the chGal3 relocalization assay in SH-SY5Y human neuroblastoma cells
following exposure to well-defined exogenous fluorescently-labeled assemblies of these
proteins. In the sections below, we note vesicle rupture induced by tau and HTTExon1Q45 as indicated by colocalization between chGal3 puncta and fluorescently-labeled
amyloid assemblies. Furthermore, we find a significant increase in vesicle rupture
potency for assemblies composed of tau 1N4R compared with those composed of tau
1N3R, implicating differences in vesicle rupture potency as contributors to specific
disease phenotypes for distinct tau isoform strains. These findings highlight the
conserved nature of endocytic vesicle rupture in the cell-to-cell propagation pathway of
amyloid proteins composed of multiple neurodegenerative disease-related proteins.
Multiple Isoforms of Wild-Type Full-Length Tau Induce Endocytic Vesicle Rupture
In the diverse set of diseases characterized by tau inclusions, some diseases like
AD, CTE, and TD are characterized by inclusions of both 3R and 4R tau isoforms, whereas
inclusions of 3R isoforms predominate in PiD and 4R isoforms predominate in PSP, CBD,
and AGD [488]. Because various isoform compositions can result in unique strain
conformations that induce distinct disease phenotypes upon cell-to-cell propagation, we
hypothesized that assemblies of tau1N4R and tau1N3R would both induce vesicle
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rupture, but that differences in the potency of vesicle rupture induction may underlie
strain-specific disease phenotypes as they do for a-syn strains in PD. To test this
hypothesis, we generated in vitro fibrillar assemblies of full-length WT tau 1N4R and tau
1N3R from recombinant purified protein in a fashion similar to a-syn fibrillar polymorph
production, including prolonged assembly reactions, fluorophore labeling, and
fragmentation by sonication to produce homogenous preparations of tau fibrils of a
smaller size distribution to be taken up by endocytosis in target cells. This species of tau
assembly was chosen not only because of the efficacy of this amyloid assembly form for
a-syn-induced vesicle rupture, but also to allow a direct comparison with vesicle rupture
induced by a-syn assemblies of a similar size distribution, so that only protein
composition and conformation differ. TEM analysis revealed that the assemblies were of
fibrillar nature following aggregation, and maintained this fibrillar architecture following
fragmentation despite the decrease in fibril size (Figure 17). SY5YchGal3cells were then
exposed for 24 hr to these fibrillar tau assemblies, followed by an assessment of chGal3
relocalization to indicate endocytic vesicle rupture as for asyn assemblies. We noted
chGal3 relocalization to a punctate phenotype upon exposure of cells to fibrillar
assemblies of full-length WT tau 1N4R and 1N3R isoforms, whereas chGal3 remained
diffuse in unexposed cells (Figure 18). We observed robust colocalization between
chGal3+ ruptured vesicles and both isoforms of fluorescently-labeled fibrillar tau (Figure
18, arrowheads). This observation strongly suggests that fibrils composed of multiple
isoforms of WT full-length tau cause vesicular membrane damage upon cellular entry.
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Figure 17. Structural characterization of WT full-length tau polymorphs. Morphologies
of tau 1N4R and tau 1N3R assemblies/strains. Representative negatively stained TEM of
tau 1N4R and tau 1N3R polymorphs, shown before and after fragmentation. Fibrillar
assemblies were fragmented for 20 min at a constant temperature (20 °C) in 2 mL
Eppendorf tubes in a VialTweeter powered by an ultrasonic processor UIS250v (250
watts, 24 kHz, Hielscher Ultrasonic, Teltow, Germany) set at 75% amplitude, 0.5 s pulses
every 1 s. Scale bar, 200 nm.
Quantification of punctate chGal3 clearly indicates that both isoforms of fibrillar fulllength WT tau rupture endocytic vesicles to a significant extent compared to unexposed
cells, with a further significant increase in rupture potency induced by fibrillar tau 1N4R
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Figure 18. Vesicle rupture induced by multiple isoforms of wild-type full-length tau.
SY5YchGal3 cells were subjected to 24 hr exposure to 660nM exogenous Atto488labeled fragmented assemblies of tau 1N3R or tau 1N4R in the culture media, followed
by fixation and DAPI staining in PBS. Tau-induced vesicle rupture (arrowheads) identified
by chGal3 puncta colocalizing with tau. Left panel inset box is enlarged and separated in
right panels. Images representative of at least 20 images per treatment in 3
independent experiments. Scale bar=10 µm (left), 1 µm (right 3 panels).
compared to 1N3R (Figure 19). These findings provide the first demonstration that fibrils
composed of multiple full-length wild-type tau isoforms 1N4R and 1N3R are capable of
inducing vesicle rupture following endocytosis, and like a-syn, that the intrinsic isoform
composition and structural conformation of tau fibrillar polymorphs dictates endocytic
vesicle rupture potency. We have again implicated variations in vesicle rupture potency
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Figure 19. Tau isoform composition and strain conformation dictate vesicle rupture
potency. Manual quantification of fold change in mean number of chGal3+ puncta per
cell +/- SEM induced by assemblies of tau isoforms, with N>135 cells per type in total
from 3 independent experiments. ANOVA p <0.0001, * denotes significance compared
to unexposed cells (p<0.0001) and # denotes significance compared to tau 1N3R
(p<0.0001) as determined by Tukey’s post-hoc multiple comparison test.
in strain-specific differences in pathology. This observation underscores the importance
of this conserved endocytic vesicle rupture event as essential in the cell-to-cell
propagation life cycle of tau amyloid assemblies in diverse tauopathies.
Assemblies of Polyglutamine-Expanded Huntingtin Induce Vesicle Rupture
CAG repeat expansion in HTTExon1 yields a polyglutamine-rich huntingtin
protein with an increased propensity to spontaneously aggregate into a fibrillar amyloid
morphology when the polyglutamine tract expands to 37 glutamine residues or beyond
(HTTExon1-Q³37) [524], causing HD in patients with this dominantly-inherited genetic
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mutation [523]. Because HTTExon1 amyloid assemblies also propagate from cell-to-cell
in a prion-like manner and serve as seeds and templates for further aggregation, we
hypothesized that assemblies of HTTExon1 containing a polyglutamine tract of
pathologic length (Q45) would induce vesicle rupture following endocytosis. To test this
hypothesis, we again generated in vitro fibrillar assemblies of HTTExon1-Q45 from
recombinant purified protein, just as for a-syn and tau fibrillar polymorphs, using
prolonged assembly reactions combined with subsequent fragmentation to produce
homogenous small fibrillar preparations of HTTExon1 fibrils of an equivalent size
distribution to fragmented polymorphs of a-syn and tau. Because of this preparation
scheme, the size distribution of HTTExon1 assemblies is standardized with that of a-syn
and tau fibrillar polymorphs, allowing comparisons of vesicle rupture ability based only
on protein composition and conformation in the preparation form most potent for
inducing vesicle rupture, short amyloid fibrils. TEM analysis revealed that HTTExon1-Q45
assemblies are composed of amyloid fibrils just as assemblies of a-syn and tau, and
short fibrillar preparations are induced by sonication (Figure 20). As for other amyloid
preparations, we also utilized amine-reactive fluorophore labeling of HTTExon1 fibrils
for fluorescent microscopic detection, but despite the presence of four reactive primary
amine groups within the HTTExon1 amino acid sequence, we were unable to achieve
sufficient fluorescent labeling perhaps due to the limited accessibility of these amine
groups within the fibrillar aggregate.
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Figure 20. Structural characterization of HTTExon1-Q45 polymorph. Morphology of
HTTExon1-Q45 assemblies/strain. Representative negatively stained TEM of HTTExon1Q45 polymorph, shown before and after fragmentation. Fibrillar assemblies were
fragmented for 20 min at a constant temperature (20 °C) in 2 mL Eppendorf tubes in a
VialTweeter powered by an ultrasonic processor UIS250v (250 watts, 24 kHz, Hielscher
Ultrasonic, Teltow, Germany) set at 75% amplitude, 0.5 s pulses every 1 s. Scale bar, 200
nm.
SY5YchGal3cells were exposed for 24 hr to these fibrillar HTTExon1-Q45
assemblies, and chGal3 relocalization was assessed as an indicator of endocytic vesicle
rupture in target cells following their uptake of amyloid fibrils. We noted chGal3
relocalization to a punctate phenotype upon cellular exposure to HTTExon1-Q45 fibrillar
assemblies, whereas chGal3 again remained diffuse in unexposed cells (Figure 21). This
observation strongly implies that amyloid fibrils composed of HTTExon1 with a
pathologic stretch of polyglutamine residues also cause endocytic vesicular rupture just
like amyloid fibrils of asyn and tau. Due to the insufficient labeling of fibrillar HTTExon1Q45, we were unable to visualize colocalization of assemblies with chGal3+ ruptured
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Figure 21. Vesicle rupture induced by HTTExon1-Q45 polymorph. SY5YchGal3 cells
were subjected to 24 hr exposure to 660nM exogenous Atto488-labeled fragmented
assemblies of HTTExon1-Q45 in the culture media, followed by fixation and DAPI
staining in PBS. HTTExon1-Q45-induced vesicle rupture identified by chGal3 puncta. Left
panel inset box is enlarged and separated in right panel. Images representative of at
least 20 images per treatment in 5 independent experiments. Scale bar=15 µm (left), 3
µm (right).
vesicles. However, quantification of punctate chGal3 clearly indicates that fibrillar
HTTExon1-Q45 induces significant vesicle rupture as compared to unexposed cells

(Figure 22). These findings provide the first demonstration that fibrils composed of
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HTTExon1 with pathologic polyglutamine repeats are capable of inducing vesicle rupture
following endocytosis as a means of propagating their misfolded amyloid structure from
the extracellular to the intracellular environment. This observation is of critical
importance for understanding HD progression, and the conserved nature of vesicle
rupture induced following endocytosis of a-syn, tau, and HTTExon1 amyloid assemblies
raises the possibility that therapeutic strategies targeting this pathologic cellular entry
mechanism may be applied to reverse or prevent numerous proteinopathies.
Significance
The above results have uncovered a conserved role for endocytic vesicle rupture
as a mechanism of cellular invasion by amyloid assemblies of multiple
neurodegenerative disease-related proteins. Just as for a-syn in PD, amyloid assemblies
of tau and HTTExon1 are known to propagate from one cell to another, templating their
misfolded conformation onto soluble constituent monomers and inducing neurotoxicity
through a variety of mechanisms in the cells encountered along the transmission
pathway [465, 488, 522]. Much remains to be determined regarding the mechanisms
employed by amyloid protein assemblies during this pathological progression, especially
to understand if any mechanisms are shared between these prion-like amyloid proteins
or if each transmission process is as distinct as the respective etiological protein. Given
that the propagation of amyloid proteins underlies pathological disease progression,
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Figure 22. HTTExon1-Q45 assemblies induce significant increase in vesicle rupture
compared to unexposed cells. Manual quantification of fold change in mean number of
chGal3+ puncta per cell +/- SEM induced by assemblies of HTTExon1-Q45, with N>441
cells per type in total from 5 independent experiments. * denotes significance
compared to unexposed cells (p<0.0001) by unpaired student’s t test.
insights into their intracellular and intercellular life cycle are incredibly important for a
more complete picture of disease pathogenesis.
Critically, the incongruity between the cellular uptake of exogenous aggregates
into the endocytic vesicle and the seeding of further aggregation in the cytosol is shared
among the propagation pathways of a-syn, tau, and HTTExon1 amyloid aggregates [448,
465, 522, 531]. Given the common ability of a-syn aggregates to rupture endocytic
vesicles as a means of escape, and the utility of the chGal3 relocalization assay to
provide a reliable indication of this vesicular damage [4, 280, 619, 620], we examined
the vesicle rupture capability of tau and HTTExon1 amyloid assemblies. This process of

cellular invasion has never been investigated for HTTExon1 amyloids, and even for
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amyloid aggregates of tau, the studies examining its vesicle rupture capability have
significant limitations to the scope of their conclusions. One study found an ability of
P301L mutant tau aggregates to induce vesicle rupture in rat primary neurons
expressing chGal3, although the assembly form of exogenous tau was poorly
characterized since fluorescently-labeled whole cell lysates from HEK293 cells
expressing P301L mutant tau were used as a treatment [507]. Another study utilized
full-length WT 2N4R tau assemblies generated in vitro from recombinant purified
protein, although these preparations were heterogeneous and of high molecular weight
given that fragmentation was not performed, observing that these preparations induce
vesicle rupture as seen by chGal3 relocalization in a non-neuronal HeLa cell model [560].
Both studies are limited in that the exogenous tau assemblies used to demonstrate
vesicle rupture induction are not characterized to an extent that allows determination
of a specific effect of distinct tau assembly species. We employed in vitro generation of
tau assemblies composed of multiple isoforms of WT full-length tau, followed by
sonication to homogenize the assembly population size distribution by fragmenting
larger fibrillar assemblies into smaller amyloid fibrils more readily taken up through
endocytosis into target cells. The structurally well-defined nature of these WT full-length
tau assemblies guarantees the specific measurement of vesicle rupture induced by short
fibrillar tau assemblies.
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In demonstrating that fibrillar assemblies of tau 1N4R, tau 1N3R, and HTTExon1Q45 rupture endocytic vesicles following cellular uptake, we have provided an
explanation for the invasion mechanism by which exogenous fibrils contact intracellular
monomers. The shared ability of a-syn, tau, and HTTExon1 assemblies to induce
endocytic vesicle rupture implies that this pathological activity is a result of the fibrillar
amyloid architecture common to many aggregation-prone proteins. Endocytic vesicle
rupture is a shared mechanism of cellular invasion by these diverse prion-like amyloid
proteins, despite differences in conformations and compositions, because of the short
fibrillar amyloid structure standardized among a-syn, tau, and HTTExon1 preparations,
enabling endocytic uptake, vesicle rupture, seeding, and cell-to-cell propagation. We
have further demonstrated that assemblies of tau isoform 1N4R are significantly more
potent in their induction of vesicle rupture compared with assemblies of tau isoform
1N3R, indicating that unique combinations of tau composition and conformation dictate
vesicle rupture potency just as for a-syn-induced rupture. These variations in vesicle
rupture potency between different tau isoform strains may contribute to the variety of
disease phenotypes displayed by tauopathies. These findings are significant because of
the determination that endocytic vesicle rupture, conserved for fibrillar assemblies of
amyloid proteins in multiple neurodegenerative diseases, is a key mechanism during the
cellular invasion phase of the cell-to-cell propagation life cycle.

CHAPTER FIVE
ENDOCYTIC VESICLE RUPTURE CONTRIBUTES TO INCLUSION FORMATION AND CELL-TOCELL PROPAGATION IN PARKINSON’S DISEASE PATHOLOGY
Rationale
With the clear understanding that endocytic vesicle rupture is a conserved
mechanism of cellular invasion by fibrillar assemblies of amyloid proteins, we next
sought to determine the relevance of this damaging mechanism of cellular invasion in
PD, investigating the contribution of a-syn-mediated endocytic vesicle rupture and its
consequences to established aspects of PD pathology and propagation. Despite the
highly reproducible nature of our findings demonstrating the induction of vesicle
rupture by multiple fibrillar amyloid assemblies in recipient SY5YchGal3 cells, this
immortalized human neuroblastoma cell line is not the model system most
representative of neuronal physiology, and thus conclusions drawn from the use of this
cell line leave doubt as to the occurrence of a-syn mediated endocytic vesicle rupture in
authentic disease. SH-SY5Y cells, widely used as a neuron-like cell line, are comprised of
a mixed phenotypic culture derived from a metastatic bone tumor biopsy, and despite
the expression of tyrosine hydroxylase (TH) characteristic of dopaminergic neurons,
numerous caveats exist when using cells derived from malignant tumors [651].
Alternatively, human midbrain dopaminergic neurons differentiated from hiPSCs are
post-mitotic and display typical physiological characteristics and responses of
161

dopaminergic neurons. These cells are >90% neurons (MAP2+/nestin-) of a
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dopaminergic identity (>85% FoxA2+, >75% TH+), and exhibit spontaneous and evoked
action potentials and excitatory post-synaptic currents. As such, hiPSC-derived
dopaminergic neurons expressing the chGal3 marker of vesicle damage represent a
model system representative of human PD wherein to examine the process of a-synmediated endocytic vesicle rupture. With the aim of determining the occurrence of
endocytic vesicle rupture in a more physiologically-relevant model system, we sought to
examine chGal3 relocalization in hiPSC-derived dopaminergic neurons following a-syn
aggregate exposure, hypothesizing that a-syn assemblies would also induce endocytic
vesicle rupture in this model system.
Among the known consequences of endocytic vesicle rupture are the production
of damaged vesicular debris needing to be cleared through autophagic degradation and
the dysfunctional lysosomal degradation resulting from LMP. Given that a-syn
aggregates invade target cells that may already be experiencing some degree of
degradative dysfunction for a variety of reasons in PD [340-343], the effect of endocytic
vesicle rupture on normal intracellular vesicle trafficking and degradation processes is
relevant for disease pathogenesis. Vesicles damaged by pathogen invasion are targeted
for autophagic degradation [560, 570, 576, 579, 597-600, 602, 603, 615], significantly
increasing the burden of autophagic substrates in need of clearance. Furthermore, LMP
itself directly depletes the pool of lysosomes competent to ultimately perform the
clearance of autophagic substrates, resulting in accumulation of autophagosomes and
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eventual neuronal degeneration because this degradative dysfunction [130, 615]. This
dual effect whereby the mechanism of cellular invasion both increases the substrate
burden for degradative processes while at the same time inducing degradative
dysfunction is expected to be at work with a-syn cellular invasion, and represents a
significant challenge to functional proteostasis. With the aim of defining the impact of
a-syn-mediated endocytic vesicle rupture on normal vesicular trafficking and
degradation, we sought to examine the phenotype of ruptured vesicles as well as their
recruitment to the ALP, hypothesizing that ruptured lysosomes and their a-syn cargo
become targets for autophagic degradation.
As the proposed mechanism for the vesicular escape of exogenous fibrillar
amyloid seeds to interact with cytosolic expressed monomeric constituents and
template further aggregation, the relationship between amyloid-induced endocytic
vesicle rupture and further seeding and inclusion formation needs more clarity.
Interestingly, the very same small fragmented amyloid fibrils that are most potent for
inducing endocytic vesicle rupture in our studies are known to also be most potent for
seeding and templating of further aggregation [209-211]. Theories on the formation of
cytosolic proteinaceous inclusions such as LBs center around the idea of aggresomes
representing a protective response of cells overwhelmed by the burden of misfolded
proteins and their inability to effectively degrade them [118, 124]. Condensing
misfolded protein aggregates into a larger inclusion may be a cellular effort to increase
efficiency of autophagic clearance, although failure of autophagy results in the recycling

locus becoming a junkyard instead [118]. Consistent with this idea, LBs are known to
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contain a-syn-associated vesicles as well as dysfunctional lysosomes and
autophagosomes [128, 131, 134]. While the merging of misfolded a-syn aggregates and
associated degradative vesicles may be originally intended to facilitate degradation,
dysfunction in degradative processes instead results in agglomerations becoming
pathological LB inclusions. With the aim of determining the influence of a-syn-induced
endocytic vesicle rupture on pathologic inclusion formation, we sought to examine asyn-containing LB inclusions in cultured cells and in PD brain, hypothesizing that Gal3
localization would indicate involvement of endocytic vesicle rupture in the formation of
these intracellular proteinaceous inclusions.
Finally, because the same cellular stressors induced by endocytic vesicle rupture,
such as ALP dysfunction and oxidative stress, are also well-known causes of a-syn
release and intercellular propagation, the influence of endocytic vesicle rupture on asyn cell-to-cell spreading is an important unanswered question. Diverse cellular
stressors prompt a-syn release from cells affected by its aggregation and accumulation
[294, 468-471, 473, 479, 484, 485], raising the possibility that consequences of the
endocytic vesicle rupture entry mechanism may contribute to mechanisms of release.
Many of the non-classical a-syn release mechanisms involve an association between asyn and vesicles; within intracellular vesicles or autophagosomes that fuse with the
plasma membrane to release their contents [468-471], on the internal or external leaflet
of exosomes [473, 478, 479], or within lysosomes that traffic to neighboring cells inside

TNTs [445]. Since Gal3 is also released from cells through a non-classical mechanism
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[591-593], some a-syn release could be in association with Gal3+ ruptured vesicles it
induces during its cellular invasion. With the aim of elucidating the contribution of
endocytic vesicle rupture to a-syn cell-to-cell propagation, we sought to examine the
extracellular localization and intercellular movement of a-syn aggregates following
invasion via rupture, hypothesizing that the damaging consequences of endocytic
vesicle rupture would promote pathologic a-syn release in association with ruptured
vesicles.
In the sections below, we utilize a combination of approaches to demonstrate
that a-syn-induced ruptured lysosomes are targeted for autophagic degradation, that
merging of ruptured vesicles containing a-syn promotes LB inclusion formation, and
that ruptured vesicles may act as both a stimulus and a vector for a-syn cell-to-cell
propagation. These findings illustrate the impact of endocytic vesicle rupture in PD
pathology and raise new possibilities for therapeutic targets based on its involvement
and consequences.
Alpha-Synuclein Induces Vesicle Rupture in Human Dopaminergic Neurons Derived
From Induced Pluripotent Stem Cells
Given the consistency of our observation that fibrillar assemblies of amyloid
proteins induce endocytic vesicle rupture in recipient cells, we sought to extend our
findings by performing the chGal3 relocalization assay in an authentic human
dopaminergic neuron to determine the occurrence of endocytic vesicle rupture induced

by a-syn following endocytosis in this model. We hypothesized that a-syn induced

166

vesicle rupture would be a conserved phenotype in multiple cellular model systems. To
confirm our observations in a setting more representative of that in human PD, we
utilized hiPSC-derived dopaminergic neurons as a model of neuronal physiology. hiPSCderived dopaminergic neurons stably overexpressed the chGal3 marker of vesicle
rupture using lentiviral transduction, and we exposed these cells for 48hr to fragmented
WT a-syn PFFs. We observed chGal3 relocalization to distinct puncta, and many chGal3+
ruptured vesicles colocalized with a-syn fibrils fluorescence (Figure 23). This observation
demonstrates that a-syn assemblies induce endocytic vesicle rupture in hiPSC-derived
dopaminergic neurons, and validates our earlier results obtained in the SY5YchGal3
model of vesicle rupture.
Lysosomes Ruptured by Alpha-Synuclein are Targeted for Autophagic Degradation
It is known that recognition of ruptured vesicles by cytosolic galectins targets
these vesicles for autophagic degradation [560, 570, 576, 579, 597-600, 602, 603, 615].
However, it remains unclear to what degree a-syn can prevent these ruptured vesicles
from re-establishing a low pH during autophagic degradation, and how lysosomal
rupture by a-syn affects normal vesicular trafficking in the ALP. We hypothesized that
ruptured lysosomes would also become autophagic substrates just like their aggregated
a-syn cargo. To more deeply understand the effect of lysosomal rupture on vesicular
trafficking and degradation pathways, we first sought to determine the degree to which
ruptured lysosomes become incorporated into autophagosomes. In agreement with our
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Figure 23. a-Syn induces vesicle rupture in human dopaminergic neurons derived from
induced pluripotent stem cells. hiPSC-derived chGal3 dopaminergic neurons were
subjected to 48 hr treatment with 200 nM exogenous Dylight488-labeled WT a-syn PFFs
in the culture media, followed by live cell imaging to identify vesicle rupture. Treatment
with a-syn induced vesicle rupture and subsequent chGal3 relocalization to discrete
puncta that colocalized with a-syn fluorescence (arrowheads). Inset box in top left
image is enlarged and separated in other panels into Overlay, a-syn fluorescence, or
chGal3 fluorescence. Images are representative of at least 10 images from 3
independent experiments. Scale bar = 10 µm for left panel and 3 µm for inset-enlarged
panels.
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previously published data [4], we observed that chGal3+ ruptured vesicles containing asyn fibrils colocalized with the lysosomal marker lysosome-associated membrane
protein 1 (LAMP1) upon immunofluorescent labeling (Figure 24A). We generated SHSY5Y cells expressing both the chGal3 marker of ruptured vesicles and a YFP-LC3
construct to identify autophagosomes. Upon exposure of these cells to Dylight650labeled WT a-syn PFFs for 24 hr in the culture media, we observed that many chGal3+
ruptured vesicles containing a-syn colocalized with YFP-LC3+ autophagosomes,
although a-syn-containing ruptured vesicles and autophagosomes existed
independently as well (Figure 24B). While these findings indicate that a-syn-induced
ruptured lysosomes become targeted to autophagic degradation, they do not allow a
real-time monitoring of vesicular pH and membrane integrity throughout the duration
of this pathway.
To follow the fate of vesicles ruptured by a-syn in real-time, we performed live
cell imaging using the LysoTracker Deep Red dye to label and track acidic organelles in
live cells. This fluorescent acidotropic probe selectively accumulates in cellular
compartments with low internal pH. Whereas the presence of chGal3 demonstrates that
an individual vesicle has been previously ruptured, the accumulation of LysoTracker in
ruptured vesicles to mark a low pH indicates re-establishment of a pH gradient through
the autophagic degradation system. At single time points, individual Z-stack images
were acquired to determine the degree of colocalization of Dylight488-labeled WT a-syn
assemblies, chGal3, and LysoTracker. These images revealed that a subset of a-syn+,
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Figure 24. Lysosomes ruptured by a-syn are targeted for autophagic degradation.
Vesicular identity and pH status of a-syn-induced chGal3+ ruptured vesicles identified
by (A) 24 hr exposure of SY5YchGal3 cells to 660nM exogenous Atto488-labeled WT αsyn fibrils followed by fixation and staining for LAMP1, (B) 24 hr exposure of SY5YchGal3
YFP-LC3 cells to 660nM exogenous Dylight650-labeled WT α-syn PFFs followed by live
cell imaging, and (C) 24 hr exposure of SY5YchGal3 cells to 200nM exogenous
Dylight488-labeled WT α-syn assemblies followed by loading of Lysotracker Deep Red
dye and live cell imaging. Inset box from top image is enlarged and separated in below
images. Colocalization between all three channels shown with arrowheads. Images are
representative of at least 10 images from 3 independent experiments. Scale bar = 15 µm
for top panel and 3 µm for inset-enlarged lower panels.
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chGal3+ ruptured vesicles were additionally LysoTracker+, indicating a re-establishment
of the pH gradient during autophagic degradation of ruptured vesicles. In these cells,
instances of a-syn+, chGal3+ vesicles were also observed, as were a-syn puncta that did
not colocalize with either chGal3 or LysoTracker (Figure 24C). Additionally, live cell
imaging of chGal3-expressing N27 rat dopaminergic neuronal cells exposed to
DyLight488-labeled WT a-syn assemblies in the presence of Lysotracker indicated the
accumulation of multiple smaller a-syn-containing ruptured vesicles within a larger low
pH compartment (Figure 25, arrowheads). This observation indicates ongoing
autophagic recruitment of ruptured vesicles induced by a-syn endocytic uptake. These
findings demonstrate that lysosomes ruptured by fibrillar amyloid assemblies of a-syn
are targeted for autophagic degradation and thus re-establish a low pH gradient. The
damaged vesicles and vesicular debris created by lysosomal rupture following a-syn
endocytosis therefore add to the cellular burden of substrates needing to be degraded
through the ALP.
Fusion of Ruptured Vesicles Leads to the Formation of Large Cytoplasmic
Inclusions of Alpha-Synuclein
We next used live cell imaging to monitor the intracellular trafficking of vesicles
ruptured by a-syn assemblies to determine their relationship with the subsequent
formation of cytoplasmic a-syn-containing LB inclusions. Because endocytic vesicle
rupture is the damaging mechanism whereby exogenous a-syn seeds come into contact
with expressed monomeric a-syn in the cytosol and can subsequently template further
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Figure 25. Ruptured vesicles containing a-syn present in large low pH compartment.
N27chGal3 cells were subjected to 24 hr treatment with 200nM exogenous Dylight488labeled WT a-syn assemblies in the culture media, followed by live cell imaging to
identify vesicle rupture. chGal3+ ruptured vesicles (red) can be observed colocalizing
with a-syn assemblies (green) and low pH compartments (Lysotracker, blue) in this
snapshot of the live cell movie. Additionally, large low pH compartments are seen
containing multiple smaller ruptured vesicles that colocalize with a-syn (arrowheads).
Scale bar is 10 µm.
aggregation and LB formation [200, 202, 209-213, 347], we hypothesized that endocytic
vesicle rupture would be involved in the formation of a-syn LB inclusions. Time lapse
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imaging revealed that colocalization between α-syn assemblies and the chGal3 marker
of vesicle rupture was maintained as the ruptured vesicles and a-syn cargo trafficked
considerable distances throughout the cell. In many instances, colocalizing vesicles
could be observed trafficking throughout both the soma and cellular projections of
chGal3-expressing hiPSC-derived dopaminergic neurons, SH-SY5Y cells, and N27 cells.
We also observed evidence of vesicle fusion in which multiple smaller vesicles
containing both a-syn assemblies and chGal3 appear to merge together into a larger
inclusion during the acquisition period. In N27chGal3 cells exposed to Dylight488labeled WT a-syn assemblies and loaded with Lysotracker, multiple smaller low pH
compartments each containing a-syn and the chGal3 marker of previous membrane
rupture merge together into a larger compartment (Figure 26). This merging of a-syncontaining ruptured vesicles also occurred in SY5YchGal3 cells exposed to Dylight488labeled WT a-syn assemblies (Figure 27). This merging of ruptured vesicles containing
chGal3 and a-syn assemblies produced larger structures that substantially exceeded the
size of the individual ruptured vesicles from which they were derived. Such structures
were also observed in fixed cell images following exposure of SY5YchGal3 cells to
exogenous Dylight-488 labeled a-syn assemblies, and in some cases these larger
structures assumed the appearance of a LB in which a large perinuclear a-syn inclusion
was surrounded by a peripheral border of chGal3 (Figure 28). This phenotype of chGal3
enrichment at the periphery of a-syn LB inclusions indicates previous membrane
rupture in the a-syn-containing endocytic vesicles that subsequently merged together
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Figure 26. Fusion of ruptured vesicles containing a-syn in N27chGal3 cells. N27chGal3
cells (red) were incubated with Dylight488-conjugated WT a-syn assemblies (green) for
24 hr. Prior to live cell imaging, cells were incubated with 20 nM Lysotracker (blue) for
30 minutes. Colocalization between these three channels is seen in white. Inset box at
top left is enlarged in other panels, and timed snapshots of this region are shown with
the time stamp in the bottom left of each frame. Z-stack images were acquired at ~28
second intervals for 12 minutes. Scale bars are 20 µm in top left and 3 µm in panels
enlarged from inset box.
into a larger inclusion. Despite the degradative intention behind the merging of vesicles
and a-syn aggregates into aggresomes, this process ultimately facilitates LB inclusion
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Figure 27. Fusion of ruptured vesicles containing a-syn in SY5YchGal3 cells. SY5YchGal3
cells (red) were incubated with Dylight488-conjugated WT a-syn assemblies (green) for
24 hr. Timed snapshots are shown with the time stamp in the bottom left of each frame.
Z-stack images were acquired at ~13 second intervals for 10 minutes. Scale bar = 5 μm.
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Figure 28. a-Syn LB inclusion surrounded by corona of chGal3 in SY5YchGal3 cells.
SY5YchGal3 cells (red) were subjectd to 24h exposure to 200nM exgenous Dylight488labeled A53T a-syn assemblies (green), followed by fixation and DAPI staining (blue) in
PBS. Image separated into overlay, chGal3, and a-syn fluorescence. Scale bar = 10 µm.
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formation when degradation becomes compromised [118]. Gal3 presence around the LB
is an indicator of the accumulation of ruptured vesicles unable to be degraded in
aggresomes. These findings highlight the close relationship between ruptured vesicles
and a-syn LB inclusions, where fusion of a-syn-containing ruptured vesicles and the
specific enrichment of chGal3 surrounding a larger LB inclusion implicate endocytic
vesicle rupture in the formation of pathologic intracellular a-syn inclusions.
Vesicle Rupture Markers Surround Alpha-Synuclein in Lewy Bodies
The data above suggest that the failed degradation of a-syn fibrils within the
autophagic compartment following vesicle rupture leads to the gradual fusion of these
vesicles into structures resembling LBs. To determine the influence of endocytic vesicle
rupture on LB inclusion formation in authentic PD, we examined a-syn-containing LBs in
human post mortem SN tissue sections from PD patients, hypothesizing that
endogenous Gal3 localization would also implicate endocytic vesicle rupture in LB
formation in vivo. To determine if LBs present in PD patients exhibit a similar phenotype
to that in SY5YchGal3 cells exposed to exogenous a-syn assemblies, we performed
immunofluorescence microscopic analysis on SN sections, staining these sections with
antibodies specific for pS129 a-syn as a marker of LBs and endogenous Gal3, detected
by secondary antibodies conjugated to Cy2 and Cy5, respectively. In these sections, we
observed numerous examples of pS129 a-syn+ inclusions that closely resembled LBs.
Many of these LBs demonstrated a characteristic peripheral outward-radiating
filamentous halo of pS129 a-syn and a dim center, consistent with other published
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reports detailing the ultrastructure of LBs where a-syn staining comprises a peripheral
halo surrounding a dense granular core with a high abundance of ubiquitin staining
[117, 118]. Additionally, we observed that a majority of the LBs present in these sections
exhibited a corona of Gal3 surrounding the aggregated pS129 a-syn within the LB
(Figure 29). Of the 305 LBs identified in samples from 5 PD patients, 170 (~56%) of these
LBs exhibited a discernable Gal3 corona. No similar fluorescent pattern was observed in
the neighboring fluorescent channel (Cy3) under identical acquisition conditions or in
tissue sections from the same patient stained with secondary antibodies alone,
demonstrating that this observation is not due to signal bleedthrough or tissue
autofluorescence. The presence of Gal3 at the periphery of LBs suggests that this region
contains membrane components where the lectin ligands present on the luminal leaflet
of vesicles had been previously exposed to the cytoplasm. Notably, normal autophagic
degradative mechanisms do not result in the cytoplasmic exposure of these lectin
ligands. Thus, the Gal3 corona around LBs is evidence of previous membrane
perturbations having occurred in the lipid components which form the periphery of
these structures. This observation implicates endocytic vesicle rupture in the formation
of LBs in authentic PD, meaning that the cellular response of merging ruptured vesicles
and a-syn cargo to facilitate degradation instead promotes pathologic inclusion
formation when degradative mechanisms are dysfunctional.
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Figure 29. LB inclusions from PD brain surrounded by corona of Gal3. Brain sections
from H&Y5 PD patients were immunostained for pS129 a-syn (FITC, green) and Gal3
(Cy5, red), and additionally imaged in the Cy3 channel to detect tissue autofluorescence
(blue). Six representative images of LBs are shown from three PD patients, and left
Overlay panel is separated into single channels for a-syn fluorescence, Gal3
fluorescence, and autofluorescence to appreciate the degree of partial colocalization
between Gal3 corona and radiating halo of pS129 a-syn within LBs. Scale bar = 5 µm.

Ruptured Vesicles Containing Alpha-Synuclein are Released and
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Propagate Between Cells
In addition to the intracellular consequence of promoting pathologic LB inclusion
formation, endocytic vesicle rupture is also known to induce cellular stressors that can
stimulate a-syn release and cell-to-cell propagation [294, 468-471, 473, 479, 484, 485].
With this fact in mind, we aimed to clarify the contribution of a-syn induced endocytic
vesicle rupture to its cell-to-cell propagation. We hypothesized that a-syn-mediated
lysosomal rupture and its consequences would prompt a-syn cellular release in
association with ruptured vesicles. To test this hypothesis, we examined both the
extracellular localization and the intercellular movement of exogenous a-syn aggregates
using a combination of fixed and live cell imaging. Under identical conditions to those
that produce intracellular vesicle rupture following endocytosis of exogenous a-syn
aggregates, we observe instances where chGal3+ ruptured vesicles containing a-syn are
present in the extracellular environment (Figure 30). Given that this now extracellular asyn aggregate remains associated with a lipid vesicle exhibiting an enrichment of chGal3
derived from the cytosol of the original recipient cell, this finding indicates the existence
of a process for the cellular release of a-syn-containing ruptured vesicles. Using live cell
imaging of hiPSC-derived chGal3 dopaminergic neurons exposed to Dylight488-labeled
a-syn PFFs, we have also observed the intercellular movement of a-syn aggregates
contained within ruptured vesicles (Figure 31), indicating that this process of a-syn
cellular release within ruptured vesicles can facilitate cell-to-cell propagation. While

180

Figure 30. Ruptured vesicles containing a-syn observed in the extracellular
environment. Annular chGal3+ ruptured vesicle containing a-syn found in the
extracellular environment adjacent to SY5YchGal3 cell affected by a-syn-induced vesicle
rupture. SY5Y chGal3 cells were treated for 24 hr with Dylight488-labeled a-syn
aggregates. Highlighted extracellular vesicle within inset box is not connected to any
portion of adjacent cell or its processes. Inset box in merged panel (left) is enlarged and
separated by channel (right) to emphasize co-localization. Blue DAPI-stained nucleus
shown. Scale bar = 10 µm left, 1.5 µm right.
much remains to be understood regarding the specific factors that stimulate this release
of ruptured vesicles and a-syn cargo as well as its mechanistic underpinnings, these
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Figure 31. Ruptured vesicles containing a-syn propagate between hiPSC-derived
chGal3 dopaminergic neurons. hiPSC-derived chGal3 dopaminergic neurons (red) were
subjected to 48 hr treatment with 200 nM exogenous Dylight488-labeled WT a-syn PFFs
(green) in the culture media, followed by live cell imaging to identify vesicle rupture.
Ruptured vesicles containing a-syn seen in yellow. Inset box enlarged at bottom right,
with timed snapshots shown at the times indicated in the bottom right of each frame.
Scale bar = 15 µm.
results indicate that endocytic vesicle rupture and its consequences can act as both a
stimulus and a vector for pathologic a-syn cell-to-cell propagation.
Significance
The above results have established the contribution of endocytic vesicle rupture
to dysfunctional degradative processes, intracellular inclusion formation, and
intercellular aggregate transmission, making this damaging mechanism of cellular
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invasion clearly relevant for PD pathology and progression. Although much remains to
be determined regarding the life cycle of a-syn within and between diseased neurons,
this examination of the intersection of endocytic vesicle rupture and established aspects
of PD pathology brings the research endeavor one step closer to an understanding of
pathogenesis necessary for effective therapeutic intervention. Beginning with the
demonstration that a-syn aggregates induce endocytic vesicle rupture in hiPSC-derived
chGal3 dopaminergic neurons just as they do in SH-SY5YchGal3 cells verifies the
occurrence of this invasion mechanism in a model system more representative of
neuronal physiology. This validation establishes the utility of the chGal3 relocalization
assay for detecting this vesicle damage, and again underscores the conserved nature of
endocytic vesicle rupture as a mechanism of amyloid protein escape from the vesicular
compartment during the propagation pathway. Furthermore, these findings confirm
that, just like those ruptured by invading pathogens or sterile damage [560, 570, 597,
601-603, 615], lysosomes ruptured by a-syn become targets of autophagy, adding to
the cellular burden of substrates requiring clearance via the ALP. The combination of
lysosomal dysfunction induced by a-syn mediated LMP [4] and the addition of damaged
or destroyed lysosomal vesicles to the already overwhelming buildup of ALP substrates
in PD [130]that now also include the invading misfolded a-syn aggregates themselves is
a clear cause of dysregulated proteostasis.
Two of the most problematic aspects of proteinopathies include the prion-like
seeding and templating of further amyloid misfolding upon cellular invasion and the cell-
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to-cell propagation of amyloid aggregates [3, 465, 647, 648]. With our findings, we have
established a role for endocytic vesicle rupture as contributing to both. We first
examined the trafficking of ruptured vesicles and their a-syn cargo, and noted the
merging or coalescence of multiple smaller ruptured vesicles into larger low pH
compartments representing ongoing autophagic degradation. However, the presence of
Gal3 at the periphery of LB inclusions in SY5YchGal3 cells and in PD SN brain tissue
suggests that degradative mechanisms fail to cope with the accumulation of ruptured
vesicles and misfolded protein, which instead results in LB inclusion formation.
Moreover, understanding that the increased lysosomal, autophagic, and oxidative stress
resulting from endocytic vesicle rupture is known to contribute to a-syn release and
intercellular spreading [468, 469, 479, 485], we identified a process of a-syn cellular
release within ruptured vesicles that is competent to shuttle a-syn aggregate cargo
between cells. These observations implicate the mechanism of endocytic vesicle rupture
as contributing to inclusion formation and cell-to-cell propagation in PD, providing both
the substance and the stimulus for both pathological processes. We have provided an
explanation for how the damaging mechanism of cellular invasion through endocytic
vesicle rupture directly contributes to PD pathology and progression, and these findings
are significant because the multifaceted nature of this invasion mechanism and its
consequences could provide numerous new therapeutic targets for reversing or
preventing disease.

CHAPTER SIX
CONCLUSIONS
Introduction
No disease modifying therapy exists for numerous neurodegenerative diseases
characterized and defined by the accumulation of misfolded amyloid proteins. aSynucleinopathies, tauopathies, and polyglutamine expansion diseases each encompass
several diverse neurodegenerative diseases exhibiting the accumulation of insoluble
fibrillar amyloid aggregates of a-syn, tau, and polyglutamine-containing proteins
respectively. These diverse proteinopathies have also been referred to as prionopathies
for their numerous similarities to prion diseases [42]. As prion-like proteins, amyloid
assemblies of a-syn, tau, and HTTExon1 exhibit misfolding into an insoluble, fibrillar bsheet-rich amyloid structure, induce seeding and templating of additional misfolding in
their cytosolic monomeric constituent proteins, and undergo spreading from affected to
naïve cells throughout the nervous system [488, 522, 634]. Given that the prion-like
mechanisms for amyloid protein aggregation and propagation are remarkably conserved
between neurodegenerative diseases, and even that the fibrillar amyloid structure itself
occurring as a final product of constituent assembly is structurally very similar in these
diseases despite being composed of different proteins, there is a possibility that
understanding the mechanisms underlying a single disease may lead to insights about
184
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many, forming the foundation for future disease-modifying therapeutic strategies [3].
To realize this potential, much remains to be learned about the mechanisms by which
misfolded amyloid aggregates corrupt their soluble counterparts, disrupt cellular
homeostasis, and transmit their pathologic protein misfolding from cell-to-cell.
Examining the specific steps in the intracellular and intercellular life cycle of
amyloid proteins through the lens of host-pathogen interactions is beneficial for
understanding the consequences of and cellular response to this prion-like process.
Using the situation of a-syn in PD, our group was the first to demonstrate that fibrillar
protein aggregates cause lysosomal rupture following their endocytic uptake, occurring
in a fashion identical to infection by bacterial or viral pathogens [4, 280]. Despite the
new insight gained from this finding, many key questions remained about its
mechanism, its contribution to cellular dysfunction, and its relevance to the pathology
of PD and other proteinopathies. The studies discussed in this dissertation aimed to
address the above questions, with the goal of exploring endocytic vesicle rupture as a
mechanism of cellular invasion for several amyloid proteins. Furthermore, focusing on
a-syn in PD, we aimed to define specific protein modifications that influence vesicle
rupture potency, as well as determine the effect of a-syn-mediated vesicle rupture on
cellular homeostasis and aggregate propagation. Below we revisit key findings identified
in each chapter and discuss how they contribute to an enhanced understanding of
amyloid protein propagation in neurodegenerative disease. We also point out questions
that remain unanswered and needing to be addressed in future work. With more insight
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into the pathological life cycle of misfolded amyloid proteins, new therapeutic targets
are identified that may allow future treatment targeted to disease pathogenesis.
Endocytic Vesicle Rupture is a Conserved Mechanism of Cellular Invasion by
Amyloid Proteins
Building from our earlier work demonstrating that heterogeneous aggregates of
a-syn rupture lysosomes following their endocytic uptake, we next sought to determine
if this endocytic vesicle rupture phenomenon is a specific effect of a-syn aggregates, or
if aggregates of other neurodegenerative disease-associated amyloid proteins were also
capable of inducing this type of vesicular membrane damage following endocytosis. The
rationale for this hypothesis was that misfolded higher-order aggregates of many
aggregation-prone neurodegenerative disease-associated proteins adopt a stable,
protease-resistant, detergent-insoluble fibrillar b-sheet rich architecture known as
amyloid that is very similar despite these protein aggregates being composed of
different proteins for each disease [2, 3, 465, 647, 652]. This characteristic amyloid
structure also defines the disease-associated prion PrPSc [6, 11, 12], and it is this
structure that imparts to prions the ability to corrupt like monomeric constituents
through templating and seeding of further aggregation [17]. Thus, given the similarities
in their structure, we hypothesized that amyloid assemblies of tau and HTTExon1 would
also induce endocytic vesicle rupture following their cellular uptake by endocytosis.
Endocytosis is the predominant mechanism for the cellular uptake of fibrillar
assemblies of a-syn, tau, and HTTExon1, being too large for direct translocation across
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the plasma membrane [448-450, 498, 506-508, 531]. However, if these fibrillar amyloid
proteins are very elongated and/or tightly bundled with many other fibrils due to
ongoing aggregation, then these elongated or grouped fibrils are too large to enter cells
via endocytosis. Instead, smaller fibrillar forms such as fragments of longer a-syn, tau,
or prion fibrils are the assembly species most efficiently taken up by endocytosis [45,
200, 509]. Following cellular entry in this manner, the question of how amyloid
aggregates escape from the vesicular compartment was unanswered for assemblies of
tau and HTTExon1 just as it had been for a-syn prior to our demonstration of a-syn
induced vesicle rupture [448, 465, 522, 531]. To properly assess this possibility of
endocytic vesicle rupture representing a shared invasion mechanism for these various
aggregated amyloid proteins, we employed an in vitro aggregation protocol of
recombinant purified a-syn, tau, and HTTExon1 that relies on the combination of
extended aggregation times to produce elongated fibrils and the subsequent
fragmentation of these elongated fibrils by sonication to produce homogenous
populations of smaller fibrillar assemblies that retain their original b-sheet-rich
architecture that had been present in the elongated fibril after aggregation. Not only
does this aggregation scheme allow for a homogenous, uniform population of similar
size distribution between samples of a-syn, tau, and HTTExon1 (Figures 14, 17, 20),
standardizing the variable of aggregate size for the comparison of vesicle rupture, the
fragmentation of larger fibrils to smaller fibrillar forms matches the species of amyloid
proteins known to best invade recipient cells through endocytosis.
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When we incubated small fibrillar forms of a-syn, tau, and HTTExon1 with our
SY5YchGal3 cell model of vesicle rupture, we observed a shared ability of these fibrillar
amyloid proteins to induce chGal3 relocalization indicative of endocytic vesicle rupture
(Figures 15, 18, 21). The specific enrichment of cytosolic chGal3 at the site of ruptured
vesicles colocalized strikingly with the fluorescence from internalized amyloid
assemblies of a-syn and tau, although we were unable to visualize this colocalization of
ruptured vesicles with assemblies of HTTExon1 due to technical limitations of the
fluorescent labeling approach. To extend and validate the observation of amyloidinduced endocytic vesicle rupture in a more physiologically-relevant model system, we
utilized hiPSC-derived dopaminergic neurons expressing the chGal3 construct as more
closely resembling authentic neuronal physiology. In this system, hiPSC-derived
dopaminergic neurons that successfully expressed the chGal3 protein indicated clear
relocalization of its expression to cytosolic punctate structures that colocalized with the
fluorescence of exogenous a-syn PFFs, indicating the induction of endocytic vesicle
rupture in these neurons just as in SY5YchGal3 cells (Figure 23). These findings allow us
to confidently conclude that endocytic vesicle rupture is the mechanism by which
fibrillar assemblies of amyloid proteins escape from the vesicular compartment
following their uptake, and the recruitment of cytosolic chGal3 is a reliable indicator of
this damage caused during invasion (Figure 32, middle).
The pattern of colocalization between exogenous fluorescently-labeled amyloid
protein assemblies and the chGal3 indicator of vesicle rupture warrants further

189

Figure 32. Schematic of amyloid-induced vesicle rupture and its consequences. Fibrillar
amyloid protein assembly (green) taken up into endocytic vesicle along with bgalactoside sugars (orange) from the outer leaflet of the plasma membrane now on the
inner leaflet of the internalized vesicle. Endocytic vesicle rupture induced by amyloid
protein aggregates is indicated by the enrichment of cytosolic Gal3 (red cytoplasm, red
dots) at the site of membrane damage where it binds to b-galactoside sugars exposed
upon vesicle rupture (middle). Colocalization (yellow) can be observed between amyloid
assembly fluorescence and chGal3 in inset middle image. Cellular homeostasis depends
on the balance between amyloid protein degradation (left) and amyloid protein
accumulation (right). Degradation of ruptured vesicles and amyloid protein cargo occurs
via autophagy (left), where ruptured vesicles containing a-syn can be observed in low
pH compartments positive for the autophagic marker LC3 (inset left images).
Accumulation of ruptured vesicles and amyloid protein cargo occurs when degradative
mechanisms are dysfunctional or overwhelmed (right), prompting both inclusion
formation, where the presence of Gal3 at the periphery indicates merging of previous
ruptured vesicles into the larger cytoplasmic inclusion (inset right images), and cellular
release of ruptured vesicles and amyloid protein cargo.
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investigation. We often observe localization of fluorescent amyloid assemblies to curved
or comma-shaped structures at the periphery of larger annular or ring-like intracellular
ruptured vesicles, closely associated with the vesicular membrane rather than occupying
the visible vesicular lumen (Figure 32, inset middle image). In addition, smaller punctate
or dot-like structures are also observed, where more exact overlap between amyloid
assembly and chGal3 fluorescence is observed (Figure 32, inset middle image). While
both phenotypes of intracellular vesicles exhibit rupture as indicated by chGal3
enrichment, their dramatically different appearances suggest involvement of diverse
intracellular vesicle phenotypes in the process of endocytic vesicle rupture. Our previous
work demonstrated vesicle rupture of endosomes and lysosomes by a-syn aggregates,
with a higher number of ruptured vesicles exhibiting a lysosomal phenotype [4]. The
results presented here validate the observation of lysosomal rupture, and demonstrate
that ruptured lysosomes are recruited to autophagosomes for degradation (Figure 24).
The chGal3 relocalization assay does not allow us to distinguish if one vesicular
phenotype is more predominantly affected by amyloid-mediated vesicle rupture, as the
recruitment of cytosolic galectins is an all-or-none phenomenon that occurs
immediately following rupture and the presence of this indicator would persist as
vesicles move through intracellular trafficking and degradative pathways. Thus,
additional study must be performed to more completely understand the stage within
the endocytic pathway when endocytic vesicle rupture is induced by exogenous amyloid
assemblies. This question has important implications for the consequences of amyloid-

mediated vesicle rupture, as early egress from the endocytic pathway during the
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endosomal stage is employed by pathogens such as adenovirus which have an
evolutionary pressure to avoid lysosomal degradation [575, 606, 609]. Early endocytic
vesicle rupture thus causes fewer LMP events and avoids the more severe proteolytic
toxicity and oxidative stress resulting from cathepsin leakage. It is possible that various
amyloid protein assemblies induce vesicle rupture at different endocytic stages, and
thus would be expected to have very different consequences for the host cell.
With the finding that endocytic vesicle rupture is a conserved mechanism of
cellular invasion by aseemblies of numerous amyloid proteins, we have contributed an
important advance in the understanding of the amyloid cell-to-cell propagation
pathway. Although the existence of a mechanism to physically disrupt the endocytic
vesicle compartment had been hypothesized, and always assumed to exist given the
induction of intracellular aggregation by exogenous seeds, such a mechanism had never
been specifically demonstrated for aggregates of a-syn, tau, and HTTExon1 prior to this
work. Future studies will expand these observations and the understanding of the
endocytic vesicle rupture entry mechanism by examining the cell-to-cell propagation
pathway of additional amyloid proteins such as Ab, SOD-1, and TDP-43. Probing this
cellular invasion mechanism for specific factors that increase or decrease its potency
may reveal mechanisms whereby it can be inhibited, and thus represent attractive
future therapeutic targets to prevent or reverse disease progression.
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Alpha-Synuclein Serine-129 Phosphorylation and Assembly Strain Conformation
Determine Endocytic Vesicle Rupture Potency
Given the conserved nature of endocytic vesicle rupture in the cellular invasion
of amyloid proteins during neurodegenerative disease, we next sought to determine
specific protein modifications that dictate the potency of this cellular entry mechanism.
We focused this effort on amyloid assemblies of a-syn in PD, examining familial
missense mutation, pS129 phosphorylation, and strain conformation as three factors
highly implicated in disease pathogenesis. An increased understanding of the vesicle
rupture entry mechanism from the perspective of factors that increase or decrease its
potency may generate new therapeutic targets to intervene on amyloid protein cell-tocell propagation.
We began by investigating the influence of missense mutations in the a-syn
protein associated with familial, early-onset PD, with the hypothesis that an increased
potency of endocytic vesicle rupture induced by amyloid assemblies of these mutants
may account for their earlier disease onset. Although only 10% of PD cases have a
genetic cause and the remaining 90% are idiopathic cases [229, 230], examination of asyn familial missense mutants is valuable because the onset of PD is directly attributable
to alterations in the a-syn protein, and insights gained from examining these forms of asyn may lead to new information about the behavior of WT a-syn becoming misfolded
and causing toxicity in the vast majority of PD cases. When we produced aggregates of
WT, E46K, A53T, A30P, and G51D a-syn in vitro from recombinant purified protein
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(Figure 9), and exposed target SY5YchGal3 cells to these exogenous aggregates in the
culture media, we noted clear vesicle rupture as indicated by the colocalization of a-syn
aggregates with distinct chGal3 puncta at the site of vesicle damage (Figure 10).
Quantification of this phenomenon revealed an identical propensity to induce vesicle
rupture between WT and familial mutant a-syn (Figure 11), indicating that individual
amino acid missense mutations do not alter the structural characteristics of the
resulting amyloid aggregate enough to influence its vesicle rupture potency. Although
this finding again emphasizes the conserved nature of endocytic vesicle rupture induced
by a variety of amyloid protein assemblies, we were unable to observe a significant
change in vesicle rupture potency with assemblies composed of any missense mutant
form of a-syn. These findings are limited, though, in the preparation scheme utilized to
generate amyloid aggregates. The intermediate aggregation period and lack of
fragmentation utilized in these studies results in a heterogeneous population of
aggregates that may contain large, small, or even monomeric forms of a-syn. Future
studies will examine the impact of familial disease-associated a-syn missense variants in
the context of assembly populations of a homogenous size distribution.
Given the preferential and consistent upregulation of S129 phosphorylation in
PD [260], and the fact that 90% of a-syn in pathological LB inclusions is phosphorylated
at S129 compared to less than 5% of soluble a-syn exhibiting this PTM [119-122], we
next investigated the influence of S129 phosphorylation on endocytic vesicle rupture
potency alone or in combination with a-syn familial missense mutations. Despite the
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prevalence of this a-syn PTM, its influence on a-syn pathology is still poorly understood.
Even the question of whether S129 phosphorylation is a cause or a consequence of asyn toxicity is unanswered. We reasoned that S129 phosphorylation would affect
aggregate structure, membrane binding, or both in such a way that increases the
endocytic vesicle rupture potency of assemblies exhibiting this PTM. To address this
hypothesis, we generated aggregates of recombinant purified WT, A30P, and A53T asyn that had been expressed in E.coli with or without PLK2, which induces specific
phosphorylation only at S129. Incubation of recipient SY5YchGal3 cells with these
exogenous aggregates results in clear induction of endocytic vesicle rupture as shown by
relocalization of chGal3 to the site of vesicle rupture and colocalization with a-syn
fluorescence (Figure 12). Quantification of this experimental data, which had been
acquired and analyzed in a blinded fashion, revealed a consistent 50% increase in vesicle
rupture potency induced by S129 phosphorylation (Figure 13). Our observation that
S129 phosphorylation increases the potency of endocytic vesicle rupture, combined
with the specific enrichment of this PTM in pathologic LB inclusions, raises the
possibility that these two events are linked, and that increases in endocytic vesicle
rupture potency by pathologic pS129 a-syn increases the likelihood of LB inclusion
formation. Whether S129 phosphorylation occurs to cause a-syn pathological behavior
or simply results from already increased pathological characteristics, once a-syn
aggregates become phosphorylated, before or after their assembly, S129
phosphorylation induces more toxicity because of increased vesicle rupture potency.

Finally, given the fact that distinct a-syn strain conformations underlie the
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tremendous heterogeneity of disease phenotypes in the a-synucleinopathy diseases PD,
DLB, and MSA [304], we next examined the influence of a-syn strain conformation on
endocytic vesicle rupture potency with the hypothesis that differences in rupture
potency induced by distinct a-syn strains may result in strain-specific differences in
disease phenotype. Distinct a-syn strains exhibiting different structures, levels of
toxicity, and seeding and propagation properties have been generated in vitro by
varying the conditions of aggregation [218, 305-310, 315], and the existence of distinct
strains in vivo has been verified with PD and MSA samples [312-314]. Strain diversity is
encoded by variable conformations of PrP, a-syn, tau, and HTTExon1 in their respective
proteinopathies, and these differences may account for differences in disease pattern as
even slight changes to aggregate conformation may have a big impact on biological
behavior. We hypothesized that variable strain conformations exposing different
surfaces and exhibiting distinct physical properties would dictate membrane association
and subsequent endocytic vesicle rupture potency. To test this hypothesis, distinct asyn strains generated in vitro from WT a-syn and fragmented to produce smaller sized
fibrillar assemblies (Figure 14) were used as a treatment for recipient SY5YchGal3 cells,
and their relative abilities to induce vesicle rupture were quantified. We observed
vesicle rupture in response to endocytosis of all fibrillar strains of a-syn examined,
although vesicle rupture was not observed in response to treatment with a-syn
monomers or oligomers (Figure 15). Quantification revealed significant increases in
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vesicle rupture induced by a-syn fibrils, fibrils-65, and fibrils-91, but a-syn ribbons were
unable to induce a significant increase in vesicle rupture compared to unexposed cells
(Figure 16) despite observing instances of a-syn ribbons fluorescence colocalizing with
chGal3 puncta just as for other a-syn fibrillar strains. These findings indicate that the
fibrillar nature of a-syn assemblies is necessary but not sufficient for the ability to
induce vesicle rupture, and the intrinsic conformation of a-syn fibrillar polymorphs
dictates endocytic vesicle rupture potency. Because a-syn fibrils have been shown to
induce higher levels of toxicity in vitro [305] and in vivo [218] compared with a-syn
ribbons, and these two polymorphs yield different synucleinopathies when injected into
recipient animals [218], we believe that differences in endocytic vesicle rupture potency
may account for strain-specific differences in disease pathology. Additionally, in the
setting of endocytic vesicle rupture induced by multiple isoforms of full-length WT tau,
we observed a significant increase in vesicle rupture potency for tau isoform 1N4R
compared with tau isoform 1N3R (Figure 19), indicating that vesicle rupture induction
may also underlie phenotypic variability among tauopathies just as for asynucleinopathies. Finally, in an intriguing turn of events, since the completion of our
work examining the effect of S129 phosphorylation on vesicle rupture potency, another
study found that pS129 a-syn assembles into a unique strain conformation distinct from
non-pS129 a-syn [316], offering an explanation for our observed increase in vesicle
rupture potency with S129 phosphorylation based on the existence of a unique strain
conformation that may be capable of more potent endocytic vesicle rupture induction.

Our work examining the mechanism of endocytic vesicle rupture induced by
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fibrillar amyloid protein assemblies forms the basis for the established induction of
seeding and templating of expressed proteins by invading exogenous assemblies. In the
life cycle of amyloid protein cell-to-cell propagation, exogenous amyloid assemblies
need to break out of the endocytic vesicle to access the cytosolic “replication
machinery”, additional monomeric constituent building blocks. Such a mechanism is
deviously employed by intracellular bacteria and viruses, which escape the vesicular
compartment and evade cellular defense responses, sometimes even using these
responses to their advantage [572]. Bacteria and viruses have an evolutionary pressure
to develop these characteristics or else face extinction. Aggregated amyloid proteins do
not have this evolutionary pressure or agenda. These proteins are pulled away from
their endogenous roles when they become misfolded and aggregated, and their
accumulation results in highly-stable protein aggregates whose behavior is dictated only
by the environmental conditions they experience. Seeding of additional monomeric
misfolding is part of the definition of prion-like proteins, and this seeding process
cannot occur unless the exogenous amyloid seed contacts intracellular naïve monomeric
constituents to serve as a template for further misfolding. While many groups have
separately established the importance of both uptake by endocytosis [448-450, 498,
506-508, 531] and induction of intracellular seeding [18, 19, 21, 197, 200-202, 212, 213,
347, 478, 490, 498, 510, 525, 526, 534], these two essential aspects of the amyloid
protein propagation pathway have never been linked [448, 465, 522, 531]. No study,
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until our prior work [4], had directly assessed the ability of amyloid proteins to escape
the endocytic compartment. Additionally, building on these previous findings, the
specific aggregate species involved and the molecular determinants of rupture potency
remained to be determined. We have established that short fragments of fibrillar
amyloid assemblies represent the aggregate species most potent for inducing vesicle
rupture, perfectly aligning with the prevailing view that these same species most easily
enter recipient cells via endocytosis [45, 200, 509], most effectively disrupt artificial
liposomes [557], most potently induce seeding [22-25, 209-211, 525, 527, 653] and
toxicity [129, 389-393], and most efficiently propagate from one cell to another [202,
203, 212, 213, 219, 439, 441, 442]. These findings add endocytic vesicle rupture to the
list of characteristics of prion-like amyloid proteins, with its amyloid structure imparting
this function just as it does for seeding/templating and propagation. Due to the
conserved nature of endocytic vesicle rupture for the cellular entry of amyloid protein
assemblies from multiple neurodegenerative diseases, there may be a shared
therapeutic approach that could have a broad impact.
Affected Cells Target Ruptured Vesicles and Alpha-Synuclein Cargo to Autophagy
Knowing that endocytic vesicle rupture represents the mechanism for the
cellular invasion of exogenous amyloid assemblies, we next sought to examine the
impact of this vesicle damage on vesicular trafficking and degradation processes.
Although we have exploited their properties as PRRs, recognizing exposed b-galactoside
sugars abnormally present in the cytosol [570, 571], for the fluorescent microscopic
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detection of endocytic vesicle rupture events[619, 620], cytosolic galectins such as Gal3
and Gal8 play an integral role in degradative and innate immune defense responses
within cells affected by endocytic vesicle rupture [570, 579, 587-589, 602, 603]. In the
context of infectious pathogens or sterile damage that cause endocytic vesicle rupture
in an identical fashion to that induced by invading amyloid protein assemblies, it is
known that ruptured vesicles become recognized by the autophagic machinery for
degradation [570, 576, 579, 597-600, 603], and as a result of recruitment to the ALP can
subsequently recover a low pH despite their previous rupture [560, 615]. We examined
the situation of a-syn-induced endocytic vesicle rupture to learn if this process of
autophagic recruitment of ruptured vesicles also occurs in the context of a-syn invasion,
or if ongoing membrane damage would prevent autophagic recruitment and reestablishment of a low pH environment. To do this, we utilized immunofluorescent
detection of the lysosomal marker LAMP1 in addition to live cell imaging of YFP-labeled
LC3 and the identification of low pH compartments labeled by Lysotracker in
SY5YchGal3 cells exposed to a-syn assemblies. We confirmed our previous finding that
lysosomes are ruptured by a-syn aggregates [4] by demonstrating colocalization of
chGal3+ ruptured vesicles containing a-syn with LAMP1 (Figure 24). Furthermore, we
also confirmed that, like ruptured vesicles caused by invading pathogens or sterile
damage, lysosomes ruptured by a-syn aggregates are recruited to LC3+
autophagosomes and re-establish a low pH gradient (Figure 24, 25). This recruitment of
damaged vesicles and a-syn cargo to the ALP counteracts accumulation of misfolded

proteins and dysfunctional organelles (Figure 32, left), but would also be expected to
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add to the overall burden of substrates needing to be cleared through this degradative
mechanism, causing an increased workload for this system to maintain proteostasis.
Future studies will examine the signaling cascades that mediate this targeting of
ruptured vesicles to the ALP, and determine if enhancing their detection and
recruitment and/or boosting the overall degradative capacity of the pathway may have
therapeutic efficacy for tipping the scale back in the direction of equilibrium.
Endocytic Vesicle Rupture Can Promote Inclusion Formation
As the mechanism for exogenous pre-formed amyloid assemblies to trigger the
aggregation and intracellular inclusion formation of expressed naïve constituents,
endocytic vesicle rupture delivers the seed to the cytoplasm where it continues its
prion-like cascade. Additionally, rupture of lysosomes by invading amyloid assemblies
directly impairs lysosomal degradation by causing cathepsin leakage and produces
oxidative stress [4]. Given these roles, endocytic vesicle rupture is uniquely positioned
to provide both the substance, misfolded seeds and damaged vesicles, and the stimulus,
degradative dysfunction, for pathologic proteinaceous inclusion formation. The
prevailing hypothesis regarding the formation of LB inclusions of a-syn is that this
process is related to the formation of aggresomes, agglomerations of degradative
substrates occurring as a protective mechanism of the cell to more efficiently facilitate
degradation [118, 124]. This observation is supported by numerous demonstration of
LBs as clusters of vesicles containing lysosomal and autophagic markers and proteolytic

201
enzymes [128-135]. Additionally, activation of autophagy can facilitate the dissolution of
larger inclusions, increasing the number of smaller cytoplasmic aggregates [327].
Alternatively, mature fibrillar inclusion bodies are known to be refractory to lysosomal
or autophagic clearance [134, 334], exemplified by the buildup of dysfunctional
lysosomes and autophagosomes [131, 339, 346]. When degradative mechanisms are
dysfunctional, the merging of substrates into aggresome-like structures instead
facilitates LB inclusion formation [118, 124] (Figure 32, right). Given the nature of
vesicles ruptured by a-syn as targeted for autophagic degradation just like their
misfolded protein aggregate cargo, and the contribution of a-syn-mediated LMP to
degradative dysfunction, we reasoned that endocytic vesicle rupture may contribute to
pathological inclusion formation. To test this hypothesis, we examined intracellular
trafficking of ruptured vesicles for the presence and formation of intracellular inclusions,
and investigated the localization of endogenous Gal3 in PD post-mortem SN tissue. Livecell imaging of ruptured vesicles containing a-syn demonstrated instances where
multiple smaller ruptured vesicles merged into larger low pH inclusions (Figure 25, 26,
27), and large perinuclear inclusions of exogenous a-syn identified by fixed cell imaging
exhibited a corona of chGal3 fluorescence around the periphery of the inclusion,
indicating rupture in the vesicles that merged to create the inclusion (Figure 28, 32 right
inset image). Finally, immunofluorescent detection of pS129+ LBs and endogenous Gal3
in the post-mortem SN of PD patients also demonstrated Gal3 localization as a corona
surrounding pathological LB inclusions, indicating a history of previous membrane

rupture as preceding LB formation (Figure 29, 32 right inset image). The observation
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that Gal3 is trapped within the majority of LBs (≥55%) in the brains of PD patients
suggests that these proteinaceous inclusions do not originate solely from the
aggregation of expressed, misfolded α-syn, but rather have as their origin the invasion
of exogenous a-syn fibrils through endocytic vesicle rupture. Indeed, the trafficking of
exogenous fibrils from affected to naïve cells, either naked or encapsulated within
intracellular vesicles, would lead through vesicle rupture to their accumulation into LBs
and the trapping of Gal3 within these LBs. While these findings demonstrate that
endocytic vesicle contributes to pathological inclusion formation in authentic PD, we
have, to date, only characterized LB inclusions in 5 separate patients, all of whom were
in a very advanced H&Y5 stage of PD. Future studies will expand this work by including
more patient-derived samples from various disease stages and brain regions, and focus
on characterizing the involvement of vesicle rupture in the stages of LB development in
various brain regions. Also, pathological examination of endocytic vesicle rupture in
fetal dopaminergic graft tissue implanted into the brains of PD patients would provide
an elegant way to focus our analysis exclusively on a-syn pathology arising from
exogenous amyloid aggregates, as young fetal dopaminergic grafts would not be
expected to develop LB pathology spontaneously. The finding that ~55% of SN LBs
exhibit a discernable Gal3 corona that indicates vesicle rupture may increase if the
source of LB pathology is exclusively exogenous, and would need to induce endocytic
vesicle rupture to trigger inclusion formation in recipient cells.
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Endocytic Vesicle Rupture Can Promote Alpha-Synuclein Cell-to-Cell Propagation
Many of the same stimuli prompting intracellular inclusion formation, such as
lysosomal or autophagic dysfunction and oxidative stress, are also known to promote
the pathological release and cell-to-cell transmission of amyloid protein aggregates
[294, 468-471, 473, 479, 485, 518] (Figure 32, right). We aimed to determine if
endocytic vesicle rupture could fulfill this criterion as well. Interestingly given the
association of the invading amyloid aggregate with an, albeit ruptured, intracellular
vesicle, there have been numerous mechanisms of non-classical secretion proposed for
both a-syn and Gal3 that raise the possibility that a-syn aggregates may be released
into the extracellular environment through fusion of intracellular vesicles with the
plasma membrane or through release of vesicles as exosomes [468-473, 478, 480, 591593]. These types of non-classical release mechanisms have also been demonstrated for
amyloid assemblies of tau and HTTExon1 [444, 516-519]. Interestingly, prions and
amyloid assemblies of a-syn, tau, and HTTExon1 have each been shown to traffick from
affected to naïve cells within TNTs, and also to upregulate the cellular expression of
TNTs to facilitate their own transmission [47, 48, 445, 520, 521, 535]. In the case of asyn, TNT-mediated transmission was shown to occur within the lumen of lysosomes,
raising the intriguing possibility that ruptured lysosomes containing a-syn may be
involved in this process [445]. Finally, the same small fibrillar forms of amyloid
assemblies most potent for inducing vesicle rupture are most often the species
responsible for cell-to-cell propagation [202, 203, 212, 213, 219, 439, 441, 442],
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suggesting that cellular invasion and release may be intertwined when induced by these
pathogenic amyloid species. To assess the involvement of endocytic vesicle rupture in
the cellular release and intercellular propagation of a-syn aggregates, we examined the
extracellular localization and the intercellular movement of a-syn containing ruptured
vesicles. We observed ruptured vesicles containing a-syn present in the extracellular
environment (Figure 30), and we furthermore captured an instance of a-syn
intercellular trafficking between chGal3-expressing hiPSC-derived dopaminergic neurons
that revealing a-syn propagation occurring within a ruptured vesicle (Figure 31). While
these findings are preliminary and in need of additional verification, our observation
that a-syn release and cell-to-cell propagation can occur in association with ruptured
vesicles has great importance for understanding disease pathogenesis. Future work will
focus on characterizing the population of free and membrane-associated a-syn,
investigating the cellular factors that facilitate release, and examining the potential
chaperone or facilitative role for Gal3 in recognizing ruptured vesicle damage and
trafficking with a-syn to the extracellular environment and to neighboring cells. We
believe that the damaging mechanism of cellular invasion by a-syn assemblies and other
aggregated amyloid proteins through endocytic vesicle rupture sets into a motion a
positive feedback loop whereby the cellular stressors induced by this damage lead to
the inability of the damaged vesicle and its a-syn cargo to be degraded via autophagy
and instead result in pathological inclusion formation, amyloid protein release, and cellto-cell propagation of misfolded protein pathology.

Concluding Remarks
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The above results have uncovered a conserved role for endocytic vesicle rupture
in the cell-to-cell propagation pathway of fibrillar amyloid protein assemblies. In the
intracellular and intercellular life cycle of misfolded amyloid protein aggregates, thought
to underlie the inexorable progression of numerous neurodegenerative diseases, the
mechanism by which amyloid aggregates escape from the vesicular compartment
following their endocytic uptake was unknown. We have characterized this process in
multiple model systems, observing its occurrence as a common mechanism of amyloid
aggregate invasion in immortalized cells and hiPSC-derived dopaminergic neurons.
Furthermore, in a fashion resembling the cellular infection by bacterial and viral
pathogens, lysosomes ruptured by a-syn are targeted for autophagic degradation, but
not before their problematic permeabilization releases proteolytic cathepsins and
mitochondrial ROS creating an environment of oxidative and degradative stress.
Dysfunctional degradative processes may fail to cope with the burden of misfolded
protein aggregates and damaged vesicles, instead causing pathological inclusion
formation and cellular release of pathologic a-syn species. The localization of Gal3 to
the periphery of LB inclusions in PD brain implicates amyloid assembly-mediated
endocytic vesicle rupture as occurring in authentic human disease, and provides a
unique opportunity for further assessment of this phenomenon as a therapeutic target
to prevent or reverse neurodegenerative proteinopathies.

APPENDIX
ADDITIONAL FIGURES FOR REFERENCE

206

207

Figure 33. chGal3+ ruptured vesicles containing a-syn observed in undeconvolved and
deconvolved fluorescent microscopic images. Image of SY5YchGal3 cells exposed to WT
a-syn fibrils from Figure 15, shown as undeconvolved and deconvolved images. As in
Figure 15, Overlay images are separated into separate channels for either a-syn
fluorescence or chGal3 fluorescence, and inset box in top images is enlarged in bottom
images. Arrowheads indicate colocalization between chGal3+ ruptured vesicles
appearing as discrete puncta and a-syn assemblies, observed in both undeconvolved
and deconvolved image sets.

Figure 34. Three-dimensional surfaces encapsulating a-syn-containing chGal3+
ruptured vesicles superimposed onto deconvolved fluorescent microscopic images.
Image of SY5YchGal3 cells exposed to A53T a-syn assemblies from Figure 12, analyzed
for puncta formation by use of the Surpass Mode of the Imaris software package
(Bitplane). A three-dimensional surface was created around chGal3 puncta by designing
an algorithm for each experiment that specifically detected punctate events that
increased in intensity sufficiently above background fluorescence. Algorithm-detected
semi-spherical chGal3+ puncta are seen in gray, either superimposed on fluorescent
image in left panel or alone in right panel.

1.

REFERENCES
Prusiner, S.B., Novel proteinaceous infectious particles cause scrapie. Science,
1982. 216(4542): p. 136-44.

2.

Colby, D.W. and Prusiner, S.B., Prions. Cold Spring Harb Perspect Biol, 2011. 3(1):
p. a006833.

3.

Prusiner, S.B., Cell biology. A unifying role for prions in neurodegenerative
diseases. Science, 2012. 336(6088): p. 1511-3.

4.

Freeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage,
A.M., Sudholt, S., Rana, A., O'Connor, C., Wiethoff, C.M., and Campbell, E.M.,
Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive
oxygen species following endocytosis. PLoS ONE, 2013. 8(4): p. e62143.

5.

Bolton, D.C., McKinley, M.P., and Prusiner, S.B., Identification of a protein that
purifies with the scrapie prion. Science, 1982. 218(4579): p. 1309-11.

6.

McKinley, M.P., Bolton, D.C., and Prusiner, S.B., A protease-resistant protein is a
structural component of the scrapie prion. Cell, 1983. 35(1): p. 57-62.

7.

Prusiner, S.B., Groth, D.F., McKinley, M.P., Cochran, S.P., Bowman, K.A., and
Kasper, K.C., Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc
Natl Acad Sci U S A, 1981. 78(7): p. 4606-10.

8.

Chesebro, B., Race, R., Wehrly, K., Nishio, J., Bloom, M., Lechner, D., Bergstrom,
S., Robbins, K., Mayer, L., Keith, J.M., and et al., Identification of scrapie prion
protein-specific mRNA in scrapie-infected and uninfected brain. Nature, 1985.
315(6017): p. 331-3.

9.

Oesch, B., Westaway, D., Walchli, M., McKinley, M.P., Kent, S.B., Aebersold, R.,
Barry, R.A., Tempst, P., Teplow, D.B., Hood, L.E., and et al., A cellular gene
encodes scrapie PrP 27-30 protein. Cell, 1985. 40(4): p. 735-46.

10.

Basler, K., Oesch, B., Scott, M., Westaway, D., Walchli, M., Groth, D.F., McKinley,
M.P., Prusiner, S.B., and Weissmann, C., Scrapie and cellular PrP isoforms are
encoded by the same chromosomal gene. Cell, 1986. 46(3): p. 417-28.

208

11.

209
Pan, K.M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn,
I., Huang, Z., Fletterick, R.J., Cohen, F.E., and et al., Conversion of alpha-helices
into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl
Acad Sci U S A, 1993. 90(23): p. 10962-6.

12.

Caughey, B.W., Dong, A., Bhat, K.S., Ernst, D., Hayes, S.F., and Caughey, W.S.,
Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water
by infrared spectroscopy. Biochemistry, 1991. 30(31): p. 7672-80.

13.

Brown, P., The phenotypic expression of different mutations in transmissible
human spongiform encephalopathy. Rev Neurol (Paris), 1992. 148(5): p. 317-27.

14.

Hsiao, K., Baker, H.F., Crow, T.J., Poulter, M., Owen, F., Terwilliger, J.D.,
Westaway, D., Ott, J., and Prusiner, S.B., Linkage of a prion protein missense
variant to Gerstmann-Straussler syndrome. Nature, 1989. 338(6213): p. 342-5.

15.

Sigurdson, C.J., Nilsson, K.P., Hornemann, S., Heikenwalder, M., Manco, G.,
Schwarz, P., Ott, D., Rulicke, T., Liberski, P.P., Julius, C., Falsig, J., Stitz, L.,
Wuthrich, K., and Aguzzi, A., De novo generation of a transmissible spongiform
encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A, 2009. 106(1): p.
304-9.

16.

Prusiner, S.B., Scott, M., Foster, D., Pan, K.M., Groth, D., Mirenda, C., Torchia, M.,
Yang, S.L., Serban, D., Carlson, G.A., and et al., Transgenetic studies implicate
interactions between homologous PrP isoforms in scrapie prion replication. Cell,
1990. 63(4): p. 673-86.

17.

Kocisko, D.A., Come, J.H., Priola, S.A., Chesebro, B., Raymond, G.J., Lansbury,
P.T., and Caughey, B., Cell-free formation of protease-resistant prion protein.
Nature, 1994. 370(6489): p. 471-4.

18.

Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H.P., DeArmond, S.J.,
Prusiner, S.B., Aguet, M., and Weissmann, C., Normal development and
behaviour of mice lacking the neuronal cell-surface PrP protein. Nature, 1992.
356(6370): p. 577-82.

19.

Bueler, H., Aguzzi, A., Sailer, A., Greiner, R.A., Autenried, P., Aguet, M., and
Weissmann, C., Mice devoid of PrP are resistant to scrapie. Cell, 1993. 73(7): p.
1339-47.

20.

Aguzzi, A. and Polymenidou, M., Mammalian prion biology: one century of
evolving concepts. Cell, 2004. 116(2): p. 313-27.

210

21.

Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y.,
Marino, S., Weissmann, C., and Aguzzi, A., Normal host prion protein necessary
for scrapie-induced neurotoxicity. Nature, 1996. 379(6563): p. 339-43.

22.

Silveira, J.R., Raymond, G.J., Hughson, A.G., Race, R.E., Sim, V.L., Hayes, S.F., and
Caughey, B., The most infectious prion protein particles. Nature, 2005. 437(7056):
p. 257-61.

23.

Saborio, G.P., Permanne, B., and Soto, C., Sensitive detection of pathological
prion protein by cyclic amplification of protein misfolding. Nature, 2001.
411(6839): p. 810-3.

24.

Castilla, J., Saa, P., Hetz, C., and Soto, C., In vitro generation of infectious scrapie
prions. Cell, 2005. 121(2): p. 195-206.

25.

Tanaka, M., Collins, S.R., Toyama, B.H., and Weissman, J.S., The physical basis of
how prion conformations determine strain phenotypes. Nature, 2006. 442(7102):
p. 585-9.

26.

Gajdusek, D.C., Unconventional viruses and the origin and disappearance of kuru.
Science, 1977. 197(4307): p. 943-60.

27.

Bernoulli, C., Siegfried, J., Baumgartner, G., Regli, F., Rabinowicz, T., Gajdusek,
D.C., and Gibbs, C.J., Jr., Danger of accidental person-to-person transmission of
Creutzfeldt-Jakob disease by surgery. Lancet, 1977. 1(8009): p. 478-9.

28.

Davanipour, Z., Goodman, L., Alter, M., Sobel, E., Asher, D., and Gajdusek, D.C.,
Possible modes of transmission of Creutzfeldt-Jakob disease. N Engl J Med, 1984.
311(24): p. 1582-3.

29.

Brown, P., Gajdusek, D.C., Gibbs, C.J., Jr., and Asher, D.M., Potential epidemic of
Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med,
1985. 313(12): p. 728-31.

30.

Duffy, P., Wolf, J., Collins, G., DeVoe, A.G., Streeten, B., and Cowen, D., Letter:
Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J
Med, 1974. 290(12): p. 692-3.

31.

Brown, P., Preece, M.A., and Will, R.G., "Friendly fire" in medicine: hormones,
homografts, and Creutzfeldt-Jakob disease. Lancet, 1992. 340(8810): p. 24-7.

32.

Collinge, J., Sidle, K.C., Meads, J., Ironside, J., and Hill, A.F., Molecular analysis of
prion strain variation and the aetiology of 'new variant' CJD. Nature, 1996.
383(6602): p. 685-90.

33.

211
Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., Alperovitch, A.,
Poser, S., Pocchiari, M., Hofman, A., and Smith, P.G., A new variant of
Creutzfeldt-Jakob disease in the UK. Lancet, 1996. 347(9006): p. 921-5.

34.

Bruce, M.E., Will, R.G., Ironside, J.W., McConnell, I., Drummond, D., Suttie, A.,
McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H., and Bostock,
C.J., Transmissions to mice indicate that 'new variant' CJD is caused by the BSE
agent. Nature, 1997. 389(6650): p. 498-501.

35.

Hill, A.F., Desbruslais, M., Joiner, S., Sidle, K.C., Gowland, I., Collinge, J., Doey, L.J.,
and Lantos, P., The same prion strain causes vCJD and BSE. Nature, 1997.
389(6650): p. 448-50, 526.

36.

Peden, A.H., Head, M.W., Ritchie, D.L., Bell, J.E., and Ironside, J.W., Preclinical
vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet,
2004. 364(9433): p. 527-9.

37.

Fraser, H., Neuronal spread of scrapie agent and targeting of lesions within the
retino-tectal pathway. Nature, 1982. 295(5845): p. 149-50.

38.

Klein, M.A., Frigg, R., Flechsig, E., Raeber, A.J., Kalinke, U., Bluethmann, H., Bootz,
F., Suter, M., Zinkernagel, R.M., and Aguzzi, A., A crucial role for B cells in
neuroinvasive scrapie. Nature, 1997. 390(6661): p. 687-90.

39.

Blattler, T., Brandner, S., Raeber, A.J., Klein, M.A., Voigtlander, T., Weissmann, C.,
and Aguzzi, A., PrP-expressing tissue required for transfer of scrapie infectivity
from spleen to brain. Nature, 1997. 389(6646): p. 69-73.

40.

Glatzel, M., Heppner, F.L., Albers, K.M., and Aguzzi, A., Sympathetic innervation
of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron, 2001.
31(1): p. 25-34.

41.

Prinz, M., Heikenwalder, M., Junt, T., Schwarz, P., Glatzel, M., Heppner, F.L., Fu,
Y.X., Lipp, M., and Aguzzi, A., Positioning of follicular dendritic cells within the
spleen controls prion neuroinvasion. Nature, 2003. 425(6961): p. 957-62.

42.

Renner, M. and Melki, R., Protein aggregation and prionopathies. Pathol Biol
(Paris), 2014. 62(3): p. 162-8.

43.

Hijazi, N., Kariv-Inbal, Z., Gasset, M., and Gabizon, R., PrPSc incorporation to cells
requires endogenous glycosaminoglycan expression. J Biol Chem, 2005. 280(17):
p. 17057-61.

44.

212
Magalhaes, A.C., Baron, G.S., Lee, K.S., Steele-Mortimer, O., Dorward, D., Prado,
M.A., and Caughey, B., Uptake and neuritic transport of scrapie prion protein
coincident with infection of neuronal cells. J Neurosci, 2005. 25(21): p. 5207-16.

45.

Greil, C.S., Vorberg, I.M., Ward, A.E., Meade-White, K.D., Harris, D.A., and Priola,
S.A., Acute cellular uptake of abnormal prion protein is cell type and scrapiestrain independent. Virology, 2008. 379(2): p. 284-93.

46.

Goold, R., McKinnon, C., Rabbanian, S., Collinge, J., Schiavo, G., and Tabrizi, S.J.,
Alternative fates of newly formed PrPSc upon prion conversion on the plasma
membrane. J Cell Sci, 2013. 126(Pt 16): p. 3552-62.

47.

Kanu, N., Imokawa, Y., Drechsel, D.N., Williamson, R.A., Birkett, C.R., Bostock,
C.J., and Brockes, J.P., Transfer of scrapie prion infectivity by cell contact in
culture. Curr Biol, 2002. 12(7): p. 523-30.

48.

Gousset, K., Schiff, E., Langevin, C., Marijanovic, Z., Caputo, A., Browman, D.T.,
Chenouard, N., de Chaumont, F., Martino, A., Enninga, J., Olivo-Marin, J.C.,
Mannel, D., and Zurzolo, C., Prions hijack tunnelling nanotubes for intercellular
spread. Nat Cell Biol, 2009. 11(3): p. 328-36.

49.

Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., and
Raposo, G., Cells release prions in association with exosomes. Proc Natl Acad Sci
U S A, 2004. 101(26): p. 9683-8.

50.

Vella, L.J., Sharples, R.A., Lawson, V.A., Masters, C.L., Cappai, R., and Hill, A.F.,
Packaging of prions into exosomes is associated with a novel pathway of PrP
processing. J Pathol, 2007. 211(5): p. 582-90.

51.

Bartz, J.C., Prion Strain Diversity. Cold Spring Harb Perspect Med, 2016.
10.1101/cshperspect.a024349.

52.

Ghaemmaghami, S., Biology and Genetics of PrP Prion Strains. Cold Spring Harb
Perspect Med, 2016. 10.1101/cshperspect.a026922.

53.

Pattison, I.H. and Jones, K.M., The possible nature of the transmissible agent of
scrapie. Vet Rec, 1967. 80(1): p. 2-9.

54.

Dickinson, A.G. and Meikle, V.M., A comparison of some biological characteristics
of the mouse-passaged scrapie agents, 22A and ME7. Genet Res, 1969. 13(2): p.
213-25.

55.

Fraser, H. and Dickinson, A.G., Distribution of experimentally induced scrapie
lesions in the brain. Nature, 1967. 216(5122): p. 1310-1.

56.

213
Fraser, H. and Dickinson, A.G., The sequential development of the brain lesion of
scrapie in three strains of mice. J Comp Pathol, 1968. 78(3): p. 301-11.

57.

Fraser, H. and Dickinson, A.G., Scrapie in mice. Agent-strain differences in the
distribution and intensity of grey matter vacuolation. J Comp Pathol, 1973. 83(1):
p. 29-40.

58.

Hecker, R., Taraboulos, A., Scott, M., Pan, K.M., Yang, S.L., Torchia, M.,
Jendroska, K., DeArmond, S.J., and Prusiner, S.B., Replication of distinct scrapie
prion isolates is region specific in brains of transgenic mice and hamsters. Genes
Dev, 1992. 6(7): p. 1213-28.

59.

DeArmond, S.J., Yang, S.L., Lee, A., Bowler, R., Taraboulos, A., Groth, D., and
Prusiner, S.B., Three scrapie prion isolates exhibit different accumulation patterns
of the prion protein scrapie isoform. Proc Natl Acad Sci U S A, 1993. 90(14): p.
6449-53.

60.

Jeffrey, M., Martin, S., and Gonzalez, L., Cell-associated variants of diseasespecific prion protein immunolabelling are found in different sources of sheep
transmissible spongiform encephalopathy. J Gen Virol, 2003. 84(Pt 4): p. 103345.

61.

Kascsak, R.J., Rubenstein, R., Merz, P.A., Tonna-DeMasi, M., Fersko, R., Carp, R.I.,
Wisniewski, H.M., and Diringer, H., Mouse polyclonal and monoclonal antibody
to scrapie-associated fibril proteins. J Virol, 1987. 61(12): p. 3688-93.

62.

Bessen, R.A. and Marsh, R.F., Biochemical and physical properties of the prion
protein from two strains of the transmissible mink encephalopathy agent. J Virol,
1992. 66(4): p. 2096-101.

63.

Telling, G.C., Parchi, P., DeArmond, S.J., Cortelli, P., Montagna, P., Gabizon, R.,
Mastrianni, J., Lugaresi, E., Gambetti, P., and Prusiner, S.B., Evidence for the
conformation of the pathologic isoform of the prion protein enciphering and
propagating prion diversity. Science, 1996. 274(5295): p. 2079-82.

64.

Sim, V.L. and Caughey, B., Ultrastructures and strain comparison of underglycosylated scrapie prion fibrils. Neurobiol Aging, 2009. 30(12): p. 2031-42.

65.

Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F.E., and
Prusiner, S.B., Eight prion strains have PrP(Sc) molecules with different
conformations. Nat Med, 1998. 4(10): p. 1157-65.

66.

214
Legname, G., Nguyen, H.O., Peretz, D., Cohen, F.E., DeArmond, S.J., and Prusiner,
S.B., Continuum of prion protein structures enciphers a multitude of prion isolatespecified phenotypes. Proc Natl Acad Sci U S A, 2006. 103(50): p. 19105-10.

67.

Ayers, J.I., Schutt, C.R., Shikiya, R.A., Aguzzi, A., Kincaid, A.E., and Bartz, J.C., The
strain-encoded relationship between PrP replication, stability and processing in
neurons is predictive of the incubation period of disease. PLoS Pathog, 2011. 7(3):
p. e1001317.

68.

Colby, D.W., Wain, R., Baskakov, I.V., Legname, G., Palmer, C.G., Nguyen, H.O.,
Lemus, A., Cohen, F.E., DeArmond, S.J., and Prusiner, S.B., Protease-sensitive
synthetic prions. PLoS Pathog, 2010. 6(1): p. e1000736.

69.

Legname, G., Baskakov, I.V., Nguyen, H.O., Riesner, D., Cohen, F.E., DeArmond,
S.J., and Prusiner, S.B., Synthetic mammalian prions. Science, 2004. 305(5684): p.
673-6.

70.

Legname, G., Nguyen, H.O., Baskakov, I.V., Cohen, F.E., Dearmond, S.J., and
Prusiner, S.B., Strain-specified characteristics of mouse synthetic prions. Proc Natl
Acad Sci U S A, 2005. 102(6): p. 2168-73.

71.

Parkinson, J., An Essay on the Shaking Palsy. Sherwood, Neely, and Jones, 1817.

72.

Charcot, J.-M., De la paralysie agitante, in Oeuvres Compl`etes (t 1) Le ̧cons sur
les maladies du syst`eme nerveux. 1872, A Delahaye: Paris. p. 155-188.

73.

Goetz, C.G., The history of Parkinson's disease: early clinical descriptions and
neurological therapies. Cold Spring Harb Perspect Med, 2011. 1(1): p. a008862.

74.

Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G.,
Kieburtz, K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., and Tanner,
C.M., Projected number of people with Parkinson disease in the most populous
nations, 2005 through 2030. Neurology, 2007. 68(5): p. 384-6.

75.

de Lau, L.M. and Breteler, M.M., Epidemiology of Parkinson's disease. Lancet
Neurol, 2006. 5(6): p. 525-35.

76.

Driver, J.A., Logroscino, G., Gaziano, J.M., and Kurth, T., Incidence and remaining
lifetime risk of Parkinson disease in advanced age. Neurology, 2009. 72(5): p.
432-8.

77.

Pringsheim, T., Jette, N., Frolkis, A., and Steeves, T.D., The prevalence of
Parkinson's disease: a systematic review and meta-analysis. Mov Disord, 2014.
29(13): p. 1583-90.

215

78.

Kalia, L.V. and Lang, A.E., Parkinson's disease. The Lancet, 2015. 386(9996): p.
896-912.

79.

Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A.,
Bloch, D.A., and Nelson, L.M., Incidence of Parkinson's disease: variation by age,
gender, and race/ethnicity. Am J Epidemiol, 2003. 157(11): p. 1015-22.

80.

Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso,
J., Marek, K., Litvan, I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B.,
Chan, P., Bloem, B.R., Adler, C.H., and Deuschl, G., MDS clinical diagnostic criteria
for Parkinson's disease. Mov Disord, 2015. 30(12): p. 1591-601.

81.

Bartels, A.L. and Leenders, K.L., Parkinson's disease: the syndrome, the
pathogenesis and pathophysiology. Cortex, 2009. 45(8): p. 915-21.

82.

Brooks, D.J., The early diagnosis of Parkinson's disease. Ann Neurol, 1998. 44(3
Suppl 1): p. S10-8.

83.

Jankovic, J., Parkinson's disease: clinical features and diagnosis. J Neurol
Neurosurg Psychiatry, 2008. 79(4): p. 368-76.

84.

Hawkes, C.H., The prodromal phase of sporadic Parkinson's disease: does it exist
and if so how long is it? Mov Disord, 2008. 23(13): p. 1799-807.

85.

Postuma, R.B., Aarsland, D., Barone, P., Burn, D.J., Hawkes, C.H., Oertel, W., and
Ziemssen, T., Identifying prodromal Parkinson's disease: pre-motor disorders in
Parkinson's disease. Mov Disord, 2012. 27(5): p. 617-26.

86.

Khoo, T.K., Yarnall, A.J., Duncan, G.W., Coleman, S., O'Brien, J.T., Brooks, D.J.,
Barker, R.A., and Burn, D.J., The spectrum of nonmotor symptoms in early
Parkinson disease. Neurology, 2013. 80(3): p. 276-81.

87.

Berg, D., Postuma, R.B., Adler, C.H., Bloem, B.R., Chan, P., Dubois, B., Gasser, T.,
Goetz, C.G., Halliday, G., Joseph, L., Lang, A.E., Liepelt-Scarfone, I., Litvan, I.,
Marek, K., Obeso, J., Oertel, W., Olanow, C.W., Poewe, W., Stern, M., and
Deuschl, G., MDS research criteria for prodromal Parkinson's disease. Mov
Disord, 2015. 30(12): p. 1600-11.

88.

Barker, R.A. and Williams-Gray, C.H., Review: The spectrum of clinical features
seen with alpha synuclein pathology. Neuropathol Appl Neurobiol, 2016. 42(1):
p. 6-19.

216

89.

Leentjens, A.F., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I.H., and
Starkstein, S.E., Symptomatology and markers of anxiety disorders in Parkinson's
disease: a cross-sectional study. Mov Disord, 2011. 26(3): p. 484-92.

90.

Aarsland, D., Pahlhagen, S., Ballard, C.G., Ehrt, U., and Svenningsson, P.,
Depression in Parkinson disease--epidemiology, mechanisms and management.
Nat Rev Neurol, 2011. 8(1): p. 35-47.

91.

Brown, R.G., Landau, S., Hindle, J.V., Playfer, J., Samuel, M., Wilson, K.C., Hurt,
C.S., Anderson, R.J., Carnell, J., Dickinson, L., Gibson, G., van Schaick, R.,
Sellwood, K., Thomas, B.A., Burn, D.J., and Group, P.-P.S., Depression and anxiety
related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry, 2011.
82(7): p. 803-9.

92.

Williams-Gray, C.H., Mason, S.L., Evans, J.R., Foltynie, T., Brayne, C., Robbins,
T.W., and Barker, R.A., The CamPaIGN study of Parkinson's disease: 10-year
outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry,
2013. 84(11): p. 1258-64.

93.

Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M., and Morris, J.G., The Sydney
multicenter study of Parkinson's disease: the inevitability of dementia at 20
years. Mov Disord, 2008. 23(6): p. 837-44.

94.

McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H.,
Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G.,
Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S.,
Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T.,
Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A.,
Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A.,
Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q.,
Yamada, M., and Consortium on, D.L.B., Diagnosis and management of dementia
with Lewy bodies: third report of the DLB Consortium. Neurology, 2005. 65(12):
p. 1863-72.

95.

Vann Jones, S.A. and O'Brien, J.T., The prevalence and incidence of dementia with
Lewy bodies: a systematic review of population and clinical studies. Psychol Med,
2014. 44(4): p. 673-83.

96.

Connolly, B.S. and Lang, A.E., Pharmacological treatment of Parkinson disease: a
review. Jama, 2014. 311(16): p. 1670-83.

217

97.

Fasano, A., Daniele, A., and Albanese, A., Treatment of motor and non-motor
features of Parkinson's disease with deep brain stimulation. Lancet Neurol, 2012.
11(5): p. 429-42.

98.

Hely, M.A., Morris, J.G., Reid, W.G., and Trafficante, R., Sydney Multicenter Study
of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Mov Disord, 2005. 20(2): p. 190-9.

99.

Ben-Shlomo, Y., Wenning, G.K., Tison, F., and Quinn, N.P., Survival of patients
with pathologically proven multiple system atrophy: a meta-analysis. Neurology,
1997. 48(2): p. 384-93.

100.

Gilman, S., Wenning, G.K., Low, P.A., Brooks, D.J., Mathias, C.J., Trojanowski, J.Q.,
Wood, N.W., Colosimo, C., Durr, A., Fowler, C.J., Kaufmann, H., Klockgether, T.,
Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K.,
and Vidailhet, M., Second consensus statement on the diagnosis of multiple
system atrophy. Neurology, 2008. 71(9): p. 670-6.

101.

Schrag, A., Ben-Shlomo, Y., and Quinn, N.P., Prevalence of progressive
supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet,
1999. 354(9192): p. 1771-5.

102.

Lewy, F.H., Paralysis agitans, in Pathologische Anatomie. Handbuch der
Neurologie, M. Lewandowsky, Editor. 1912, Springer-Verlag: Berlin. p. 920-933.

103.

Rodrigues e Silva, A.M., Geldsetzer, F., Holdorff, B., Kielhorn, F.W., BalzerGeldsetzer, M., Oertel, W.H., Hurtig, H., and Dodel, R., Who was the man who
discovered the "Lewy bodies"? Mov Disord, 2010. 25(12): p. 1765-73.

104.

Tretiakoff, C., Contributions a l’etude de l’anatomie pathologique du locus niger
de soemmering avec quelques deductions relatives a la pathogenie des troubles
de tonus musculaire et de la maladie de Parkinson. 1919, L'Assistance Publique
des Hopitaux de Paris: Paris.

105.

Lees, A.J., Selikhova, M., Andrade, L.A., and Duyckaerts, C., The black stuff and
Konstantin Nikolaevich Tretiakoff. Mov Disord, 2008. 23(6): p. 777-83.

106.

Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., and Takahashi, H., The
Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol
Neurobiol, 2013. 47(2): p. 495-508.

107.

Lowe, J., Blanchard, A., Morrell, K., Lennox, G., Reynolds, L., Billett, M., Landon,
M., and Mayer, R.J., Ubiquitin is a common factor in intermediate filament
inclusion bodies of diverse type in man, including those of Parkinson's disease,

218
Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar
astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver
disease. J Pathol, 1988. 155(1): p. 9-15.
108.

Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M., and Ihara, Y., Lewy bodies
are ubiquitinated. A light and electron microscopic immunocytochemical study.
Acta Neuropathol, 1988. 75(4): p. 345-53.

109.

Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and
Goedert, M., Alpha-synuclein in Lewy bodies. Nature, 1997. 388(6645): p. 839-40.

110.

Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M.,
Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease
and dementia with Lewy bodies. Proc Natl Acad Sci U S A, 1998. 95: p. 64696473.

111.

Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q.,
and Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic
Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 1998. 152(4): p.
879-84.

112.

Wakabayashi, K., Yoshimoto, M., Tsuji, S., and Takahashi, H., Alpha-synuclein
immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.
Neurosci Lett, 1998. 249(2-3): p. 180-2.

113.

Tu, P.H., Galvin, J.E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S.,
Iwatsubo, T., Trojanowski, J.Q., and Lee, V.M., Glial cytoplasmic inclusions in
white matter oligodendrocytes of multiple system atrophy brains contain
insoluble alpha-synuclein. Ann Neurol, 1998. 44(3): p. 415-22.

114.

Arima, K., Ueda, K., Sunohara, N., Arakawa, K., Hirai, S., Nakamura, M.,
Tonozuka-Uehara, H., and Kawai, M., NACP/alpha-synuclein immunoreactivity in
fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in
the pontine nuclei in multiple system atrophy. Acta Neuropathol, 1998. 96(5): p.
439-44.

115.

Wakabayashi, K., Hayashi, S., Kakita, A., Yamada, M., Toyoshima, Y., Yoshimoto,
M., and Takahashi, H., Accumulation of alpha-synuclein/NACP is a
cytopathological feature common to Lewy body disease and multiple system
atrophy. Acta Neuropathol, 1998. 96(5): p. 445-52.

219

116.

Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L., and Masliah, E.,
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative
disorders. Am J Pathol, 1998. 152(2): p. 367-72.

117.

Gai, W.P., Yuan, H.X., Li, X.Q., Power, J.T., Blumbergs, P.C., and Jensen, P.H., In
situ and in vitro study of colocalization and segregation of alpha-synuclein,
ubiquitin, and lipids in Lewy bodies. Exp Neurol, 2000. 166(2): p. 324-33.

118.

Olanow, C.W., Perl, D.P., DeMartino, G.N., and McNaught, K.S., Lewy-body
formation is an aggresome-related process: a hypothesis. Lancet Neurol, 2004.
3(8): p. 496-503.

119.

Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg,
M.S., Shen, J., Takio, K., and Iwatsubo, T., alpha-Synuclein is phosphorylated in
synucleinopathy lesions. Nat Cell Biol, 2002. 4(2): p. 160-4.

120.

Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee,
V.M., Trojanowski, J.Q., Mann, D., and Iwatsubo, T., Phosphorylated alphasynuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem, 2002.
277(50): p. 49071-6.

121.

Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello,
R.J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P.S., Shen, X.,
Chataway, T., Schlossmacher, M.G., Seubert, P., Schenk, D., Sinha, S., Gai, W.P.,
and Chilcote, T.J., Phosphorylation of Ser-129 is the dominant pathological
modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol
Chem, 2006. 281(40): p. 29739-52.

122.

Waxman, E.A. and Giasson, B.I., Specificity and regulation of casein kinasemediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol, 2008.
67(5): p. 402-16.

123.

Xia, Q., Liao, L., Cheng, D., Duong, D.M., Gearing, M., Lah, J.J., Levey, A.I., and
Peng, J., Proteomic identification of novel proteins associated with Lewy bodies.
Front Biosci, 2008. 13: p. 3850-6.

124.

Kopito, R.R., Aggresomes, inclusion bodies and protein aggregation. Trends Cell
Biol, 2000. 10(12): p. 524-30.

125.

Saito, Y., Kawashima, A., Ruberu, N.N., Fujiwara, H., Koyama, S., Sawabe, M.,
Arai, T., Nagura, H., Yamanouchi, H., Hasegawa, M., Iwatsubo, T., and Murayama,
S., Accumulation of phosphorylated alpha-synuclein in aging human brain. J
Neuropathol Exp Neurol, 2003. 62(6): p. 644-54.

220

126.

Kuusisto, E., Parkkinen, L., and Alafuzoff, I., Morphogenesis of Lewy bodies:
dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp
Neurol, 2003. 62(12): p. 1241-53.

127.

Dale, G.E., Probst, A., Luthert, P., Martin, J., Anderton, B.H., and Leigh, P.N.,
Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta
Neuropathol, 1992. 83(5): p. 525-9.

128.

Soper, J.H., Roy, S., Stieber, A., Lee, E., Wilson, R.B., Trojanowski, J.Q., Burd, C.G.,
and Lee, V.M., Alpha-synuclein-induced aggregation of cytoplasmic vesicles in
Saccharomyces cerevisiae. Mol Biol Cell, 2008. 19(3): p. 1093-103.

129.

Gosavi, N., Lee, H.J., Lee, J.S., Patel, S., and Lee, S.J., Golgi fragmentation occurs
in the cells with prefibrillar alpha-synuclein aggregates and precedes the
formation of fibrillar inclusion. J Biol Chem, 2002. 277(50): p. 48984-92.

130.

Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., and
Vila, M., Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci, 2010.
30(37): p. 12535-44.

131.

Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E.,
Hansen, L., Adame, A., Galasko, D., and Masliah, E., Selective molecular
alterations in the autophagy pathway in patients with Lewy body disease and in
models of alpha-synucleinopathy. PLoS ONE, 2010. 5(2): p. e9313.

132.

Tanji, K., Mori, F., Kakita, A., Takahashi, H., and Wakabayashi, K., Alteration of
autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease.
Neurobiol Dis, 2011. 43(3): p. 690-7.

133.

Higashi, S., Moore, D.J., Minegishi, M., Kasanuki, K., Fujishiro, H., Kabuta, T.,
Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., Hino, H., Kosaka, K., Sato, K.,
Arai, H., Wada, K., and Iseki, E., Localization of MAP1-LC3 in vulnerable neurons
and Lewy bodies in brains of patients with dementia with Lewy bodies. J
Neuropathol Exp Neurol, 2011. 70(4): p. 264-80.

134.

Tanik, S.A., Schultheiss, C.E., Volpicelli-Daley, L.A., Brunden, K.R., and Lee, V.M.,
Lewy body-like alpha-synuclein aggregates resist degradation and impair
macroautophagy. J Biol Chem, 2013. 288(21): p. 15194-210.

135.

Goker-Alpan, O., Stubblefield, B.K., Giasson, B.I., and Sidransky, E.,
Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body
disorders. Acta Neuropathol, 2010. 120(5): p. 641-9.

221

136.

Lee, G., Tanaka, M., Park, K., Lee, S.S., Kim, Y.M., Junn, E., Lee, S.H., and
Mouradian, M.M., Casein kinase II-mediated phosphorylation regulates alphasynuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem,
2004. 279(8): p. 6834-9.

137.

Chen, L. and Feany, M.B., Alpha-synuclein phosphorylation controls neurotoxicity
and inclusion formation in a Drosophila model of Parkinson disease. Nat
Neurosci, 2005. 8(5): p. 657-63.

138.

Tofaris, G.K., Razzaq, A., Ghetti, B., Lilley, K.S., and Spillantini, M.G.,
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not
associated with impairment of proteasome function. J Biol Chem, 2003. 278(45):
p. 44405-11.

139.

Bodner, R.A., Outeiro, T.F., Altmann, S., Maxwell, M.M., Cho, S.H., Hyman, B.T.,
McLean, P.J., Young, A.B., Housman, D.E., and Kazantsev, A.G., Pharmacological
promotion of inclusion formation: a therapeutic approach for Huntington's and
Parkinson's diseases. Proc Natl Acad Sci U S A, 2006. 103(11): p. 4246-51.

140.

Maroteaux, L., Campanelli, J.T., and Scheller, R.H., Synuclein: a neuron-specific
protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 1988.
8(8): p. 2804-15.

141.

Maroteaux, L. and Scheller, R.H., The rat brain synucleins; family of proteins
transiently associated with neuronal membrane. Brain Res Mol Brain Res, 1991.
11(3-4): p. 335-43.

142.

Jakes, R., Spillantini, M.G., and Goedert, M., Identification of two distinct
synucleins from human brain. FEBS Lett, 1994. 345(1): p. 27-32.

143.

Bendor, J.T., Logan, T.P., and Edwards, R.H., The function of alpha-synuclein.
Neuron, 2013. 79(6): p. 1044-66.

144.

Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A.,
and Saitoh, T., The precursor protein of non-A beta component of Alzheimer's
disease amyloid is a presynaptic protein of the central nervous system. Neuron,
1995. 14(2): p. 467-75.

145.

Campion, D., Martin, C., Heilig, R., Charbonnier, F., Moreau, V., Flaman, J.M.,
Petit, J.L., Hannequin, D., Brice, A., and Frebourg, T., The NACP/synuclein gene:
chromosomal assignment and screening for alterations in Alzheimer disease.
Genomics, 1995. 26(2): p. 254-7.

222

146.

Chen, X., de Silva, H.A., Pettenati, M.J., Rao, P.N., St George-Hyslop, P., Roses,
A.D., Xia, Y., Horsburgh, K., Ueda, K., and Saitoh, T., The human NACP/alphasynuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis.
Genomics, 1995. 26(2): p. 425-7.

147.

Barbour, R., Kling, K., Anderson, J.P., Banducci, K., Cole, T., Diep, L., Fox, M.,
Goldstein, J.M., Soriano, F., Seubert, P., and Chilcote, T.J., Red blood cells are the
major source of alpha-synuclein in blood. Neurodegener Dis, 2008. 5(2): p. 55-9.

148.

Bartels, T., Choi, J.G., and Selkoe, D.J., alpha-Synuclein occurs physiologically as a
helically folded tetramer that resists aggregation. Nature, 2011. 477(7362): p.
107-10.

149.

Fauvet, B., Mbefo, M.K., Fares, M.B., Desobry, C., Michael, S., Ardah, M.T., Tsika,
E., Coune, P., Prudent, M., Lion, N., Eliezer, D., Moore, D.J., Schneider, B.,
Aebischer, P., El-Agnaf, O.M., Masliah, E., and Lashuel, H.A., alpha-Synuclein in
central nervous system and from erythrocytes, mammalian cells, and Escherichia
coli exists predominantly as disordered monomer. J Biol Chem, 2012. 287(19): p.
15345-64.

150.

Burre, J., Vivona, S., Diao, J., Sharma, M., Brunger, A.T., and Sudhof, T.C.,
Properties of native brain alpha-synuclein. Nature, 2013. 498(7453): p. E4-6;
discussion E6-7.

151.

Davidson, W.S., Jonas, A., Clayton, D.F., and George, J.M., Stabilization of alphasynuclein secondary structure upon binding to synthetic membranes. J Biol Chem,
1998. 273(16): p. 9443-9449.

152.

Eliezer, D., Kutluay, E., Bussell, R., Jr., and Browne, G., Conformational properties
of alpha-synuclein in its free and lipid-associated states. J Mol Biol, 2001. 307(4):
p. 1061-73.

153.

Snead, D. and Eliezer, D., Alpha-synuclein function and dysfunction on cellular
membranes. Exp Neurobiol, 2014. 23(4): p. 292-313.

154.

Chandra, S., Chen, X., Rizo, J., Jahn, R., and Sudhof, T.C., A broken alpha -helix in
folded alpha -Synuclein. J Biol Chem, 2003. 278(17): p. 15313-8.

155.

Ulmer, T.S., Bax, A., Cole, N.B., and Nussbaum, R.L., Structure and dynamics of
micelle-bound human alpha-synuclein. J Biol Chem, 2005. 280(10): p. 9595-603.

156.

Trexler, A.J. and Rhoades, E., Alpha-synuclein binds large unilamellar vesicles as
an extended helix. Biochemistry, 2009. 48(11): p. 2304-2306.

223

157.

Robotta, M., Braun, P., van Rooijen, B., Subramaniam, V., Huber, M., and
Drescher, M., Direct evidence of coexisting horseshoe and extended helix
conformations of membrane-bound alpha-synuclein. Chemphyschem, 2011.
12(2): p. 267-9.

158.

Middleton, E.R. and Rhoades, E., Effects of curvature and composition on alphasynuclein binding to lipid vesicles. Biophys J, 2010. 99(7): p. 2279-88.

159.

Fusco, G., De Simone, A., Arosio, P., Vendruscolo, M., Veglia, G., and Dobson,
C.M., Structural Ensembles of Membrane-bound alpha-Synuclein Reveal the
Molecular Determinants of Synaptic Vesicle Affinity. Sci Rep, 2016. 6: p. 27125.

160.

Kubo, S., Nemani, V.M., Chalkley, R.J., Anthony, M.D., Hattori, N., Mizuno, Y.,
Edwards, R.H., and Fortin, D.L., A combinatorial code for the interaction of alphasynuclein with membranes. J Biol Chem, 2005. 280(36): p. 31664-72.

161.

Martinez, Z., Zhu, M., Han, S., and Fink, A.L., GM1 specifically interacts with
alpha-synuclein and inhibits fibrillation. Biochemistry, 2007. 46(7): p. 1868-77.

162.

Ferreon, A.C., Gambin, Y., Lemke, E.A., and Deniz, A.A., Interplay of alphasynuclein binding and conformational switching probed by single-molecule
fluorescence. Proc Natl Acad Sci U S A, 2009. 106(14): p. 5645-50.

163.

Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E.,
Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer,
D., and Rosenthal, A., Mice lacking alpha-synuclein display functional deficits in
the nigrostriatal dopamine system. Neuron, 2000. 25(1): p. 239-52.

164.

Murphy, D.D., Rueter, S.M., Trojanowski, J.Q., and Lee, V.M., Synucleins are
developmentally expressed, and alpha-synuclein regulates the size of the
presynaptic vesicular pool in primary hippocampal neurons. J Neurosci, 2000.
20(9): p. 3214-20.

165.

Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, K.L.,
Orrison, B., Chen, A., Ellis, C.E., Paylor, R., Lu, B., and Nussbaum, R.L., Synaptic
vesicle depletion correlates with attenuated synaptic responses to prolonged
repetitive stimulation in mice lacking alpha-synuclein. J Neurosci, 2002. 22(20): p.
8797-807.

166.

Pranke, I.M., Morello, V., Bigay, J., Gibson, K., Verbavatz, J.M., Antonny, B., and
Jackson, C.L., alpha-Synuclein and ALPS motifs are membrane curvature sensors
whose contrasting chemistry mediates selective vesicle binding. J Cell Biol, 2011.
194(1): p. 89-103.

167.

224
Chen, R.H., Wislet-Gendebien, S., Samuel, F., Visanji, N.P., Zhang, G., Marsilio, D.,
Langman, T., Fraser, P.E., and Tandon, A., alpha-Synuclein membrane association
is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol
Chem, 2013. 288(11): p. 7438-49.

168.

Vargas, K.J., Makani, S., Davis, T., Westphal, C.H., Castillo, P.E., and Chandra, S.S.,
Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci, 2014.
34(28): p. 9364-76.

169.

Fusco, G., Pape, T., Stephens, A.D., Mahou, P., Costa, A.R., Kaminski, C.F.,
Kaminski Schierle, G.S., Vendruscolo, M., Veglia, G., Dobson, C.M., and De
Simone, A., Structural basis of synaptic vesicle assembly promoted by alphasynuclein. Nat Commun, 2016. 7: p. 12563.

170.

Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M., and Sudhof, T.C.,
Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell,
2005. 123(3): p. 383-96.

171.

Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., and Sudhof,
T.C., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.
Science, 2010. 329(5999): p. 1663-7.

172.

Cartelli, D., Aliverti, A., Barbiroli, A., Santambrogio, C., Ragg, E.M., Casagrande,
F.V., Cantele, F., Beltramone, S., Marangon, J., De Gregorio, C., Pandini, V.,
Emanuele, M., Chieregatti, E., Pieraccini, S., Holmqvist, S., Bubacco, L., Roybon,
L., Pezzoli, G., Grandori, R., Arnal, I., and Cappelletti, G., alpha-Synuclein is a
Novel Microtubule Dynamase. Sci Rep, 2016. 6: p. 33289.

173.

Ludtmann, M.H., Angelova, P.R., Ninkina, N.N., Gandhi, S., Buchman, V.L., and
Abramov, A.Y., Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain
ATP Synthase. J Neurosci, 2016. 36(41): p. 10510-10521.

174.

Calo, L., Wegrzynowicz, M., Santivanez-Perez, J., and Grazia Spillantini, M.,
Synaptic failure and alpha-synuclein. Mov Disord, 2016. 31(2): p. 169-77.

175.

Collier, T.J., Redmond, D.E., Jr., Steece-Collier, K., Lipton, J.W., and Manfredsson,
F.P., Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian
Pathology? Evidence from Non-human Primates. Front Neurosci, 2016. 10: p. 12.

176.

Benskey, M.J., Perez, R.G., and Manfredsson, F.P., The contribution of alpha
synuclein to neuronal survival and function - Implications for Parkinson's disease.
J Neurochem, 2016. 137(3): p. 331-59.

225

177.

Miake, H., Mizusawa, H., Iwatsubo, T., and Hasegawa, M., Biochemical
characterization of the core structure of alpha-synuclein filaments. J Biol Chem,
2002. 277(21): p. 19213-9.

178.

Crowther, R.A., Daniel, S.E., and Goedert, M., Characterisation of isolated alphasynuclein filaments from substantia nigra of Parkinson's disease brain.
Neuroscience Letters, 2000. 292(2): p. 128-130.

179.

Tsika, E., Moysidou, M., Guo, J., Cushman, M., Gannon, P., Sandaltzopoulos, R.,
Giasson, B.I., Krainc, D., Ischiropoulos, H., and Mazzulli, J.R., Distinct regionspecific alpha-synuclein oligomers in A53T transgenic mice: implications for
neurodegeneration. J Neurosci, 2010. 30(9): p. 3409-18.

180.

Roberts, R.F., Wade-Martins, R., and Alegre-Abarrategui, J., Direct visualization of
alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's
disease brain. Brain, 2015. 138(Pt 6): p. 1642-57.

181.

Theillet, F.X., Binolfi, A., Bekei, B., Martorana, A., Rose, H.M., Stuiver, M., Verzini,
S., Lorenz, D., van Rossum, M., Goldfarb, D., and Selenko, P., Structural disorder
of monomeric alpha-synuclein persists in mammalian cells. Nature, 2016.
530(7588): p. 45-50.

182.

Ullman, O., Fisher, C.K., and Stultz, C.M., Explaining the structural plasticity of
alpha-synuclein. J Am Chem Soc, 2011. 133(48): p. 19536-46.

183.

Uversky, V.N., Li, J., and Fink, A.L., Evidence for a partially folded intermediate in
alpha-synuclein fibril formation. J Biol Chem, 2001. 276(14): p. 10737-44.

184.

Grey, M., Linse, S., Nilsson, H., Brundin, P., and Sparr, E., Membrane interaction
of alpha-synuclein in different aggregation states. J Parkinsons Dis, 2011. 1(4): p.
359-71.

185.

Galvagnion, C., Buell, A.K., Meisl, G., Michaels, T.C., Vendruscolo, M., Knowles,
T.P., and Dobson, C.M., Lipid vesicles trigger alpha-synuclein aggregation by
stimulating primary nucleation. Nat Chem Biol, 2015. 11(3): p. 229-34.

186.

Galvagnion, C., Brown, J.W., Ouberai, M.M., Flagmeier, P., Vendruscolo, M.,
Buell, A.K., Sparr, E., and Dobson, C.M., Chemical properties of lipids strongly
affect the kinetics of the membrane-induced aggregation of alpha-synuclein.
Proc Natl Acad Sci U S A, 2016. 113(26): p. 7065-70.

187.

Grey, M., Dunning, C.J., Gaspar, R., Grey, C., Brundin, P., Sparr, E., and Linse, S.,
Acceleration of alpha-synuclein aggregation by exosomes. J Biol Chem, 2015.
290(5): p. 2969-82.

226

188.

Jiang, P., Gan, M., Yen, S.H., Moussaud, S., McLean, P.J., and Dickson, D.W.,
Proaggregant nuclear factor(s) trigger rapid formation of alpha-synuclein
aggregates in apoptotic neurons. Acta Neuropathol, 2016. 132(1): p. 77-91.

189.

Jiang, P., Gan, M., Yen, S.H., McLean, P.J., and Dickson, D.W., Histones facilitate
alpha-synuclein aggregation during neuronal apoptosis. Acta Neuropathol, 2017.
133(4): p. 547-558.

190.

Giasson, B.I., Murray, I.V., Trojanowski, J.Q., and Lee, V.M., A hydrophobic
stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for
filament assembly. J Biol Chem, 2001. 276(4): p. 2380-6.

191.

Waxman, E.A., Mazzulli, J.R., and Giasson, B.I., Characterization of hydrophobic
residue requirements for alpha-synuclein fibrillization. Biochemistry, 2009.
48(40): p. 9427-36.

192.

Rodriguez, J.A., Ivanova, M.I., Sawaya, M.R., Cascio, D., Reyes, F.E., Shi, D.,
Sangwan, S., Guenther, E.L., Johnson, L.M., Zhang, M., Jiang, L., Arbing, M.A.,
Nannenga, B.L., Hattne, J., Whitelegge, J., Brewster, A.S., Messerschmidt, M.,
Boutet, S., Sauter, N.K., Gonen, T., and Eisenberg, D.S., Structure of the toxic core
of alpha-synuclein from invisible crystals. Nature, 2015. 525(7570): p. 486-90.

193.

Tuttle, M.D., Comellas, G., Nieuwkoop, A.J., Covell, D.J., Berthold, D.A., Kloepper,
K.D., Courtney, J.M., Kim, J.K., Barclay, A.M., Kendall, A., Wan, W., Stubbs, G.,
Schwieters, C.D., Lee, V.M., George, J.M., and Rienstra, C.M., Solid-state NMR
structure of a pathogenic fibril of full-length human alpha-synuclein. Nat Struct
Mol Biol, 2016. 23(5): p. 409-15.

194.

Der-Sarkissian, A., Jao, C.C., Chen, J., and Langen, R., Structural organization of
alpha-synuclein fibrils studied by site-directed spin labeling. J Biol Chem, 2003.
278(39): p. 37530-5.

195.

Crowther, R.A., Jakes, R., Spillantini, M.G., and Goedert, M., Synthetic filaments
assembled from C-terminally truncated alpha-synuclein. FEBS Lett, 1998. 436(3):
p. 309-12.

196.

Crystal, A.S., Giasson, B.I., Crowe, A., Kung, M.P., Zhuang, Z.P., Trojanowski, J.Q.,
and Lee, V.M.Y., A comparison of amyloid fibrillogenesis using the novel
fluorescent compound K114. J Neurochem, 2003. 86(6): p. 1359-1368.

197.

Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., and Biere, A.L.,
alpha-synuclein fibrillogenesis is nucleation-dependent - Implications for the
pathogenesis of Parkinson's disease. J Biol Chem, 1999. 274(28): p. 19509-19512.

227

198.

Fink, A.L., The aggregation and fibrillation of alpha-synuclein. Acc Chem Res,
2006. 39(9): p. 628-34.

199.

Wordehoff, M.M., Bannach, O., Shaykhalishahi, H., Kulawik, A., Schiefer, S.,
Willbold, D., Hoyer, W., and Birkmann, E., Single fibril growth kinetics of alphasynuclein. J Mol Biol, 2015. 427(6 Pt B): p. 1428-35.

200.

Luk, K.C., Song, C., O'Brien, P., Stieber, A., Branch, J.R., Brunden, K.R.,
Trojanowski, J.Q., and Lee, V.M., Exogenous alpha-synuclein fibrils seed the
formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl
Acad Sci U S A, 2009. 106(47): p. 20051-6.

201.

Nonaka, T., Watanabe, S.T., Iwatsubo, T., and Hasegawa, M., Seeded aggregation
and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative
diseases. J Biol Chem, 2010. 285(45): p. 34885-98.

202.

Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A.,
Meaney, D.F., Trojanowski, J.Q., and Lee, V.M., Exogenous alpha-synuclein fibrils
induce Lewy body pathology leading to synaptic dysfunction and neuron death.
Neuron, 2011. 72(1): p. 57-71.

203.

Volpicelli-Daley, L.A., Luk, K.C., and Lee, V.M., Addition of exogenous alphasynuclein preformed fibrils to primary neuronal cultures to seed recruitment of
endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat
Protoc, 2014. 9(9): p. 2135-46.

204.

Pinotsi, D., Michel, C.H., Buell, A.K., Laine, R.F., Mahou, P., Dobson, C.M.,
Kaminski, C.F., and Kaminski Schierle, G.S., Nanoscopic insights into seeding
mechanisms and toxicity of alpha-synuclein species in neurons. Proc Natl Acad Sci
U S A, 2016. 113(14): p. 3815-9.

205.

Lashuel, H.A., Overk, C.R., Oueslati, A., and Masliah, E., The many faces of alphasynuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci,
2013. 14(1): p. 38-48.

206.

Luk, K.C., Covell, D.J., Kehm, V.M., Zhang, B., Song, I.Y., Byrne, M.D., Pitkin, R.M.,
Decker, S.C., Trojanowski, J.Q., and Lee, V.M., Molecular and Biological
Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. Cell Rep,
2016. 16(12): p. 3373-87.

207.

Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal,
M., Clarke, R.W., Dunne, P., Aprile, F.A., Bertoncini, C.W., Wood, N.W., Knowles,

228
T.P., Dobson, C.M., and Klenerman, D., Direct observation of the interconversion
of normal and toxic forms of alpha-synuclein. Cell, 2012. 149(5): p. 1048-59.
208.

Lorenzen, N., Nielsen, S.B., Buell, A.K., Kaspersen, J.D., Arosio, P., Vad, B.S.,
Paslawski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., Enghild,
J.J., Pedersen, J.S., Dobson, C.M., Knowles, T.P., and Otzen, D.E., The role of
stable alpha-synuclein oligomers in the molecular events underlying amyloid
formation. J Am Chem Soc, 2014. 136(10): p. 3859-68.

209.

Iljina, M., Garcia, G.A., Horrocks, M.H., Tosatto, L., Choi, M.L., Ganzinger, K.A.,
Abramov, A.Y., Gandhi, S., Wood, N.W., Cremades, N., Dobson, C.M., Knowles,
T.P., and Klenerman, D., Kinetic model of the aggregation of alpha-synuclein
provides insights into prion-like spreading. Proc Natl Acad Sci U S A, 2016. 113(9):
p. E1206-15.

210.

Pieri, L., Madiona, K., and Melki, R., Structural and functional properties of
prefibrillar alpha-synuclein oligomers. Sci Rep, 2016. 6: p. 24526.

211.

Tarutani, A., Suzuki, G., Shimozawa, A., Nonaka, T., Akiyama, H., Hisanaga, S.I.,
and Hasegawa, M., Effect of Fragmented Pathogenic alpha-Synuclein Seeds on
Prion-like Propagation. J Biol Chem, 2016. 10.1074/jbc.M116.734707.

212.

Luk, K.C., Kehm, V.M., Zhang, B., O'Brien, P., Trojanowski, J.Q., and Lee, V.M.,
Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly
progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med, 2012.
209(5): p. 975-86.

213.

Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., and Lee,
V.M., Pathological alpha-synuclein transmission initiates Parkinson-like
neurodegeneration in nontransgenic mice. Science, 2012. 338(6109): p. 949-53.

214.

Mougenot, A.L., Nicot, S., Bencsik, A., Morignat, E., Verchere, J., Lakhdar, L.,
Legastelois, S., and Baron, T., Prion-like acceleration of a synucleinopathy in a
transgenic mouse model. Neurobiol Aging, 2012. 33(9): p. 2225-8.

215.

Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama,
H., Mann, D.M., and Hasegawa, M., Prion-like spreading of pathological alphasynuclein in brain. Brain, 2013. 136(Pt 4): p. 1128-38.

216.

Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba,
A., Fernagut, P.O., Blesa, J., Parent, A., Perier, C., Farinas, I., Obeso, J.A., Bezard,
E., and Vila, M., Lewy body extracts from Parkinson disease brains trigger alpha-

229
synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol,
2014. 75(3): p. 351-62.
217.

Paumier, K.L., Luk, K.C., Manfredsson, F.P., Kanaan, N.M., Lipton, J.W., Collier,
T.J., Steece-Collier, K., Kemp, C.J., Celano, S., Schulz, E., Sandoval, I.M., Fleming,
S., Dirr, E., Polinski, N.K., Trojanowski, J.Q., Lee, V.M., and Sortwell, C.E.,
Intrastriatal injection of pre-formed mouse alpha-synuclein fibrils into rats
triggers alpha-synuclein pathology and bilateral nigrostriatal degeneration.
Neurobiol Dis, 2015. 82: p. 185-99.

218.

Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R.,
Giugliano, M., Van den Haute, C., Melki, R., and Baekelandt, V., alpha-Synuclein
strains cause distinct synucleinopathies after local and systemic administration.
Nature, 2015. 522(7556): p. 340-4.

219.

Rey, N.L., Steiner, J.A., Maroof, N., Luk, K.C., Madaj, Z., Trojanowski, J.Q., Lee,
V.M., and Brundin, P., Widespread transneuronal propagation of alphasynucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's
disease. J Exp Med, 2016. 213(9): p. 1759-78.

220.

Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A.,
Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa,
S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M.,
Duvoisin, R.C., Di Iorio, G., Golbe, L.I., and Nussbaum, R.L., Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science, 1997.
276(5321): p. 2045-7.

221.

Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H.,
Epplen, J.T., Schols, L., and Riess, O., Ala30Pro mutation in the gene encoding
alpha-synuclein in Parkinson's disease. Nat Genet, 1998. 18(2): p. 106-8.

222.

Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I.,
Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E.,
del Ser, T., Munoz, D.G., and de Yebenes, J.G., The new mutation, E46K, of alphasynuclein causes Parkinson and Lewy body dementia. Ann Neurol, 2004. 55(2): p.
164-73.

223.

Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L.,
Madiona, K., Durr, A., Melki, R., Verny, C., Brice, A., and French Parkinson's
Disease Genetics Study, G., G51D alpha-synuclein mutation causes a novel
parkinsonian-pyramidal syndrome. Ann Neurol, 2013. 73(4): p. 459-71.

224.

230
Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah,
B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J.O., Rajput, A., Rajput,
A.H., Jon Stoessl, A., and Farrer, M.J., Alpha-synuclein p.H50Q, a novel
pathogenic mutation for Parkinson's disease. Mov Disord, 2013. 28(6): p. 811-3.

225.

Hoffman-Zacharska, D., Koziorowski, D., Ross, O.A., Milewski, M., Poznanski, J.,
Jurek, M., Wszolek, Z.K., Soto-Ortolaza, A., Slawek, J., Janik, P., Jamrozik, Z.,
Potulska-Chromik, A., Jasinska-Myga, B., Opala, G., Krygowska-Wajs, A.,
Czyzewski, K., Dickson, D.W., Bal, J., and Friedman, A., Novel A18T and pA29S
substitutions in alpha-synuclein may be associated with sporadic Parkinson's
disease. Parkinsonism Relat Disord, 2013. 19(11): p. 1057-60.

226.

Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J.,
Tienari, P.J., Poyhonen, M., and Paetau, A., Novel alpha-synuclein mutation A53E
associated with atypical multiple system atrophy and Parkinson's disease-type
pathology. Neurobiol Aging, 2014. 35(9): p. 2180 e1-5.

227.

Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J.,
Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A.,
Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista,
M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K., alpha-Synuclein locus
triplication causes Parkinson's disease. Science, 2003. 302(5646): p. 841.

228.

Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X.,
Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N.,
Defebvre, L., Amouyel, P., Farrer, M., and Destée, A., α-synuclein locus
duplication as a cause of familial Parkinson's disease. The Lancet, 2004.
364(9440): p. 1167-1169.

229.

Thomas, B. and Beal, M.F., Parkinson's disease. Hum Mol Genet, 2007. 16 Spec
No. 2: p. R183-94.

230.

McDonnell, S.K., Schaid, D.J., Elbaz, A., Strain, K.J., Bower, J.H., Ahlskog, J.E.,
Maraganore, D.M., and Rocca, W.A., Complex segregation analysis of Parkinson's
disease: The Mayo Clinic Family Study. Ann Neurol, 2006. 59(5): p. 788-95.

231.

Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T.,
Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa,
K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N.,
Murata, M., Nakamura, Y., and Toda, T., Genome-wide association study
identifies common variants at four loci as genetic risk factors for Parkinson's
disease. Nat Genet, 2009. 41(12): p. 1303-7.

231

232.

Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D.,
Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff,
M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C.,
Houlden, H., Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D.,
Fernandez, H.H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van
der Brug, M., Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao,
J., Huang, X., Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A.,
Singleton, A.B., and Gasser, T., Genome-wide association study reveals genetic
risk underlying Parkinson's disease. Nat Genet, 2009. 41(12): p. 1308-12.

233.

Edwards, T.L., Scott, W.K., Almonte, C., Burt, A., Powell, E.H., Beecham, G.W.,
Wang, L., Zuchner, S., Konidari, I., Wang, G., Singer, C., Nahab, F., Scott, B.,
Stajich, J.M., Pericak-Vance, M., Haines, J., Vance, J.M., and Martin, E.R.,
Genome-wide association study confirms SNPs in SNCA and the MAPT region as
common risk factors for Parkinson disease. Ann Hum Genet, 2010. 74(2): p. 97109.

234.

Soldner, F., Stelzer, Y., Shivalila, C.S., Abraham, B.J., Latourelle, J.C., Barrasa, M.I.,
Goldmann, J., Myers, R.H., Young, R.A., and Jaenisch, R., Parkinson-associated
risk variant in distal enhancer of alpha-synuclein modulates target gene
expression. Nature, 2016. 533(7601): p. 95-9.

235.

Perrin, R.J., Woods, W.S., Clayton, D.F., and George, J.M., Interaction of human
alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural
analysis using site-directed mutagenesis. J Biol Chem, 2000. 275(44): p. 34393-8.

236.

McLean, P.J., Kawamata, H., Ribich, S., and Hyman, B.T., Membrane association
and protein conformation of alpha-synuclein in intact neurons. Effect of
Parkinson's disease-linked mutations. J Biol Chem, 2000. 275(12): p. 8812-6.

237.

Jo, E., Fuller, N., Rand, R.P., St George-Hyslop, P., and Fraser, P.E., Defective
membrane interactions of familial Parkinson's disease mutant A30P alphasynuclein. J Mol Biol, 2002. 315(4): p. 799-807.

238.

Bussell, R., Jr. and Eliezer, D., Effects of Parkinson's disease-linked mutations on
the structure of lipid-associated alpha-synuclein. Biochemistry, 2004. 43(16): p.
4810-8.

239.

Ulmer, T.S. and Bax, A., Comparison of structure and dynamics of micelle-bound
human alpha-synuclein and Parkinson disease variants. J Biol Chem, 2005.
280(52): p. 43179-87.

232

240.

Perlmutter, J.D., Braun, A.R., and Sachs, J.N., Curvature dynamics of alphasynuclein familial Parkinson disease mutants: molecular simulations of the
micelle- and bilayer-bound forms. J Biol Chem, 2009. 284(11): p. 7177-89.

241.

Choi, W., Zibaee, S., Jakes, R., Serpell, L.C., Davletov, B., Crowther, R.A., and
Goedert, M., Mutation E46K increases phospholipid binding and assembly into
filaments of human alpha-synuclein. FEBS Lett, 2004. 576(3): p. 363-8.

242.

Fares, M.B., Ait-Bouziad, N., Dikiy, I., Mbefo, M.K., Jovicic, A., Kiely, A., Holton,
J.L., Lee, S.J., Gitler, A.D., Eliezer, D., and Lashuel, H.A., The novel Parkinson's
disease linked mutation G51D attenuates in vitro aggregation and membrane
binding of alpha-synuclein, and enhances its secretion and nuclear localization in
cells. Hum Mol Genet, 2014. 23(17): p. 4491-509.

243.

Ghosh, D., Sahay, S., Ranjan, P., Salot, S., Mohite, G.M., Singh, P.K., Dwivedi, S.,
Carvalho, E., Banerjee, R., Kumar, A., and Maji, S.K., The newly discovered
Parkinson's disease associated Finnish mutation (A53E) attenuates alphasynuclein aggregation and membrane binding. Biochemistry, 2014. 53(41): p.
6419-21.

244.

Ysselstein, D., Joshi, M., Mishra, V., Griggs, A.M., Asiago, J.M., McCabe, G.P.,
Stanciu, L.A., Post, C.B., and Rochet, J.C., Effects of impaired membrane
interactions on alpha-synuclein aggregation and neurotoxicity. Neurobiol Dis,
2015. 79: p. 150-63.

245.

Conway, K.A., Harper, J.D., and Lansbury, P.T., Accelerated in vitro fibril
formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Nat Med, 1998. 4(11): p. 1318-20.

246.

Giasson, B.I., Uryu, K., Trojanowski, J.Q., and Lee, V.M.Y., Mutant and wild type
human alpha-synucleins assemble into elongated filaments with distinct
morphologies in vitro. J Biol Chem, 1999. 274(12): p. 7619-7622.

247.

Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A.,
Martin, F., Sitney, K., Denis, P., Louis, J.C., Wypych, J., Biere, A.L., and Citron, M.,
Both familial Parkinson's disease mutations accelerate alpha-synuclein
aggregation. J Biol Chem, 1999. 274(14): p. 9843-6.

248.

Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., and Lansbury,
P.T., Jr., Acceleration of oligomerization, not fibrillization, is a shared property of
both alpha-synuclein mutations linked to early-onset Parkinson's disease:
implications for pathogenesis and therapy. Proc Natl Acad Sci U S A, 2000. 97(2):
p. 571-6.

249.

233
Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q., and Lee, V.M.,
Neuronal alpha-synucleinopathy with severe movement disorder in mice
expressing A53T human alpha-synuclein. Neuron, 2002. 34(4): p. 521-33.

250.

Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R.,
Englander, S.W., Axelsen, P.H., and Giasson, B.I., The E46K mutation in alphasynuclein increases amyloid fibril formation. J Biol Chem, 2005. 280(9): p. 7800-7.

251.

Ono, K., Ikeda, T., Takasaki, J., and Yamada, M., Familial Parkinson disease
mutations influence alpha-synuclein assembly. Neurobiol Dis, 2011. 43(3): p. 71524.

252.

Rutherford, N.J., Moore, B.D., Golde, T.E., and Giasson, B.I., Divergent effects of
the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J
Neurochem, 2014. 131(6): p. 859-67.

253.

Lazaro, D.F., Dias, M.C., Carija, A., Navarro, S., Madaleno, C.S., Tenreiro, S.,
Ventura, S., and Outeiro, T.F., The effects of the novel A53E alpha-synuclein
mutation on its oligomerization and aggregation. Acta Neuropathol Commun,
2016. 4(1): p. 128.

254.

Ghosh, D., Mondal, M., Mohite, G.M., Singh, P.K., Ranjan, P., Anoop, A., Ghosh,
S., Jha, N.N., Kumar, A., and Maji, S.K., The Parkinson's disease-associated H50Q
mutation accelerates alpha-Synuclein aggregation in vitro. Biochemistry, 2013.
52(40): p. 6925-7.

255.

Khalaf, O., Fauvet, B., Oueslati, A., Dikiy, I., Mahul-Mellier, A.L., Ruggeri, F.S.,
Mbefo, M.K., Vercruysse, F., Dietler, G., Lee, S.J., Eliezer, D., and Lashuel, H.A.,
The H50Q mutation enhances alpha-synuclein aggregation, secretion, and
toxicity. J Biol Chem, 2014. 289(32): p. 21856-76.

256.

Lazaro, D.F., Rodrigues, E.F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T.,
Guerreiro, P., Gerhardt, E., Krohnert, K., Klucken, J., Pereira, M.D., Popova, B.,
Kruse, N., Mollenhauer, B., Rizzoli, S.O., Braus, G.H., Danzer, K.M., and Outeiro,
T.F., Systematic comparison of the effects of alpha-synuclein mutations on its
oligomerization and aggregation. PLoS Genet, 2014. 10(11): p. e1004741.

257.

Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T.P., Dobson, C.M., Buell,
A.K., and Galvagnion, C., Mutations associated with familial Parkinson's disease
alter the initiation and amplification steps of alpha-synuclein aggregation. Proc
Natl Acad Sci U S A, 2016. 113(37): p. 10328-33.

234

258.

Sierecki, E., Giles, N., Bowden, Q., Polinkovsky, M.E., Steinbeck, J., Arrioti, N.,
Rahman, D., Bhumkar, A., Nicovich, P.R., Ross, I., Parton, R.G., Bocking, T., and
Gambin, Y., Nanomolar oligomerization and selective co-aggregation of alphasynuclein pathogenic mutants revealed by single-molecule fluorescence. Sci Rep,
2016. 6: p. 37630.

259.

Beyer, K. and Ariza, A., alpha-Synuclein posttranslational modification and
alternative splicing as a trigger for neurodegeneration. Mol Neurobiol, 2013.
47(2): p. 509-24.

260.

Oueslati, A., Implication of Alpha-Synuclein Phosphorylation at S129 in
Synucleinopathies: What Have We Learned in the Last Decade? J Parkinsons Dis,
2016. 6(1): p. 39-51.

261.

Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L.,
Kahle, P.J., and Haass, C., Constitutive phosphorylation of the Parkinson's disease
associated alpha-synuclein. J Biol Chem, 2000. 275(1): p. 390-7.

262.

Neumann, M., Kahle, P.J., Giasson, B.I., Ozmen, L., Borroni, E., Spooren, W.,
Muller, V., Odoy, S., Fujiwara, H., Hasegawa, M., Iwatsubo, T., Trojanowski, J.Q.,
Kretzschmar, H.A., and Haass, C., Misfolded proteinase K-resistant
hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor
deterioration and in human alpha-synucleinopathies. J Clin Invest, 2002. 110(10):
p. 1429-39.

263.

Nishie, M., Mori, F., Fujiwara, H., Hasegawa, M., Yoshimoto, M., Iwatsubo, T.,
Takahashi, H., and Wakabayashi, K., Accumulation of phosphorylated alphasynuclein in the brain and peripheral ganglia of patients with multiple system
atrophy. Acta Neuropathol, 2004. 107(4): p. 292-8.

264.

Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Spooren, W., Fuss,
B., Mallon, B., Macklin, W.B., Fujiwara, H., Hasegawa, M., Iwatsubo, T.,
Kretzschmar, H.A., and Haass, C., Hyperphosphorylation and insolubility of alphasynuclein in transgenic mouse oligodendrocytes. EMBO Rep, 2002. 3(6): p. 583-8.

265.

McCormack, A.L., Mak, S.K., and Di Monte, D.A., Increased alpha-synuclein
phosphorylation and nitration in the aging primate substantia nigra. Cell Death
Dis, 2012. 3: p. e315.

266.

Zhou, J., Broe, M., Huang, Y., Anderson, J.P., Gai, W.P., Milward, E.A., Porritt, M.,
Howells, D., Hughes, A.J., Wang, X., and Halliday, G.M., Changes in the solubility
and phosphorylation of alpha-synuclein over the course of Parkinson's disease.
Acta Neuropathol, 2011. 121(6): p. 695-704.

267.

235
Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., Matsumoto,
K., Nakamura, A., Tada, N., Kobayashi, K., Iwatsubo, T., and Yoshimoto, M.,
Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of
transgenic mice that express human alpha-synuclein. J Neurosci Res, 2007. 85(8):
p. 1819-25.

268.

Mbefo, M.K., Paleologou, K.E., Boucharaba, A., Oueslati, A., Schell, H., Fournier,
M., Olschewski, D., Yin, G., Zweckstetter, M., Masliah, E., Kahle, P.J., Hirling, H.,
and Lashuel, H.A., Phosphorylation of synucleins by members of the Polo-like
kinase family. J Biol Chem, 2010. 285(4): p. 2807-22.

269.

Waxman, E.A. and Giasson, B.I., Characterization of kinases involved in the
phosphorylation of aggregated alpha-synuclein. J Neurosci Res, 2011. 89(2): p.
231-47.

270.

Paleologou, K.E., Oueslati, A., Shakked, G., Rospigliosi, C.C., Kim, H.Y., Lamberto,
G.R., Fernandez, C.O., Schmid, A., Chegini, F., Gai, W.P., Chiappe, D., Moniatte,
M., Schneider, B.L., Aebischer, P., Eliezer, D., Zweckstetter, M., Masliah, E., and
Lashuel, H.A., Phosphorylation at S87 is enhanced in synucleinopathies, inhibits
alpha-synuclein oligomerization, and influences synuclein-membrane
interactions. J Neurosci, 2010. 30(9): p. 3184-98.

271.

Tenreiro, S., Reimao-Pinto, M.M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D.,
Rosado-Ramos, R., Amen, T., Waiss, M., Magalhaes, F., Gomes, A., Santos, C.N.,
Kaganovich, D., and Outeiro, T.F., Phosphorylation modulates clearance of alphasynuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet, 2014.
10(5): p. e1004302.

272.

Visanji, N.P., Wislet-Gendebien, S., Oschipok, L.W., Zhang, G., Aubert, I., Fraser,
P.E., and Tandon, A., Effect of Ser-129 phosphorylation on interaction of alphasynuclein with synaptic and cellular membranes. J Biol Chem, 2011. 286(41): p.
35863-73.

273.

Oueslati, A., Schneider, B.L., Aebischer, P., and Lashuel, H.A., Polo-like kinase 2
regulates selective autophagic alpha-synuclein clearance and suppresses its
toxicity in vivo. Proc Natl Acad Sci U S A, 2013. 110(41): p. E3945-54.

274.

Shahpasandzadeh, H., Popova, B., Kleinknecht, A., Fraser, P.E., Outeiro, T.F., and
Braus, G.H., Interplay between sumoylation and phosphorylation for protection
against alpha-synuclein inclusions. J Biol Chem, 2014. 289(45): p. 31224-40.

275.

Chau, K.Y., Ching, H.L., Schapira, A.H., and Cooper, J.M., Relationship between
alpha synuclein phosphorylation, proteasomal inhibition and cell death:

relevance to Parkinson's disease pathogenesis. J Neurochem, 2009. 110(3): p.
1005-13.

236

276.

Pronin, A.N., Morris, A.J., Surguchov, A., and Benovic, J.L., Synucleins are a novel
class of substrates for G protein-coupled receptor kinases. J Biol Chem, 2000.
275(34): p. 26515-22.

277.

Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C.H., Koyama,
S., Nagasawa, H., Kimura, H., Kawanami, T., Kurita, K., Tajima, K., Daimon, M.,
Baba, M., Kido, T., Saino, S., Goto, K., Asao, H., Kitanaka, C., Takashita, E., Hongo,
S., Nakamura, T., Kayama, T., Suzuki, Y., Kobayashi, K., Katagiri, T., Kurokawa, K.,
Kurimura, M., Toyoshima, I., Niizato, K., Tsuchiya, K., Iwatsubo, T., Muramatsu,
M., Matsumine, H., and Kato, T., The role of G-protein-coupled receptor kinase 5
in pathogenesis of sporadic Parkinson's disease. J Neurosci, 2006. 26(36): p.
9227-38.

278.

Inglis, K.J., Chereau, D., Brigham, E.F., Chiou, S.S., Schobel, S., Frigon, N.L., Yu, M.,
Caccavello, R.J., Nelson, S., Motter, R., Wright, S., Chian, D., Santiago, P., Soriano,
F., Ramos, C., Powell, K., Goldstein, J.M., Babcock, M., Yednock, T., Bard, F., Basi,
G.S., Sham, H., Chilcote, T.J., McConlogue, L., Griswold-Prenner, I., and
Anderson, J.P., Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine
129 in central nervous system. J Biol Chem, 2009. 284(5): p. 2598-602.

279.

Paleologou, K.E., Schmid, A.W., Rospigliosi, C.C., Kim, H.Y., Lamberto, G.R.,
Fredenburg, R.A., Lansbury, P.T., Jr., Fernandez, C.O., Eliezer, D., Zweckstetter,
M., and Lashuel, H.A., Phosphorylation at Ser-129 but not the phosphomimics
S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem, 2008. 283(24): p.
16895-905.

280.

Samuel, F., Flavin, W.P., Iqbal, S., Pacelli, C., Sri Renganathan, S.D., Trudeau, L.E.,
Campbell, E.M., Fraser, P.E., and Tandon, A., Effects of Serine 129
Phosphorylation on alpha-Synuclein Aggregation, Membrane Association, and
Internalization. J Biol Chem, 2016. 291(9): p. 4374-85.

281.

Schreurs, S., Gerard, M., Derua, R., Waelkens, E., Taymans, J.M., Baekelandt, V.,
and Engelborghs, Y., In vitro phosphorylation does not influence the aggregation
kinetics of WT alpha-synuclein in contrast to its phosphorylation mutants. Int J
Mol Sci, 2014. 15(1): p. 1040-67.

282.

Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson, V.L.,
Dawson, T.M., Iwatsubo, T., and Ross, C.A., Alpha-synuclein phosphorylation
enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J
Neurosci, 2005. 25(23): p. 5544-52.

237

283.

Takahashi, M., Ko, L.W., Kulathingal, J., Jiang, P., Sevlever, D., and Yen, S.H.,
Oxidative stress-induced phosphorylation, degradation and aggregation of alphasynuclein are linked to upregulated CK2 and cathepsin D. Eur J Neurosci, 2007.
26(4): p. 863-74.

284.

Chen, L., Periquet, M., Wang, X., Negro, A., McLean, P.J., Hyman, B.T., and Feany,
M.B., Tyrosine and serine phosphorylation of alpha-synuclein have opposing
effects on neurotoxicity and soluble oligomer formation. J Clin Invest, 2009.
119(11): p. 3257-65.

285.

Sato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S., and Kato, T.,
Authentically phosphorylated alpha-synuclein at Ser129 accelerates
neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci,
2011. 31(46): p. 16884-94.

286.

Azeredo da Silveira, S., Schneider, B.L., Cifuentes-Diaz, C., Sage, D., Abbas-Terki,
T., Iwatsubo, T., Unser, M., and Aebischer, P., Phosphorylation does not prompt,
nor prevent, the formation of alpha-synuclein toxic species in a rat model of
Parkinson's disease. Hum Mol Genet, 2009. 18(5): p. 872-87.

287.

Fiske, M., Valtierra, S., Solvang, K., Zorniak, M., White, M., Herrera, S.,
Konnikova, A., Brezinsky, R., and Debburman, S., Contribution of Alanine-76 and
Serine Phosphorylation in alpha-Synuclein Membrane Association and
Aggregation in Yeasts. Parkinsons Dis, 2011. 2011: p. 392180.

288.

Kuwahara, T., Tonegawa, R., Ito, G., Mitani, S., and Iwatsubo, T., Phosphorylation
of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering
its membrane binding property in Caenorhabditis elegans. J Biol Chem, 2012.
287(10): p. 7098-109.

289.

Escobar, V.D., Kuo, Y.M., Orrison, B.M., Giasson, B.I., and Nussbaum, R.L.,
Transgenic mice expressing S129 phosphorylation mutations in alpha-synuclein.
Neurosci Lett, 2014. 563: p. 96-100.

290.

Conway, K.A., Rochet, J.C., Bieganski, R.M., and Lansbury, P.T., Jr., Kinetic
stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein
adduct. Science, 2001. 294(5545): p. 1346-9.

291.

Li, J., Zhu, M., Manning-Bog, A.B., Di Monte, D.A., and Fink, A.L., Dopamine and
L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's
disease. FASEB J, 2004. 18(9): p. 962-4.

292.

238
Norris, E.H., Giasson, B.I., Hodara, R., Xu, S., Trojanowski, J.Q., Ischiropoulos, H.,
and Lee, V.M., Reversible inhibition of alpha-synuclein fibrillization by
dopaminochrome-mediated conformational alterations. J Biol Chem, 2005.
280(22): p. 21212-9.

293.

Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., Galatis, D.,
Sharples, R.A., Curtain, C.C., Ali, F.E., Cherny, R.A., Culvenor, J.G., Bottomley, S.P.,
Masters, C.L., Barnham, K.J., and Hill, A.F., Dopamine promotes alpha-synuclein
aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.
FASEB J, 2005. 19(10): p. 1377-9.

294.

Lee, H.J., Baek, S.M., Ho, D.H., Suk, J.E., Cho, E.D., and Lee, S.J., Dopamine
promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp
Mol Med, 2011. 43(4): p. 216-22.

295.

Mazzulli, J.R., Mishizen, A.J., Giasson, B.I., Lynch, D.R., Thomas, S.A., Nakashima,
A., Nagatsu, T., Ota, A., and Ischiropoulos, H., Cytosolic catechols inhibit alphasynuclein aggregation and facilitate the formation of intracellular soluble
oligomeric intermediates. J Neurosci, 2006. 26(39): p. 10068-78.

296.

Tsujimura, A., Taguchi, K., Watanabe, Y., Tatebe, H., Tokuda, T., Mizuno, T., and
Tanaka, M., Lysosomal enzyme cathepsin B enhances the aggregate forming
activity of exogenous alpha-synuclein fibrils. Neurobiol Dis, 2015. 73: p. 244-53.

297.

Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., and Masliah,
E., Oxidative stress induces amyloid-like aggregate formation of NACP/alphasynuclein in vitro. Neuroreport, 1999. 10(4): p. 717-21.

298.

Hashimoto, M., Takeda, A., Hsu, L.J., Takenouchi, T., and Masliah, E., Role of
cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy Body
Disease. Journal of Biological Chemistry, 1999. 274(41): p. 28849-28852.

299.

Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T.M., and Subramaniam, V.,
Dependence of alpha-synuclein aggregate morphology on solution conditions. J
Mol Biol, 2002. 322(2): p. 383-93.

300.

Roeters, S.J., Iyer, A., Pletikapic, G., Kogan, V., Subramaniam, V., and Woutersen,
S., Evidence for Intramolecular Antiparallel Beta-Sheet Structure in AlphaSynuclein Fibrils from a Combination of Two-Dimensional Infrared Spectroscopy
and Atomic Force Microscopy. Sci Rep, 2017. 7: p. 41051.

301.

Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T.P.,
Linse, S., and Dobson, C.M., Solution conditions determine the relative

239
importance of nucleation and growth processes in alpha-synuclein aggregation.
Proc Natl Acad Sci U S A, 2014. 111(21): p. 7671-6.
302.

Cho, M.K., Nodet, G., Kim, H.Y., Jensen, M.R., Bernado, P., Fernandez, C.O.,
Becker, S., Blackledge, M., and Zweckstetter, M., Structural characterization of
alpha-synuclein in an aggregation prone state. Protein Sci, 2009. 18(9): p. 18406.

303.

Lv, Z., Krasnoslobodtsev, A.V., Zhang, Y., Ysselstein, D., Rochet, J.C., Blanchard,
S.C., and Lyubchenko, Y.L., Effect of acidic pH on the stability of alpha-synuclein
dimers. Biopolymers, 2016. 105(10): p. 715-24.

304.

Melki, R., Role of Different Alpha-Synuclein Strains in Synucleinopathies,
Similarities with other Neurodegenerative Diseases. J Parkinsons Dis, 2015. 5(2):
p. 217-27.

305.

Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P.H., Habenstein, B.,
Madiona, K., Olieric, V., Bockmann, A., Meier, B.H., and Melki, R., Structural and
functional characterization of two alpha-synuclein strains. Nat Commun, 2013. 4:
p. 2575.

306.

Gath, J., Bousset, L., Habenstein, B., Melki, R., Bockmann, A., and Meier, B.H.,
Unlike twins: an NMR comparison of two alpha-synuclein polymorphs featuring
different toxicity. PLoS ONE, 2014. 9(3): p. e90659.

307.

Gath, J., Habenstein, B., Bousset, L., Melki, R., Meier, B.H., and Bockmann, A.,
Solid-state NMR sequential assignments of alpha-synuclein. Biomol NMR Assign,
2012. 6(1): p. 51-5.

308.

Gath, J., Bousset, L., Habenstein, B., Melki, R., Meier, B.H., and Bockmann, A., Yet
another polymorph of alpha-synuclein: solid-state sequential assignments.
Biomol NMR Assign, 2014. 8(2): p. 395-404.

309.

Verasdonck, J., Bousset, L., Gath, J., Melki, R., Bockmann, A., and Meier, B.H.,
Further exploration of the conformational space of alpha-synuclein fibrils: solidstate NMR assignment of a high-pH polymorph. Biomol NMR Assign, 2016. 10(1):
p. 5-12.

310.

Makky, A., Bousset, L., Polesel-Maris, J., and Melki, R., Nanomechanical
properties of distinct fibrillar polymorphs of the protein alpha-synuclein. Sci Rep,
2016. 6: p. 37970.

311.

Guo, J.L., Covell, D.J., Daniels, J.P., Iba, M., Stieber, A., Zhang, B., Riddle, D.M.,
Kwong, L.K., Xu, Y., Trojanowski, J.Q., and Lee, V.M., Distinct alpha-synuclein

240
strains differentially promote tau inclusions in neurons. Cell, 2013. 154(1): p. 10317.
312.

Watts, J.C., Giles, K., Oehler, A., Middleton, L., Dexter, D.T., Gentleman, S.M.,
DeArmond, S.J., and Prusiner, S.B., Transmission of multiple system atrophy
prions to transgenic mice. Proc Natl Acad Sci U S A, 2013. 110(48): p. 19555-60.

313.

Prusiner, S.B., Woerman, A.L., Mordes, D.A., Watts, J.C., Rampersaud, R., Berry,
D.B., Patel, S., Oehler, A., Lowe, J.K., Kravitz, S.N., Geschwind, D.H., Glidden, D.V.,
Halliday, G.M., Middleton, L.T., Gentleman, S.M., Grinberg, L.T., and Giles, K.,
Evidence for alpha-synuclein prions causing multiple system atrophy in humans
with parkinsonism. Proc Natl Acad Sci U S A, 2015. 112(38): p. E5308-17.

314.

Woerman, A.L., Stohr, J., Aoyagi, A., Rampersaud, R., Krejciova, Z., Watts, J.C.,
Ohyama, T., Patel, S., Widjaja, K., Oehler, A., Sanders, D.W., Diamond, M.I.,
Seeley, W.W., Middleton, L.T., Gentleman, S.M., Mordes, D.A., Sudhof, T.C.,
Giles, K., and Prusiner, S.B., Propagation of prions causing synucleinopathies in
cultured cells. Proc Natl Acad Sci U S A, 2015. 112(35): p. E4949-58.

315.

Kim, C., Lv, G., Lee, J.S., Jung, B.C., Masuda-Suzukake, M., Hong, C.S., Valera, E.,
Lee, H.J., Paik, S.R., Hasegawa, M., Masliah, E., Eliezer, D., and Lee, S.J., Exposure
to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril. Sci Rep,
2016. 6: p. 30891.

316.

Ma, M.R., Hu, Z.W., Zhao, Y.F., Chen, Y.X., and Li, Y.M., Phosphorylation induces
distinct alpha-synuclein strain formation. Sci Rep, 2016. 6: p. 37130.

317.

Lynch-Day, M.A., Mao, K., Wang, K., Zhao, M., and Klionsky, D.J., The role of
autophagy in Parkinson's disease. Cold Spring Harb Perspect Med, 2012. 2(4): p.
a009357.

318.

Lopes da Fonseca, T., Villar-Pique, A., and Outeiro, T.F., The Interplay between
Alpha-Synuclein Clearance and Spreading. Biomolecules, 2015. 5(2): p. 435-71.

319.

Frake, R.A., Ricketts, T., Menzies, F.M., and Rubinsztein, D.C., Autophagy and
neurodegeneration. J Clin Invest, 2015. 125(1): p. 65-74.

320.

Menzies, F.M., Fleming, A., and Rubinsztein, D.C., Compromised autophagy and
neurodegenerative diseases. Nat Rev Neurosci, 2015. 16(6): p. 345-57.

321.

Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N., and Rubinsztein, D.C., AlphaSynuclein is degraded by both autophagy and the proteasome. J Biol Chem, 2003.
278(27): p. 25009-13.

322.

241
Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D., Impaired
degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
Science, 2004. 305(5688): p. 1292-5.

323.

Vogiatzi, T., Xilouri, M., Vekrellis, K., and Stefanis, L., Wild type alpha-synuclein is
degraded by chaperone-mediated autophagy and macroautophagy in neuronal
cells. J Biol Chem, 2008. 283(35): p. 23542-56.

324.

Salvador, N., Aguado, C., Horst, M., and Knecht, E., Import of a cytosolic protein
into lysosomes by chaperone-mediated autophagy depends on its folding state. J
Biol Chem, 2000. 275(35): p. 27447-56.

325.

Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A.C., Mazzulli, J.,
Mosharov, E.V., Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W.,
Przedborski, S., Ischiropoulos, H., Lansbury, P.T., Sulzer, D., and Cuervo, A.M.,
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J
Clin Invest, 2008. 118(2): p. 777-88.

326.

Pan, T., Kondo, S., Le, W., and Jankovic, J., The role of autophagy-lysosome
pathway in neurodegeneration associated with Parkinson's disease. Brain, 2008.
131(Pt 8): p. 1969-78.

327.

Rideout, H.J., Lang-Rollin, I., and Stefanis, L., Involvement of macroautophagy in
the dissolution of neuronal inclusions. Int J Biochem Cell Biol, 2004. 36(12): p.
2551-62.

328.

Yu, W.H., Dorado, B., Figueroa, H.Y., Wang, L., Planel, E., Cookson, M.R., Clark,
L.N., and Duff, K.E., Metabolic activity determines efficacy of macroautophagic
clearance of pathological oligomeric alpha-synuclein. Am J Pathol, 2009. 175(2):
p. 736-47.

329.

Kilpatrick, K., Zeng, Y., Hancock, T., and Segatori, L., Genetic and chemical
activation of TFEB mediates clearance of aggregated alpha-synuclein. PLoS ONE,
2015. 10(3): p. e0120819.

330.

Dinter, E., Saridaki, T., Nippold, M., Plum, S., Diederichs, L., Komnig, D., Fensky,
L., May, C., Marcus, K., Voigt, A., Schulz, J.B., and Falkenburger, B.H., Rab7
induces clearance of alpha-synuclein aggregates. J Neurochem, 2016. 138(5): p.
758-74.

331.

Dahmene, M., Berard, M., and Oueslati, A., Dissecting the Molecular Pathway
Involved in PLK2 Kinase-mediated alpha-Synuclein-selective Autophagic
Degradation. J Biol Chem, 2017. 292(9): p. 3919-3928.

332.

242
Sevlever, D., Jiang, P., and Yen, S.H., Cathepsin D is the main lysosomal enzyme
involved in the degradation of alpha-synuclein and generation of its carboxyterminally truncated species. Biochemistry, 2008. 47(36): p. 9678-87.

333.

Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H.,
Saftig, P., Woulfe, J., Feany, M.B., Myllykangas, L., Schlossmacher, M.G., and
Tyynela, J., Cathepsin D expression level affects alpha-synuclein processing,
aggregation, and toxicity in vivo. Mol Brain, 2009. 2: p. 5.

334.

Lee, H.J., Khoshaghideh, F., Patel, S., and Lee, S.J., Clearance of alpha-synuclein
oligomeric intermediates via the lysosomal degradation pathway. J Neurosci,
2004. 24(8): p. 1888-96.

335.

Mak, S.K., McCormack, A.L., Manning-Bog, A.B., Cuervo, A.M., and Di Monte,
D.A., Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem, 2010.
285(18): p. 13621-9.

336.

Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D., and Stefanis, L., Abberant alphasynuclein confers toxicity to neurons in part through inhibition of chaperonemediated autophagy. PLoS ONE, 2009. 4(5): p. e5515.

337.

Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J.,
Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C., and Agid, Y., Apoptosis and
autophagy in nigral neurons of patients with Parkinson's disease. Histol
Histopathol, 1997. 12(1): p. 25-31.

338.

Stefanis, L., Larsen, K.E., Rideout, H.J., Sulzer, D., and Greene, L.A., Expression of
A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations
of the ubiquitin-dependent degradation system, loss of dopamine release, and
autophagic cell death. J Neurosci, 2001. 21(24): p. 9549-60.

339.

Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame,
A., Wyss-Coray, T., and Masliah, E., Beclin 1 gene transfer activates autophagy
and ameliorates the neurodegenerative pathology in alpha-synuclein models of
Parkinson's and Lewy body diseases. J Neurosci, 2009. 29(43): p. 13578-88.

340.

Winslow, A.R., Chen, C.W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E.,
Peden, A.A., Lichtenberg, M., Menzies, F.M., Ravikumar, B., Imarisio, S., Brown,
S., O'Kane, C.J., and Rubinsztein, D.C., alpha-Synuclein impairs macroautophagy:
implications for Parkinson's disease. J Cell Biol, 2010. 190(6): p. 1023-37.

341.

Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and
Bjorklund, A., TFEB-mediated autophagy rescues midbrain dopamine neurons

243
from alpha-synuclein toxicity. Proc Natl Acad Sci U S A, 2013. 110(19): p. E181726.
342.

Kim, C., Ho, D.H., Suk, J.E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E.,
Hwang, D., Lee, H.J., and Lee, S.J., Neuron-released oligomeric alpha-synuclein is
an endogenous agonist of TLR2 for paracrine activation of microglia. Nat
Commun, 2013. 4: p. 1562.

343.

Kim, C., Rockenstein, E., Spencer, B., Kim, H.K., Adame, A., Trejo, M., Stafa, K.,
Lee, H.J., Lee, S.J., and Masliah, E., Antagonizing Neuronal Toll-like Receptor 2
Prevents Synucleinopathy by Activating Autophagy. Cell Rep, 2015. 13(4): p. 77182.

344.

Meredith, G.E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R.C., Jr., and
Lau, Y.S., Lysosomal malfunction accompanies alpha-synuclein aggregation in a
progressive mouse model of Parkinson's disease. Brain Res, 2002. 956(1): p. 15665.

345.

Rockenstein, E., Schwach, G., Ingolic, E., Adame, A., Crews, L., Mante, M.,
Pfragner, R., Schreiner, E., Windisch, M., and Masliah, E., Lysosomal pathology
associated with alpha-synuclein accumulation in transgenic models using an
eGFP fusion protein. J Neurosci Res, 2005. 80(2): p. 247-59.

346.

Chu, Y., Dodiya, H., Aebischer, P., Olanow, C.W., and Kordower, J.H., Alterations
in lysosomal and proteasomal markers in Parkinson's disease: relationship to
alpha-synuclein inclusions. Neurobiol Dis, 2009. 35(3): p. 385-98.

347.

Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B.,
Masliah, E., and Lee, S.J., Inclusion formation and neuronal cell death through
neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A,
2009. 106(31): p. 13010-5.

348.

Bae, E.J., Lee, H.J., Jang, Y.H., Michael, S., Masliah, E., Min, D.S., and Lee, S.J.,
Phospholipase D1 regulates autophagic flux and clearance of alpha-synuclein
aggregates. Cell Death Differ, 2014. 21(7): p. 1132-41.

349.

Xilouri, M., Brekk, O.R., Polissidis, A., Chrysanthou-Piterou, M., Kloukina, I., and
Stefanis, L., Impairment of chaperone-mediated autophagy induces
dopaminergic neurodegeneration in rats. Autophagy, 2016. 12(11): p. 2230-2247.

350.

Sidransky, E. and Lopez, G., The link between the GBA gene and parkinsonism.
The Lancet Neurology, 2012. 11(11): p. 986-998.

351.

244
Wong, Y.C. and Krainc, D., Lysosomal trafficking defects link Parkinson's disease
with Gaucher's disease. Mov Disord, 2016. 31(11): p. 1610-1618.

352.

Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R.,
Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.M., Clark, L.N., Condroyer, C., De
Marco, E.V., Durr, A., Eblan, M.J., Fahn, S., Farrer, M.J., Fung, H.C., Gan-Or, Z.,
Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C.,
Kropp, P., Lang, A.E., Lee-Chen, G.J., Lesage, S., Marder, K., Mata, I.F., Mirelman,
A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A.,
Pereira, L.V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R.,
Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.K.,
Tayebi, N., Toda, T., Troiano, A.R., Tsuji, S., Wittstock, M., Wolfsberg, T.G., Wu,
Y.R., Zabetian, C.P., Zhao, Y., and Ziegler, S.G., Multicenter analysis of
glucocerebrosidase mutations in Parkinson's disease. N Engl J Med, 2009.
361(17): p. 1651-61.

353.

Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G., Chinnery,
P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P., Engelborghs, S., De Deyn, P.P.,
Van Broeckhoven, C., Mann, D.M., Snowden, J., Pickering-Brown, S., Halliwell, N.,
Davidson, Y., Gibbons, L., Harris, J., Sheerin, U.M., Bras, J., Hardy, J., Clark, L.,
Marder, K., Honig, L.S., Berg, D., Maetzler, W., Brockmann, K., Gasser, T.,
Novellino, F., Quattrone, A., Annesi, G., De Marco, E.V., Rogaeva, E., Masellis, M.,
Black, S.E., Bilbao, J.M., Foroud, T., Ghetti, B., Nichols, W.C., Pankratz, N.,
Halliday, G., Lesage, S., Klebe, S., Durr, A., Duyckaerts, C., Brice, A., Giasson, B.I.,
Trojanowski, J.Q., Hurtig, H.I., Tayebi, N., Landazabal, C., Knight, M.A., Keller, M.,
Singleton, A.B., Wolfsberg, T.G., and Sidransky, E., A multicenter study of
glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol, 2013.
70(6): p. 727-35.

354.

Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A.K., Schulte, C., Maetzler, W.,
Gasser, T., and Berg, D., GBA-associated Parkinson's disease: reduced survival
and more rapid progression in a prospective longitudinal study. Mov Disord,
2015. 30(3): p. 407-11.

355.

Alcalay, R.N., Levy, O.A., Waters, C.C., Fahn, S., Ford, B., Kuo, S.H., Mazzoni, P.,
Pauciulo, M.W., Nichols, W.C., Gan-Or, Z., Rouleau, G.A., Chung, W.K., Wolf, P.,
Oliva, P., Keutzer, J., Marder, K., and Zhang, X., Glucocerebrosidase activity in
Parkinson's disease with and without GBA mutations. Brain, 2015. 138(Pt 9): p.
2648-58.

356.

Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A.,
Sidransky, E., Grabowski, G.A., and Krainc, D., Gaucher disease

245
glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in
synucleinopathies. Cell, 2011. 146(1): p. 37-52.
357.

Sardi, S.P., Clarke, J., Kinnecom, C., Tamsett, T.J., Li, L., Stanek, L.M., Passini,
M.A., Grabowski, G.A., Schlossmacher, M.G., Sidman, R.L., Cheng, S.H., and
Shihabuddin, L.S., CNS expression of glucocerebrosidase corrects alpha-synuclein
pathology and memory in a mouse model of Gaucher-related synucleinopathy.
Proc Natl Acad Sci U S A, 2011. 108(29): p. 12101-6.

358.

Mazzulli, J.R., Zunke, F., Isacson, O., Studer, L., and Krainc, D., alpha-Synucleininduced lysosomal dysfunction occurs through disruptions in protein trafficking in
human midbrain synucleinopathy models. Proc Natl Acad Sci U S A, 2016. 113(7):
p. 1931-6.

359.

Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., and
Schapira, A.H., Glucocerebrosidase deficiency in substantia nigra of parkinson
disease brains. Ann Neurol, 2012. 72(3): p. 455-63.

360.

Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.S., Sidransky, E.,
Cooper, A., Garner, B., and Halliday, G.M., Reduced glucocerebrosidase is
associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain,
2014. 137(Pt 3): p. 834-48.

361.

Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., KurzawaAkanbi, M., Chinnery, P.F., Morris, C.M., Calabresi, P., Parnetti, L., and Beccari, T.,
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and
dementia with Lewy bodies. Mol Neurodegener, 2015. 10: p. 15.

362.

Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hallett, P., and Isacson, O.,
Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann
Clin Transl Neurol, 2015. 2(4): p. 433-8.

363.

Schondorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B.,
Sardi, S.P., Valsecchi, M., Hoffmann, S., Schwarz, L.K., Hedrich, U., Berg, D.,
Shihabuddin, L.S., Hu, J., Pruszak, J., Gygi, S.P., Sonnino, S., Gasser, T., and
Deleidi, M., iPSC-derived neurons from GBA1-associated Parkinson's disease
patients show autophagic defects and impaired calcium homeostasis. Nat
Commun, 2014. 5: p. 4028.

364.

Fernandes, H.J., Hartfield, E.M., Christian, H.C., Emmanoulidou, E., Zheng, Y.,
Booth, H., Bogetofte, H., Lang, C., Ryan, B.J., Sardi, S.P., Badger, J., Vowles, J.,
Evetts, S., Tofaris, G.K., Vekrellis, K., Talbot, K., Hu, M.T., James, W., Cowley, S.A.,
and Wade-Martins, R., ER Stress and Autophagic Perturbations Lead to Elevated

246
Extracellular alpha-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine
Neurons. Stem Cell Reports, 2016. 6(3): p. 342-56.
365.

Davis, M.Y., Trinh, K., Thomas, R.E., Yu, S., Germanos, A.A., Whitley, B.N., Sardi,
S.P., Montine, T.J., and Pallanck, L.J., Glucocerebrosidase Deficiency in Drosophila
Results in alpha-Synuclein-Independent Protein Aggregation and
Neurodegeneration. PLoS Genet, 2016. 12(3): p. e1005944.

366.

Magalhaes, J., Gegg, M.E., Migdalska-Richards, A., Doherty, M.K., Whitfield, P.D.,
and Schapira, A.H., Autophagic lysosome reformation dysfunction in
glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol
Genet, 2016. 25(16): p. 3432-3445.

367.

Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L.P.,
Goebel, I., Mubaidin, A.F., Wriekat, A.L., Roeper, J., Al-Din, A., Hillmer, A.M.,
Karsak, M., Liss, B., Woods, C.G., Behrens, M.I., and Kubisch, C., Hereditary
parkinsonism with dementia is caused by mutations in ATP13A2, encoding a
lysosomal type 5 P-type ATPase. Nat Genet, 2006. 38(10): p. 1184-91.

368.

Di Fonzo, A., Chien, H.F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G., Fabbrini,
G., Marconi, R., Fincati, E., Abbruzzese, G., Marini, P., Squitieri, F., Horstink,
M.W., Montagna, P., Libera, A.D., Stocchi, F., Goldwurm, S., Ferreira, J.J., Meco,
G., Martignoni, E., Lopiano, L., Jardim, L.B., Oostra, B.A., Barbosa, E.R., Italian
Parkinson Genetics, N., and Bonifati, V., ATP13A2 missense mutations in juvenile
parkinsonism and young onset Parkinson disease. Neurology, 2007. 68(19): p.
1557-62.

369.

Abeliovich, A. and Gitler, A.D., Defects in trafficking bridge Parkinson's disease
pathology and genetics. Nature, 2016. 539(7628): p. 207-216.

370.

Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.H.,
Doudnikoff, E., Vital, A., Vila, M., Klein, C., and Bezard, E., Loss of P-type ATPase
ATP13A2/PARK9 function induces general lysosomal deficiency and leads to
Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A, 2012. 109(24): p.
9611-6.

371.

Usenovic, M., Tresse, E., Mazzulli, J.R., Taylor, J.P., and Krainc, D., Deficiency of
ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and
neurotoxicity. J Neurosci, 2012. 32(12): p. 4240-6.

372.

Kett, L.R., Stiller, B., Bernath, M.M., Tasset, I., Blesa, J., Jackson-Lewis, V., Chan,
R.B., Zhou, B., Di Paolo, G., Przedborski, S., Cuervo, A.M., and Dauer, W.T., alphaSynuclein-independent histopathological and motor deficits in mice lacking the

247
endolysosomal Parkinsonism protein Atp13a2. J Neurosci, 2015. 35(14): p. 572442.
373.

Bae, E.J., Yang, N.Y., Lee, C., Kim, S., Lee, H.J., and Lee, S.J., Haploinsufficiency of
cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission
of alpha-synuclein aggregates. Cell Death Dis, 2015. 6: p. e1901.

374.

Crabtree, D., Dodson, M., Ouyang, X., Boyer-Guittaut, M., Liang, Q., Ballestas,
M.E., Fineberg, N., and Zhang, J., Over-expression of an inactive mutant
cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SHSY5Y cells. J Neurochem, 2014. 128(6): p. 950-61.

375.

Xilouri, M., Brekk, O.R., Landeck, N., Pitychoutis, P.M., Papasilekas, T.,
Papadopoulou-Daifoti, Z., Kirik, D., and Stefanis, L., Boosting chaperonemediated autophagy in vivo mitigates alpha-synuclein-induced
neurodegeneration. Brain, 2013. 136(Pt 7): p. 2130-46.

376.

Sardi, S.P., Clarke, J., Viel, C., Chan, M., Tamsett, T.J., Treleaven, C.M., Bu, J.,
Sweet, L., Passini, M.A., Dodge, J.C., Yu, W.H., Sidman, R.L., Cheng, S.H., and
Shihabuddin, L.S., Augmenting CNS glucocerebrosidase activity as a therapeutic
strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc
Natl Acad Sci U S A, 2013. 110(9): p. 3537-42.

377.

Mazzulli, J.R., Zunke, F., Tsunemi, T., Toker, N.J., Jeon, S., Burbulla, L.F., Patnaik,
S., Sidransky, E., Marugan, J.J., Sue, C.M., and Krainc, D., Activation of betaGlucocerebrosidase Reduces Pathological alpha-Synuclein and Restores
Lysosomal Function in Parkinson's Patient Midbrain Neurons. J Neurosci, 2016.
36(29): p. 7693-706.

378.

El-Agnaf, O.M., Jakes, R., Curran, M.D., Middleton, D., Ingenito, R., Bianchi, E.,
Pessi, A., Neill, D., and Wallace, A., Aggregates from mutant and wild-type alphasynuclein proteins and NAC peptide induce apoptotic cell death in human
neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS
Lett, 1998. 440(1-2): p. 71-5.

379.

Yamada, M., Iwatsubo, T., Mizuno, Y., and Mochizuki, H., Overexpression of
alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons,
phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to
pathogenetic changes in Parkinson's disease. J Neurochem, 2004. 91(2): p. 45161.

380.

248
Tofaris, G.K., Goedert, M., and Spillantini, M.G., The Transcellular Propagation
and Intracellular Trafficking of alpha-Synuclein. Cold Spring Harb Perspect Med,
2016. 10.1101/cshperspect.a024380.

381.

Scott, D.A., Tabarean, I., Tang, Y., Cartier, A., Masliah, E., and Roy, S., A
pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced
neurodegeneration. J Neurosci, 2010. 30(24): p. 8083-95.

382.

Shrivastava, A.N., Redeker, V., Fritz, N., Pieri, L., Almeida, L.G., Spolidoro, M.,
Liebmann, T., Bousset, L., Renner, M., Lena, C., Aperia, A., Melki, R., and Triller,
A., alpha-synuclein assemblies sequester neuronal alpha3-Na+/K+-ATPase and
impair Na+ gradient. EMBO J, 2015. 34(19): p. 2408-23.

383.

Bourdenx, M., Bezard, E., and Dehay, B., Lysosomes and alpha-synuclein form a
dangerous duet leading to neuronal cell death. Front Neuroanat, 2014. 8: p. 83.

384.

Volpicelli-Daley, L.A., Effects of alpha-synuclein on axonal transport. Neurobiol
Dis, 2016. 10.1016/j.nbd.2016.12.008.

385.

Lamberts, J.T., Hildebrandt, E.N., and Brundin, P., Spreading of alpha-synuclein in
the face of axonal transport deficits in Parkinson's disease: a speculative
synthesis. Neurobiol Dis, 2015. 77: p. 276-83.

386.

Chu, Y., Morfini, G.A., Langhamer, L.B., He, Y., Brady, S.T., and Kordower, J.H.,
Alterations in axonal transport motor proteins in sporadic and experimental
Parkinson's disease. Brain, 2012. 135(Pt 7): p. 2058-73.

387.

Chung, C.Y., Koprich, J.B., Siddiqi, H., and Isacson, O., Dynamic changes in
presynaptic and axonal transport proteins combined with striatal
neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV
alpha-synucleinopathy. J Neurosci, 2009. 29(11): p. 3365-73.

388.

Oikawa, T., Nonaka, T., Terada, M., Tamaoka, A., Hisanaga, S., and Hasegawa, M.,
alpha-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation
and Inhibiting Microtubule Assembly. J Biol Chem, 2016. 291(29): p. 15046-56.

389.

Goldberg, M.S. and Lansbury, P.T., Is there a cause-and-effect relationship
between alpha-synuclein fibrillization and Parkinson's disease? Nature Cell
Biology, 2000. 2: p. E115-E119.

390.

Cremades, N., Chen, S.W., and Dobson, C.M., Structural Characteristics of alphaSynuclein Oligomers. Int Rev Cell Mol Biol, 2017. 329: p. 79-143.

249

391.

Outeiro, T.F., Putcha, P., Tetzlaff, J.E., Spoelgen, R., Koker, M., Carvalho, F.,
Hyman, B.T., and McLean, P.J., Formation of toxic oligomeric alpha-synuclein
species in living cells. PLoS ONE, 2008. 3(4): p. e1867.

392.

Karpinar, D.P., Balija, M.B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N.,
Kim, H.Y., Taschenberger, G., Falkenburger, B.H., Heise, H., Kumar, A., Riedel, D.,
Fichtner, L., Voigt, A., Braus, G.H., Giller, K., Becker, S., Herzig, A., Baldus, M.,
Jackle, H., Eimer, S., Schulz, J.B., Griesinger, C., and Zweckstetter, M., Pre-fibrillar
alpha-synuclein variants with impaired beta-structure increase neurotoxicity in
Parkinson's disease models. EMBO J, 2009. 28(20): p. 3256-68.

393.

Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C.,
Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira,
H., Consiglio, A., Pham, E., Masliah, E., Gage, F.H., and Riek, R., In vivo
demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A,
2011. 108(10): p. 4194-9.

394.

Villar-Pique, A., Lopes da Fonseca, T., Sant'Anna, R., Szego, E.M., FonsecaOrnelas, L., Pinho, R., Carija, A., Gerhardt, E., Masaracchia, C., Abad Gonzalez, E.,
Rossetti, G., Carloni, P., Fernandez, C.O., Foguel, D., Milosevic, I., Zweckstetter,
M., Ventura, S., and Outeiro, T.F., Environmental and genetic factors support the
dissociation between alpha-synuclein aggregation and toxicity. Proc Natl Acad Sci
U S A, 2016. 113(42): p. E6506-E6515.

395.

Lam, H.T., Graber, M.C., Gentry, K.A., and Bieschke, J., Stabilization of alphaSynuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity
and Toxicity. Biochemistry, 2016. 55(4): p. 675-85.

396.

Braak, H. and Del Tredici, K., Potential Pathways of Abnormal Tau and alphaSynuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. Cold
Spring Harb Perspect Biol, 2016. 10.1101/cshperspect.a023630.

397.

Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., and Braak, E.,
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol
Aging, 2003. 24(2): p. 197-211.

398.

Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici, K., Stages in
the development of Parkinson's disease-related pathology. Cell Tissue Res, 2004.
318(1): p. 121-34.

399.

Braak, H., Bohl, J.R., Muller, C.M., Rub, U., de Vos, R.A., and Del Tredici, K.,
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body

pathology associated with sporadic Parkinson's disease reconsidered. Mov
Disord, 2006. 21(12): p. 2042-51.

250

400.

Braak, H., Rub, U., Gai, W.P., and Del Tredici, K., Idiopathic Parkinson's disease:
possible routes by which vulnerable neuronal types may be subject to
neuroinvasion by an unknown pathogen. J Neural Transm (Vienna), 2003. 110(5):
p. 517-36.

401.

Braak, H., de Vos, R.A., Bohl, J., and Del Tredici, K., Gastric alpha-synuclein
immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged
for Parkinson's disease-related brain pathology. Neurosci Lett, 2006. 396(1): p.
67-72.

402.

Del Tredici, K. and Braak, H., Review: Sporadic Parkinson's disease: development
and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol,
2016. 42(1): p. 33-50.

403.

Wakabayashi, K., Takahashi, H., Ohama, E., and Ikuta, F., Parkinson's disease: an
immunohistochemical study of Lewy body-containing neurons in the enteric
nervous system. Acta Neuropathol, 1990. 79(6): p. 581-3.

404.

Beach, T.G., Adler, C.H., Sue, L.I., Vedders, L., Lue, L., White Iii, C.L., Akiyama, H.,
Caviness, J.N., Shill, H.A., Sabbagh, M.N., Walker, D.G., and Arizona Parkinson's
Disease, C., Multi-organ distribution of phosphorylated alpha-synuclein
histopathology in subjects with Lewy body disorders. Acta Neuropathol, 2010.
119(6): p. 689-702.

405.

Gelpi, E., Navarro-Otano, J., Tolosa, E., Gaig, C., Compta, Y., Rey, M.J., Marti, M.J.,
Hernandez, I., Valldeoriola, F., Rene, R., and Ribalta, T., Multiple organ
involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord,
2014. 29(8): p. 1010-8.

406.

Shannon, K.M., Keshavarzian, A., Dodiya, H.B., Jakate, S., and Kordower, J.H., Is
alpha-synuclein in the colon a biomarker for premotor Parkinson's disease?
Evidence from 3 cases. Mov Disord, 2012. 27(6): p. 716-9.

407.

Shannon, K.M., Keshavarzian, A., Mutlu, E., Dodiya, H.B., Daian, D., Jaglin, J.A.,
and Kordower, J.H., Alpha-synuclein in colonic submucosa in early untreated
Parkinson's disease. Mov Disord, 2012. 27(6): p. 709-15.

408.

Scheperjans, F., Aho, V., Pereira, P.A., Koskinen, K., Paulin, L., Pekkonen, E.,
Haapaniemi, E., Kaakkola, S., Eerola-Rautio, J., Pohja, M., Kinnunen, E., Murros,

251
K., and Auvinen, P., Gut microbiota are related to Parkinson's disease and clinical
phenotype. Mov Disord, 2015. 30(3): p. 350-8.
409.

Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E.,
Challis, C., Schretter, C.E., Rocha, S., Gradinaru, V., Chesselet, M.F., Keshavarzian,
A., Shannon, K.M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., and
Mazmanian, S.K., Gut Microbiota Regulate Motor Deficits and
Neuroinflammation in a Model of Parkinson's Disease. Cell, 2016. 167(6): p.
1469-1480 e12.

410.

Lema Tome, C.M., Tyson, T., Rey, N.L., Grathwohl, S., Britschgi, M., and Brundin,
P., Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-is there a link? Mol Neurobiol, 2013. 47(2): p. 561-74.

411.

Svensson, E., Horvath-Puho, E., Thomsen, R.W., Djurhuus, J.C., Pedersen, L.,
Borghammer, P., and Sorensen, H.T., Vagotomy and subsequent risk of
Parkinson's disease. Ann Neurol, 2015. 78(4): p. 522-9.

412.

Rey, N.L., Wesson, D.W., and Brundin, P., The olfactory bulb as the entry site for
prion-like propagation in neurodegenerative diseases. Neurobiol Dis, 2016.
10.1016/j.nbd.2016.12.013.

413.

Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Bjorklund, T., Wang,
Z.Y., Roybon, L., Melki, R., and Li, J.Y., Direct evidence of Parkinson pathology
spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol,
2014. 128(6): p. 805-20.

414.

Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., Lee, S., Regenhardt,
R.W., McGarvey, N.H., Ayers, J.I., Notterpek, L., Borchelt, D.R., Golde, T.E., and
Giasson, B.I., Intramuscular injection of alpha-synuclein induces CNS alphasynuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc
Natl Acad Sci U S A, 2014. 111(29): p. 10732-7.

415.

Ayers, J.I., Brooks, M.M., Rutherford, N.J., Howard, J.K., Sorrentino, Z.A., Riffe,
C.J., and Giasson, B.I., Robust Central Nervous System Pathology in Transgenic
Mice following Peripheral Injection of alpha-Synuclein Fibrils. J Virol, 2017.
10.1128/JVI.02095-16.

416.

Breid, S., Bernis, M.E., Babila, J.T., Garza, M.C., Wille, H., and Tamguney, G.,
Neuroinvasion of alpha-Synuclein Prionoids after Intraperitoneal and Intraglossal
Inoculation. J Virol, 2016. 90(20): p. 9182-93.

252

417.

Engelender, S. and Isacson, O., The Threshold Theory for Parkinson's Disease.
Trends Neurosci, 2017. 40(1): p. 4-14.

418.

Ulusoy, A., Phillips, R.J., Helwig, M., Klinkenberg, M., Powley, T.L., and Di Monte,
D.A., Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic
projections. Acta Neuropathol, 2016. 133(3): p. 381-393.

419.

Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W., Lewy
body-like pathology in long-term embryonic nigral transplants in Parkinson's
disease. Nat Med, 2008. 14(5): p. 504-6.

420.

Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T.,
Quinn, N.P., Rehncrona, S., Bjorklund, A., Widner, H., Revesz, T., Lindvall, O., and
Brundin, P., Lewy bodies in grafted neurons in subjects with Parkinson's disease
suggest host-to-graft disease propagation. Nat Med, 2008. 14(5): p. 501-3.

421.

Mendez, I., Vinuela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H.,
Tierney, T., Holness, R., Dagher, A., Trojanowski, J.Q., and Isacson, O., Dopamine
neurons implanted into people with Parkinson's disease survive without
pathology for 14 years. Nat Med, 2008. 14(5): p. 507-9.

422.

Kordower, J.H., Chu, Y., Hauser, R.A., Olanow, C.W., and Freeman, T.B.,
Transplanted dopaminergic neurons develop PD pathologic changes: a second
case report. Mov Disord, 2008. 23(16): p. 2303-6.

423.

Li, J.Y., Englund, E., Widner, H., Rehncrona, S., Bjorklund, A., Lindvall, O., and
Brundin, P., Characterization of Lewy body pathology in 12- and 16-year-old
intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.
Mov Disord, 2010. 25(8): p. 1091-6.

424.

Kordower, J.H., Dodiya, H.B., Kordower, A.M., Terpstra, B., Paumier, K.,
Madhavan, L., Sortwell, C., Steece-Collier, K., and Collier, T.J., Transfer of hostderived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis,
2011. 43(3): p. 552-7.

425.

Kordower, J.H., Goetz, C.G., Chu, Y., Halliday, G.M., Nicholson, D.A., Musial, T.,
Marmion, D.J., Stoessl, A.J., Sossi, V., Freeman, T.B., and Olanow, C.W., Robust
graft survival and normalized dopaminergic innervation does not obligate
recovery in a pd patient. Ann Neurol, 2016. 81(1): p. 46-57.

426.

Li, W., Englund, E., Widner, H., Mattsson, B., van Westen, D., Latt, J., Rehncrona,
S., Brundin, P., Bjorklund, A., Lindvall, O., and Li, J.Y., Extensive graft-derived
dopaminergic innervation is maintained 24 years after transplantation in the

degenerating parkinsonian brain. Proc Natl Acad Sci U S A, 2016. 113(23): p.
6544-9.

253

427.

El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson,
M.J., Curran, M.D., Court, J.A., Mann, D.M., Ikeda, S., Cookson, M.R., Hardy, J.,
and Allsop, D., Alpha-synuclein implicated in Parkinson's disease is present in
extracellular biological fluids, including human plasma. FASEB J, 2003. 17(13): p.
1945-7.

428.

Tokuda, T., Salem, S.A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M.M.,
Locascio, J.J., Schlossmacher, M.G., and El-Agnaf, O.M., Decreased alphasynuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's
disease. Biochem Biophys Res Commun, 2006. 349(1): p. 162-6.

429.

Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T.F., Pepivani, I., Ng, J.,
Schulz-Schaeffer, W., Kretzschmar, H.A., McLean, P.J., Trenkwalder, C., Sarracino,
D.A., Vonsattel, J.P., Locascio, J.J., El-Agnaf, O.M., and Schlossmacher, M.G.,
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional
study in patients with neurodegeneration. Exp Neurol, 2008. 213(2): p. 315-25.

430.

El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Curran, M.D., Gibson, M.J., Court,
J.A., Schlossmacher, M.G., and Allsop, D., Detection of oligomeric forms of alphasynuclein protein in human plasma as a potential biomarker for Parkinson's
disease. FASEB J, 2006. 20(3): p. 419-25.

431.

Horrocks, M.H., Lee, S.F., Gandhi, S., Magdalinou, N.K., Chen, S.W., Devine, M.J.,
Tosatto, L., Kjaergaard, M., Beckwith, J.S., Zetterberg, H., Iljina, M., Cremades, N.,
Dobson, C.M., Wood, N.W., and Klenerman, D., Single-Molecule Imaging of
Individual Amyloid Protein Aggregates in Human Biofluids. ACS Chem Neurosci,
2016. 7(3): p. 399-406.

432.

Majbour, N.K., Vaikath, N.N., Eusebi, P., Chiasserini, D., Ardah, M., Varghese, S.,
Haque, M.E., Tokuda, T., Auinger, P., Calabresi, P., Parnetti, L., and El-Agnaf,
O.M., Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's
disease progression. Mov Disord, 2016. 31(10): p. 1535-1542.

433.

Wang, Y., Shi, M., Chung, K.A., Zabetian, C.P., Leverenz, J.B., Berg, D., Srulijes, K.,
Trojanowski, J.Q., Lee, V.M., Siderowf, A.D., Hurtig, H., Litvan, I., Schiess, M.C.,
Peskind, E.R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., Goldstein,
D.S., Jensen, P.H., Yang, H., Cain, K.C., and Zhang, J., Phosphorylated alphasynuclein in Parkinson's disease. Sci Transl Med, 2012. 4(121): p. 121ra20.

254

434.

Mollenhauer, B., Trautmann, E., Otte, B., Ng, J., Spreer, A., Lange, P., SixelDoring, F., Hakimi, M., Vonsattel, J.P., Nussbaum, R., Trenkwalder, C., and
Schlossmacher, M.G., alpha-Synuclein in human cerebrospinal fluid is principally
derived from neurons of the central nervous system. J Neural Transm (Vienna),
2012. 119(7): p. 739-46.

435.

Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K.,
Ioannou, P.C., and Vekrellis, K., Assessment of alpha-synuclein secretion in mouse
and human brain parenchyma. PLoS ONE, 2011. 6(7): p. e22225.

436.

Shahnawaz, M., Tokuda, T., Waragai, M., Mendez, N., Ishii, R., Trenkwalder, C.,
Mollenhauer, B., and Soto, C., Development of a Biochemical Diagnosis of
Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in
Cerebrospinal Fluid. JAMA Neurol, 2017. 74(2): p. 163-172.

437.

Edgren, G., Hjalgrim, H., Rostgaard, K., Lambert, P., Wikman, A., Norda, R.,
Titlestad, K.E., Erikstrup, C., Ullum, H., Melbye, M., Busch, M.P., and Nyren, O.,
Transmission of Neurodegenerative Disorders Through Blood Transfusion: A
Cohort Study. Ann Intern Med, 2016. 165(5): p. 316-24.

438.

George, S., Rey, N.L., Reichenbach, N., Steiner, J.A., and Brundin, P., alphaSynuclein: the long distance runner. Brain Pathol, 2013. 23(3): p. 350-7.

439.

Mason, D.M., Nouraei, N., Pant, D.B., Miner, K.M., Hutchison, D.F., Luk, K.C.,
Stolz, J.F., and Leak, R.K., Transmission of alpha-synucleinopathy from olfactory
structures deep into the temporal lobe. Mol Neurodegener, 2016. 11(1): p. 49.

440.

Spencer, B., Valera, E., Rockenstein, E., Overk, C., Mante, M., Adame, A., Zago,
W., Seubert, P., Barbour, R., Schenk, D., Games, D., Rissman, R.A., and Masliah,
E., Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in
the axon and degeneration in a combined viral vector and transgenic model of
synucleinopathy. Acta Neuropathol Commun, 2017. 5(1): p. 7.

441.

Rey, N.L., Petit, G.H., Bousset, L., Melki, R., and Brundin, P., Transfer of human
alpha-synuclein from the olfactory bulb to interconnected brain regions in mice.
Acta Neuropathol, 2013. 126(4): p. 555-73.

442.

Helwig, M., Klinkenberg, M., Rusconi, R., Musgrove, R.E., Majbour, N.K., El-Agnaf,
O.M., Ulusoy, A., and Di Monte, D.A., Brain propagation of transduced alphasynuclein involves non-fibrillar protein species and is enhanced in alpha-synuclein
null mice. Brain, 2016. 139(Pt 3): p. 856-70.

443.

255
Freundt, E.C., Maynard, N., Clancy, E.K., Roy, S., Bousset, L., Sourigues, Y., Covert,
M., Melki, R., Kirkegaard, K., and Brahic, M., Neuron-to-neuron transmission of
alpha-synuclein fibrils through axonal transport. Ann Neurol, 2012. 72(4): p. 51724.

444.

Brahic, M., Bousset, L., Bieri, G., Melki, R., and Gitler, A.D., Axonal transport and
secretion of fibrillar forms of alpha-synuclein, Abeta42 peptide and HTTExon 1.
Acta Neuropathol, 2016. 131(4): p. 539-48.

445.

Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L., Olivo-Marin,
J.C., Melki, R., and Zurzolo, C., Tunneling nanotubes spread fibrillar alphasynuclein by intercellular trafficking of lysosomes. EMBO J, 2016. 35(19): p. 21202138.

446.

Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., McGarvey, N.H.,
Rutherford, N.J., Ceballos-Diaz, C., Robertson, J., Golde, T.E., and Giasson, B.I.,
Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread
pathology in mice. Acta Neuropathol, 2014. 127(5): p. 645-65.

447.

Kumari, S., Mg, S., and Mayor, S., Endocytosis unplugged: multiple ways to enter
the cell. Cell Res, 2010. 20(3): p. 256-75.

448.

Steiner, J.A., Angot, E., and Brundin, P., A deadly spread: cellular mechanisms of
alpha-synuclein transfer. Cell Death Differ, 2011. 18(9): p. 1425-33.

449.

Sung, J.Y., Kim, J., Paik, S.R., Park, J.H., Ahn, Y.S., and Chung, K.C., Induction of
neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol
Chem, 2001. 276(29): p. 27441-8.

450.

Lee, H.J., Suk, J.E., Bae, E.J., Lee, J.H., Paik, S.R., and Lee, S.J., Assemblydependent endocytosis and clearance of extracellular alpha-synuclein. Int J
Biochem Cell Biol, 2008. 40(9): p. 1835-49.

451.

Lee, H.J., Suk, J.E., Bae, E.J., and Lee, S.J., Clearance and deposition of
extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res
Commun, 2008. 372(3): p. 423-8.

452.

Liu, J., Zhou, Y., Wang, Y., Fong, H., Murray, T.M., and Zhang, J., Identification of
proteins involved in microglial endocytosis of alpha-synuclein. J Proteome Res,
2007. 6(9): p. 3614-27.

453.

Lee, H.J., Suk, J.E., Patrick, C., Bae, E.J., Cho, J.H., Rho, S., Hwang, D., Masliah, E.,
and Lee, S.J., Direct transfer of alpha-synuclein from neuron to astroglia causes

inflammatory responses in synucleinopathies. J Biol Chem, 2010. 285(12): p.
9262-72.

256

454.

Hansen, C., Angot, E., Bergstrom, A.L., Steiner, J.A., Pieri, L., Paul, G., Outeiro,
T.F., Melki, R., Kallunki, P., Fog, K., Li, J.Y., and Brundin, P., alpha-Synuclein
propagates from mouse brain to grafted dopaminergic neurons and seeds
aggregation in cultured human cells. J Clin Invest, 2011. 121(2): p. 715-25.

455.

Konno, M., Hasegawa, T., Baba, T., Miura, E., Sugeno, N., Kikuchi, A., Fiesel, F.C.,
Sasaki, T., Aoki, M., Itoyama, Y., and Takeda, A., Suppression of dynamin GTPase
decreases alpha-synuclein uptake by neuronal and oligodendroglial cells: a
potent therapeutic target for synucleinopathy. Mol Neurodegener, 2012. 7: p. 38.

456.

Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P., and Angot, E., Alphasynuclein transfers from neurons to oligodendrocytes. Glia, 2014. 62(3): p. 38798.

457.

Reyes, J.F., Olsson, T.T., Lamberts, J.T., Devine, M.J., Kunath, T., and Brundin, P.,
A cell culture model for monitoring alpha-synuclein cell-to-cell transfer. Neurobiol
Dis, 2015. 77: p. 266-75.

458.

Monsellier, E., Bousset, L., and Melki, R., alpha-Synuclein and huntingtin exon 1
amyloid fibrils bind laterally to the cellular membrane. Sci Rep, 2016. 6: p. 19180.

459.

Zeineddine, R., Pundavela, J.F., Corcoran, L., Stewart, E.M., Do-Ha, D., Bax, M.,
Guillemin, G., Vine, K.L., Hatters, D.M., Ecroyd, H., Dobson, C.M., Turner, B.J.,
Ooi, L., Wilson, M.R., Cashman, N.R., and Yerbury, J.J., SOD1 protein aggregates
stimulate macropinocytosis in neurons to facilitate their propagation. Mol
Neurodegener, 2015. 10: p. 57.

460.

Holmes, B.B., DeVos, S.L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja,
M.O., Brodsky, F.M., Marasa, J., Bagchi, D.P., Kotzbauer, P.T., Miller, T.M., PapyGarcia, D., and Diamond, M.I., Heparan sulfate proteoglycans mediate
internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci
U S A, 2013. 110(33): p. E3138-47.

461.

Mao, X., Ou, M.T., Karuppagounder, S.S., Kam, T.I., Yin, X., Xiong, Y., Ge, P.,
Umanah, G.E., Brahmachari, S., Shin, J.H., Kang, H.C., Zhang, J., Xu, J., Chen, R.,
Park, H., Andrabi, S.A., Kang, S.U., Goncalves, R.A., Liang, Y., Zhang, S., Qi, C.,
Lam, S., Keiler, J.A., Tyson, J., Kim, D., Panicker, N., Yun, S.P., Workman, C.J.,
Vignali, D.A., Dawson, V.L., Ko, H.S., and Dawson, T.M., Pathological alphasynuclein transmission initiated by binding lymphocyte-activation gene 3.
Science, 2016. 353(6307).

257

462.

Apetri, M.M., Harkes, R., Subramaniam, V., Canters, G.W., Schmidt, T., and
Aartsma, T.J., Direct Observation of alpha-Synuclein Amyloid Aggregates in
Endocytic Vesicles of Neuroblastoma Cells. PLoS ONE, 2016. 11(4): p. e0153020.

463.

Domert, J., Sackmann, C., Severinsson, E., Agholme, L., Bergstrom, J., Ingelsson,
M., and Hallbeck, M., Aggregated Alpha-Synuclein Transfer Efficiently between
Cultured Human Neuron-Like Cells and Localize to Lysosomes. PLoS ONE, 2016.
11(12): p. e0168700.

464.

Angot, E., Steiner, J.A., Lema Tome, C.M., Ekstrom, P., Mattsson, B., Bjorklund,
A., and Brundin, P., Alpha-synuclein cell-to-cell transfer and seeding in grafted
dopaminergic neurons in vivo. PLoS ONE, 2012. 7(6): p. e39465.

465.

Guo, J.L. and Lee, V.M., Cell-to-cell transmission of pathogenic proteins in
neurodegenerative diseases. Nat Med, 2014. 20(2): p. 130-8.

466.

Lee, H.J., Bae, E.J., and Lee, S.J., Extracellular alpha--synuclein-a novel and crucial
factor in Lewy body diseases. Nat Rev Neurol, 2014. 10(2): p. 92-8.

467.

Marques, O. and Outeiro, T.F., Alpha-synuclein: from secretion to dysfunction
and death. Cell Death Dis, 2012. 3: p. e350.

468.

Lee, H.J., Patel, S., and Lee, S.J., Intravesicular localization and exocytosis of
alpha-synuclein and its aggregates. J Neurosci, 2005. 25(25): p. 6016-24.

469.

Jang, A., Lee, H.J., Suk, J.E., Jung, J.W., Kim, K.P., and Lee, S.J., Non-classical
exocytosis of alpha-synuclein is sensitive to folding states and promoted under
stress conditions. J Neurochem, 2010. 113(5): p. 1263-74.

470.

Ejlerskov, P., Rasmussen, I., Nielsen, T.T., Bergstrom, A.L., Tohyama, Y., Jensen,
P.H., and Vilhardt, F., Tubulin polymerization-promoting protein (TPPP/p25alpha)
promotes unconventional secretion of alpha-synuclein through exophagy by
impairing autophagosome-lysosome fusion. J Biol Chem, 2013. 288(24): p.
17313-35.

471.

Christensen, D.P., Ejlerskov, P., Rasmussen, I., and Vilhardt, F., Reciprocal signals
between microglia and neurons regulate alpha-synuclein secretion by exophagy
through a neuronal cJUN-N-terminal kinase-signaling axis. J Neuroinflammation,
2016. 13(1): p. 59.

472.

Hasegawa, T., Konno, M., Baba, T., Sugeno, N., Kikuchi, A., Kobayashi, M., Miura,
E., Tanaka, N., Tamai, K., Furukawa, K., Arai, H., Mori, F., Wakabayashi, K., Aoki,
M., Itoyama, Y., and Takeda, A., The AAA-ATPase VPS4 regulates extracellular

258
secretion and lysosomal targeting of alpha-synuclein. PLoS ONE, 2011. 6(12): p.
e29460.
473.

Poehler, A.M., Xiang, W., Spitzer, P., May, V.E., Meixner, H., Rockenstein, E.,
Chutna, O., Outeiro, T.F., Winkler, J., Masliah, E., and Klucken, J., Autophagy
modulates SNCA/alpha-synuclein release, thereby generating a hostile
microenvironment. Autophagy, 2014. 10(12): p. 2171-92.

474.

Sung, J.Y., Park, S.M., Lee, C.H., Um, J.W., Lee, H.J., Kim, J., Oh, Y.J., Lee, S.T.,
Paik, S.R., and Chung, K.C., Proteolytic cleavage of extracellular secreted {alpha}synuclein via matrix metalloproteinases. J Biol Chem, 2005. 280(26): p. 25216-24.

475.

Chivet, M., Hemming, F., Pernet-Gallay, K., Fraboulet, S., and Sadoul, R.,
Emerging role of neuronal exosomes in the central nervous system. Front Physiol,
2012. 3: p. 145.

476.

Loov, C., Scherzer, C.R., Hyman, B.T., Breakefield, X.O., and Ingelsson, M., alphaSynuclein in Extracellular Vesicles: Functional Implications and Diagnostic
Opportunities. Cell Mol Neurobiol, 2016. 36(3): p. 437-48.

477.

Vella, L.J., Hill, A.F., and Cheng, L., Focus on Extracellular Vesicles: Exosomes and
Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and
Parkinson's Disease. Int J Mol Sci, 2016. 17(2): p. 173.

478.

Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M.,
Margaritis, L.H., Stefanis, L., and Vekrellis, K., Cell-produced alpha-synuclein is
secreted in a calcium-dependent manner by exosomes and impacts neuronal
survival. J Neurosci, 2010. 30(20): p. 6838-51.

479.

Danzer, K.M., Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, L.,
Vanderburg, C.R., and McLean, P.J., Exosomal cell-to-cell transmission of alpha
synuclein oligomers. Mol Neurodegener, 2012. 7: p. 42.

480.

Kunadt, M., Eckermann, K., Stuendl, A., Gong, J., Russo, B., Strauss, K., Rai, S.,
Kugler, S., Falomir Lockhart, L., Schwalbe, M., Krumova, P., Oliveira, L.M., Bahr,
M., Mobius, W., Levin, J., Giese, A., Kruse, N., Mollenhauer, B., Geiss-Friedlander,
R., Ludolph, A.C., Freischmidt, A., Feiler, M.S., Danzer, K.M., Zweckstetter, M.,
Jovin, T.M., Simons, M., Weishaupt, J.H., and Schneider, A., Extracellular vesicle
sorting of alpha-Synuclein is regulated by sumoylation. Acta Neuropathol, 2015.
129(5): p. 695-713.

481.

Spencer, B., Kim, C., Gonzalez, T., Bisquertt, A., Patrick, C., Rockenstein, E.,
Adame, A., Lee, S.J., Desplats, P., and Masliah, E., alpha-Synuclein interferes with

the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.
Hum Mol Genet, 2016. 25(6): p. 1100-15.

259

482.

McCann, H., Cartwright, H., and Halliday, G.M., Neuropathology of alphasynuclein propagation and braak hypothesis. Mov Disord, 2016. 31(2): p. 152-60.

483.

Borland, H. and Vilhardt, F., Prelysosomal Compartments in the Unconventional
Secretion of Amyloidogenic Seeds. Int J Mol Sci, 2017. 10.3390/ijms18010227.

484.

Lee, H.J., Cho, E.D., Lee, K.W., Kim, J.H., Cho, S.G., and Lee, S.J., Autophagic
failure promotes the exocytosis and intercellular transfer of alpha-synuclein. Exp
Mol Med, 2013. 45: p. e22.

485.

Alvarez-Erviti, L., Seow, Y., Schapira, A.H., Gardiner, C., Sargent, I.L., Wood, M.J.,
and Cooper, J.M., Lysosomal dysfunction increases exosome-mediated alphasynuclein release and transmission. Neurobiol Dis, 2011. 42(3): p. 360-7.

486.

Bae, E.J., Yang, N.Y., Song, M., Lee, C.S., Lee, J.S., Jung, B.C., Lee, H.J., Kim, S.,
Masliah, E., Sardi, S.P., and Lee, S.J., Glucocerebrosidase depletion enhances cellto-cell transmission of alpha-synuclein. Nat Commun, 2014. 5: p. 4755.

487.

Kim, D.K., Lim, H.S., Kawasaki, I., Shim, Y.H., Vaikath, N.N., El-Agnaf, O.M., Lee,
H.J., and Lee, S.J., Anti-aging treatments slow propagation of synucleinopathy by
restoring lysosomal function. Autophagy, 2016. 12(10): p. 1849-1863.

488.

Clavaguera, F., Tolnay, M., and Goedert, M., The Prion-Like Behavior of
Assembled Tau in Transgenic Mice. Cold Spring Harb Perspect Med, 2016.
10.1101/cshperspect.a024372.

489.

Frost, B., Ollesch, J., Wille, H., and Diamond, M.I., Conformational diversity of
wild-type Tau fibrils specified by templated conformation change. J Biol Chem,
2009. 284(6): p. 3546-51.

490.

Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A.,
Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., Miller, T.M., Grinberg, L.T.,
Seeley, W.W., and Diamond, M.I., Distinct tau prion strains propagate in cells and
mice and define different tauopathies. Neuron, 2014. 82(6): p. 1271-88.

491.

Guo, J.L., Narasimhan, S., Changolkar, L., He, Z., Stieber, A., Zhang, B., Gathagan,
R.J., Iba, M., McBride, J.D., Trojanowski, J.Q., and Lee, V.M., Unique pathological
tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic
mice. J Exp Med, 2016. 213(12): p. 2635-2654.

492.

260
Kaufman, S.K., Sanders, D.W., Thomas, T.L., Ruchinskas, A.J., Vaquer-Alicea, J.,
Sharma, A.M., Miller, T.M., and Diamond, M.I., Tau Prion Strains Dictate Patterns
of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron,
2016. 92(4): p. 796-812.

493.

Holmes, B.B. and Diamond, M.I., Cellular Models for the Study of Prions. Cold
Spring Harb Perspect Med, 2016. 10.1101/cshperspect.a024026.

494.

Guo, J.L. and Lee, V.M., Neurofibrillary tangle-like tau pathology induced by
synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett,
2013. 587(6): p. 717-23.

495.

Guo, J.L., Buist, A., Soares, A., Callaerts, K., Calafate, S., Stevenaert, F., Daniels,
J.P., Zoll, B.E., Crowe, A., Brunden, K.R., Moechars, D., and Lee, V.M., The
Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO
THERAPIES FOR TAUOPATHIES. J Biol Chem, 2016. 291(25): p. 13175-93.

496.

Braak, H. and Braak, E., Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol, 1991. 82(4): p. 239-59.

497.

McKee, A.C., Stern, R.A., Nowinski, C.J., Stein, T.D., Alvarez, V.E., Daneshvar,
D.H., Lee, H.S., Wojtowicz, S.M., Hall, G., Baugh, C.M., Riley, D.O., Kubilus, C.A.,
Cormier, K.A., Jacobs, M.A., Martin, B.R., Abraham, C.R., Ikezu, T., Reichard, R.R.,
Wolozin, B.L., Budson, A.E., Goldstein, L.E., Kowall, N.W., and Cantu, R.C., The
spectrum of disease in chronic traumatic encephalopathy. Brain, 2013. 136(Pt 1):
p. 43-64.

498.

Frost, B., Jacks, R.L., and Diamond, M.I., Propagation of tau misfolding from the
outside to the inside of a cell. J Biol Chem, 2009. 284(19): p. 12845-52.

499.

Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, A.,
Fraser, G., Stalder, A.K., Beibel, M., Staufenbiel, M., Jucker, M., Goedert, M., and
Tolnay, M., Transmission and spreading of tauopathy in transgenic mouse brain.
Nat Cell Biol, 2009. 11(7): p. 909-13.

500.

Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz,
M.J., Kiritoshi, T., Neugebauer, V., Jackson, G.R., and Kayed, R., Alzheimer brainderived tau oligomers propagate pathology from endogenous tau. Sci Rep, 2012.
2: p. 700.

501.

Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., Probst,
A., Winkler, D.T., Reichwald, J., Staufenbiel, M., Ghetti, B., Goedert, M., and

261
Tolnay, M., Brain homogenates from human tauopathies induce tau inclusions in
mouse brain. Proc Natl Acad Sci U S A, 2013. 110(23): p. 9535-40.
502.

Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., and Lee, V.M.,
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a
transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci, 2013. 33(3): p.
1024-37.

503.

Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., de
Wit, J., Verstreken, P., and Moechars, D., Synaptic Contacts Enhance Cell-to-Cell
Tau Pathology Propagation. Cell Rep, 2015. 11(8): p. 1176-83.

504.

Le, M.N., Kim, W., Lee, S., McKee, A.C., and Hall, G.F., Multiple mechanisms of
extracellular tau spreading in a non-transgenic tauopathy model. Am J
Neurodegener Dis, 2012. 1(3): p. 316-33.

505.

Kriegel, J., Papadopoulos, Z., and McKee, A.C., Chronic Traumatic
Encephalopathy: Is Latency in Symptom Onset Explained by Tau Propagation?
Cold Spring Harb Perspect Med, 2017. 10.1101/cshperspect.a024059.

506.

Guo, J.L. and Lee, V.M., Seeding of normal Tau by pathological Tau conformers
drives pathogenesis of Alzheimer-like tangles. J Biol Chem, 2011. 286(17): p.
15317-31.

507.

Calafate, S., Flavin, W., Verstreken, P., and Moechars, D., Loss of Bin1 Promotes
the Propagation of Tau Pathology. Cell Rep, 2016. 17(4): p. 931-940.

508.

Michel, C.H., Kumar, S., Pinotsi, D., Tunnacliffe, A., St George-Hyslop, P.,
Mandelkow, E., Mandelkow, E.M., Kaminski, C.F., and Kaminski Schierle, G.S.,
Extracellular monomeric tau protein is sufficient to initiate the spread of tau
protein pathology. J Biol Chem, 2014. 289(2): p. 956-67.

509.

Wu, J.W., Herman, M., Liu, L., Simoes, S., Acker, C.M., Figueroa, H., Steinberg, J.I.,
Margittai, M., Kayed, R., Zurzolo, C., Di Paolo, G., and Duff, K.E., Small misfolded
Tau species are internalized via bulk endocytosis and anterogradely and
retrogradely transported in neurons. J Biol Chem, 2013. 288(3): p. 1856-70.

510.

Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., and Diamond, M.I., Transcellular propagation of Tau aggregation by fibrillar species. J Biol Chem, 2012.
287(23): p. 19440-51.

511.

Chai, X., Dage, J.L., and Citron, M., Constitutive secretion of tau protein by an
unconventional mechanism. Neurobiol Dis, 2012. 48(3): p. 356-66.

512.

262
Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W., and Hanger, D.P., Physiological
release of endogenous tau is stimulated by neuronal activity. EMBO Rep, 2013.
14(4): p. 389-94.

513.

Yamada, K., Cirrito, J.R., Stewart, F.R., Jiang, H., Finn, M.B., Holmes, B.B., Binder,
L.I., Mandelkow, E.M., Diamond, M.I., Lee, V.M., and Holtzman, D.M., In vivo
microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels
in P301S human tau transgenic mice. J Neurosci, 2011. 31(37): p. 13110-7.

514.

Tapiola, T., Alafuzoff, I., Herukka, S.K., Parkkinen, L., Hartikainen, P., Soininen, H.,
and Pirttila, T., Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as
biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol,
2009. 66(3): p. 382-9.

515.

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E.,
Wozniak, D.F., Diamond, M.I., and Holtzman, D.M., Anti-tau antibodies that block
tau aggregate seeding in vitro markedly decrease pathology and improve
cognition in vivo. Neuron, 2013. 80(2): p. 402-14.

516.

Dujardin, S., Begard, S., Caillierez, R., Lachaud, C., Delattre, L., Carrier, S., Loyens,
A., Galas, M.C., Bousset, L., Melki, R., Auregan, G., Hantraye, P., Brouillet, E.,
Buee, L., and Colin, M., Ectosomes: a new mechanism for non-exosomal secretion
of tau protein. PLoS ONE, 2014. 9(6): p. e100760.

517.

Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee,
A.C., Alvarez, V.E., Lee, N.C., and Hall, G.F., Exosome-associated tau is secreted in
tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early
Alzheimer disease. J Biol Chem, 2012. 287(6): p. 3842-9.

518.

Saman, S., Lee, N.C., Inoyo, I., Jin, J., Li, Z., Doyle, T., McKee, A.C., and Hall, G.F.,
Proteins recruited to exosomes by tau overexpression implicate novel cellular
mechanisms linking tau secretion with Alzheimer's disease. J Alzheimers Dis,
2014. 40 Suppl 1: p. S47-70.

519.

Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B.,
Butovsky, O., Kugler, S., and Ikezu, T., Depletion of microglia and inhibition of
exosome synthesis halt tau propagation. Nat Neurosci, 2015. 18(11): p. 1584-93.

520.

Tardivel, M., Begard, S., Bousset, L., Dujardin, S., Coens, A., Melki, R., Buee, L.,
and Colin, M., Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of
pathological Tau protein assemblies. Acta Neuropathol Commun, 2016. 4(1): p.
117.

263

521.

Abounit, S., Wu, J.W., Duff, K., Victoria, G.S., and Zurzolo, C., Tunneling
nanotubes: A possible highway in the spreading of tau and other prion-like
proteins in neurodegenerative diseases. Prion, 2016. 10(5): p. 344-351.

522.

Pearce, M.M. and Kopito, R.R., Prion-Like Characteristics of PolyglutamineContaining Proteins. Cold Spring Harb Perspect Med, 2017.
10.1101/cshperspect.a024257.

523.

Jimenez-Sanchez, M., Licitra, F., Underwood, B.R., and Rubinsztein, D.C.,
Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
Cold Spring Harb Perspect Med, 2016. 10.1101/cshperspect.a024240.

524.

Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank,
R., Bates, G.P., Davies, S.W., Lehrach, H., and Wanker, E.E., Huntingtin-encoded
polyglutamine expansions form amyloid-like protein aggregates in vitro and in
vivo. Cell, 1997. 90(3): p. 549-58.

525.

Chen, S., Berthelier, V., Yang, W., and Wetzel, R., Polyglutamine aggregation
behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol,
2001. 311(1): p. 173-82.

526.

Preisinger, E., Jordan, B.M., Kazantsev, A., and Housman, D., Evidence for a
recruitment and sequestration mechanism in Huntington's disease. Philos Trans R
Soc Lond B Biol Sci, 1999. 354(1386): p. 1029-34.

527.

Chen, S., Berthelier, V., Hamilton, J.B., O'Nuallain, B., and Wetzel, R., Amyloid-like
features of polyglutamine aggregates and their assembly kinetics. Biochemistry,
2002. 41(23): p. 7391-9.

528.

Kegel, K.B., Sapp, E., Yoder, J., Cuiffo, B., Sobin, L., Kim, Y.J., Qin, Z.H., Hayden,
M.R., Aronin, N., Scott, D.L., Isenberg, G., Goldmann, W.H., and DiFiglia, M.,
Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol
Chem, 2005. 280(43): p. 36464-73.

529.

Kegel, K.B., Schewkunow, V., Sapp, E., Masso, N., Wanker, E.E., DiFiglia, M., and
Goldmann, W.H., Polyglutamine expansion in huntingtin increases its insertion
into lipid bilayers. Biochem Biophys Res Commun, 2009. 387(3): p. 472-5.

530.

Trevino, R.S., Lauckner, J.E., Sourigues, Y., Pearce, M.M., Bousset, L., Melki, R.,
and Kopito, R.R., Fibrillar structure and charge determine the interaction of
polyglutamine protein aggregates with the cell surface. J Biol Chem, 2012.
287(35): p. 29722-8.

531.

264
Ruiz-Arlandis, G., Pieri, L., Bousset, L., and Melki, R., Binding, internalization and
fate of Huntingtin Exon1 fibrillar assemblies in mitotic and nonmitotic
neuroblastoma cells. Neuropathol Appl Neurobiol, 2016. 42(2): p. 137-52.

532.

Yang, W., Dunlap, J.R., Andrews, R.B., and Wetzel, R., Aggregated polyglutamine
peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet, 2002.
11(23): p. 2905-17.

533.

Ren, P.H., Lauckner, J.E., Kachirskaia, I., Heuser, J.E., Melki, R., and Kopito, R.R.,
Cytoplasmic penetration and persistent infection of mammalian cells by
polyglutamine aggregates. Nat Cell Biol, 2009. 11(2): p. 219-25.

534.

Herrera, F., Tenreiro, S., Miller-Fleming, L., and Outeiro, T.F., Visualization of cellto-cell transmission of mutant huntingtin oligomers. PLoS Curr, 2011. 3: p.
RRN1210.

535.

Costanzo, M., Abounit, S., Marzo, L., Danckaert, A., Chamoun, Z., Roux, P., and
Zurzolo, C., Transfer of polyglutamine aggregates in neuronal cells occurs in
tunneling nanotubes. J Cell Sci, 2013. 126(Pt 16): p. 3678-85.

536.

Varkey, J., Isas, J.M., Mizuno, N., Jensen, M.B., Bhatia, V.K., Jao, C.C., Petrlova, J.,
Voss, J.C., Stamou, D.G., Steven, A.C., and Langen, R., Membrane curvature
induction and tubulation are common features of synucleins and apolipoproteins.
J Biol Chem, 2010. 285(42): p. 32486-93.

537.

Braun, A.R., Sevcsik, E., Chin, P., Rhoades, E., Tristram-Nagle, S., and Sachs, J.N.,
alpha-Synuclein induces both positive mean curvature and negative Gaussian
curvature in membranes. J Am Chem Soc, 2012. 134(5): p. 2613-20.

538.

Westphal, C.H. and Chandra, S.S., Monomeric synucleins generate membrane
curvature. J Biol Chem, 2013. 288(3): p. 1829-40.

539.

Braun, A.R., Lacy, M.M., Ducas, V.C., Rhoades, E., and Sachs, J.N., alphaSynuclein-induced membrane remodeling is driven by binding affinity, partition
depth, and interleaflet order asymmetry. J Am Chem Soc, 2014. 136(28): p. 996272.

540.

Shi, Z., Sachs, J.N., Rhoades, E., and Baumgart, T., Biophysics of alpha-synuclein
induced membrane remodelling. Phys Chem Chem Phys, 2015. 17(24): p. 155618.

541.

Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and
Lansbury, P.T., Jr., Vesicle permeabilization by protofibrillar alpha-synuclein:

implications for the pathogenesis and treatment of Parkinson's disease.
Biochemistry, 2001. 40(26): p. 7812-9.

265

542.

Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T., and
Lansbury, P.T., α-Synuclein, Especially the Parkinson's Disease-associated
Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal of Molecular
Biology, 2002. 322(5): p. 1089-1102.

543.

Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., and Lansbury, P.T., Jr.,
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature,
2002. 418(6895): p. 291.

544.

Volles, M.J. and Lansbury, P.T., Vesicle Permeabilization by Protofibrillar αSynuclein Is Sensitive to Parkinson's Disease-Linked Mutations and Occurs by a
Pore-like Mechanism†. Biochemistry, 2002. 41(14): p. 4595-4602.

545.

Caughey, B. and Lansbury, P.T., Protofibrils, pores, fibrils, and
neurodegeneration: separating the responsible protein aggregates from the
innocent bystanders. Annu Rev Neurosci, 2003. 26: p. 267-98.

546.

Giehm, L., Svergun, D.I., Otzen, D.E., and Vestergaard, B., Low-resolution
structure of a vesicle disrupting &alpha;-synuclein oligomer that accumulates
during fibrillation. Proc Natl Acad Sci U S A, 2011. 108(8): p. 3246-51.

547.

Tsigelny, I.F., Sharikov, Y., Wrasidlo, W., Gonzalez, T., Desplats, P.A., Crews, L.,
Spencer, B., and Masliah, E., Role of alpha-synuclein penetration into the
membrane in the mechanisms of oligomer pore formation. FEBS J, 2012. 279(6):
p. 1000-13.

548.

Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B.,
Ghiso, J., and Lal, R., Amyloid ion channels: a common structural link for proteinmisfolding disease. Proc Natl Acad Sci U S A, 2005. 102(30): p. 10427-32.

549.

Furukawa, K., Matsuzaki-Kobayashi, M., Hasegawa, T., Kikuchi, A., Sugeno, N.,
Itoyama, Y., Wang, Y., Yao, P.J., Bushlin, I., and Takeda, A., Plasma membrane ion
permeability induced by mutant alpha-synuclein contributes to the degeneration
of neural cells. J Neurochem, 2006. 97(4): p. 1071-7.

550.

Danzer, K.M., Haasen, D., Karow, A.R., Moussaud, S., Habeck, M., Giese, A.,
Kretzschmar, H., Hengerer, B., and Kostka, M., Different species of alphasynuclein oligomers induce calcium influx and seeding. J Neurosci, 2007. 27(34):
p. 9220-32.

266

551.

Feng, L.R., Federoff, H.J., Vicini, S., and Maguire-Zeiss, K.A., Alpha-synuclein
mediates alterations in membrane conductance: a potential role for alphasynuclein oligomers in cell vulnerability. Eur J Neurosci, 2010. 32(1): p. 10-7.

552.

Angelova, P.R., Ludtmann, M.H., Horrocks, M.H., Negoda, A., Cremades, N.,
Klenerman, D., Dobson, C.M., Wood, N.W., Pavlov, E.V., Gandhi, S., and
Abramov, A.Y., Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J
Cell Sci, 2016. 129(9): p. 1792-801.

553.

Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E., and
Glabe, C.G., Permeabilization of lipid bilayers is a common conformationdependent activity of soluble amyloid oligomers in protein misfolding diseases. J
Biol Chem, 2004. 279(45): p. 46363-6.

554.

Stockl, M.T., Zijlstra, N., and Subramaniam, V., alpha-Synuclein oligomers: an
amyloid pore? Insights into mechanisms of alpha-synuclein oligomer-lipid
interactions. Mol Neurobiol, 2013. 47(2): p. 613-21.

555.

Zhu, M., Li, J., and Fink, A.L., The association of alpha-synuclein with membranes
affects bilayer structure, stability, and fibril formation. J Biol Chem, 2003.
278(41): p. 40186-97.

556.

Pieri, L., Madiona, K., Bousset, L., and Melki, R., Fibrillar alpha-synuclein and
huntingtin exon 1 assemblies are toxic to the cells. Biophys J, 2012. 102(12): p.
2894-905.

557.

Smith, R.A., Nabok, A., Blakeman, B.J., Xue, W.F., Abell, B., and Smith, D.P.,
Analysis of Toxic Amyloid Fibril Interactions at Natively Derived Membranes by
Ellipsometry. PLoS ONE, 2015. 10(7): p. e0132309.

558.

Chaudhary, H., Stefanovic, A.N., Subramaniam, V., and Claessens, M.M.,
Membrane interactions and fibrillization of alpha-synuclein play an essential role
in membrane disruption. FEBS Lett, 2014. 588(23): p. 4457-63.

559.

Luby-Phelps, K., Cytoarchitecture and physical properties of cytoplasm: volume,
viscosity, diffusion, intracellular surface area. Int Rev Cytol, 2000. 192: p. 189221.

560.

Papadopoulos, C., Kirchner, P., Bug, M., Grum, D., Koerver, L., Schulze, N.,
Poehler, R., Dressler, A., Fengler, S., Arhzaouy, K., Lux, V., Ehrmann, M., Weihl,
C.C., and Meyer, H., VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive
clearance of ruptured lysosomes by autophagy. EMBO J, 2017. 36(2): p. 135-150.

267

561.

McLaurin, J. and Chakrabartty, A., Membrane disruption by Alzheimer betaamyloid peptides mediated through specific binding to either phospholipids or
gangliosides. Implications for neurotoxicity. J Biol Chem, 1996. 271(43): p. 264829.

562.

Yang, A.J., Chandswangbhuvana, D., Margol, L., and Glabe, C.G., Loss of
endosomal/lysosomal membrane impermeability is an early event in amyloid
Abeta1-42 pathogenesis. J Neurosci Res, 1998. 52(6): p. 691-8.

563.

Milanesi, L., Sheynis, T., Xue, W.F., Orlova, E.V., Hellewell, A.L., Jelinek, R.,
Hewitt, E.W., Radford, S.E., and Saibil, H.R., Direct three-dimensional
visualization of membrane disruption by amyloid fibrils. Proc Natl Acad Sci U S A,
2012. 109(50): p. 20455-60.

564.

Goodchild, S.C., Sheynis, T., Thompson, R., Tipping, K.W., Xue, W.F., Ranson,
N.A., Beales, P.A., Hewitt, E.W., and Radford, S.E., beta2-Microglobulin amyloid
fibril-induced membrane disruption is enhanced by endosomal lipids and acidic
pH. PLoS ONE, 2014. 9(8): p. e104492.

565.

Hughes, R.C., The galectin family of mammalian carbohydrate-binding molecules.
Biochem Soc Trans, 1997. 25(4): p. 1194-8.

566.

Cooper, D.N. and Barondes, S.H., God must love galectins; he made so many of
them. Glycobiology, 1999. 9(10): p. 979-84.

567.

Leffler, H., Carlsson, S., Hedlund, M., Qian, Y., and Poirier, F., Introduction to
galectins. Glycoconj J, 2004. 19(7-9): p. 433-40.

568.

Cummings, R.D. and Liu, F.T., Galectins, in Essentials of Glycobiology, A. Varki, et
al., Editors. 2009, Cold Spring Harbor Laboratory Press: Cold Spring Harbor (NY).

569.

Di Lella, S., Sundblad, V., Cerliani, J.P., Guardia, C.M., Estrin, D.A., Vasta, G.R., and
Rabinovich, G.A., When galectins recognize glycans: from biochemistry to
physiology and back again. Biochemistry, 2011. 50(37): p. 7842-57.

570.

Thurston, T.L., Wandel, M.P., von Muhlinen, N., Foeglein, A., and Randow, F.,
Galectin 8 targets damaged vesicles for autophagy to defend cells against
bacterial invasion. Nature, 2012. 482(7385): p. 414-8.

571.

Coers, J., Self and non-self discrimination of intracellular membranes by the
innate immune system. PLoS Pathog, 2013. 9(9): p. e1003538.

572.

Randow, F. and Munz, C., Autophagy in the regulation of pathogen replication
and adaptive immunity. Trends Immunol, 2012. 33(10): p. 475-87.

573.

268
Pareja, M.E. and Colombo, M.I., Autophagic clearance of bacterial pathogens:
molecular recognition of intracellular microorganisms. Front Cell Infect
Microbiol, 2013. 3: p. 54.

574.

Creasey, E.A. and Isberg, R.R., Maintenance of vacuole integrity by bacterial
pathogens. Curr Opin Microbiol, 2014. 17: p. 46-52.

575.

Wiethoff, C.M. and Nemerow, G.R., Adenovirus membrane penetration: Tickling
the tail of a sleeping dragon. Virology, 2015. 479-480: p. 591-9.

576.

Dupont, N., Lacas-Gervais, S., Bertout, J., Paz, I., Freche, B., Van Nhieu, G.T., van
der Goot, F.G., Sansonetti, P.J., and Lafont, F., Shigella phagocytic vacuolar
membrane remnants participate in the cellular response to pathogen invasion
and are regulated by autophagy. Cell Host Microbe, 2009. 6(2): p. 137-49.

577.

Paz, I., Sachse, M., Dupont, N., Mounier, J., Cederfur, C., Enninga, J., Leffler, H.,
Poirier, F., Prevost, M.C., Lafont, F., and Sansonetti, P., Galectin-3, a marker for
vacuole lysis by invasive pathogens. Cell Microbiol, 2010. 12(4): p. 530-44.

578.

Ray, K., Bobard, A., Danckaert, A., Paz-Haftel, I., Clair, C., Ehsani, S., Tang, C.,
Sansonetti, P., Tran, G.V., and Enninga, J., Tracking the dynamic interplay
between bacterial and host factors during pathogen-induced vacuole rupture in
real time. Cell Microbiol, 2010. 12(4): p. 545-56.

579.

Li, S., Wandel, M.P., Li, F., Liu, Z., He, C., Wu, J., Shi, Y., and Randow, F., Sterical
hindrance promotes selectivity of the autophagy cargo receptor NDP52 for the
danger receptor galectin-8 in antibacterial autophagy. Sci Signal, 2013. 6(261): p.
ra9.

580.

Ehsani, S., Santos, J.C., Rodrigues, C.D., Henriques, R., Audry, L., Zimmer, C.,
Sansonetti, P., Tran Van Nhieu, G., and Enninga, J., Hierarchies of host factor
dynamics at the entry site of Shigella flexneri during host cell invasion. Infect
Immun, 2012. 80(7): p. 2548-57.

581.

Liu, F.T., Galectins: a new family of regulators of inflammation. Clin Immunol,
2000. 97(2): p. 79-88.

582.

Rabinovich, G.A., Rubinstein, N., and Toscano, M.A., Role of galectins in
inflammatory and immunomodulatory processes. Biochim Biophys Acta, 2002.
1572(2-3): p. 274-84.

583.

Rabinovich, G.A., Baum, L.G., Tinari, N., Paganelli, R., Natoli, C., Liu, F.T., and
Iacobelli, S., Galectins and their ligands: amplifiers, silencers or tuners of the
inflammatory response? Trends Immunol, 2002. 23(6): p. 313-20.

584.

269
Rabinovich, G.A., Liu, F.T., Hirashima, M., and Anderson, A., An emerging role for
galectins in tuning the immune response: lessons from experimental models of
inflammatory disease, autoimmunity and cancer. Scand J Immunol, 2007. 66(23): p. 143-58.

585.

Vasta, G.R., Roles of galectins in infection. Nat Rev Microbiol, 2009. 7(6): p. 42438.

586.

Vasta, G.R., Galectins as pattern recognition receptors: structure, function, and
evolution. Adv Exp Med Biol, 2012. 946: p. 21-36.

587.

Walther, M., Kuklinski, S., Pesheva, P., Guntinas-Lichius, O., Angelov, D.N., Neiss,
W.F., Asou, H., and Probstmeier, R., Galectin-3 is upregulated in microglial cells
in response to ischemic brain lesions, but not to facial nerve axotomy. J Neurosci
Res, 2000. 61(4): p. 430-5.

588.

Lalancette-Hebert, M., Swarup, V., Beaulieu, J.M., Bohacek, I., Abdelhamid, E.,
Weng, Y.C., Sato, S., and Kriz, J., Galectin-3 is required for resident microglia
activation and proliferation in response to ischemic injury. J Neurosci, 2012.
32(30): p. 10383-95.

589.

Boza-Serrano, A., Reyes, J.F., Rey, N.L., Leffler, H., Bousset, L., Nilsson, U.,
Brundin, P., Venero, J.L., Burguillos, M.A., and Deierborg, T., The role of Galectin3 in alpha-synuclein-induced microglial activation. Acta Neuropathol Commun,
2014. 2: p. 156.

590.

Mok, S.W., Riemer, C., Madela, K., Hsu, D.K., Liu, F.T., Gultner, S., Heise, I., and
Baier, M., Role of galectin-3 in prion infections of the CNS. Biochem Biophys Res
Commun, 2007. 359(3): p. 672-8.

591.

Delacour, D., Koch, A., and Jacob, R., The role of galectins in protein trafficking.
Traffic, 2009. 10(10): p. 1405-13.

592.

Sato, S., St-Pierre, C., Bhaumik, P., and Nieminen, J., Galectins in innate
immunity: dual functions of host soluble beta-galactoside-binding lectins as
damage-associated molecular patterns (DAMPs) and as receptors for pathogenassociated molecular patterns (PAMPs). Immunol Rev, 2009. 230(1): p. 172-87.

593.

Jeon, S.B., Yoon, H.J., Chang, C.Y., Koh, H.S., Jeon, S.H., and Park, E.J., Galectin-3
exerts cytokine-like regulatory actions through the JAK-STAT pathway. J
Immunol, 2010. 185(11): p. 7037-46.

594.

Burguillos, M.A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla,
A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M.J., Osman, A.M.,

Salomonsson, E., Amar, L., Persson, A., Blomgren, K., Achour, A., Englund, E.,
Leffler, H., Venero, J.L., Joseph, B., and Deierborg, T., Microglia-Secreted
Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial
Activation. Cell Rep, 2015. 10.1016/j.celrep.2015.02.012.

270

595.

Cheng, X., Boza-Serrano, A., Turesson, M.F., Deierborg, T., Ekblad, E., and Voss,
U., Galectin-3 causes enteric neuronal loss in mice after left sided permanent
middle cerebral artery occlusion, a model of stroke. Sci Rep, 2016. 6: p. 32893.

596.

Yip, P.K., Carrillo-Jimenez, A., King, P., Vilalta, A., Nomura, K., Chau, C.C., Egerton,
A.M., Liu, Z.H., Shetty, A.J., Tremoleda, J.L., Davies, M., Deierborg, T., Priestley,
J.V., Brown, G.C., Michael-Titus, A.T., Venero, J.L., and Burguillos, M.A., Galectin3 released in response to traumatic brain injury acts as an alarmin orchestrating
brain immune response and promoting neurodegeneration. Sci Rep, 2017. 7: p.
41689.

597.

Fujita, N., Morita, E., Itoh, T., Tanaka, A., Nakaoka, M., Osada, Y., Umemoto, T.,
Saitoh, T., Nakatogawa, H., Kobayashi, S., Haraguchi, T., Guan, J.L., Iwai, K.,
Tokunaga, F., Saito, K., Ishibashi, K., Akira, S., Fukuda, M., Noda, T., and
Yoshimori, T., Recruitment of the autophagic machinery to endosomes during
infection is mediated by ubiquitin. J Cell Biol, 2013. 203(1): p. 115-28.

598.

Al-Khodor, S., Marshall-Batty, K., Nair, V., Ding, L., Greenberg, D.E., and Fraser,
I.D., Burkholderia cenocepacia J2315 escapes to the cytosol and actively subverts
autophagy in human macrophages. Cell Microbiol, 2014. 16(3): p. 378-95.

599.

Choi, J., Park, S., Biering, S.B., Selleck, E., Liu, C.Y., Zhang, X., Fujita, N., Saitoh, T.,
Akira, S., Yoshimori, T., Sibley, L.D., Hwang, S., and Virgin, H.W., The
parasitophorous vacuole membrane of Toxoplasma gondii is targeted for
disruption by ubiquitin-like conjugation systems of autophagy. Immunity, 2014.
40(6): p. 924-35.

600.

Nishiumi, F., Ogawa, M., Nakura, Y., Hamada, Y., Nakayama, M., Mitobe, J.,
Hiraide, A., Sakai, N., Takeuchi, M., Yoshimori, T., and Yanagihara, I., Intracellular
fate of Ureaplasma parvum entrapped by host cellular autophagy.
Microbiologyopen, 2017. 10.1002/mbo3.441.

601.

Campbell-Valois, F.X., Sachse, M., Sansonetti, P.J., and Parsot, C., Escape of
Actively Secreting Shigella flexneri from ATG8/LC3-Positive Vacuoles Formed
during Cell-To-Cell Spread Is Facilitated by IcsB and VirA. MBio, 2015. 6(3): p.
e02567-14.

602.

271
Chauhan, S., Kumar, S., Jain, A., Ponpuak, M., Mudd, M.H., Kimura, T., Choi, S.W.,
Peters, R., Mandell, M., Bruun, J.A., Johansen, T., and Deretic, V., TRIMs and
Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in
Endomembrane Damage Homeostasis. Dev Cell, 2016. 39(1): p. 13-27.

603.

Chen, X., Khambu, B., Zhang, H., Gao, W., Li, M., Chen, X., Yoshimori, T., and Yin,
X.M., Autophagy induced by calcium phosphate precipitates targets damaged
endosomes. J Biol Chem, 2014. 289(16): p. 11162-74.

604.

Wiethoff, C.M., Wodrich, H., Gerace, L., and Nemerow, G.R., Adenovirus protein
VI mediates membrane disruption following capsid disassembly. J Virol, 2005.
79(4): p. 1992-2000.

605.

Maier, O., Galan, D.L., Wodrich, H., and Wiethoff, C.M., An N-terminal domain of
adenovirus protein VI fragments membranes by inducing positive membrane
curvature. Virology, 2010. 402(1): p. 11-9.

606.

Maier, O., Marvin, S.A., Wodrich, H., Campbell, E.M., and Wiethoff, C.M.,
Spatiotemporal dynamics of adenovirus membrane rupture and endosomal
escape. J Virol, 2012. 86(19): p. 10821-8.

607.

Martinez, R., Burrage, A.M., Wiethoff, C.M., and Wodrich, H., High temporal
resolution imaging reveals endosomal membrane penetration and escape of
adenoviruses in real time. Methods Mol Biol, 2013. 1064: p. 211-26.

608.

Luisoni, S., Suomalainen, M., Boucke, K., Tanner, L.B., Wenk, M.R., Guan, X.L.,
Grzybek, M., Coskun, U., and Greber, U.F., Co-option of Membrane Wounding
Enables Virus Penetration into Cells. Cell Host Microbe, 2015. 18(1): p. 75-85.

609.

McGuire, K.A., Barlan, A.U., Griffin, T.M., and Wiethoff, C.M., Adenovirus type 5
rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and
production of reactive oxygen species. J Virol, 2011. 85(20): p. 10806-13.

610.

Boya, P. and Kroemer, G., Lysosomal membrane permeabilization in cell death.
Oncogene, 2008. 27(50): p. 6434-51.

611.

Serrano-Puebla, A. and Boya, P., Lysosomal membrane permeabilization in cell
death: new evidence and implications for health and disease. Ann N Y Acad Sci,
2016. 1371(1): p. 30-44.

612.

Boya, P., Andreau, K., Poncet, D., Zamzami, N., Perfettini, J.L., Metivier, D.,
Ojcius, D.M., Jaattela, M., and Kroemer, G., Lysosomal membrane
permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp
Med, 2003. 197(10): p. 1323-34.

272

613.

Blomgran, R., Zheng, L., and Stendahl, O., Cathepsin-cleaved Bid promotes
apoptosis in human neutrophils via oxidative stress-induced lysosomal
membrane permeabilization. J Leukoc Biol, 2007. 81(5): p. 1213-23.

614.

Droga-Mazovec, G., Bojic, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U.,
Salvesen, G.S., Stoka, V., Turk, V., and Turk, B., Cysteine cathepsins trigger
caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2
homologues. J Biol Chem, 2008. 283(27): p. 19140-50.

615.

Maejima, I., Takahashi, A., Omori, H., Kimura, T., Takabatake, Y., Saitoh, T.,
Yamamoto, A., Hamasaki, M., Noda, T., Isaka, Y., and Yoshimori, T., Autophagy
sequesters damaged lysosomes to control lysosomal biogenesis and kidney
injury. EMBO J, 2013. 32(17): p. 2336-47.

616.

Heid, M.E., Keyel, P.A., Kamga, C., Shiva, S., Watkins, S.C., and Salter, R.D.,
Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal
damage and inflammasome activation. J Immunol, 2013. 191(10): p. 5230-8.

617.

Jaattela, M. and Nylandsted, J., Methods for Probing Lysosomal Membrane
Permeabilization. Cold Spring Harb Protoc, 2015. 2015(11): p. 975-8.

618.

Vila, M., Bove, J., Dehay, B., Rodriguez-Muela, N., and Boya, P., Lysosomal
membrane permeabilization in Parkinson disease. Autophagy, 2011. 7(1): p. 98100.

619.

Aits, S., Jaattela, M., and Nylandsted, J., Methods for the quantification of
lysosomal membrane permeabilization: a hallmark of lysosomal cell death.
Methods Cell Biol, 2015. 126: p. 261-85.

620.

Aits, S., Kricker, J., Liu, B., Ellegaard, A.M., Hamalisto, S., Tvingsholm, S., CorcelleTermeau, E., Hogh, S., Farkas, T., Holm Jonassen, A., Gromova, I., Mortensen, M.,
and Jaattela, M., Sensitive detection of lysosomal membrane permeabilization by
lysosomal galectin puncta assay. Autophagy, 2015. 11(8): p. 1408-24.

621.

Ellegaard, A.M., Jaattela, M., and Nylandsted, J., Visualizing Lysosomal
Membrane Permeabilization by Fluorescent Dextran Release. Cold Spring Harb
Protoc, 2015. 2015(10): p. 900-3.

622.

Groth-Pedersen, L., Jaattela, M., and Nylandsted, J., A Method to Monitor
Lysosomal Membrane Permeabilization by Immunocytochemistry. Cold Spring
Harb Protoc, 2015. 2015(10): p. 904-7.

273

623.

Jaattela, M. and Nylandsted, J., Quantification of Lysosomal Membrane
Permeabilization by Cytosolic Cathepsin and beta-N-Acetyl-Glucosaminidase
Activity Measurements. Cold Spring Harb Protoc, 2015. 2015(11): p. 1017-23.

624.

Melachroinou, K., Xilouri, M., Emmanouilidou, E., Masgrau, R., Papazafiri, P.,
Stefanis, L., and Vekrellis, K., Deregulation of calcium homeostasis mediates
secreted alpha-synuclein-induced neurotoxicity. Neurobiol Aging, 2013. 34(12): p.
2853-65.

625.

Jaiswal, J.K., Andrews, N.W., and Simon, S.M., Membrane proximal lysosomes are
the major vesicles responsible for calcium-dependent exocytosis in nonsecretory
cells. J Cell Biol, 2002. 159(4): p. 625-35.

626.

Kimura, T., Jia, J., Kumar, S., Choi, S.W., Gu, Y., Mudd, M., Dupont, N., Jiang, S.,
Peters, R., Farzam, F., Jain, A., Lidke, K.A., Adams, C.M., Johansen, T., and
Deretic, V., Dedicated SNAREs and specialized TRIM cargo receptors mediate
secretory autophagy. EMBO J, 2017. 36(1): p. 42-60.

627.

Kaul, S., Anantharam, V., Kanthasamy, A., and Kanthasamy, A.G., Wild-type
alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to
protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death.
Brain Res Mol Brain Res, 2005. 139(1): p. 137-52.

628.

Jo, E., McLaurin, J., Yip, C.M., St George-Hyslop, P., and Fraser, P.E., alphaSynuclein membrane interactions and lipid specificity. J Biol Chem, 2000. 275(44):
p. 34328-34.

629.

Ghee, M., Melki, R., Michot, N., and Mallet, J., PA700, the regulatory complex of
the 26S proteasome, interferes with alpha-synuclein assembly. FEBS J, 2005.
272(16): p. 4023-33.

630.

Pieri, L., Chafey, P., Le Gall, M., Clary, G., Melki, R., and Redeker, V., Cellular
response of human neuroblastoma cells to alpha-synuclein fibrils, the main
constituent of Lewy bodies. Biochim Biophys Acta, 2016. 1860(1 Pt A): p. 8-19.

631.

Monsellier, E., Redeker, V., Ruiz-Arlandis, G., Bousset, L., and Melki, R., Molecular
interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin
exon 1 modulates aggregation. J Biol Chem, 2015. 290(5): p. 2560-76.

632.

Chu, Y., Mickiewicz, A.L., and Kordower, J.H., alpha-synuclein aggregation
reduces nigral myocyte enhancer factor-2D in idiopathic and experimental
Parkinson's disease. Neurobiol Dis, 2011. 41(1): p. 71-82.

633.

274
Herva, M.E. and Spillantini, M.G., Parkinson's disease as a member of Prion-like
disorders. Virus Res, 2015. 207: p. 38-46.

634.

Brundin, P., Ma, J., and Kordower, J.H., How strong is the evidence that
Parkinson's disease is a prion disorder? Curr Opin Neurol, 2016. 29(4): p. 459-66.

635.

Dehay, B., Vila, M., Bezard, E., Brundin, P., and Kordower, J.H., Alpha-synuclein
propagation: New insights from animal models. Mov Disord, 2016. 31(2): p. 1618.

636.

Emmanouilidou, E. and Vekrellis, K., Exocytosis and Spreading of Normal and
Aberrant alpha-Synuclein. Brain Pathol, 2016. 26(3): p. 398-403.

637.

Hasegawa, M., Nonaka, T., and Masuda-Suzukake, M., alpha-Synuclein:
Experimental Pathology. Cold Spring Harb Perspect Med, 2016.
10.1101/cshperspect.a024273.

638.

Tofaris, G.K., Lysosome-dependent pathways as a unifying theme in Parkinson's
disease. Mov Disord, 2012. 27(11): p. 1364-9.

639.

Coskun, P., Wyrembak, J., Schriner, S.E., Chen, H.W., Marciniack, C., Laferla, F.,
and Wallace, D.C., A mitochondrial etiology of Alzheimer and Parkinson disease.
Biochim Biophys Acta, 2012. 1820(5): p. 553-64.

640.

Lee, S.J., Desplats, P., Lee, H.J., Spencer, B., and Masliah, E., Cell-to-cell
transmission of alpha-synuclein aggregates. Methods Mol Biol, 2012. 849: p.
347-59.

641.

Tenreiro, S., Eckermann, K., and Outeiro, T.F., Protein phosphorylation in
neurodegeneration: friend or foe? Front Mol Neurosci, 2014. 7: p. 42.

642.

Lee, S.J., Desplats, P., Sigurdson, C., Tsigelny, I., and Masliah, E., Cell-to-cell
transmission of non-prion protein aggregates. Nat Rev Neurol, 2010. 6(12): p.
702-6.

643.

Tyson, T., Steiner, J.A., and Brundin, P., Sorting out release, uptake and
processing of alpha-synuclein during prion-like spread of pathology. J
Neurochem, 2016. 139 Suppl 1: p. 275-289.

644.

Brundin, P., Li, J.Y., Holton, J.L., Lindvall, O., and Revesz, T., Research in motion:
the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci, 2008.
9(10): p. 741-5.

275

645.

Valera, E. and Masliah, E., Therapeutic approaches in Parkinson's disease and
related disorders. J Neurochem, 2016. 139 Suppl 1: p. 346-352.

646.

Goedert, M., Clavaguera, F., and Tolnay, M., The propagation of prion-like
protein inclusions in neurodegenerative diseases. Trends Neurosci, 2010. 33(7):
p. 317-25.

647.

Jucker, M. and Walker, L.C., Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature, 2013. 501(7465): p. 45-51.

648.

Goedert, M., Masuda-Suzukake, M., and Falcon, B., Like prions: the propagation
of aggregated tau and alpha-synuclein in neurodegeneration. Brain, 2017. 140(Pt
2): p. 266-278.

649.

Walker, L.C., Schelle, J., and Jucker, M., The Prion-Like Properties of Amyloid-beta
Assemblies: Implications for Alzheimer's Disease. Cold Spring Harb Perspect Med,
2016. 10.1101/cshperspect.a024398.

650.

Polymenidou, M. and Cleveland, D.W., Biological Spectrum of Amyotrophic
Lateral Sclerosis Prions. Cold Spring Harb Perspect Med, 2017.
10.1101/cshperspect.a024133.

651.

Kovalevich, J. and Langford, D., Considerations for the use of SH-SY5Y
neuroblastoma cells in neurobiology. Methods Mol Biol, 2013. 1078: p. 9-21.

652.

Aguzzi, A. and Rajendran, L., The transcellular spread of cytosolic amyloids,
prions, and prionoids. Neuron, 2009. 64(6): p. 783-90.

653.

Alosco, M.L., Tripodis, Y., Jarnagin, J., Baugh, C.M., Martin, B., Chaisson, C.E.,
Estochen, N., Song, L., Cantu, R.C., Jeromin, A., and Stern, R.A., Repetitive head
impact exposure and later-life plasma total tau in former National Football
League players. Alzheimers Dement (Amst), 2017. 7: p. 33-40.

VITA
The author, William P. Flavin, was born in Park Ridge, IL on June 26, 1989 to
Michael and Karen Flavin. He attended the University of Notre Dame in Notre Dame,
Indiana where he earned a Bachelor of Science degree, cum laude, in Biochemistry in
May 2011. After graduation, William matriculated into the Loyola University Chicago
Stritch School of Medicine MD/PhD Program. After completing two years of medical
school, he began his graduate education in the Integrative Cell Biology Program under
the mentorship of Dr. Edward M. Campbell.
William’s dissertation work on endocytic vesicle rupture in the pathogenesis and
propagation of neurodegenerative proteinopathies was supported by an Arthur J.
Schmitt Fellowship in Leadership and Service. After completion of his graduate studies,
William will return to medical school for the final two years of clinical training.

276

